<div class="mw-parser-output"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Class of medications</div>
<p class="mw-empty-elt">
</p>
<style data-mw-deduplicate="TemplateStyles:r1066479718">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}</style><table class="infobox"><tbody><tr><th colspan="2" class="infobox-above" style="background-color: #ddbbee">Antipsychotic</th></tr><tr><td colspan="2" class="infobox-subheader"><i><a href="/wiki/Drug_class" title="Drug class">Drug class</a></i></td></tr><tr><td colspan="2" class="infobox-image"><a href="/wiki/File:Zyprexa.PNG" class="image"><img alt="Zyprexa.PNG" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Zyprexa.PNG/280px-Zyprexa.PNG" decoding="async" width="280" height="210" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Zyprexa.PNG/420px-Zyprexa.PNG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Zyprexa.PNG/560px-Zyprexa.PNG 2x" data-file-width="908" data-file-height="681" /></a><div class="infobox-caption"><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a>, an example of a second-generation (<i>atypical</i>) antipsychotic</div></td></tr><tr><th colspan="2" class="infobox-header" style="background: #e8e8e8;">Class identifiers</th></tr><tr><th scope="row" class="infobox-label"><a href="/wiki/Synonym" title="Synonym">Synonyms</a></th><td class="infobox-data">Neuroleptics, major tranquilizers<sup id="cite_ref-Fin2009_1-0" class="reference"><a href="#cite_note-Fin2009-1">&#91;1&#93;</a></sup></td></tr><tr><th scope="row" class="infobox-label">Use</th><td class="infobox-data">Principally: <a href="/wiki/Schizophrenia" title="Schizophrenia">Schizophrenia</a>, <a href="/wiki/Schizoaffective_disorder" title="Schizoaffective disorder">Schizoaffective disorder</a>, <a href="/wiki/Dementia" title="Dementia">Dementia</a>, <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a>, <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">Bipolar disorder</a>, irritability in <a href="/wiki/Autism_spectrum" title="Autism spectrum">autism spectrum disorder</a></td></tr><tr><th colspan="2" class="infobox-header" style="background: #e8e8e8;">Clinical data</th></tr><tr><th scope="row" class="infobox-label"><a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th><td class="infobox-data"><span title="www.drugs.com"><a rel="nofollow" class="external text" href="https://www.drugs.com/drug-class/antipsychotics.html">Drug Classes</a></span></td></tr><tr><th colspan="2" class="infobox-header" style="background: #e8e8e8;">External links</th></tr><tr><th scope="row" class="infobox-label"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th><td class="infobox-data"><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?field=uid&amp;term=D014150">D014150</a></span></td></tr><tr><td colspan="2" class="infobox-below" style="background: #e8e8e8; text-align: center"><a href="https://www.wikidata.org/wiki/Q208144" class="extiw" title="d:Q208144">In Wikidata</a></td></tr></tbody></table>
<p><b>Antipsychotics</b>, also known as <b>neuroleptics</b>,<sup id="cite_ref-Fin2009_1-1" class="reference"><a href="#cite_note-Fin2009-1">&#91;1&#93;</a></sup> are a class of <a href="/wiki/Psychiatric_medication" title="Psychiatric medication">psychotropic medication</a> primarily used to manage <a href="/wiki/Psychosis" title="Psychosis">psychosis</a> (including <a href="/wiki/Delusion" title="Delusion">delusions</a>, <a href="/wiki/Hallucination" title="Hallucination">hallucinations</a>, <a href="/wiki/Paranoia" title="Paranoia">paranoia</a> or <a href="/wiki/Disordered_thought" class="mw-redirect" title="Disordered thought">disordered thought</a>), principally in <a href="/wiki/Schizophrenia" title="Schizophrenia">schizophrenia</a> but also in a range of other psychotic disorders.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup> They are also the mainstay together with <a href="/wiki/Mood_stabilizer" title="Mood stabilizer">mood stabilizers</a> in the treatment of <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a>.<sup id="cite_ref-Grande_3-0" class="reference"><a href="#cite_note-Grande-3">&#91;3&#93;</a></sup>
</p><p>Recent research has shown that use of any antipsychotic results in smaller brain tissue volumes and that this brain shrinkage is dose dependent and time dependent.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4">&#91;4&#93;</a></sup> A review of the research has also reinforced this effect.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup>
</p><p>The use of antipsychotics may result in many unwanted side effects such as <a href="/wiki/Extrapyramidal_symptoms" title="Extrapyramidal symptoms">involuntary movement disorders</a>, <a href="/wiki/Gynecomastia" title="Gynecomastia">gynecomastia</a>, <a href="/wiki/Impotence" class="mw-redirect" title="Impotence">impotence</a>, <a href="/wiki/Weight_gain" title="Weight gain">weight gain</a> and <a href="/wiki/Metabolic_syndrome" title="Metabolic syndrome">metabolic syndrome</a>. Long-term use can produce <a href="/wiki/List_of_long_term_side_effects_of_antipsychotics" title="List of long term side effects of antipsychotics">adverse effects</a> such as <a href="/wiki/Tardive_dyskinesia" title="Tardive dyskinesia">tardive dyskinesia</a>, tardive dystonia, and tardive akathisia.
</p><p>First-generation antipsychotics (e.g. <a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>), known as <a href="/wiki/Typical_antipsychotics" class="mw-redirect" title="Typical antipsychotics">typical antipsychotics</a>, were first introduced in the 1950s, and others were developed until the early 1970s.<sup id="cite_ref-Shen_6-0" class="reference"><a href="#cite_note-Shen-6">&#91;6&#93;</a></sup> Second-generation antipsychotics, known as <a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">atypical antipsychotics</a>, were introduced firstly with <a href="/wiki/Clozapine" title="Clozapine">clozapine</a> in the early 1970s followed by others (e.g. <a href="/wiki/Risperidone" title="Risperidone">risperidone</a>).<sup id="cite_ref-Aringhieri_7-0" class="reference"><a href="#cite_note-Aringhieri-7">&#91;7&#93;</a></sup> Both generations of medication <a href="/wiki/Dopamine_receptor_antagonist" class="mw-redirect" title="Dopamine receptor antagonist">block receptors in the brain for dopamine</a>, but atypicals tend to act on <a href="/wiki/5-HT_receptors" class="mw-redirect" title="5-HT receptors">serotonin receptors</a> as well. <i>Neuroleptic</i>, originating from <a href="/wiki/Greek_language" title="Greek language">Greek</a>: <span title="Ancient Greek (to 1453)-language text"><span lang="grc"><a href="https://en.wiktionary.org/wiki/%CE%BD%CE%B5%E1%BF%A6%CF%81%CE%BF%CE%BD" class="extiw" title="wikt:νεῦρον">νεῦρον</a></span></span> (<i>neuron</i>) and <span title="Ancient Greek (to 1453)-language text"><span lang="grc"><a href="https://en.wiktionary.org/wiki/%CE%BB%CE%B1%CE%BC%CE%B2%CE%AC%CE%BD%CF%89" class="extiw" title="wikt:λαμβάνω">λαμβάνω</a></span></span> (<i>take hold of</i>)—thus meaning <i>"which takes the nerve"</i>—refers to both common <a href="/wiki/Neurological" class="mw-redirect" title="Neurological">neurological</a> effects and side effects.<sup id="cite_ref-king_8-0" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup>
</p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Medical_uses"><span class="tocnumber">1</span> <span class="toctext">Medical uses</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Schizophrenia"><span class="tocnumber">1.1</span> <span class="toctext">Schizophrenia</span></a>
<ul>
<li class="toclevel-3 tocsection-3"><a href="#Prevention_of_psychosis_and_symptom_improvement"><span class="tocnumber">1.1.1</span> <span class="toctext">Prevention of psychosis and symptom improvement</span></a></li>
<li class="toclevel-3 tocsection-4"><a href="#First_episode_psychosis"><span class="tocnumber">1.1.2</span> <span class="toctext">First episode psychosis</span></a></li>
<li class="toclevel-3 tocsection-5"><a href="#Recurrent_psychotic_episodes"><span class="tocnumber">1.1.3</span> <span class="toctext">Recurrent psychotic episodes</span></a></li>
<li class="toclevel-3 tocsection-6"><a href="#Maintenance_therapy"><span class="tocnumber">1.1.4</span> <span class="toctext">Maintenance therapy</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-7"><a href="#Bipolar_disorder"><span class="tocnumber">1.2</span> <span class="toctext">Bipolar disorder</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Dementia"><span class="tocnumber">1.3</span> <span class="toctext">Dementia</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Major_depressive_disorder"><span class="tocnumber">1.4</span> <span class="toctext">Major depressive disorder</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Other"><span class="tocnumber">1.5</span> <span class="toctext">Other</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Typicals_vs_atypicals"><span class="tocnumber">1.6</span> <span class="toctext">Typicals vs atypicals</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Adverse_effects"><span class="tocnumber">2</span> <span class="toctext">Adverse effects</span></a>
<ul>
<li class="toclevel-2 tocsection-13"><a href="#By_rate"><span class="tocnumber">2.1</span> <span class="toctext">By rate</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Long-term_effects"><span class="tocnumber">2.2</span> <span class="toctext">Long-term effects</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Discontinuation"><span class="tocnumber">2.3</span> <span class="toctext">Discontinuation</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-16"><a href="#List_of_agents"><span class="tocnumber">3</span> <span class="toctext">List of agents</span></a>
<ul>
<li class="toclevel-2 tocsection-17"><a href="#First-generation_(typical)"><span class="tocnumber">3.1</span> <span class="toctext">First-generation (typical)</span></a>
<ul>
<li class="toclevel-3 tocsection-18"><a href="#Butyrophenones"><span class="tocnumber">3.1.1</span> <span class="toctext">Butyrophenones</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#Diphenylbutylpiperidines"><span class="tocnumber">3.1.2</span> <span class="toctext">Diphenylbutylpiperidines</span></a></li>
<li class="toclevel-3 tocsection-20"><a href="#Phenothiazines"><span class="tocnumber">3.1.3</span> <span class="toctext">Phenothiazines</span></a></li>
<li class="toclevel-3 tocsection-21"><a href="#Thioxanthenes"><span class="tocnumber">3.1.4</span> <span class="toctext">Thioxanthenes</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-22"><a href="#Disputed/unknown"><span class="tocnumber">3.2</span> <span class="toctext">Disputed/unknown</span></a>
<ul>
<li class="toclevel-3 tocsection-23"><a href="#Benzamides"><span class="tocnumber">3.2.1</span> <span class="toctext">Benzamides</span></a></li>
<li class="toclevel-3 tocsection-24"><a href="#Tricyclics"><span class="tocnumber">3.2.2</span> <span class="toctext">Tricyclics</span></a></li>
<li class="toclevel-3 tocsection-25"><a href="#Others"><span class="tocnumber">3.2.3</span> <span class="toctext">Others</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-26"><a href="#Second-generation_(atypical)"><span class="tocnumber">3.3</span> <span class="toctext">Second-generation (atypical)</span></a>
<ul>
<li class="toclevel-3 tocsection-27"><a href="#Benzamides_2"><span class="tocnumber">3.3.1</span> <span class="toctext">Benzamides</span></a></li>
<li class="toclevel-3 tocsection-28"><a href="#Benzisoxazoles/benzisothiazoles"><span class="tocnumber">3.3.2</span> <span class="toctext">Benzisoxazoles/benzisothiazoles</span></a></li>
<li class="toclevel-3 tocsection-29"><a href="#Butyrophenones_2"><span class="tocnumber">3.3.3</span> <span class="toctext">Butyrophenones</span></a></li>
<li class="toclevel-3 tocsection-30"><a href="#Phenylpiperazines/quinolinones"><span class="tocnumber">3.3.4</span> <span class="toctext">Phenylpiperazines/quinolinones</span></a></li>
<li class="toclevel-3 tocsection-31"><a href="#Tricyclics_2"><span class="tocnumber">3.3.5</span> <span class="toctext">Tricyclics</span></a></li>
<li class="toclevel-3 tocsection-32"><a href="#Others_2"><span class="tocnumber">3.3.6</span> <span class="toctext">Others</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-33"><a href="#Mechanism_of_action"><span class="tocnumber">4</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-1 tocsection-34"><a href="#Comparison_of_medications"><span class="tocnumber">5</span> <span class="toctext">Comparison of medications</span></a></li>
<li class="toclevel-1 tocsection-35"><a href="#History"><span class="tocnumber">6</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-36"><a href="#Society_and_culture"><span class="tocnumber">7</span> <span class="toctext">Society and culture</span></a>
<ul>
<li class="toclevel-2 tocsection-37"><a href="#Terminology"><span class="tocnumber">7.1</span> <span class="toctext">Terminology</span></a></li>
<li class="toclevel-2 tocsection-38"><a href="#Sales"><span class="tocnumber">7.2</span> <span class="toctext">Sales</span></a></li>
<li class="toclevel-2 tocsection-39"><a href="#Overprescription"><span class="tocnumber">7.3</span> <span class="toctext">Overprescription</span></a></li>
<li class="toclevel-2 tocsection-40"><a href="#Legal"><span class="tocnumber">7.4</span> <span class="toctext">Legal</span></a></li>
<li class="toclevel-2 tocsection-41"><a href="#Formulations"><span class="tocnumber">7.5</span> <span class="toctext">Formulations</span></a></li>
<li class="toclevel-2 tocsection-42"><a href="#Recreational_use"><span class="tocnumber">7.6</span> <span class="toctext">Recreational use</span></a></li>
<li class="toclevel-2 tocsection-43"><a href="#Controversy"><span class="tocnumber">7.7</span> <span class="toctext">Controversy</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-44"><a href="#Special_populations"><span class="tocnumber">8</span> <span class="toctext">Special populations</span></a></li>
<li class="toclevel-1 tocsection-45"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-46"><a href="#Notes"><span class="tocnumber">10</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1 tocsection-47"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-48"><a href="#Further_reading"><span class="tocnumber">12</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-49"><a href="#External_links"><span class="tocnumber">13</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Medical_uses">Medical uses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=1" title="Edit section: Medical uses">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Antipsychotics are most frequently used for the following conditions:
</p>
<ul><li><a href="/wiki/Schizophrenia" title="Schizophrenia">Schizophrenia</a></li>
<li><a href="/wiki/Schizoaffective_disorder" title="Schizoaffective disorder">Schizoaffective disorder</a> most commonly in conjunction with either an <a href="/wiki/Antidepressant" title="Antidepressant">antidepressant</a> (in the case of the depressive subtype) or a <a href="/wiki/Mood_stabiliser" class="mw-redirect" title="Mood stabiliser">mood stabiliser</a> (in the case of the bipolar subtype).</li>
<li><a href="/wiki/Bipolar_disorder" title="Bipolar disorder">Bipolar disorder</a> (acute mania and mixed episodes) may be treated with either typical or atypical antipsychotics, although atypical antipsychotics are usually preferred because they tend to have more favourable adverse effect profiles<sup id="cite_ref-Lancet2009_9-0" class="reference"><a href="#cite_note-Lancet2009-9">&#91;9&#93;</a></sup> and, according to a recent meta-analysis, they tend to have a lower liability for causing conversion from mania to depression.<sup id="cite_ref-Haldep_10-0" class="reference"><a href="#cite_note-Haldep-10">&#91;10&#93;</a></sup></li>
<li><a href="/wiki/Psychotic_depression" title="Psychotic depression">Psychotic depression</a>. In this indication it is a common practice for the psychiatrist to prescribe a combination of an atypical antipsychotic and an antidepressant as this practice is best supported by the evidence.<sup id="cite_ref-Maudsley_11-0" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup></li>
<li><a href="/wiki/Treatment-resistant_depression#Adding_medication" title="Treatment-resistant depression">Treatment resistant depression</a> as an adjunct to standard antidepressant therapy.<sup id="cite_ref-Maudsley_11-1" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup></li></ul>
<p>Antipsychotics are generally not recommended for treating behavioral problems associated with <a href="/wiki/Dementia" title="Dementia">dementia</a>, given that the risk of use tends to be greater than the potential benefit.<sup id="cite_ref-Choose2013_12-0" class="reference"><a href="#cite_note-Choose2013-12">&#91;12&#93;</a></sup> The same can be said for <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, in which they are not recommended as first-line therapy.<sup id="cite_ref-Choose2013_12-1" class="reference"><a href="#cite_note-Choose2013-12">&#91;12&#93;</a></sup> There are evidence-based indications for using antipsychotics in children (e.g. tic disorder, bipolar disorder, psychosis), but the use of antipsychotics outside of those contexts (e.g. to treat behavioral problems) warrants significant caution.<sup id="cite_ref-Choose2013_12-2" class="reference"><a href="#cite_note-Choose2013-12">&#91;12&#93;</a></sup>
</p><p>Antipsychotics are used to treat tics associated with <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a>.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup> <a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a>, an <a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">atypical antipsychotic</a>, is used as add-on medication to ameliorate sexual dysfunction as a symptom of <a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">Selective serotonin reuptake inhibitor</a> antidepressants in women.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup><sup class="reference nowrap"><span title="Page / location: 10">&#58;&#8202;10&#8202;</span></sup> <a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a> is used to treat <a href="/wiki/Generalized_anxiety_disorder" title="Generalized anxiety disorder">generalized anxiety disorder</a>.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Schizophrenia">Schizophrenia</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=2" title="Edit section: Schizophrenia">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<style data-mw-deduplicate="TemplateStyles:r1033289096">.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}</style><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Schizophrenia#Medication" title="Schizophrenia">Schizophrenia §&#160;Medication</a></div>
<p>Antipsychotic drug treatment is a key component of <a href="/wiki/Schizophrenia#Medication" title="Schizophrenia">schizophrenia treatment recommendations</a> by the <a href="/wiki/National_Institute_of_Health_and_Care_Excellence" class="mw-redirect" title="National Institute of Health and Care Excellence">National Institute of Health and Care Excellence</a> (NICE),<sup id="cite_ref-NICE_16-0" class="reference"><a href="#cite_note-NICE-16">&#91;16&#93;</a></sup> the <a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a>,<sup id="cite_ref-APA_17-0" class="reference"><a href="#cite_note-APA-17">&#91;17&#93;</a></sup> and the British Society for Psychopharmacology.<sup id="cite_ref-BAP_18-0" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup> The main aim of treatment with antipsychotics is to reduce the <a href="/wiki/Schizophrenia#Positive_symptoms" title="Schizophrenia">positive symptoms</a> of psychosis that include delusions and hallucinations.  There is mixed evidence to support a significant impact of antipsychotic use on <a href="/wiki/Schizophrenia#Negative_symptoms" title="Schizophrenia">negative symptoms</a> (such as apathy, lack of emotional affect, and lack of interest in social interactions) or on the <a href="/wiki/Schizophrenia#Cognitive_symptoms" title="Schizophrenia">cognitive symptoms</a> (memory impairments, reduced ability to plan and execute tasks).<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup><sup id="cite_ref-ReferenceA_20-0" class="reference"><a href="#cite_note-ReferenceA-20">&#91;20&#93;</a></sup> In general, the efficacy of antipsychotic treatment in reducing both positive and negative symptoms appears to increase with increasing severity of baseline symptoms.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> All antipsychotic medications work relatively the same way, by antagonizing D2 dopamine receptors. However, there are some differences when it comes to typical and atypical antipsychotics. For example, atypical antipsychotic medications have been seen to lower the neurocognitive impairment associated with schizophrenia more so than conventional antipsychotics, although the reasoning and mechanics of this are still unclear to researchers.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>
</p><p>Applications of antipsychotic drugs in the treatment of schizophrenia include prophylaxis in those showing symptoms that suggest that they are at high risk of developing psychosis, treatment of first episode psychosis, maintenance therapy (a form of prophylaxis, maintenance therapy aims to maintain therapeutic benefit and prevent symptom relapse), and treatment of recurrent episodes of acute psychosis.<sup id="cite_ref-BAP_18-1" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Prevention_of_psychosis_and_symptom_improvement">Prevention of psychosis and symptom improvement</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=3" title="Edit section: Prevention of psychosis and symptom improvement">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Test batteries such as the PACE (Personal Assessment and Crisis Evaluation Clinic) and COPS (Criteria of Prodromal Syndromes), which measure low-level psychotic symptoms and cognitive disturbances, are used to evaluate people with early, low-level symptoms of psychosis. Test results are combined with family history information to identify patients in the "high-risk" group; they are considered to have a 20–40% risk of progression to frank psychosis within two years.<sup id="cite_ref-BAP_18-2" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup> These patients are often treated with low doses of antipsychotic drugs with the goal of reducing their symptoms and preventing progression to frank psychosis. While generally useful for reducing symptoms, clinical trials to date show little evidence that early use of antipsychotics improves long-term outcomes in those with prodromal symptoms, either alone or in combination with cognitive-behavioral therapy.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="First_episode_psychosis">First episode psychosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=4" title="Edit section: First episode psychosis">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>First episode psychosis (FEP) is the first time that psychotic symptoms are presented. NICE recommends that all persons presenting with first episode psychosis be treated with both an antipsychotic drug, and <a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">cognitive behavioral therapy</a> (CBT). NICE further recommends that those expressing a preference for CBT alone are informed that combination treatment is more effective.<sup id="cite_ref-NICE_16-1" class="reference"><a href="#cite_note-NICE-16">&#91;16&#93;</a></sup> A diagnosis of schizophrenia is not made at this time as it takes longer to determine by both <a href="/wiki/DSM-5" title="DSM-5">DSM-5</a> and <a href="/wiki/ICD-11" title="ICD-11">ICD-11</a>, and only around 60% of those presenting with a first episode psychosis will later be diagnosed with schizophrenia.<sup id="cite_ref-McGorry_24-0" class="reference"><a href="#cite_note-McGorry-24">&#91;24&#93;</a></sup>
</p><p>The conversion rate for a first episode <a href="/wiki/Drug_induced_psychosis" class="mw-redirect" title="Drug induced psychosis">drug induced psychosis</a> to bipolar disorder or schizophrenia are lower, with 30% of people converting to either bipolar disorder or schizophrenia.<sup id="cite_ref-drug_25-0" class="reference"><a href="#cite_note-drug-25">&#91;25&#93;</a></sup> NICE makes no distinction between a substance-induced psychosis, and any other form of psychosis. The rate of conversion differs for different classes of drug.<sup id="cite_ref-drug_25-1" class="reference"><a href="#cite_note-drug-25">&#91;25&#93;</a></sup>
</p><p>Pharmacological options for the specific treatment of FEP have been discussed in recent reviews.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup> The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. Evidence that early treatment has a favorable effect on long term outcomes is equivocal.<sup id="cite_ref-NICE_16-2" class="reference"><a href="#cite_note-NICE-16">&#91;16&#93;</a></sup><sup id="cite_ref-BAP_18-3" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Recurrent_psychotic_episodes">Recurrent psychotic episodes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=5" title="Edit section: Recurrent psychotic episodes">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Placebo-controlled trials of both first and second generation antipsychotic drugs consistently demonstrate the superiority of active drug to placebo in suppressing psychotic symptoms.<sup id="cite_ref-BAP_18-4" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup> A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia acute psychotic episodes showed an effect size of about 0.5.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup>  There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents.<sup id="cite_ref-NICE_16-3" class="reference"><a href="#cite_note-NICE-16">&#91;16&#93;</a></sup><sup id="cite_ref-Leucht_2013_29-0" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>  The efficacy of such drugs is suboptimal. Few patients achieve complete resolution of symptoms. Response rates, calculated using various cutoff values for symptom reduction, are low and their interpretation is complicated by high placebo response rates and selective publication of clinical trial results.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Maintenance_therapy">Maintenance therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=6" title="Edit section: Maintenance therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>The majority of patients treated with an antipsychotic drug will experience a response within four weeks. The goals of continuing treatment are to maintain suppression of symptoms, prevent relapse, improve quality of life, and support engagement in psychosocial therapy.<sup id="cite_ref-BAP_18-5" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup>
</p><p>Maintenance therapy with antipsychotic drugs is clearly superior to placebo in preventing relapse but is associated with weight gain, movement disorders, and high dropout rates.<sup id="cite_ref-Ceraso_2020_31-0" class="reference"><a href="#cite_note-Ceraso_2020-31">&#91;31&#93;</a></sup> A 3-year trial following persons receiving maintenance therapy after an acute psychotic episode found that 33% obtained long-lasting symptom reduction, 13% achieved remission, and only 27% experienced satisfactory quality of life. The effect of relapse prevention on long term outcomes is uncertain, as historical studies show little difference in long term outcomes before and after the introduction of antipsychotic drugs.<sup id="cite_ref-BAP_18-6" class="reference"><a href="#cite_note-BAP-18">&#91;18&#93;</a></sup>
</p><p>While maintenance therapy clearly reduces the rate of relapses requiring hospitalization, a large observational study in Finland found that, in people that eventually discontinued antipsychotics, the risk of being hospitalized again for a mental health problem or dying increased the longer they were dispensed (and presumably took) antipsychotics prior to stopping therapy. If people did not stop taking antipsychotics, they remained at low risk for relapse and hospitalization compared to those that stopped taking antipsychotics.<sup id="cite_ref-Tiihonen_Tanskanen_Taipale_2018_pp._765–773_32-0" class="reference"><a href="#cite_note-Tiihonen_Tanskanen_Taipale_2018_pp._765–773-32">&#91;32&#93;</a></sup> The authors speculated that the difference may be because the people that discontinued treatment after a longer time had more severe mental illness than those that discontinued antipsychotic therapy sooner.<sup id="cite_ref-Tiihonen_Tanskanen_Taipale_2018_pp._765–773_32-1" class="reference"><a href="#cite_note-Tiihonen_Tanskanen_Taipale_2018_pp._765–773-32">&#91;32&#93;</a></sup>
</p><p>A significant challenge in the use of antipsychotic drugs for the prevention of relapse is the poor rate of adherence. In spite of the relatively high rates of adverse effects associated with these drugs, some evidence, including higher dropout rates in placebo arms compared to treatment arms in randomized clinical trials, suggest that most patients who discontinue treatment do so because of suboptimal efficacy.<sup id="cite_ref-Ceraso_2020_31-1" class="reference"><a href="#cite_note-Ceraso_2020-31">&#91;31&#93;</a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup> If someone experiences psychotic symptoms due to nonadherence, they may be compelled to treatment through a process called <a href="/wiki/Involuntary_commitment" title="Involuntary commitment">involuntary commitment</a>, in which they can be forced to accept treatment (including antipsychotics). A person can also be committed to treatment outside of a hospital, called <a href="/wiki/Outpatient_commitment" title="Outpatient commitment">outpatient commitment</a>.
</p><p>Antipsychotics in <a href="/wiki/Depot_injection" title="Depot injection">long-acting injectable</a> (LAI), or "depot", form have been suggested as a method of decreasing medication nonadherence (sometimes also called non-compliance).<sup id="cite_ref-lai_34-0" class="reference"><a href="#cite_note-lai-34">&#91;34&#93;</a></sup> NICE advises LAIs be offered to patients when preventing covert, intentional nonadherence is a clinical priority.<sup id="cite_ref-nice-full-guidelines_35-0" class="reference"><a href="#cite_note-nice-full-guidelines-35">&#91;35&#93;</a></sup> LAIs are used to ensure adherence in outpatient commitment.<sup id="cite_ref-cto_36-0" class="reference"><a href="#cite_note-cto-36">&#91;36&#93;</a></sup> A meta-analysis found that LAIs resulted in lower rates of rehospitalization with a hazard ratio of 0.83, however these results were not statistically significant (the 95% confidence interval was 0.62 to 1.11).<sup id="cite_ref-lai_34-1" class="reference"><a href="#cite_note-lai-34">&#91;34&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Bipolar_disorder">Bipolar disorder</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=7" title="Edit section: Bipolar disorder">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">Bipolar disorder</a></div>
<p>Antipsychotics are routinely used, often in conjunction with <a href="/wiki/Mood_stabilizer" title="Mood stabilizer">mood stabilisers</a> such as <a href="/wiki/Lithium_(medication)" title="Lithium (medication)">lithium</a>/<a href="/wiki/Valproate_semisodium" class="mw-redirect" title="Valproate semisodium">valproate</a>, as a first-line treatment for manic and mixed episodes associated with bipolar disorder.<sup id="cite_ref-Maudsley_11-2" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup><sup id="cite_ref-Young_37-0" class="reference"><a href="#cite_note-Young-37">&#91;37&#93;</a></sup> The reason for this combination is the therapeutic delay of the aforementioned mood stabilisers (for valproate therapeutic effects are usually seen around five days after treatment is commenced whereas lithium usually takes at least a week<sup id="cite_ref-Young_37-1" class="reference"><a href="#cite_note-Young-37">&#91;37&#93;</a></sup> before the full therapeutic effects are seen) and the comparatively rapid antimanic effects of antipsychotic drugs.<sup id="cite_ref-pmid20402706_38-0" class="reference"><a href="#cite_note-pmid20402706-38">&#91;38&#93;</a></sup> The antipsychotics have a documented efficacy when used alone in acute mania/mixed episodes.<sup id="cite_ref-Lancet2009_9-1" class="reference"><a href="#cite_note-Lancet2009-9">&#91;9&#93;</a></sup>
</p><p>Three atypical antipsychotics (<a href="/wiki/Lurasidone" title="Lurasidone">lurasidone</a>,<sup id="cite_ref-Lur_39-0" class="reference"><a href="#cite_note-Lur-39">&#91;39&#93;</a></sup> <a href="/wiki/Olanzapine" title="Olanzapine">olanzapine</a><sup id="cite_ref-OLD_40-0" class="reference"><a href="#cite_note-OLD-40">&#91;40&#93;</a></sup> and <a href="/wiki/Quetiapine" title="Quetiapine">quetiapine</a><sup id="cite_ref-QuetD_41-0" class="reference"><a href="#cite_note-QuetD-41">&#91;41&#93;</a></sup>) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine<sup id="cite_ref-OlanM_42-0" class="reference"><a href="#cite_note-OlanM-42">&#91;42&#93;</a></sup> and quetiapine<sup id="cite_ref-QuetM1_43-0" class="reference"><a href="#cite_note-QuetM1-43">&#91;43&#93;</a></sup><sup id="cite_ref-QuetM2_44-0" class="reference"><a href="#cite_note-QuetM2-44">&#91;44&#93;</a></sup> have been proven to be effective broad-spectrum (i.e. against all three types of relapse—manic, mixed and depressive) prophylactic (or <i>maintenance</i>) treatments in patients with bipolar disorder. A recent Cochrane review also found that olanzapine had a less favourable risk/benefit ratio than <a href="/wiki/Lithium_(medication)" title="Lithium (medication)">lithium</a> as a maintenance treatment for bipolar disorder.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">&#91;45&#93;</a></sup>
</p><p>The <a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a> and the UK <a href="/wiki/National_Institute_for_Health_and_Care_Excellence" title="National Institute for Health and Care Excellence">National Institute for Health and Care Excellence</a> recommend antipsychotics for managing acute psychotic episodes in schizophrenia or bipolar disorder, and as a longer-term maintenance treatment for reducing the likelihood of further episodes.<sup id="cite_ref-pmid15000267_46-0" class="reference"><a href="#cite_note-pmid15000267-46">&#91;46&#93;</a></sup><sup id="cite_ref-Centre_47-0" class="reference"><a href="#cite_note-Centre-47">&#91;47&#93;</a></sup> They state that response to any given antipsychotic can be variable so that trials may be necessary, and that lower doses are to be preferred where possible. A number of studies have looked at levels of "compliance" or "adherence" with antipsychotic regimes and found that discontinuation (stopping taking them) by patients is associated with higher rates of relapse, including hospitalization.
</p>
<h3><span class="mw-headline" id="Dementia">Dementia</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=8" title="Edit section: Dementia">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Psychosis and agitation develop in as many as 80 percent of people living in nursing homes.<sup id="cite_ref-pmid21191528_48-0" class="reference"><a href="#cite_note-pmid21191528-48">&#91;48&#93;</a></sup> Despite a lack of <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">FDA</a> approval and <a href="/wiki/Boxed_warning" title="Boxed warning">black-box warnings</a>, <a href="/wiki/Atypical_antipsychotics" class="mw-redirect" title="Atypical antipsychotics">atypical antipsychotics</a> are very often prescribed to people with <a href="/wiki/Dementia" title="Dementia">dementia</a>.<sup id="cite_ref-pmid21191528_48-1" class="reference"><a href="#cite_note-pmid21191528-48">&#91;48&#93;</a></sup> An assessment for an underlying cause of behavior is needed before prescribing antipsychotic medication for symptoms of <a href="/wiki/Dementia" title="Dementia">dementia</a>.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49">&#91;49&#93;</a></sup> Antipsychotics in old age dementia showed a modest benefit compared to placebo in managing aggression or psychosis, but this is combined with a fairly large increase in serious adverse events. Thus, antipsychotics should not be used routinely to treat dementia with aggression or psychosis, but may be an option in a few cases where there is severe distress or risk of physical harm to others.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">&#91;50&#93;</a></sup> Psychosocial interventions may reduce the need for antipsychotics.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51">&#91;51&#93;</a></sup> In 2005, the FDA issued an advisory warning of an increased risk of death when atypical antipsychotics are used in dementia.<sup id="cite_ref-pmid21191528_48-2" class="reference"><a href="#cite_note-pmid21191528-48">&#91;48&#93;</a></sup> In the subsequent 5 years, the use of atypical antipsychotics to treat dementia decreased by nearly 50%.<sup id="cite_ref-pmid21191528_48-3" class="reference"><a href="#cite_note-pmid21191528-48">&#91;48&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Major_depressive_disorder">Major depressive disorder</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=9" title="Edit section: Major depressive disorder">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A number of atypical antipsychotics have some benefits when used in addition to other treatments in <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a>.<sup id="cite_ref-Cochrane_Dep_52-0" class="reference"><a href="#cite_note-Cochrane_Dep-52">&#91;52&#93;</a></sup><sup id="cite_ref-Plos_53-0" class="reference"><a href="#cite_note-Plos-53">&#91;53&#93;</a></sup> Aripiprazole, quetiapine extended-release, and olanzapine (when used in conjunction with <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a>) have received the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) labelling for this indication.<sup id="cite_ref-DrugPoint_54-0" class="reference"><a href="#cite_note-DrugPoint-54">&#91;54&#93;</a></sup> There is, however, a greater risk of side effects with their use compared to using traditional antidepressants.<sup id="cite_ref-Cochrane_Dep_52-1" class="reference"><a href="#cite_note-Cochrane_Dep-52">&#91;52&#93;</a></sup> The greater risk of serious side effects with antipsychotics is why, e.g., quetiapine was denied approval as monotherapy for major depressive disorder or generalized anxiety disorder, and instead was only approved as an adjunctive treatment in combination with traditional antidepressants.<sup id="cite_ref-AACAP_FDA_Psychopharm_QTP_Recap_55-0" class="reference"><a href="#cite_note-AACAP_FDA_Psychopharm_QTP_Recap-55">&#91;55&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Other">Other</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=10" title="Edit section: Other">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Besides the above uses antipsychotics may be used for <a href="/wiki/Obsessive%E2%80%93compulsive_disorder" title="Obsessive–compulsive disorder">obsessive–compulsive disorder</a>, <a href="/wiki/Post-traumatic_stress_disorder" title="Post-traumatic stress disorder">post-traumatic stress disorder</a>, <a href="/wiki/Personality_disorders" class="mw-redirect" title="Personality disorders">personality disorders</a>, <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a>, <a href="/wiki/Autism" title="Autism">autism</a> and agitation in those with dementia.<sup id="cite_ref-Rand2012_56-0" class="reference"><a href="#cite_note-Rand2012-56">&#91;56&#93;</a></sup> Evidence however does not support the use of atypical antipsychotics in <a href="/wiki/Eating_disorder" title="Eating disorder">eating disorders</a> or personality disorder.<sup id="cite_ref-Off-Label_Use_57-0" class="reference"><a href="#cite_note-Off-Label_Use-57">&#91;57&#93;</a></sup> The atypical antipsychotic <a href="/wiki/Risperidone" title="Risperidone">risperidone</a> may be useful for <a href="/wiki/Obsessive%E2%80%93compulsive_disorder" title="Obsessive–compulsive disorder">obsessive–compulsive disorder</a>.<sup id="cite_ref-Rand2012_56-1" class="reference"><a href="#cite_note-Rand2012-56">&#91;56&#93;</a></sup> The use of low doses of antipsychotics for <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, while common, is not recommended as there is little evidence of benefit and concerns regarding adverse effects.<sup id="cite_ref-Off-Label_Use_57-1" class="reference"><a href="#cite_note-Off-Label_Use-57">&#91;57&#93;</a></sup><sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup> Low dose antipsychotics may also be used in treatment of impulse-behavioural and cognitive-perceptual symptoms of <a href="/wiki/Borderline_personality_disorder" title="Borderline personality disorder">borderline personality disorder</a>.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup>
</p><p>In children they may be used in those with <a href="/wiki/Disruptive_behavior_disorder" class="mw-redirect" title="Disruptive behavior disorder">disruptive behavior disorders</a>, <a href="/wiki/Mood_disorder" title="Mood disorder">mood disorders</a> and <a href="/wiki/Pervasive_developmental_disorder" title="Pervasive developmental disorder">pervasive developmental disorders</a> or <a href="/wiki/Intellectual_disability" title="Intellectual disability">intellectual disability</a>.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup> Antipsychotics are only weakly recommended for Tourette syndrome, because although they are effective, side effects are common.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">&#91;61&#93;</a></sup> The situation is similar for those on the <a href="/wiki/Autism_spectrum" title="Autism spectrum">autism spectrum</a>.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup>
Much of the evidence for the off-label use of antipsychotics (for example, for dementia, OCD, PTSD, Personality Disorders, Tourette's) was of insufficient scientific quality to support such use, especially as there was strong evidence of increased risks of stroke, tremors, significant weight gain, sedation, and gastrointestinal problems.<sup id="cite_ref-63" class="reference"><a href="#cite_note-63">&#91;63&#93;</a></sup> A UK review of unlicensed usage in children and adolescents reported a similar mixture of findings and concerns.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">&#91;64&#93;</a></sup> A survey of children with <a href="/wiki/Pervasive_developmental_disorder" title="Pervasive developmental disorder">pervasive developmental disorder</a> found that 16.5% were taking an antipsychotic drug, most commonly for irritability, aggression, and agitation. Both <a href="/wiki/Risperidone" title="Risperidone">risperidone</a> and <a href="/wiki/Aripiprazole" title="Aripiprazole">aripiprazole</a> have been approved by the US FDA for the treatment of irritability in autistic children and adolescents.<sup id="cite_ref-DD_65-0" class="reference"><a href="#cite_note-DD-65">&#91;65&#93;</a></sup>
</p><p>Aggressive challenging behavior in adults with <a href="/wiki/Intellectual_disability" title="Intellectual disability">intellectual disability</a> is often treated with antipsychotic drugs despite lack of an evidence base. A recent <a href="/wiki/Randomized_controlled_trial" title="Randomized controlled trial">randomized controlled trial</a>, however, found no benefit over <a href="/wiki/Placebo" title="Placebo">placebo</a> and recommended that the use of antipsychotics in this way should no longer be regarded as an acceptable routine treatment.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66">&#91;66&#93;</a></sup>
</p><p>Antipsychotics may be an option, together with stimulants, in people with ADHD and aggressive behavior when other treatments have not worked.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67">&#91;67&#93;</a></sup> They have not been found to be useful for the prevention of <a href="/wiki/Delirium" title="Delirium">delirium</a> among those admitted to hospital.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">&#91;68&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Typicals_vs_atypicals">Typicals vs atypicals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=11" title="Edit section: Typicals vs atypicals">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>It is unclear whether the <a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">atypical (second-generation) antipsychotics</a> offer advantages over older, first generation antipsychotics.<sup id="cite_ref-ReferenceA_20-1" class="reference"><a href="#cite_note-ReferenceA-20">&#91;20&#93;</a></sup><sup id="cite_ref-69" class="reference"><a href="#cite_note-69">&#91;69&#93;</a></sup> <a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a>, <a href="/wiki/Olanzapine" title="Olanzapine">olanzapine</a>, <a href="/wiki/Risperidone" title="Risperidone">risperidone</a> and <a href="/wiki/Clozapine" title="Clozapine">clozapine</a> may be more effective but are associated with greater side effects.<sup id="cite_ref-barry_2012_70-0" class="reference"><a href="#cite_note-barry_2012-70">&#91;70&#93;</a></sup> Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages.<sup id="cite_ref-AFP07_71-0" class="reference"><a href="#cite_note-AFP07-71">&#91;71&#93;</a></sup>
</p><p>Clozapine is an effective treatment for those who respond poorly to other drugs ("treatment-resistant" or "refractory" schizophrenia),<sup id="cite_ref-72" class="reference"><a href="#cite_note-72">&#91;72&#93;</a></sup> but it has the potentially serious side effect of <a href="/wiki/Agranulocytosis" title="Agranulocytosis">agranulocytosis</a> (lowered <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a> count) in less than 4% of people.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup>
</p><p>Due to bias in the research the accuracy of comparisons of atypical antipsychotics is a concern.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup>
</p><p>In 2005, a US government body, the <a href="/wiki/National_Institute_of_Mental_Health" title="National Institute of Mental Health">National Institute of Mental Health</a> published the results of a major independent study (the CATIE project).<sup id="cite_ref-75" class="reference"><a href="#cite_note-75">&#91;75&#93;</a></sup> No other atypical studied (<a href="/wiki/Risperidone" title="Risperidone">risperidone</a>, <a href="/wiki/Quetiapine" title="Quetiapine">quetiapine</a>, and <a href="/wiki/Ziprasidone" title="Ziprasidone">ziprasidone</a>) did better than the typical perphenazine on the measures used, nor did they produce fewer adverse effects than the typical antipsychotic perphenazine, although more patients discontinued perphenazine owing to <a href="/wiki/Extrapyramidal_symptoms" title="Extrapyramidal symptoms">extrapyramidal effects</a> compared to the atypical agents (8% vs. 2% to 4%).<sup id="cite_ref-Lancet2009_9-2" class="reference"><a href="#cite_note-Lancet2009-9">&#91;9&#93;</a></sup>
</p><p>Atypical antipsychotics do not appear to lead to improved rates of medication adherence compared to typical antipsychotics.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76">&#91;76&#93;</a></sup>
</p><p>Many researchers question the first-line prescribing of atypicals over typicals, and some even question the distinction between the two classes.<sup id="cite_ref-77" class="reference"><a href="#cite_note-77">&#91;77&#93;</a></sup><sup id="cite_ref-78" class="reference"><a href="#cite_note-78">&#91;78&#93;</a></sup><sup id="cite_ref-79" class="reference"><a href="#cite_note-79">&#91;79&#93;</a></sup> In contrast, other researchers point to the significantly higher risk of <a href="/wiki/Tardive_dyskinesia" title="Tardive dyskinesia">tardive dyskinesia</a> and other extrapyramidal symptoms with the typicals and for this reason alone recommend first-line treatment with the atypicals, notwithstanding a greater propensity for metabolic adverse effects in the latter.<sup id="cite_ref-pmid10190226_80-0" class="reference"><a href="#cite_note-pmid10190226-80">&#91;80&#93;</a></sup> The UK government organization <a href="/wiki/National_Institute_for_Health_and_Care_Excellence" title="National Institute for Health and Care Excellence">NICE</a> recently revised its recommendation favoring atypicals, to advise that the choice should be an individual one based on the particular profiles of the individual drug and on the patient's preferences.
</p><p>The re-evaluation of the evidence has not necessarily slowed the bias toward prescribing the atypicals.<sup id="cite_ref-pmid20098227_81-0" class="reference"><a href="#cite_note-pmid20098227-81">&#91;81&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Adverse_effects">Adverse effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=12" title="Edit section: Adverse effects">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">For more detailed comparison of atypical antipsychotics, see <a href="/wiki/Atypical_antipsychotic#Adverse_effects" title="Atypical antipsychotic">Atypical antipsychotic §&#160;Adverse effects</a>.</div>
<p>Generally, more than one antipsychotic drug should not be used at a time because of increased adverse effects.<sup id="cite_ref-APAfive_polypharmacy_82-0" class="reference"><a href="#cite_note-APAfive_polypharmacy-82">&#91;82&#93;</a></sup>
</p><p>Very rarely antipsychotics may cause <a href="/wiki/Tardive_psychosis" title="Tardive psychosis">tardive psychosis</a>.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83">&#91;83&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="By_rate">By rate</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=13" title="Edit section: By rate">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><b>Common (≥ 1% and up to 50% incidence for <i>most</i> antipsychotic drugs) adverse effects of antipsychotics include:</b><sup id="cite_ref-84" class="reference"><a href="#cite_note-84">&#91;84&#93;</a></sup>
</p>
<ul><li>Sedation (particularly common with asenapine, clozapine, olanzapine, quetiapine, chlorpromazine and zotepine<sup id="cite_ref-Leucht_2013_29-1" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>)</li>
<li>Headaches</li>
<li>Dizziness</li>
<li>Diarrhea</li>
<li>Anxiety</li>
<li><a href="/wiki/Extrapyramidal_side_effects" class="mw-redirect" title="Extrapyramidal side effects">Extrapyramidal side effects</a> (particularly common with first-generation antipsychotics), which include:</li></ul>
<dl><dd>- <a href="/wiki/Akathisia" title="Akathisia">Akathisia</a>, an often distressing sense of inner restlessness.</dd>
<dd>- <a href="/wiki/Dystonia" title="Dystonia">Dystonia</a>, an abnormal muscle contraction</dd>
<dd>- <a href="/wiki/Pseudoparkinsonism" class="mw-redirect" title="Pseudoparkinsonism">Pseudoparkinsonism</a>, symptoms that are similar to what people with Parkinson's disease experience, including tremulousness and drooling</dd></dl>
<ul><li><a href="/wiki/Hyperprolactinaemia" title="Hyperprolactinaemia">Hyperprolactinaemia</a> (rare for those treated with clozapine, quetiapine and aripiprazole<sup id="cite_ref-Maudsley_11-3" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup><sup id="cite_ref-Leucht_2013_29-2" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>), which can cause:</li></ul>
<dl><dd>- <a href="/wiki/Galactorrhoea" class="mw-redirect" title="Galactorrhoea">Galactorrhoea</a>, the unusual secretion of breast milk.</dd>
<dd>- <a href="/wiki/Gynaecomastia" class="mw-redirect" title="Gynaecomastia">Gynaecomastia</a>, abnormal growth of breast tissue</dd>
<dd>- Sexual dysfunction (in both sexes)</dd>
<dd>- Osteoporosis</dd></dl>
<ul><li>Orthostatic hypotension</li>
<li>Weight gain (particularly prominent with clozapine, olanzapine, quetiapine and zotepine<sup id="cite_ref-Leucht_2013_29-3" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>)</li>
<li>Anticholinergic side-effects (common for olanzapine, clozapine; less likely on risperidone<sup id="cite_ref-Lieberman,_2004_85-0" class="reference"><a href="#cite_note-Lieberman,_2004-85">&#91;85&#93;</a></sup>) such as:</li></ul>
<dl><dd>- Blurred vision</dd>
<dd>- Constipation</dd>
<dd>- Dry mouth (although hypersalivation may also occur)</dd>
<dd>- Reduced perspiration</dd></dl>
<ul><li><a href="/wiki/Tardive_dyskinesia" title="Tardive dyskinesia">Tardive dyskinesia</a> appears to be more frequent with high-potency first-generation antipsychotics, such as haloperidol, and tends to appear after chronic and not acute treatment. It is characterized by slow (hence the <i>tardive</i>) repetitive, involuntary and purposeless movements, most often of the face, lips, legs, or torso, which tend to resist treatment and are frequently irreversible. The rate of appearance of TD is about 5% per year of use of antipsychotic drug (whatever the drug used).</li></ul>
<p><b>Rare/Uncommon (&lt;1% incidence for <i>most</i> antipsychotic drugs) adverse effects of antipsychotics include:</b>
</p>
<ul><li>Blood dyscrasias (e.g., agranulocytosis, leukopenia, and neutropaenia), which is more common in patients on clozapine.</li>
<li><a href="/wiki/Metabolic_syndrome" title="Metabolic syndrome">Metabolic syndrome</a> and other metabolic problems such as <a href="/wiki/Type_II_diabetes_mellitus" class="mw-redirect" title="Type II diabetes mellitus">type II diabetes mellitus</a> — particularly common with clozapine, olanzapine and zotepine. In American studies <a href="/wiki/African_Americans" title="African Americans">African Americans</a> appeared to be at a heightened risk for developing type II diabetes mellitus.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">&#91;86&#93;</a></sup> Evidence suggests that females are more sensitive to the metabolic side effects of first-generation antipsychotic drugs than males.<sup id="cite_ref-87" class="reference"><a href="#cite_note-87">&#91;87&#93;</a></sup> Metabolic adverse effects appear to be mediated by the following mechanisms:</li></ul>
<dl><dd>- Causing weight gain by antagonizing the <a href="/wiki/Histamine_H1_receptor" title="Histamine H1 receptor">histamine H<sub>1</sub></a> and serotonin <a href="/wiki/5-HT2C" class="mw-redirect" title="5-HT2C">5-HT<sub>2C</sub>receptors</a><sup id="cite_ref-GG_88-0" class="reference"><a href="#cite_note-GG-88">&#91;88&#93;</a></sup> and perhaps by interacting with other neurochemical pathways in the <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a>.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89">&#91;89&#93;</a></sup></dd></dl>
<ul><li><a href="/wiki/Neuroleptic_malignant_syndrome" title="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</a>, a potentially fatal condition characterized by:</li></ul>
<dl><dd>- Autonomic instability, which can manifest with tachycardia, nausea, vomiting, diaphoresis, etc.</dd>
<dd>- Hyperthermia — elevated body temperature.</dd>
<dd>- Mental status change (confusion, hallucinations, coma, etc.)</dd>
<dd>- Muscle rigidity</dd>
<dd>- Laboratory abnormalities (e.g., elevated <a href="/wiki/Creatine_kinase" title="Creatine kinase">creatine kinase</a>, reduced iron plasma levels, electrolyte abnormalities, etc.)</dd></dl>
<ul><li><a href="/wiki/Pancreatitis" title="Pancreatitis">Pancreatitis</a><sup id="cite_ref-pmid14524644_90-0" class="reference"><a href="#cite_note-pmid14524644-90">&#91;90&#93;</a></sup></li>
<li><a href="/wiki/QT_interval" title="QT interval">QT interval</a> prolongation — more prominent in those treated with amisulpride, pimozide, sertindole, thioridazine and ziprasidone.<sup id="cite_ref-Maudsley_11-4" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup><sup id="cite_ref-Leucht_2013_29-4" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup></li>
<li><a href="/wiki/Torsades_de_pointes" title="Torsades de pointes">Torsades de pointes</a></li>
<li><a href="/wiki/Seizures" class="mw-redirect" title="Seizures">Seizures</a>, particularly in people treated with chlorpromazine and clozapine.</li>
<li><a href="/wiki/Thromboembolism" class="mw-redirect" title="Thromboembolism">Thromboembolism</a></li>
<li><a href="/wiki/Myocardial_infarction" title="Myocardial infarction">Myocardial infarction</a></li>
<li><a href="/wiki/Stroke" title="Stroke">Stroke</a></li></ul>
<h3><span class="mw-headline" id="Long-term_effects">Long-term effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=14" title="Edit section: Long-term effects">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">See also: <a href="/wiki/List_of_long_term_side_effects_of_antipsychotics" title="List of long term side effects of antipsychotics">List of long term side effects of antipsychotics</a></div>
<p>Some studies have found decreased life expectancy associated with the use of antipsychotics, and argued that more studies are needed.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91">&#91;91&#93;</a></sup><sup id="cite_ref-92" class="reference"><a href="#cite_note-92">&#91;92&#93;</a></sup> Antipsychotics may also increase the risk of early <a href="/wiki/Death" title="Death">death</a> in individuals with <a href="/wiki/Dementia" title="Dementia">dementia</a>.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93">&#91;93&#93;</a></sup>  Antipsychotics typically worsen symptoms in people who suffer from depersonalisation disorder.<sup id="cite_ref-utdp_94-0" class="reference"><a href="#cite_note-utdp-94">&#91;94&#93;</a></sup> Antipsychotic <a href="/wiki/Polypharmacy" title="Polypharmacy">polypharmacy</a> (prescribing two or more antipsychotics at the same time for an individual) is a common practice but not evidence-based or recommended, and there are initiatives to curtail it.<sup id="cite_ref-APAfive_polypharmacy_82-1" class="reference"><a href="#cite_note-APAfive_polypharmacy-82">&#91;82&#93;</a></sup><sup id="cite_ref-95" class="reference"><a href="#cite_note-95">&#91;95&#93;</a></sup> Similarly, the use of excessively high doses (often the result of polypharmacy) continues despite clinical guidelines and evidence indicating that it is usually no more effective but is usually more harmful.<sup id="cite_ref-APAfive_polypharmacy_82-2" class="reference"><a href="#cite_note-APAfive_polypharmacy-82">&#91;82&#93;</a></sup><sup id="cite_ref-96" class="reference"><a href="#cite_note-96">&#91;96&#93;</a></sup>
</p><p>Loss of <a href="/wiki/Grey_matter" title="Grey matter">grey matter</a> and other brain structural changes over time are observed amongst people diagnosed with schizophrenia. Meta-analyses of the effects of antipsychotic treatment on grey matter volume and the brain's structure have reached conflicting conclusions.  A 2012 meta-analysis concluded that grey matter loss is greater in patients treated with first generation antipsychotics relative to those treated with atypicals, and hypothesized a protective effect of atypicals as one possible explanation.<sup id="cite_ref-97" class="reference"><a href="#cite_note-97">&#91;97&#93;</a></sup> A second meta-analysis suggested that treatment with antipsychotics was associated with increased grey matter loss.<sup id="cite_ref-98" class="reference"><a href="#cite_note-98">&#91;98&#93;</a></sup> Animal studies found that monkeys exposed to both first- and second-generation antipsychotics experience significant reduction in brain volume, resulting in an 8-11% reduction in brain volume over a 17–27 month period.<sup id="cite_ref-Nature_2005_99-0" class="reference"><a href="#cite_note-Nature_2005-99">&#91;99&#93;</a></sup>
</p><p>Subtle, long-lasting forms of <a href="/wiki/Akathisia" title="Akathisia">akathisia</a> are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia.<sup id="cite_ref-pmid14609248_100-0" class="reference"><a href="#cite_note-pmid14609248-100">&#91;100&#93;</a></sup>
</p><p>Adverse effect on <a href="/wiki/Cognitive_dysfunction" class="mw-redirect" title="Cognitive dysfunction">cognitive function</a><sup id="cite_ref-101" class="reference"><a href="#cite_note-101">&#91;101&#93;</a></sup><sup id="cite_ref-102" class="reference"><a href="#cite_note-102">&#91;102&#93;</a></sup><sup id="cite_ref-103" class="reference"><a href="#cite_note-103">&#91;103&#93;</a></sup> and increased risk of death in people with <a href="/wiki/Dementia" title="Dementia">dementia</a> along with worsening of symptoms has been describe in the literature.<sup id="cite_ref-104" class="reference"><a href="#cite_note-104">&#91;104&#93;</a></sup><sup id="cite_ref-105" class="reference"><a href="#cite_note-105">&#91;105&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Discontinuation">Discontinuation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=15" title="Edit section: Discontinuation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">See also: <a href="/wiki/Drug_withdrawal#Prescription_medicine" title="Drug withdrawal">Drug withdrawal §&#160;Prescription medicine</a></div>
<p>The <i><a href="/wiki/British_National_Formulary" title="British National Formulary">British National Formulary</a></i> recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.<sup id="cite_ref-Group_2009_192_106-0" class="reference"><a href="#cite_note-Group_2009_192-106">&#91;106&#93;</a></sup> Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.<sup id="cite_ref-Had2004_107-0" class="reference"><a href="#cite_note-Had2004-107">&#91;107&#93;</a></sup> Other symptoms may include restlessness, increased sweating, and trouble sleeping.<sup id="cite_ref-Had2004_107-1" class="reference"><a href="#cite_note-Had2004-107">&#91;107&#93;</a></sup> Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.<sup id="cite_ref-Had2004_107-2" class="reference"><a href="#cite_note-Had2004-107">&#91;107&#93;</a></sup> Symptoms generally resolve after a short period of time.<sup id="cite_ref-Had2004_107-3" class="reference"><a href="#cite_note-Had2004-107">&#91;107&#93;</a></sup>
</p><p>There is tentative evidence that discontinuation of antipsychotics can result in psychosis.<sup id="cite_ref-ReferenceB_108-0" class="reference"><a href="#cite_note-ReferenceB-108">&#91;108&#93;</a></sup> It may also result in recurrence of the condition that is being treated.<sup id="cite_ref-109" class="reference"><a href="#cite_note-109">&#91;109&#93;</a></sup> Rarely tardive dyskinesia can occur when the medication is stopped.<sup id="cite_ref-Had2004_107-4" class="reference"><a href="#cite_note-Had2004-107">&#91;107&#93;</a></sup>
</p><p>Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as <a href="/wiki/Dopamine_supersensitivity_psychosis" title="Dopamine supersensitivity psychosis">supersensitivity psychosis</a>, not to be equated with tardive dyskinesia.<sup id="cite_ref-ReferenceB_108-1" class="reference"><a href="#cite_note-ReferenceB-108">&#91;108&#93;</a></sup><sup id="cite_ref-Nakata_110-0" class="reference"><a href="#cite_note-Nakata-110">&#91;110&#93;</a></sup>
</p><p><a href="/wiki/Tardive_dyskinesia" title="Tardive dyskinesia">Tardive dyskinesia</a> may abate during withdrawal from the antipsychotic agent, or it may persist.<sup id="cite_ref-Glazer-2000_111-0" class="reference"><a href="#cite_note-Glazer-2000-111">&#91;111&#93;</a></sup>
</p><p>Withdrawal effects may also occur when switching a person from one antipsychotic to another, (it is presumed due to variations of potency and receptor activity). Such withdrawal effects can include <a href="/wiki/Cholinergic" title="Cholinergic">cholinergic</a> rebound, an activation syndrome, and motor syndromes including <a href="/wiki/Dyskinesia" title="Dyskinesia">dyskinesias</a>. These adverse effects are more likely during rapid changes between antipsychotic agents, so making a gradual change between antipsychotics minimises these withdrawal effects.<sup id="cite_ref-Lambert-2007_112-0" class="reference"><a href="#cite_note-Lambert-2007-112">&#91;112&#93;</a></sup> The <i>British National Formulary</i> recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse.<sup id="cite_ref-113" class="reference"><a href="#cite_note-113">&#91;113&#93;</a></sup> The process of cross-titration involves gradually increasing the dose of the new medication while gradually decreasing the dose of the old medication.
</p><p>City and Hackney <a href="/wiki/Clinical_Commissioning_Group" class="mw-redirect" title="Clinical Commissioning Group">Clinical Commissioning Group</a> found more than 1,000 patients in their area in July 2019 who had not had regular medication reviews or health checks because they were not registered as having serious mental illness.  On average they had been taking these drugs for six years.   If this is typical of practice in England more than 100,000 patients are probably in the same position.<sup id="cite_ref-114" class="reference"><a href="#cite_note-114">&#91;114&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="List_of_agents">List of agents</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=16" title="Edit section: List of agents">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Chlorpromazine.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/Chlorpromazine.svg/220px-Chlorpromazine.svg.png" decoding="async" width="220" height="217" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/Chlorpromazine.svg/330px-Chlorpromazine.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/47/Chlorpromazine.svg/440px-Chlorpromazine.svg.png 2x" data-file-width="512" data-file-height="504" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Chlorpromazine.svg" class="internal" title="Enlarge"></a></div>Chlorpromazine</div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Haloperidol.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/7/71/Haloperidol.svg/220px-Haloperidol.svg.png" decoding="async" width="220" height="142" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/7/71/Haloperidol.svg/330px-Haloperidol.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/71/Haloperidol.svg/440px-Haloperidol.svg.png 2x" data-file-width="512" data-file-height="330" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Haloperidol.svg" class="internal" title="Enlarge"></a></div>Haloperidol</div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Quetiapine.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Quetiapine.svg/220px-Quetiapine.svg.png" decoding="async" width="220" height="160" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Quetiapine.svg/330px-Quetiapine.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Quetiapine.svg/440px-Quetiapine.svg.png 2x" data-file-width="512" data-file-height="372" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Quetiapine.svg" class="internal" title="Enlarge"></a></div>Quetiapine</div></div></div>
<p>Clinically used antipsychotic medications are listed below by drug group. Trade names appear in parentheses. A 2013 review has stated that the division of antipsychotics into first and second generation is perhaps not accurate.<sup id="cite_ref-Leucht_2013_29-5" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>
</p><p><u>Notes:</u>
</p><p><i>† indicates drugs that are no longer (or were never) marketed in English-speaking countries. </i>
</p><p><i>‡ denotes drugs that are no longer (or were never to begin with) marketed in the United States. Some antipsychotics are not firmly placed in either first-generation or second-generation classes.</i>
</p><p><i># denotes drugs that have been withdrawn worldwide.</i>
</p>
<h3><span id="First-generation_.28typical.29"></span><span class="mw-headline" id="First-generation_(typical)">First-generation (typical)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=17" title="Edit section: First-generation (typical)">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical antipsychotic</a></div>
<h4><span class="mw-headline" id="Butyrophenones">Butyrophenones</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=18" title="Edit section: Butyrophenones">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Butyrophenones" class="mw-redirect" title="Butyrophenones">Butyrophenones</a></div>
<ul><li><a href="/wiki/Benperidol" title="Benperidol">Benperidol</a><sup>‡</sup></li>
<li><a href="/wiki/Bromperidol" title="Bromperidol">Bromperidol</a><sup>†</sup></li>
<li><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a><sup>‡</sup></li>
<li><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a></li>
<li><a href="/wiki/Moperone" title="Moperone">Moperone</a> (<i>discontinued</i>)<sup>†</sup></li>
<li><a href="/wiki/Pipamperone" title="Pipamperone">Pipamperone</a> (<i>discontinued</i>)<sup>†</sup></li>
<li><a href="/wiki/Timiperone" title="Timiperone">Timiperone</a> <sup>†</sup></li></ul>
<h4><span class="mw-headline" id="Diphenylbutylpiperidines">Diphenylbutylpiperidines</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=19" title="Edit section: Diphenylbutylpiperidines">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Fluspirilene" title="Fluspirilene">Fluspirilene</a> ‡</li>
<li><a href="/wiki/Penfluridol" title="Penfluridol">Penfluridol</a> ‡</li>
<li><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></li></ul>
<h4><span class="mw-headline" id="Phenothiazines">Phenothiazines</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=20" title="Edit section: Phenothiazines">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Phenothiazines" class="mw-redirect" title="Phenothiazines">Phenothiazines</a></div>
<ul><li><a href="/wiki/Acepromazine" title="Acepromazine">Acepromazine</a> <sup>†</sup> — although it is mostly used in veterinary medicine.</li>
<li><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="/wiki/Cyamemazine" title="Cyamemazine">Cyamemazine</a> <sup>†</sup></li>
<li><a href="/wiki/Dixyrazine" title="Dixyrazine">Dixyrazine</a> <sup>†</sup></li>
<li><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></li>
<li><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine</a><sup>‡</sup></li>
<li><a href="/wiki/Mesoridazine" title="Mesoridazine">Mesoridazine</a> (<i>discontinued</i>)<sup>†</sup></li>
<li><a href="/wiki/Perazine" title="Perazine">Perazine</a></li>
<li><a href="/wiki/Pericyazine" class="mw-redirect" title="Pericyazine">Pericyazine</a><sup>‡</sup></li>
<li><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a></li>
<li><a href="/wiki/Pipotiazine" title="Pipotiazine">Pipotiazine</a> <sup>‡</sup></li>
<li><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></li>
<li><a href="/wiki/Promazine" title="Promazine">Promazine</a> (<i>discontinued</i>)</li>
<li><a href="/wiki/Promethazine" title="Promethazine">Promethazine</a></li>
<li><a href="/wiki/Prothipendyl" title="Prothipendyl">Prothipendyl</a> <sup>†</sup></li>
<li><a href="/wiki/Thioproperazine" title="Thioproperazine">Thioproperazine</a><sup>‡</sup> (only English-speaking country it is available in is Canada)</li>
<li><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a> (<i>discontinued</i>)</li>
<li><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></li>
<li><a href="/wiki/Triflupromazine" title="Triflupromazine">Triflupromazine</a>  (<i>discontinued</i>)<sup>†</sup></li></ul>
<h4><span class="mw-headline" id="Thioxanthenes">Thioxanthenes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=21" title="Edit section: Thioxanthenes">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Thioxanthenes" class="mw-redirect" title="Thioxanthenes">Thioxanthenes</a></div>
<ul><li><a href="/wiki/Chlorprothixene" title="Chlorprothixene">Chlorprothixene</a> <sup>†</sup></li>
<li><a href="/wiki/Clopenthixol" title="Clopenthixol">Clopenthixol</a></li>
<li><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol</a> <sup>‡</sup></li>
<li><a href="/wiki/Thiothixene" class="mw-redirect" title="Thiothixene">Thiothixene</a></li>
<li><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a> <sup>‡</sup></li></ul>
<h3><span id="Disputed.2Funknown"></span><span class="mw-headline" id="Disputed/unknown">Disputed/unknown</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=22" title="Edit section: Disputed/unknown">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>This category is for drugs that have been called both first and second-generation, depending on the literature being used.
</p>
<h4><span class="mw-headline" id="Benzamides">Benzamides</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=23" title="Edit section: Benzamides">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a> <sup>‡</sup></li>
<li><a href="/wiki/Sultopride" title="Sultopride">Sultopride</a> <sup>†</sup></li>
<li><a href="/wiki/Veralipride" title="Veralipride">Veralipride</a> <sup>†</sup></li></ul>
<h4><span class="mw-headline" id="Tricyclics">Tricyclics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=24" title="Edit section: Tricyclics">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Carpipramine" title="Carpipramine">Carpipramine</a> <sup>†</sup></li>
<li><a href="/wiki/Clocapramine" title="Clocapramine">Clocapramine</a> <sup>†</sup></li>
<li><a href="/wiki/Clorotepine" title="Clorotepine">Clorotepine</a> <sup>†</sup></li>
<li><a href="/wiki/Clotiapine" title="Clotiapine">Clotiapine</a> <sup>‡</sup></li>
<li><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></li>
<li><a href="/wiki/Mosapramine" title="Mosapramine">Mosapramine</a> <sup>†</sup></li></ul>
<h4><span class="mw-headline" id="Others">Others</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=25" title="Edit section: Others">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Molindone" title="Molindone">Molindone</a> <sup>#</sup></li></ul>
<h3><span id="Second-generation_.28atypical.29"></span><span class="mw-headline" id="Second-generation_(atypical)">Second-generation (atypical)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=26" title="Edit section: Second-generation (atypical)">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1033289096"/><div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical antipsychotic</a></div>
<h4><span class="mw-headline" id="Benzamides_2">Benzamides</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=27" title="Edit section: Benzamides">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a> <sup>‡</sup> – Selective dopamine antagonist. Higher doses (greater than 400&#160;mg) act upon post-synaptic dopamine receptors resulting in a reduction in the positive symptoms of schizophrenia, such as psychosis. Lower doses, however, act upon dopamine autoreceptors, resulting in increased dopamine transmission, improving the negative symptoms of schizophrenia. Lower doses of amisulpride have also been shown to have <a href="/wiki/Antidepressant" title="Antidepressant">antidepressant</a> and <a href="/wiki/Anxiolytic" title="Anxiolytic">anxiolytic</a> effects in non-schizophrenic patients, leading to its use in <a href="/wiki/Dysthymia" title="Dysthymia">dysthymia</a> and <a href="/wiki/Social_anxiety_disorder" title="Social anxiety disorder">social phobias</a>.</li>
<li><a href="/wiki/Nemonapride" title="Nemonapride">Nemonapride</a> <sup>†</sup> – Used in Japan.</li>
<li><a href="/wiki/Remoxipride" title="Remoxipride">Remoxipride</a> <sup>#</sup> – Has a risk of causing <a href="/wiki/Aplastic_anaemia" class="mw-redirect" title="Aplastic anaemia">aplastic anaemia</a> and, hence, has been withdrawn from the market worldwide. It has also been found to possess relatively low (virtually absent) potential to induce <a href="/wiki/Hyperprolactinaemia" title="Hyperprolactinaemia">hyperprolactinaemia</a> and <a href="/wiki/Extrapyramidal_symptoms" title="Extrapyramidal symptoms">extrapyramidal symptoms</a>, likely attributable to its comparatively weak binding to (and, hence, rapid dissociation from) the D<sub>2</sub> receptor.<sup id="cite_ref-atyp_115-0" class="reference"><a href="#cite_note-atyp-115">&#91;115&#93;</a></sup></li>
<li><a href="/wiki/Sultopride" title="Sultopride">Sultopride</a> – An atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.</li></ul>
<h4><span id="Benzisoxazoles.2Fbenzisothiazoles"></span><span class="mw-headline" id="Benzisoxazoles/benzisothiazoles">Benzisoxazoles/benzisothiazoles</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=28" title="Edit section: Benzisoxazoles/benzisothiazoles">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a> – Approved by the US FDA in 2009, it is fairly well tolerated, although <a href="/wiki/Hypotension" title="Hypotension">hypotension</a>, <a href="/wiki/Dizziness" title="Dizziness">dizziness</a>, and <a href="/wiki/Somnolence" title="Somnolence">somnolence</a> were very common side effects. Has not received regulatory approval in other countries, however.</li>
<li><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a> – Approved by the US FDA for schizophrenia and bipolar depression, and for use as schizophrenia treatment in Canada.</li>
<li><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a> – Primary, active metabolite of risperidone that was approved in 2006.</li>
<li><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a> <sup>†</sup> – Has a higher incidence of extrapyramidal side effects than other atypical antipsychotics.<sup id="cite_ref-CNS_Drugs_116-0" class="reference"><a href="#cite_note-CNS_Drugs-116">&#91;116&#93;</a></sup></li>
<li><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a> – Divided dosing is recommended until initial titration is completed, at which time the drug can be administered once daily. Used off-label to treat <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a> and <a href="/wiki/Anxiety_disorder" title="Anxiety disorder">anxiety disorder</a>.</li>
<li><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a> – Approved in 2004<sup id="cite_ref-117" class="reference"><a href="#cite_note-117">&#91;117&#93;</a></sup> to treat bipolar disorder. Side-effects include a prolonged <a href="/wiki/QT_interval" title="QT interval">QT interval</a> in the heart, which can be dangerous for patients with <a href="/wiki/Heart_disease" class="mw-redirect" title="Heart disease">heart disease</a> or those taking other drugs that prolong the QT interval.</li></ul>
<h4><span class="mw-headline" id="Butyrophenones_2">Butyrophenones</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=29" title="Edit section: Butyrophenones">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Melperone" title="Melperone">Melperone</a> <sup>†</sup> – Only used in a few European countries. No English-speaking country has licensed it to date.</li>
<li><a href="/wiki/Lumateperone" title="Lumateperone">Lumateperone</a></li></ul>
<h4><span id="Phenylpiperazines.2Fquinolinones"></span><span class="mw-headline" id="Phenylpiperazines/quinolinones">Phenylpiperazines/quinolinones</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=30" title="Edit section: Phenylpiperazines/quinolinones">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a> – Partial agonist at the D<sub>2</sub> receptor unlike almost all other clinically-utilized antipsychotics.<sup id="cite_ref-118" class="reference"><a href="#cite_note-118">&#91;118&#93;</a></sup></li>
<li><a href="/wiki/Aripiprazole_lauroxil" title="Aripiprazole lauroxil">Aripiprazole lauroxil</a> – Long-acting version of aripiprazole for injection.</li>
<li><a href="/wiki/Brexpiprazole" title="Brexpiprazole">Brexpiprazole</a> – Partial agonist of the D<sub>2</sub> receptor. Successor of aripiprazole.</li>
<li><a href="/wiki/Cariprazine" title="Cariprazine">Cariprazine</a> – A D<sub>3</sub>-preferring D<sub>2</sub>/D<sub>3</sub> partial agonist.</li></ul>
<h4><span class="mw-headline" id="Tricyclics_2">Tricyclics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=31" title="Edit section: Tricyclics">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Asenapine" title="Asenapine">Asenapine</a> – Used for the treatment of schizophrenia and acute mania associated with bipolar disorder.</li>
<li><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a> – Requires routine laboratory monitoring of <a href="/wiki/Complete_blood_count" title="Complete blood count">complete blood counts</a> every one to four weeks due to the risk of <a href="/wiki/Agranulocytosis" title="Agranulocytosis">agranulocytosis</a>. It has unparalleled efficacy in the treatment of treatment-resistant schizophrenia.</li>
<li><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a> – Used to treat psychotic disorders including schizophrenia, acute <a href="/wiki/Mania" title="Mania">manic</a> episodes, and maintenance of <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a>. Used as an adjunct to antidepressant therapy, either alone or in combination with <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> as <a href="/wiki/Olanzapine/fluoxetine" title="Olanzapine/fluoxetine">Symbyax</a>.</li>
<li><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a> – Used primarily to treat bipolar disorder and schizophrenia. Also used and licensed in a few countries (including Australia, the United Kingdom and the United States) as an adjunct to antidepressant therapy in patients with <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a>. It's the only antipsychotic that's demonstrated efficacy as a monotherapy for the treatment of <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a>. It indirectly serves as a <a href="/wiki/Norepinephrine_reuptake_inhibitor" title="Norepinephrine reuptake inhibitor">norepinephrine reuptake inhibitor</a> by means of its active metabolite, norquetiapine.</li>
<li><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a> – An atypical antipsychotic indicated for acute and chronic schizophrenia. It is still used in Japan and was once used in Germany but it was discontinued.<sup>†</sup></li></ul>
<h4><span class="mw-headline" id="Others_2">Others</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=32" title="Edit section: Others">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul><li><a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a> – Approved by the PMDA in 2008. Used in Japan and South Korea.</li>
<li><a href="/wiki/Pimavanserin" title="Pimavanserin">Pimavanserin</a> – A selective 5-HT<sub>2A</sub> receptor antagonist approved for the treatment of <a href="/wiki/Parkinson%27s_disease" title="Parkinson&#39;s disease">Parkinson's disease</a> psychosis in 2016.</li>
<li><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a> <sup>‡</sup> – Developed by the Danish pharmaceutical company <a href="/wiki/H._Lundbeck" class="mw-redirect" title="H. Lundbeck">H. Lundbeck</a>. Like the other atypical antipsychotics, it is believed to have <a href="/wiki/Receptor_antagonist" title="Receptor antagonist">antagonist</a> activity at dopamine and serotonin receptors in the brain.</li></ul>
<h2><span class="mw-headline" id="Mechanism_of_action">Mechanism of action</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=33" title="Edit section: Mechanism of action">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Antipsychotic drugs such as <a href="/wiki/Haloperidol" title="Haloperidol">haloperidol</a> and <a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a> tend to block <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">D<sub>2</sub> receptors</a> in the <a href="/wiki/Dopaminergic_pathways" title="Dopaminergic pathways">dopaminergic pathways</a> of the <a href="/wiki/Human_brain" title="Human brain">brain</a>. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the <a href="/wiki/Mesolimbic_pathway" title="Mesolimbic pathway">mesolimbic pathway</a> has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder.<sup id="cite_ref-119" class="reference"><a href="#cite_note-119">&#91;119&#93;</a></sup><sup id="cite_ref-120" class="reference"><a href="#cite_note-120">&#91;120&#93;</a></sup>
</p><p>In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical neuroleptics) also antagonize <a href="/wiki/5-HT2A" class="mw-redirect" title="5-HT2A">5-HT<sub>2A</sub> receptors</a>. Different <a href="/wiki/Allele" title="Allele">alleles</a> of the 5-HT<sub>2A</sub> receptor have been associated with schizophrenia and other psychoses, including depression.<sup id="cite_ref-McDonald_41–63_121-0" class="reference"><a href="#cite_note-McDonald_41–63-121">&#91;121&#93;</a></sup><sup id="cite_ref-122" class="reference"><a href="#cite_note-122">&#91;122&#93;</a></sup> Higher concentrations of 5-HT<sub>2A</sub> receptors in cortical and subcortical areas, in particular in the right <a href="/wiki/Caudate_nucleus" title="Caudate nucleus">caudate nucleus</a> have been historically recorded.<sup id="cite_ref-McDonald_41–63_121-1" class="reference"><a href="#cite_note-McDonald_41–63-121">&#91;121&#93;</a></sup>
</p><p>Typical antipsychotics are not particularly selective and also block dopamine receptors in the <a href="/wiki/Mesocortical_pathway" title="Mesocortical pathway">mesocortical pathway</a>, <a href="/wiki/Tuberoinfundibular_pathway" title="Tuberoinfundibular pathway">tuberoinfundibular pathway</a>, and the <a href="/wiki/Nigrostriatal_pathway" title="Nigrostriatal pathway">nigrostriatal pathway</a>. Blocking D<sub>2</sub> receptors in these other pathways is thought to produce some unwanted <a href="/wiki/Adverse_effect_(medicine)" class="mw-redirect" title="Adverse effect (medicine)">side effects</a> that the typical antipsychotics can produce (see above). They were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug. High-potency antipsychotics such as <a href="/wiki/Haloperidol" title="Haloperidol">haloperidol</a>, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as <a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a> and <a href="/wiki/Thioridazine" title="Thioridazine">thioridazine</a>, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (June 2021)">citation needed</span></a></i>&#93;</sup>
</p><p><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical antipsychotic</a> drugs have a similar blocking effect on D<sub>2</sub> receptors; however, most also act on serotonin receptors, especially <a href="/wiki/5-HT2A_receptor" title="5-HT2A receptor">5-HT<sub>2A</sub></a> and <a href="/wiki/5-HT2C_receptor" title="5-HT2C receptor">5-HT<sub>2C</sub></a> receptors. Both clozapine and quetiapine appear to bind just long enough to elicit antipsychotic effects but not long enough to induce extrapyramidal side effects and prolactin hypersecretion.<sup id="cite_ref-Atypicality_123-0" class="reference"><a href="#cite_note-Atypicality-123">&#91;123&#93;</a></sup> 5-HT<sub>2A</sub> antagonism increases dopaminergic activity in the <a href="/wiki/Nigrostriatal_pathway" title="Nigrostriatal pathway">nigrostriatal pathway</a>, leading to a lowered extrapyramidal side effect liability among the atypical antipsychotics.<sup id="cite_ref-Atypicality_123-1" class="reference"><a href="#cite_note-Atypicality-123">&#91;123&#93;</a></sup><sup id="cite_ref-124" class="reference"><a href="#cite_note-124">&#91;124&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Comparison_of_medications">Comparison of medications</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=34" title="Edit section: Comparison of medications">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="wikitable collapsible collapsed" style="font-size:small; width:100%;">
<tbody><tr>
<th colspan="7">Overview
</th></tr>
<tr>
<td>
<table class="wikitable sortable" style="font-size:small; width:100%;">

<tbody><tr>
<th>Generic name</th>
<th>Class</th>
<th>Type</th>
<th>Brand name(s)</th>
<th>Launch</th>
<th>Developer/Originator(s)</th>
<th>Refs
</th></tr>
<tr>
<td><a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Solian</td>
<td>1986</td>
<td>Sanofi-Synthélabo</td>
<td><sup id="cite_ref-Sanchez2012_125-0" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-IUPACFischer2006_126-0" class="reference"><a href="#cite_note-IUPACFischer2006-126">&#91;126&#93;</a></sup><sup id="cite_ref-Lidow2000_127-0" class="reference"><a href="#cite_note-Lidow2000-127">&#91;127&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a></td>
<td>Phenylpiperazine/Quinolinone</td>
<td>Atypical</td>
<td>Abilify</td>
<td>2002</td>
<td>Otsuka/Bristol-Myers Squibb</td>
<td><sup id="cite_ref-Sanchez2012_125-1" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-0" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Aripiprazole_lauroxil" title="Aripiprazole lauroxil">Aripiprazole lauroxil</a></td>
<td>Phenylpiperazine/Quinolinone</td>
<td>Atypical</td>
<td>Aristada</td>
<td>2015</td>
<td>Alkermes</td>
<td><sup id="cite_ref-AdisInsight-Aripiprazole-Lauroxil_129-0" class="reference"><a href="#cite_note-AdisInsight-Aripiprazole-Lauroxil-129">&#91;129&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></td>
<td>Tricyclic/Dibenzoxapinopyrrole</td>
<td>Atypical</td>
<td>Saphris/Sycrest</td>
<td>2009</td>
<td>Organon/Merck</td>
<td><sup id="cite_ref-Sanchez2012_125-2" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Asenapine_130-0" class="reference"><a href="#cite_note-AdisInsight-Asenapine-130">&#91;130&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Benperidol" title="Benperidol">Benperidol</a></td>
<td>Butyrophenone</td>
<td>Typical</td>
<td>Anquil</td>
<td>1966</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-3" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a></td>
<td>Pyridinylpiperazine</td>
<td>Atypical</td>
<td>Lonasen</td>
<td>2008</td>
<td>Sumitomo Dainippon/Mitsubishi Tanabe</td>
<td><sup id="cite_ref-Sanchez2012_125-4" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Blonanserin_131-0" class="reference"><a href="#cite_note-AdisInsight-Blonanserin-131">&#91;131&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Brexpiprazole" title="Brexpiprazole">Brexpiprazole</a></td>
<td>Phenylpiperazine/Quinolinone</td>
<td>Atypical</td>
<td>Rexulti</td>
<td>2015</td>
<td>Otsuka/Lundbeck</td>
<td><sup id="cite_ref-AdisInsight-Brexpiprazole_132-0" class="reference"><a href="#cite_note-AdisInsight-Brexpiprazole-132">&#91;132&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Bromperidol" title="Bromperidol">Bromperidol</a></td>
<td>Butyrophenone</td>
<td>Typical</td>
<td>Impromem</td>
<td>1981</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-5" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-1" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Cariprazine" title="Cariprazine">Cariprazine</a></td>
<td>Phenylpiperazine</td>
<td>Atypical</td>
<td>Vraylar/Reagila</td>
<td>2015</td>
<td>Gedeon Richter/Actavis</td>
<td><sup id="cite_ref-AdisInsight-Cariprazine_133-0" class="reference"><a href="#cite_note-AdisInsight-Cariprazine-133">&#91;133&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Carpipramine" title="Carpipramine">Carpipramine</a></td>
<td>Tricyclic/Dibenzazepine</td>
<td>Disputed</td>
<td>Defecton/Prazinil</td>
<td>1977</td>
<td>Pierre Fabre</td>
<td><sup id="cite_ref-Sanchez2012_125-6" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Thorazine</td>
<td>1952</td>
<td>Rhône-Poulenc/GlaxoSmithKline</td>
<td><sup id="cite_ref-Sanchez2012_125-7" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-2" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Chlorprothixene" title="Chlorprothixene">Chlorprothixene</a></td>
<td>Tricyclic/Thioxanthene</td>
<td>Disputed</td>
<td>Truxal</td>
<td>1959</td>
<td>Roche</td>
<td><sup id="cite_ref-Sanchez2012_125-8" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-3" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup><sup id="cite_ref-Csernansky2012_134-0" class="reference"><a href="#cite_note-Csernansky2012-134">&#91;134&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clocapramine" title="Clocapramine">Clocapramine</a></td>
<td>Tricyclic/Dibenzazepine</td>
<td>Disputed</td>
<td>Clofekton/Padrasen</td>
<td>1974</td>
<td>Yoshitomi</td>
<td><sup id="cite_ref-Publishing2013_135-0" class="reference"><a href="#cite_note-Publishing2013-135">&#91;135&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clopenthixol" title="Clopenthixol">Clopenthixol</a></td>
<td>Tricyclic/Thioxanthene</td>
<td>Typical</td>
<td>Sordinol/Ciatyl</td>
<td>1961</td>
<td>Lundbeck</td>
<td><sup id="cite_ref-Publishing2013-Clopenthixol_136-0" class="reference"><a href="#cite_note-Publishing2013-Clopenthixol-136">&#91;136&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clorotepine" title="Clorotepine">Clorotepine</a></td>
<td>Tricyclic/Dibenzothiepin</td>
<td>Disputed</td>
<td>Clotepin</td>
<td>1971</td>
<td>Spofa</td>
<td><sup id="cite_ref-Protiva2010_137-0" class="reference"><a href="#cite_note-Protiva2010-137">&#91;137&#93;</a></sup><sup id="cite_ref-pmid5576292_138-0" class="reference"><a href="#cite_note-pmid5576292-138">&#91;138&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clotiapine" title="Clotiapine">Clotiapine</a></td>
<td>Tricyclic/Dibenzothiazepine</td>
<td>Disputed</td>
<td>Etumine</td>
<td>1966</td>
<td>Sandoz/Wander</td>
<td><sup id="cite_ref-GaleResearch1991_139-0" class="reference"><a href="#cite_note-GaleResearch1991-139">&#91;139&#93;</a></sup><sup id="cite_ref-pmid16126373_140-0" class="reference"><a href="#cite_note-pmid16126373-140">&#91;140&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a></td>
<td>Tricyclic/Dibenzodiazepine</td>
<td>Atypical</td>
<td>Clozaril</td>
<td>1972</td>
<td>Sandoz-Novartis</td>
<td><sup id="cite_ref-Sanchez2012_125-9" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-4" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Cyamemazine" title="Cyamemazine">Cyamemazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Disputed</td>
<td>Tercian</td>
<td>1972</td>
<td>Aventis</td>
<td><sup id="cite_ref-Sanchez2012_125-10" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid15492772_141-0" class="reference"><a href="#cite_note-pmid15492772-141">&#91;141&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a></td>
<td>Butyrophenone</td>
<td>Typical</td>
<td>Dridol/Droleptan/Inapsine</td>
<td>1963</td>
<td>Janssen-Cilag</td>
<td><sup id="cite_ref-Sanchez2012_125-11" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-LamberthDinges2012_142-0" class="reference"><a href="#cite_note-LamberthDinges2012-142">&#91;142&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol</a></td>
<td>Tricyclic/Thioxanthene</td>
<td>Typical</td>
<td>Fluanxol</td>
<td>1965</td>
<td>Lundbeck</td>
<td><sup id="cite_ref-Sanchez2012_125-12" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Pedersen1996_143-0" class="reference"><a href="#cite_note-Pedersen1996-143">&#91;143&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Prolixin</td>
<td>1959</td>
<td>Bristol-Myers Squibb</td>
<td><sup id="cite_ref-Sanchez2012_125-13" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-5" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Fluspirilene" title="Fluspirilene">Fluspirilene</a></td>
<td>Diphenylbutylpiperidine</td>
<td>Typical</td>
<td>Imap</td>
<td>1970</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-14" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a></td>
<td>Butyrophenone</td>
<td>Typical</td>
<td>Haldol</td>
<td>1959</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-15" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-6" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></td>
<td>Benzisoxazole</td>
<td>Atypical</td>
<td>Fanapt</td>
<td>2010</td>
<td>Novartis</td>
<td><sup id="cite_ref-Sanchez2012_125-16" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Iloperidone_144-0" class="reference"><a href="#cite_note-AdisInsight-Iloperidone-144">&#91;144&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Disputed</td>
<td>Nozinan/Levoprome</td>
<td>1957</td>
<td>Rhône-Poulenc</td>
<td><sup id="cite_ref-Sanchez2012_125-17" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Csernansky2012_134-1" class="reference"><a href="#cite_note-Csernansky2012-134">&#91;134&#93;</a></sup><sup id="cite_ref-Shorter2009_145-0" class="reference"><a href="#cite_note-Shorter2009-145">&#91;145&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Levosulpiride" title="Levosulpiride">Levosulpiride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Levopraid</td>
<td>1987</td>
<td>Abbott</td>
<td><sup id="cite_ref-Sanchez2012_125-18" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></td>
<td>Tricyclic/Dibenzoxazepine</td>
<td>Disputed</td>
<td>Loxitane/Loxapac</td>
<td>1975</td>
<td>Wyeth</td>
<td><sup id="cite_ref-Sanchez2012_125-19" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-7" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup><sup id="cite_ref-pmid10340686_146-0" class="reference"><a href="#cite_note-pmid10340686-146">&#91;146&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a></td>
<td>Benzisothiazole</td>
<td>Atypical</td>
<td>Latuda</td>
<td>2010</td>
<td>Sumitomo Dainippon/Sunovion</td>
<td><sup id="cite_ref-AdisInsight-Lurasidone_147-0" class="reference"><a href="#cite_note-AdisInsight-Lurasidone-147">&#91;147&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Melperone" title="Melperone">Melperone</a></td>
<td>Butyrophenone</td>
<td>Disputed</td>
<td>Buronil</td>
<td>1967</td>
<td>Lundbeck</td>
<td><sup id="cite_ref-pmid16082416_128-8" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Mesoridazine" title="Mesoridazine">Mesoridazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Serentil</td>
<td>1967</td>
<td>Novartis-Boehringer</td>
<td><sup id="cite_ref-pmid16082416_128-9" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Molindone" title="Molindone">Molindone</a></td>
<td>Dihydroindolone</td>
<td>Disputed</td>
<td>Moban</td>
<td>1975</td>
<td>Abbott</td>
<td><sup id="cite_ref-pmid16082416_128-10" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Mosapramine" title="Mosapramine">Mosapramine</a></td>
<td>Tricyclic/Dibenzazepine</td>
<td>Disputed</td>
<td>Cremin</td>
<td>1991</td>
<td>Mitsubishi Pharma</td>
<td><sup id="cite_ref-Sanchez2012_125-20" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Nemonapride" title="Nemonapride">Nemonapride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Emilace/Emirace</td>
<td>1991</td>
<td>Yamanouchi</td>
<td><sup id="cite_ref-Sanchez2012_125-21" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Nemonapride_148-0" class="reference"><a href="#cite_note-AdisInsight-Nemonapride-148">&#91;148&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a></td>
<td>Tricyclic/Thienobenzodiazepine</td>
<td>Atypical</td>
<td>Zyprexa</td>
<td>1996</td>
<td>Lilly</td>
<td><sup id="cite_ref-Sanchez2012_125-22" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-11" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a></td>
<td>Benzisoxazole</td>
<td>Atypical</td>
<td>Invega</td>
<td>2007</td>
<td>Janssen-Cilag/Johnson &amp; Johnson</td>
<td><sup id="cite_ref-Sanchez2012_125-23" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Paliperidone_149-0" class="reference"><a href="#cite_note-AdisInsight-Paliperidone-149">&#91;149&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Paliperidone_palmitate" title="Paliperidone palmitate">Paliperidone palmitate</a></td>
<td>Benzisoxazole</td>
<td>Atypical</td>
<td>Invega Sustenna/Xeplion</td>
<td>2009</td>
<td>Janssen-Cilag/Johnson &amp; Johnson</td>
<td><sup id="cite_ref-AdisInsight-Paliperidone-Palmitate_150-0" class="reference"><a href="#cite_note-AdisInsight-Paliperidone-Palmitate-150">&#91;150&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Penfluridol" title="Penfluridol">Penfluridol</a></td>
<td>Diphenylbutylpiperidine</td>
<td>Typical</td>
<td>Semap</td>
<td>1973</td>
<td>Janssen</td>
<td><sup id="cite_ref-Vardanyan2017_151-0" class="reference"><a href="#cite_note-Vardanyan2017-151">&#91;151&#93;</a></sup><sup id="cite_ref-pmid4604881_152-0" class="reference"><a href="#cite_note-pmid4604881-152">&#91;152&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Perazine" title="Perazine">Perazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Taxilan</td>
<td>1958</td>
<td>Promonta</td>
<td><sup id="cite_ref-pmid24425538_153-0" class="reference"><a href="#cite_note-pmid24425538-153">&#91;153&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Periciazine" title="Periciazine">Periciazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Neuleptil/Neulactil</td>
<td>1964</td>
<td>Rhône-Poulenc</td>
<td><sup id="cite_ref-Sanchez2012_125-24" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid24825770_154-0" class="reference"><a href="#cite_note-pmid24825770-154">&#91;154&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a></td>
<td>Benzisothiazole</td>
<td>Atypical</td>
<td>Lullan</td>
<td>2001</td>
<td>Sumitomo Dainippon/Mitsubishi Tanabe</td>
<td><sup id="cite_ref-Sanchez2012_125-25" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-AdisInsight-Perospirone_155-0" class="reference"><a href="#cite_note-AdisInsight-Perospirone-155">&#91;155&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Trilafon</td>
<td>1957</td>
<td>Schering-Plough</td>
<td><sup id="cite_ref-Sanchez2012_125-26" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-12" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pimavanserin" title="Pimavanserin">Pimavanserin</a></td>
<td>Dibenzylpiperidinylurea</td>
<td>Atypical</td>
<td>Nuplazid</td>
<td>2016</td>
<td>ACADIA Pharmaceuticals</td>
<td><sup id="cite_ref-AdisInsight-Pimavanserin_156-0" class="reference"><a href="#cite_note-AdisInsight-Pimavanserin-156">&#91;156&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></td>
<td>Diphenylbutylpiperidine</td>
<td>Typical</td>
<td>Orap</td>
<td>1969</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-27" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-13" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pipamperone" title="Pipamperone">Pipamperone</a></td>
<td>Butyrophenone</td>
<td>Disputed</td>
<td>Dipiperon</td>
<td>1961</td>
<td>Janssen</td>
<td><sup id="cite_ref-GaleResearch1991_139-1" class="reference"><a href="#cite_note-GaleResearch1991-139">&#91;139&#93;</a></sup><sup id="cite_ref-Vardanyan2017_151-1" class="reference"><a href="#cite_note-Vardanyan2017-151">&#91;151&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pipotiazine" title="Pipotiazine">Pipotiazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Piportil</td>
<td>1973</td>
<td>Rhône-Poulenc/Aventis</td>
<td><sup id="cite_ref-Sanchez2012_125-28" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Publishing2013-Pipotiazine_157-0" class="reference"><a href="#cite_note-Publishing2013-Pipotiazine-157">&#91;157&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Compazine</td>
<td>1956</td>
<td>Rhône-Poulenc/GlaxoSmithKline</td>
<td><sup id="cite_ref-Sanchez2012_125-29" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-14" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup><sup id="cite_ref-Shorter2009_145-1" class="reference"><a href="#cite_note-Shorter2009-145">&#91;145&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Promazine" title="Promazine">Promazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Sparine</td>
<td>1956</td>
<td>Wyeth</td>
<td><sup id="cite_ref-Sanchez2012_125-30" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></td>
<td>Tricyclic/Dibenzothiazepine</td>
<td>Atypical</td>
<td>Seroquel</td>
<td>1997</td>
<td>AstraZeneca</td>
<td><sup id="cite_ref-Sanchez2012_125-31" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-15" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Remoxipride" title="Remoxipride">Remoxipride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Roxiam</td>
<td>1990</td>
<td>AstraZeneca</td>
<td><sup id="cite_ref-Sanchez2012_125-32" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Lidow2000_127-1" class="reference"><a href="#cite_note-Lidow2000-127">&#91;127&#93;</a></sup><sup id="cite_ref-pmid16082416_128-16" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></td>
<td>Benzisoxazole</td>
<td>Atypical</td>
<td>Risperdal</td>
<td>1993</td>
<td>Janssen</td>
<td><sup id="cite_ref-Sanchez2012_125-33" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-17" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a></td>
<td>Imidazolidinone</td>
<td>Atypical</td>
<td>Serdolect</td>
<td>1996</td>
<td>Lundbeck</td>
<td><sup id="cite_ref-Sanchez2012_125-34" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-18" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Spiperone" title="Spiperone">Spiperone</a></td>
<td>Butyrophenone</td>
<td>Typical</td>
<td>Spiropitan</td>
<td>1969</td>
<td>Eisai</td>
<td><sup id="cite_ref-Publishing2007-Spiperone_158-0" class="reference"><a href="#cite_note-Publishing2007-Spiperone-158">&#91;158&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Dogmatil</td>
<td>1968</td>
<td>Delagrange/Fujisawa</td>
<td><sup id="cite_ref-Sanchez2012_125-35" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Lidow2000_127-2" class="reference"><a href="#cite_note-Lidow2000-127">&#91;127&#93;</a></sup><sup id="cite_ref-pmid16082416_128-19" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Sultopride" title="Sultopride">Sultopride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Barnetil</td>
<td>1976</td>
<td>Delagrange/Sanofi-Synthélabo</td>
<td><sup id="cite_ref-Sanchez2012_125-36" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Publishing2013-Sultopride_159-0" class="reference"><a href="#cite_note-Publishing2013-Sultopride-159">&#91;159&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Melleril</td>
<td>1958</td>
<td>Novartis</td>
<td><sup id="cite_ref-Sanchez2012_125-37" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-20" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Tiapride" title="Tiapride">Tiapride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Tiapridal</td>
<td>1975</td>
<td>Sanofi-Synthélabo</td>
<td><sup id="cite_ref-Sanchez2012_125-38" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Tiotixene" title="Tiotixene">Tiotixene</a></td>
<td>Tricyclic/Thioxanthene</td>
<td>Typical</td>
<td>Navane</td>
<td>1967</td>
<td>Pfizer</td>
<td><sup id="cite_ref-Sanchez2012_125-39" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-21" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup><sup id="cite_ref-Publishing2013-Tiotixene_160-0" class="reference"><a href="#cite_note-Publishing2013-Tiotixene-160">&#91;160&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Stelazine</td>
<td>1958</td>
<td>GlaxoSmithKline</td>
<td><sup id="cite_ref-Sanchez2012_125-40" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-22" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Triflupromazine" title="Triflupromazine">Triflupromazine</a></td>
<td>Tricyclic/Phenothiazine</td>
<td>Typical</td>
<td>Vesprin</td>
<td>1957</td>
<td>Bristol-Myers Squibb</td>
<td><sup id="cite_ref-Sanchez2012_125-41" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Veralipride" title="Veralipride">Veralipride</a></td>
<td>Benzamide</td>
<td>Disputed</td>
<td>Agreal</td>
<td>1980</td>
<td>Sanofi-Synthélabo</td>
<td><sup id="cite_ref-Sanchez2012_125-42" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></td>
<td>Benzisothiazole</td>
<td>Atypical</td>
<td>Geodon</td>
<td>2000</td>
<td>Pfizer</td>
<td><sup id="cite_ref-Sanchez2012_125-43" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-23" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a></td>
<td>Tricyclic/Dibenzothiepin</td>
<td>Atypical</td>
<td>Zoleptil</td>
<td>1982</td>
<td>Fujisawa</td>
<td><sup id="cite_ref-Sanchez2012_125-44" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-pmid16082416_128-24" class="reference"><a href="#cite_note-pmid16082416-128">&#91;128&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></td>
<td>Tricyclic/Thioxanthene</td>
<td>Typical</td>
<td>Clopixol/Cisordinol</td>
<td>1978</td>
<td>Lundbeck</td>
<td><sup id="cite_ref-Sanchez2012_125-45" class="reference"><a href="#cite_note-Sanchez2012-125">&#91;125&#93;</a></sup><sup id="cite_ref-Publishing2013-Clopenthixol_136-1" class="reference"><a href="#cite_note-Publishing2013-Clopenthixol-136">&#91;136&#93;</a></sup><sup id="cite_ref-Pedersen1996_143-1" class="reference"><a href="#cite_note-Pedersen1996-143">&#91;143&#93;</a></sup>
</td></tr></tbody></table>
</td></tr></tbody></table>
<table class="wikitable collapsible collapsed" style="font-size:small; width:100%;">
<tbody><tr>
<th colspan="11">Tolerability
</th></tr>
<tr>
<th>Generic name<br /><sup id="cite_ref-Lancet2009_9-3" class="reference"><a href="#cite_note-Lancet2009-9">&#91;9&#93;</a></sup><sup id="cite_ref-Maudsley_11-5" class="reference"><a href="#cite_note-Maudsley-11">&#91;11&#93;</a></sup><sup id="cite_ref-Leucht_2013_29-6" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup><sup id="cite_ref-AMH_161-0" class="reference"><a href="#cite_note-AMH-161">&#91;161&#93;</a></sup><sup id="cite_ref-BNF_162-0" class="reference"><a href="#cite_note-BNF-162">&#91;162&#93;</a></sup></th>
<th>Discontinuation rate<sup id="cite_ref-Leucht_2013_29-7" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup>
<p>(OR with 95% CI in brackets) 
</p>
</th>
<th>Anticholinergic effects</th>
<th>Sedation</th>
<th>EPSE</th>
<th>Weight Gain</th>
<th>Metabolic AEs</th>
<th>QTc prolongation
<p>(ORs &amp; 95% CIs) 
</p>
</th>
<th>PE</th>
<th>Hypotension</th>
<th>Notes (e.g. notable AEs*)
</th></tr>
<tr>
<td><a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a></td>
<td>0.43 (0.32–0.57)</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>+++ (0.66 [0.39–0.91])</td>
<td>+++/++</td>
<td>–</td>
<td><a href="/wiki/Torsades_de_Pointes" class="mw-redirect" title="Torsades de Pointes">Torsades de Pointes</a> common on overdose.<sup id="cite_ref-163" class="reference"><a href="#cite_note-163">&#91;163&#93;</a></sup> Has a comparatively low penetrability of the <a href="/wiki/Blood-brain_barrier" class="mw-redirect" title="Blood-brain barrier">blood-brain barrier</a>.
</td></tr>
<tr>
<td><a href="/wiki/Amoxapine" title="Amoxapine">Amoxapine</a></td>
<td>?</td>
<td>++</td>
<td>++</td>
<td>+/-</td>
<td>++/+</td>
<td>++/+</td>
<td>++/+</td>
<td>++/+</td>
<td>++/+</td>
<td>Amoxapine is also an antidepressant. Very toxic in overdose due to the potential for renal failure and seizures.
</td></tr>
<tr>
<td><a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a></td>
<td>0.61 (0.51–0.72)</td>
<td>–</td>
<td>+</td>
<td>+/- (<a href="/wiki/Akathisia" title="Akathisia">Akathisia</a> mostly)</td>
<td>+</td>
<td>+/-</td>
<td>– (0.01 [–0.13-0·15])</td>
<td>– (can reduce prolactin levels)</td>
<td>–</td>
<td>Only clinically-utilised antipsychotic that does not act by antagonising the <a href="/wiki/Dopamine_D2_receptor" class="mw-redirect" title="Dopamine D2 receptor">D<sub>2</sub> receptor</a> and rather partially agonises this receptor.
</td></tr>
<tr>
<td><a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></td>
<td>0.69 (0.54–0.86)</td>
<td>–</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>++/+ (0.30 [–0.04–0.65])</td>
<td>+</td>
<td>+</td>
<td>Oral hypoesthesia. Has a complex pharmacologic profile.
</td></tr>
<tr>
<td><a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a><sup id="cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-0" class="reference"><a href="#cite_note-Deeks,_ED;_Keating,_GM_65–84-164">&#91;164&#93;</a></sup><sup id="cite_ref-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594_165-0" class="reference"><a href="#cite_note-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594-165">&#91;165&#93;</a></sup></td>
<td>~0.7</td>
<td>+</td>
<td>+</td>
<td>++/+</td>
<td>+/-</td>
<td>+/-</td>
<td>-</td>
<td>++/+</td>
<td>+/-</td>
<td>Only used in a few East Asian countries.
</td></tr>
<tr>
<td><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></td>
<td>0.65 (0.5-0.84)</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>First marketed antipsychotic, sort of the prototypical low-potency first-generation (<i>typical</i>) antipsychotic.
</td></tr>
<tr>
<td><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a></td>
<td>0.46 (0.32–0.65)</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>–</td>
<td>+++</td>
<td>Notable AEs: <a href="/wiki/Agranulocytosis" title="Agranulocytosis">Agranulocytosis</a>, <a href="/wiki/Neutropaenia" class="mw-redirect" title="Neutropaenia">neutropaenia</a>, <a href="/wiki/Leukopenia" title="Leukopenia">leukopaenia</a> and <a href="/wiki/Myocarditis" title="Myocarditis">myocarditis</a>. Dose-dependent seizure risk.<sup id="cite_ref-166" class="reference"><a href="#cite_note-166">&#91;166&#93;</a></sup> Overall the most effective antipsychotic, on average. Usually reserved for treatment-resistant cases or highly suicidal patients.
</td></tr>
<tr>
<td><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a></td>
<td>?</td>
<td>+/-</td>
<td>+/-</td>
<td>+++</td>
<td>+/-</td>
<td>+/-</td>
<td>?</td>
<td>+++</td>
<td>?</td>
<td>Mostly used for postoperative nausea and vomiting.
</td></tr>
<tr>
<td><a href="/wiki/Flupenthixol" class="mw-redirect" title="Flupenthixol">Flupenthixol</a></td>
<td>?</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>Also used in lower doses for depression.
</td></tr>
<tr>
<td><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></td>
<td>0.69 (0.24–1.97)<sup id="cite_ref-167" class="reference"><a href="#cite_note-167">&#91;167&#93;</a></sup></td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>High-potency first-generation (<i>typical</i>) antipsychotic.
</td></tr>
<tr>
<td><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a></td>
<td>0.8 (0.71–0.90)</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+/-</td>
<td>+ (0.11 [0.03–0.19])</td>
<td>+++</td>
<td>+</td>
<td>Prototypical high-potency first-generation (<i>typical</i>) antipsychotic.
</td></tr>
<tr>
<td><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></td>
<td>0.69 (0.56–0.84)</td>
<td>–</td>
<td>+/-</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++ (0.34 [0.22–0.46])</td>
<td>++/+</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine</a></td>
<td>?</td>
<td>+++</td>
<td>+++</td>
<td>++/+</td>
<td>++</td>
<td>++</td>
<td>?</td>
<td>+++</td>
<td>+++</td>
<td>Also used as an analgesic, agitation, anxiety and emesis.
</td></tr>
<tr>
<td><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></td>
<td>0.52 (0.28–0.98)<sup id="cite_ref-168" class="reference"><a href="#cite_note-168">&#91;168&#93;</a></sup></td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+/-</td>
<td>?</td>
<td>+++</td>
<td>++</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a></td>
<td>0.77 (0.61-0.96)</td>
<td>-</td>
<td>-</td>
<td>++/+</td>
<td>-</td>
<td>-</td>
<td>- (–0.10 [–0.21–0.01])</td>
<td>++/+</td>
<td>–</td>
<td>May be particularly helpful in ameloriating the cognitive symptoms of schizophrenia, likely due to its <a href="/wiki/5-HT7_receptor" title="5-HT7 receptor">5-HT<sub>7</sub> receptor</a>.<sup id="cite_ref-169" class="reference"><a href="#cite_note-169">&#91;169&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Melperone" title="Melperone">Melperone</a></td>
<td>?</td>
<td>-</td>
<td>+/-</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
<td>++</td>
<td>-</td>
<td>++/+</td>
<td>Several smaller low-quality clinical studies have reported its efficacy in the treatment of treatment-resistant schizophrenia. Only approved for use in a few European countries. It is known that off-licence prescribing of melperone is occurring in the United Kingdom.<sup id="cite_ref-170" class="reference"><a href="#cite_note-170">&#91;170&#93;</a></sup> Is a butyrophenone, low-potency atypical antipsychotic that has been tried as a treatment for <a href="/wiki/Parkinson%27s_disease" title="Parkinson&#39;s disease">Parkinson's disease</a> psychosis, although with negative results.
</td></tr>
<tr>
<td><a href="/wiki/Molindone" title="Molindone">Molindone</a><sup id="cite_ref-MD_171-0" class="reference"><a href="#cite_note-MD-171">&#91;171&#93;</a></sup></td>
<td>?</td>
<td>–</td>
<td>++/+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>?</td>
<td>+++</td>
<td>+/-</td>
<td>Withdrawn from the market. Seems to promote weight loss (which is rather unusual for an antipsychotic seeing how they tend to promote weight gain).<sup id="cite_ref-MD_171-1" class="reference"><a href="#cite_note-MD-171">&#91;171&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a></td>
<td>0.46 (0.41–0.52)</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+ (0.22 [0.11–0.31])</td>
<td>+</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a></td>
<td>0.48 (0.39–0.58)</td>
<td>–</td>
<td>–</td>
<td>++/+ (dose-dependent)</td>
<td>++</td>
<td>+</td>
<td>– (0.05 [–0.18–0.26])</td>
<td>+++</td>
<td>++</td>
<td>Active metabolite of risperidone.
</td></tr>
<tr>
<td><a href="/wiki/Perazine" title="Perazine">Perazine</a></td>
<td>0.62 (0.4–1.10)<sup id="cite_ref-172" class="reference"><a href="#cite_note-172">&#91;172&#93;</a></sup></td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Limited data available on adverse effects.
</td></tr>
<tr>
<td><a href="/wiki/Periciazine" title="Periciazine">Periciazine</a></td>
<td>?</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>?</td>
<td>+++</td>
<td>++</td>
<td>Also used to treat severe anxiety. Not licensed for use in the US.
</td></tr>
<tr>
<td><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a><sup id="cite_ref-173" class="reference"><a href="#cite_note-173">&#91;173&#93;</a></sup></td>
<td>?</td>
<td>+/-</td>
<td>+</td>
<td>++/+<sup id="cite_ref-Mart_174-0" class="reference"><a href="#cite_note-Mart-174">&#91;174&#93;</a></sup></td>
<td>+/-</td>
<td>?</td>
<td>–</td>
<td>++/+</td>
<td>–</td>
<td>Usually grouped with the atypical antipsychotics despite its relatively high propensity for causing extrapyramidal side effects.<sup id="cite_ref-Mart_174-1" class="reference"><a href="#cite_note-Mart-174">&#91;174&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a></td>
<td>0.30 (0.04, 2.33)<sup id="cite_ref-175" class="reference"><a href="#cite_note-175">&#91;175&#93;</a></sup></td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>Has additional antiemetic effects.
</td></tr>
<tr>
<td><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></td>
<td>1.01 (0.30 to 3.39)<sup id="cite_ref-176" class="reference"><a href="#cite_note-176">&#91;176&#93;</a></sup></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>High potency first-generation (<i>typical</i>) antipsychotic.
</td></tr>
<tr>
<td><a href="/wiki/Pipotiazine" title="Pipotiazine">Pipotiazine</a></td>
<td>?</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>?</td>
<td>+++</td>
<td>++</td>
<td>Only available in the UK.
</td></tr>
<tr>
<td><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>+++</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+++</td>
<td>?</td>
<td>Primarily used in medicine as an <a href="/wiki/Antiemetic" title="Antiemetic">antiemetic</a>.
</td></tr>
<tr>
<td><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></td>
<td>0.61 (0.52–0.71)</td>
<td>++/+</td>
<td>++</td>
<td>–</td>
<td>++</td>
<td>++/+</td>
<td>+ (0.17 [0.06–0.29])</td>
<td>–</td>
<td>++</td>
<td>Binds to the <a href="/wiki/Dopamine_D2_receptor" class="mw-redirect" title="Dopamine D2 receptor">D<sub>2</sub> receptor</a> in a <i>hit and run</i> fashion. That is it rapidly dissociates from said receptor and hence produces antipsychotic effects but does not bind to the receptor long enough to produce extrapyramidal side effects and hyperprolactinaemia.
</td></tr>
<tr>
<td><a href="/wiki/Remoxipride" title="Remoxipride">Remoxipride</a></td>
<td>?</td>
<td>–</td>
<td>+/-</td>
<td>–</td>
<td>+/-</td>
<td>+/-</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Removed from the market amidst concerns about an alarmingly high rate of <a href="/wiki/Aplastic_anaemia" class="mw-redirect" title="Aplastic anaemia">aplastic anaemia</a>.
</td></tr>
<tr>
<td><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></td>
<td>0.53 (0.46–0.60)</td>
<td>–</td>
<td>++/+ (dose-dependent)</td>
<td>++</td>
<td>++</td>
<td>++/+</td>
<td>++ (0.25 [0.15–0.36])</td>
<td>+++</td>
<td>++</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a></td>
<td>0.78 (0.61–0.98)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>++</td>
<td>++/+</td>
<td>+++ (0.90 [0.76–1.02])</td>
<td>–</td>
<td>+++</td>
<td>Not licensed for use in the US.
</td></tr>
<tr>
<td><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a></td>
<td>1.00 (0.25–4.00)<sup id="cite_ref-177" class="reference"><a href="#cite_note-177">&#91;177&#93;</a></sup></td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>+</td>
<td>+++/++</td>
<td>-</td>
<td>Not licensed for use in the US.
</td></tr>
<tr>
<td><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></td>
<td>0.67 (0.32-1.40)<sup id="cite_ref-178" class="reference"><a href="#cite_note-178">&#91;178&#93;</a></sup></td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>Dose-dependent risk for degenerative retinopathies.<sup id="cite_ref-179" class="reference"><a href="#cite_note-179">&#91;179&#93;</a></sup> Found utility in reducing the resistance of multidrug and even extensively resistant strains of <a href="/wiki/Tuberculosis" title="Tuberculosis">tuberculosis</a> to antibiotics.
</td></tr>
<tr>
<td><a href="/wiki/Tiotixene" title="Tiotixene">Tiotixene</a></td>
<td>?</td>
<td>-</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td>++/+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></td>
<td>0.94 (0.59–1.48)<sup id="cite_ref-180" class="reference"><a href="#cite_note-180">&#91;180&#93;</a></sup></td>
<td>+/-</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>+/-</td>
<td>?</td>
<td>+++</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></td>
<td>0.72 (0.59 to 0.86)</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>–</td>
<td>++ (0.41 [0.31 to 0.51])</td>
<td>++/+</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a></td>
<td>0.69 (0.41 to 1.07)</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td>+++/++</td>
<td>+++/++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>Dose-dependent risk of seizures.<sup id="cite_ref-181" class="reference"><a href="#cite_note-181">&#91;181&#93;</a></sup> Not licensed for use in the US.
</td></tr>
<tr>
<td><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></td>
<td>?</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>?</td>
<td>+++</td>
<td>+</td>
<td>Not licensed for use in the US.
</td></tr>
<tr>
<td colspan="11" style="font-size:88%;">
<p><i>Note: "Notable" is to mean side-effects that are particularly unique to the antipsychotic drug in question. For example, clozapine is notorious for its ability to cause agranulocytosis. If data on the propensity of a particular drug to cause a particular AE is unavailable an estimation is substituted based on the pharmacologic profile of the drug. </i>
</p>
<div>
<table class="multicol" role="presentation" style="border-collapse: collapse; padding: 0; border: 0; background:transparent; width:auto;">

<tbody><tr>
<td style="text-align: left; vertical-align: top;">
<p><b>Acronyms used:</b>
</p>
<dl><dd>AE – <a href="/wiki/Adverse_effect" title="Adverse effect">Adverse effect</a></dd>
<dd>OR – <a href="/wiki/Odds_ratio" title="Odds ratio">Odds ratio</a></dd>
<dd>CI – <a href="/wiki/Confidence_Interval" class="mw-redirect" title="Confidence Interval">Confidence Interval</a></dd>
<dd>EPSE – <a href="/wiki/Extrapyramidal_symptoms" title="Extrapyramidal symptoms">Extrapyramidal Side Effect</a></dd>
<dd>QTc – Corrected <a href="/wiki/QT_interval" title="QT interval">QT interval</a></dd>
<dd>PE – Prolactin elevation</dd></dl>
</td>
<td style="text-align: left; vertical-align: top; padding-left: 5em;">
<p><b>Legend:</b><br />
</p>
<dl><dd>- very low propensity for this AE</dd>
<dd>+ low propensity/severity for this AE</dd>
<dd>++ moderate propensity/severity for this AE</dd>
<dd>+++ high propensity/severity for this AE</dd></dl>
<p>&#32;
</p>
</td></tr></tbody></table></div>
</td></tr></tbody></table>
<table class="wikitable collapsible collapsed" style="font-size:small; width:100%;">
<tbody><tr>
<th colspan="6">Efficacy
</th></tr>
<tr>
<th>Generic drug name</th>
<th>Schizophrenia<sup id="cite_ref-Lancet2009_9-4" class="reference"><a href="#cite_note-Lancet2009-9">&#91;9&#93;</a></sup><sup id="cite_ref-Leucht_2013_29-8" class="reference"><a href="#cite_note-Leucht_2013-29">&#91;29&#93;</a></sup></th>
<th>Mania<sup id="cite_ref-Lancet_11_182-0" class="reference"><a href="#cite_note-Lancet_11-182">&#91;182&#93;</a></sup><sup id="cite_ref-183" class="reference"><a href="#cite_note-183">&#91;183&#93;</a></sup></th>
<th>Bipolar depression<sup id="cite_ref-184" class="reference"><a href="#cite_note-184">&#91;184&#93;</a></sup></th>
<th>Bipolar maintenance<sup id="cite_ref-185" class="reference"><a href="#cite_note-185">&#91;185&#93;</a></sup><sup id="cite_ref-186" class="reference"><a href="#cite_note-186">&#91;186&#93;</a></sup></th>
<th>Adjunct in major depression<sup id="cite_ref-MDD_187-0" class="reference"><a href="#cite_note-MDD-187">&#91;187&#93;</a></sup>
</th></tr>
<tr>
<td>Amisulpride</td>
<td>+++</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>? (+++ in dysthymia)
</td></tr>
<tr>
<td>Aripiprazole</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>++ (prevents manic and mixed but not depressive episodes)</td>
<td>+++
</td></tr>
<tr>
<td>Asenapine</td>
<td>++/+</td>
<td>++</td>
<td>?</td>
<td>++</td>
<td>?
</td></tr>
<tr>
<td>Chlorpromazine</td>
<td>++</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Clozapine</td>
<td>+++</td>
<td>+++<sup id="cite_ref-188" class="reference"><a href="#cite_note-188">&#91;188&#93;</a></sup></td>
<td>+++</td>
<td>+++ <sup id="cite_ref-189" class="reference"><a href="#cite_note-189">&#91;189&#93;</a></sup></td>
<td>+++ <sup id="cite_ref-190" class="reference"><a href="#cite_note-190">&#91;190&#93;</a></sup>
</td></tr>
<tr>
<td>Haloperidol</td>
<td>++</td>
<td>+++</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Iloperidone</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Loxapine</td>
<td>+++/++</td>
<td>+++ (only in the treatment of agitation)</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Lurasidone</td>
<td>+</td>
<td>?</td>
<td>+++</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Melperone</td>
<td>+++</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Olanzapine</td>
<td>+++</td>
<td>+++/++</td>
<td>++</td>
<td>++ (most effective at preventing manic/mixed relapse)</td>
<td>++
</td></tr>
<tr>
<td>Paliperidone</td>
<td>++</td>
<td>+++/++</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Perospirone<sup id="cite_ref-191" class="reference"><a href="#cite_note-191">&#91;191&#93;</a></sup></td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Quetiapine</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>++
</td></tr>
<tr>
<td>Risperidone</td>
<td>+++</td>
<td>+++</td>
<td>-</td>
<td>++</td>
<td>+++
</td></tr>
<tr>
<td>Sertindole</td>
<td>++</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td>Ziprasidone</td>
<td>++/+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>?
</td></tr>
<tr>
<td>Zotepine</td>
<td>++</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?
</td></tr></tbody></table>
<table class="wikitable collapsible collapsed" style="font-size:80%; text-align:center; width:100%;">
<tbody><tr>
<th colspan="19" style="font-size:120%;">Binding affinity
</th></tr>
<tr>
<td>
<table class="wikitable sortable" style="font-size:small; width:100%;">

<tbody><tr>
<th colspan="19">K<sub>i</sub> [nM] toward cloned human receptors (unless otherwise specified)<sup id="cite_ref-192" class="reference"><a href="#cite_note-192">&#91;Note 1&#93;</a></sup>
</th></tr>
<tr>
<th>Drug name<sup id="cite_ref-GG_88-1" class="reference"><a href="#cite_note-GG-88">&#91;88&#93;</a></sup><sup id="cite_ref-193" class="reference"><a href="#cite_note-193">&#91;192&#93;</a></sup></th>
<th>SERT</th>
<th>5-HT<sub>1A</sub></th>
<th>5-HT<sub>2A</sub></th>
<th>5-HT<sub>2C</sub></th>
<th>5-HT<sub>6</sub></th>
<th>5-HT<sub>7</sub></th>
<th>α<sub>1A</sub></th>
<th>α<sub>2A</sub></th>
<th>α<sub>2C</sub></th>
<th>NET</th>
<th>D<sub>1</sub></th>
<th>D<sub>2</sub></th>
<th>D<sub>3</sub></th>
<th>D<sub>4</sub></th>
<th>5-HT<sub>2A</sub>/D<sub>2</sub></th>
<th>H<sub>1</sub></th>
<th>M<sub>1</sub></th>
<th>M<sub>3</sub>
</th></tr>
<tr>
<td>Amisulpride</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>8,304</td>
<td>&gt;10,000</td>
<td>4,154</td>
<td>73.5</td>
<td>&gt;10,000</td>
<td>1,114</td>
<td>1,540</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>2.2</td>
<td>2.4</td>
<td>2,370</td>
<td>3774.5</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Aripiprazole</td>
<td>1,081</td>
<td>5.6</td>
<td>8.7</td>
<td>22.4</td>
<td>642.4</td>
<td>9.97</td>
<td>25.85</td>
<td>74.1</td>
<td>37.63</td>
<td>2091.5</td>
<td>1,173.5</td>
<td>1.64</td>
<td>5.35</td>
<td>514</td>
<td>5.3</td>
<td>27.93</td>
<td>6,778</td>
<td>4,678
</td></tr>
<tr>
<td>Asenapine<sup id="cite_ref-pmid18308814_194-0" class="reference"><a href="#cite_note-pmid18308814-194">&#91;193&#93;</a></sup></td>
<td>ND</td>
<td>2.5</td>
<td>0.06</td>
<td>0.03</td>
<td>0.25</td>
<td>0.13</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>ND</td>
<td>1.4</td>
<td>1.3</td>
<td>0.42</td>
<td>1.1</td>
<td>0.0462</td>
<td>1.0</td>
<td>8,128</td>
<td>8,128
</td></tr>
<tr>
<td>Blonanserin<sup id="cite_ref-Ishiyama_2007_195-0" class="reference"><a href="#cite_note-Ishiyama_2007-195">&#91;194&#93;</a></sup></td>
<td>ND</td>
<td>804</td>
<td>0.812</td>
<td>26.4</td>
<td>41.9</td>
<td>183</td>
<td>26.7 (RB)</td>
<td>530 (RC)</td>
<td>ND</td>
<td>ND</td>
<td>1,070</td>
<td>0.142</td>
<td>0.494</td>
<td>150</td>
<td>5.72</td>
<td>765</td>
<td>100</td>
<td>ND
</td></tr>
<tr>
<td>Brexpiprazole</td>
<td>ND</td>
<td>0.12</td>
<td>0.47</td>
<td>ND</td>
<td>58</td>
<td>3.7</td>
<td>3.8</td>
<td>15</td>
<td>0.59</td>
<td>ND</td>
<td>160</td>
<td>0.3</td>
<td>1.1</td>
<td>6.3</td>
<td>1.567</td>
<td>19</td>
<td>ND</td>
<td>&gt;10,000
</td></tr>
<tr>
<td><i><b>N-DEBN</b></i><sup id="cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-1" class="reference"><a href="#cite_note-Deeks,_ED;_Keating,_GM_65–84-164">&#91;164&#93;</a></sup></td>
<td>ND</td>
<td>ND</td>
<td>1.28</td>
<td>4.50</td>
<td>5.03</td>
<td>206 (RC)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>1,020</td>
<td>1.38</td>
<td>0.23</td>
<td>ND</td>
<td>0.93</td>
<td>ND</td>
<td>ND</td>
<td>ND
</td></tr>
<tr>
<td>Chlorpromazine</td>
<td>1,296</td>
<td>2,115.5</td>
<td>4.5</td>
<td>15.6</td>
<td>17.0</td>
<td>28.4</td>
<td>0.28</td>
<td>184</td>
<td>46</td>
<td>2,443</td>
<td>76.3</td>
<td>1.40</td>
<td>4.65</td>
<td>5.33</td>
<td>3.21</td>
<td>3.09</td>
<td>32.3</td>
<td>57.0
</td></tr>
<tr>
<td>Clozapine</td>
<td>1,624</td>
<td>123.7</td>
<td>5.35</td>
<td>9.44</td>
<td>13.5</td>
<td>17.95</td>
<td>1.62</td>
<td>37</td>
<td>6.0</td>
<td>3,168</td>
<td>266.3</td>
<td>157</td>
<td>269.1</td>
<td>26.4</td>
<td>0.0341</td>
<td>1.13</td>
<td>6.17</td>
<td>19.25
</td></tr>
<tr>
<td><i><b>Norclozapine</b></i></td>
<td>316.6</td>
<td>13.9</td>
<td>10.9</td>
<td>11.9 (RC)</td>
<td>11.6</td>
<td>60.1</td>
<td>104.8</td>
<td>137.6</td>
<td>117.7</td>
<td>493.9</td>
<td>14.3</td>
<td>94.5</td>
<td>153</td>
<td>63.94</td>
<td>0.115</td>
<td>3.4</td>
<td>67.6</td>
<td>95.7
</td></tr>
<tr>
<td><i>cis</i>-Flupenthixol</td>
<td>ND</td>
<td>8,028</td>
<td>87.5 (HFC)</td>
<td>102.2 (RC)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>3.5</td>
<td>0.35</td>
<td>1.75</td>
<td>66.3</td>
<td>250</td>
<td>0.86</td>
<td>ND</td>
<td>ND
</td></tr>
<tr>
<td>Fluphenazine</td>
<td>5,950</td>
<td>1,039.9</td>
<td>37.93</td>
<td>982.5</td>
<td>34.67</td>
<td>8.00</td>
<td>6.45</td>
<td>314.1</td>
<td>28.9</td>
<td>3,076</td>
<td>17.33</td>
<td>0.30</td>
<td>1.75</td>
<td>40.0</td>
<td>126.4</td>
<td>14.15</td>
<td>1,095</td>
<td>1,441
</td></tr>
<tr>
<td>Haloperidol</td>
<td>3,256</td>
<td>2,066.83</td>
<td>56.81</td>
<td>4,801</td>
<td>5,133</td>
<td>377.6</td>
<td>12.0</td>
<td>801.5</td>
<td>403</td>
<td>2,112</td>
<td>121.8</td>
<td>0.7</td>
<td>3.96</td>
<td>2.71</td>
<td>81.2</td>
<td>1698</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Iloperidone</td>
<td>ND</td>
<td>93.21</td>
<td>1.94</td>
<td>147</td>
<td>63.09</td>
<td>112</td>
<td>0.3</td>
<td>160</td>
<td>16.2</td>
<td>1479</td>
<td>129.32</td>
<td>10.86</td>
<td>10.55</td>
<td>13.75</td>
<td>0.179</td>
<td>12</td>
<td>4,898</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Loxapine</td>
<td>&gt;10,000</td>
<td>2,456</td>
<td>6.63</td>
<td>13.25</td>
<td>31.0</td>
<td>87.6</td>
<td>31.0</td>
<td>150.9</td>
<td>80.0</td>
<td>5,698</td>
<td>54</td>
<td>28.1</td>
<td>19.33</td>
<td>7.80</td>
<td>0.236</td>
<td>4.90</td>
<td>119.45</td>
<td>211.33
</td></tr>
<tr>
<td><i><b>Amoxapine</b></i></td>
<td>58</td>
<td>ND</td>
<td>0.5</td>
<td>2.0 (RC)</td>
<td>50</td>
<td>40.21</td>
<td>50</td>
<td>ND</td>
<td>ND</td>
<td>16</td>
<td>ND</td>
<td>20.8</td>
<td>21.0</td>
<td>21.0</td>
<td>0.0240</td>
<td>25</td>
<td>1,000</td>
<td>1,000
</td></tr>
<tr>
<td>Lurasidone<sup id="cite_ref-Ishiyama_2007_195-1" class="reference"><a href="#cite_note-Ishiyama_2007-195">&#91;194&#93;</a></sup><sup id="cite_ref-pmid20404009_196-0" class="reference"><a href="#cite_note-pmid20404009-196">&#91;195&#93;</a></sup></td>
<td>ND</td>
<td>6.8</td>
<td>2.0</td>
<td>415</td>
<td>ND</td>
<td>0.5</td>
<td>48</td>
<td>1.6</td>
<td>10.8</td>
<td>ND</td>
<td>262</td>
<td>1.7</td>
<td>ND</td>
<td>ND</td>
<td>1.18</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Melperone</td>
<td>ND</td>
<td>2,200 (HB)</td>
<td>230</td>
<td>2,100 (HB)</td>
<td>1,254 (RC)</td>
<td>578 (HB)</td>
<td>180 (HB)</td>
<td>150 (HB)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>194</td>
<td>8.95</td>
<td>555</td>
<td>1.186</td>
<td>580</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Molindone</td>
<td>ND</td>
<td>3,797</td>
<td>3773</td>
<td>&gt;10,000</td>
<td>1,008</td>
<td>3,053</td>
<td>2,612</td>
<td>1,097</td>
<td>172.6</td>
<td>ND</td>
<td>ND</td>
<td>6.0</td>
<td>72.5</td>
<td>2,950</td>
<td>628.83</td>
<td>2,130</td>
<td>ND</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Olanzapine</td>
<td>3,676</td>
<td>2282</td>
<td>3.73</td>
<td>10.2</td>
<td>8.07</td>
<td>105.2</td>
<td>112</td>
<td>314</td>
<td>28.9</td>
<td>&gt;10,000</td>
<td>70.33</td>
<td>34.23</td>
<td>47.0</td>
<td>14.33</td>
<td>0.109</td>
<td>2.19</td>
<td>2.5</td>
<td>56.33
</td></tr>
<tr>
<td>Paliperidone</td>
<td>3,717</td>
<td>616.6</td>
<td>0.71</td>
<td>48</td>
<td>2,414</td>
<td>2.7</td>
<td>2.5</td>
<td>17.35</td>
<td>7.35</td>
<td>&gt;10,000</td>
<td>41.04</td>
<td>0.7</td>
<td>0.5</td>
<td>54.3</td>
<td>1.104</td>
<td>18.8</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Perphenazine</td>
<td>ND</td>
<td>421</td>
<td>5.6</td>
<td>132</td>
<td>17</td>
<td>23</td>
<td>10</td>
<td>810.5</td>
<td>85.2</td>
<td>ND</td>
<td>ND</td>
<td>0.14</td>
<td>0.13</td>
<td>17</td>
<td>40</td>
<td>8</td>
<td>1,500</td>
<td>1,848
</td></tr>
<tr>
<td>Pimozide</td>
<td>ND</td>
<td>650</td>
<td>48.35</td>
<td>2,112</td>
<td>71</td>
<td>0.5</td>
<td>197.7</td>
<td>1,593</td>
<td>376.5</td>
<td>ND</td>
<td>&gt;10,000</td>
<td>1.45</td>
<td>0.25</td>
<td>1.8</td>
<td>33.34</td>
<td>692.2</td>
<td>800 (HB)</td>
<td>1,955
</td></tr>
<tr>
<td>Prochlorperazine</td>
<td>ND</td>
<td>5,900 (HC)</td>
<td>15 (HC)</td>
<td>122</td>
<td>148 (RC)</td>
<td>196 (RC)</td>
<td>23.8 (HB)</td>
<td>1,694.91 (HB)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>0.65</td>
<td>2.90</td>
<td>5.40</td>
<td>23.1</td>
<td>18.86 (HB)</td>
<td>555.55 (HB)</td>
<td>ND
</td></tr>
<tr>
<td>Quetiapine</td>
<td>&gt;10,000</td>
<td>394.2</td>
<td>912</td>
<td>1,843</td>
<td>948.75</td>
<td>307.6</td>
<td>22</td>
<td>3,630</td>
<td>28.85</td>
<td>&gt;10,000</td>
<td>994.5</td>
<td>379</td>
<td>340</td>
<td>2,019</td>
<td>2.41</td>
<td>6.90</td>
<td>489</td>
<td>1631.5
</td></tr>
<tr>
<td><i><b>Norquetiapine</b></i><sup id="cite_ref-pmid24062697_197-0" class="reference"><a href="#cite_note-pmid24062697-197">&#91;196&#93;</a></sup></td>
<td>ND</td>
<td>45</td>
<td>48</td>
<td>107</td>
<td>ND</td>
<td>76</td>
<td>144</td>
<td>237</td>
<td>ND</td>
<td>12</td>
<td>99.8 (RC)</td>
<td>196</td>
<td>ND</td>
<td>ND</td>
<td>0.245</td>
<td>3.5</td>
<td>38.3 (RC)</td>
<td>ND
</td></tr>
<tr>
<td>Risperidone</td>
<td>&gt;10,000</td>
<td>422.88</td>
<td>0.17</td>
<td>12</td>
<td>2057.17</td>
<td>6.6</td>
<td>5</td>
<td>16.5</td>
<td>1.3</td>
<td>&gt;10,000</td>
<td>243.53</td>
<td>3.57</td>
<td>2.0</td>
<td>4.66</td>
<td>0.0476</td>
<td>20.05</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Sertindole</td>
<td>ND</td>
<td>280</td>
<td>0.39</td>
<td>0.9</td>
<td>5.4</td>
<td>28</td>
<td>1.8</td>
<td>640</td>
<td>450</td>
<td>ND</td>
<td>ND</td>
<td>2.35</td>
<td>2.30</td>
<td>4.92</td>
<td>0.166</td>
<td>130</td>
<td>&gt;5,000</td>
<td>2,692
</td></tr>
<tr>
<td>Sulpiride</td>
<td>ND</td>
<td>&gt;10,000</td>
<td>&gt;10,000 (RC)</td>
<td>&gt;10,000 (RC)</td>
<td>5,000 (RC)</td>
<td>4,000 (RC)</td>
<td>&gt;10,000 (RB)</td>
<td>4,893 (RB)</td>
<td>ND</td>
<td>ND</td>
<td>&gt;10,000</td>
<td>9.80</td>
<td>8.05</td>
<td>54</td>
<td>&gt;1,000</td>
<td>&gt;10,000 (RB)</td>
<td>&gt;10,000 (RB)</td>
<td>&gt;10,000 (RB)
</td></tr>
<tr>
<td>Thioridazine</td>
<td>1,259</td>
<td>144.35</td>
<td>27.67</td>
<td>53</td>
<td>57.05</td>
<td>99</td>
<td>3.15</td>
<td>134.15</td>
<td>74.9</td>
<td>842</td>
<td>94.5</td>
<td>2.20</td>
<td>1.50</td>
<td>6.00</td>
<td>12.58</td>
<td>16.5</td>
<td>12.8</td>
<td>29
</td></tr>
<tr>
<td>Tiotixene</td>
<td>3,878</td>
<td>410.2</td>
<td>50</td>
<td>1355.5</td>
<td>245.47</td>
<td>15.25</td>
<td>11.5</td>
<td>79.95</td>
<td>51.95</td>
<td>&gt;10,000</td>
<td>51</td>
<td>0.12</td>
<td>0.40</td>
<td>203</td>
<td>416.7</td>
<td>8</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Trifluoperazine</td>
<td>ND</td>
<td>950</td>
<td>74</td>
<td>378</td>
<td>144</td>
<td>290.8</td>
<td>24</td>
<td>653.7</td>
<td>391.5</td>
<td>ND</td>
<td>ND</td>
<td>1.12</td>
<td>ND</td>
<td>38.1</td>
<td>66.07</td>
<td>63</td>
<td>ND</td>
<td>1,001
</td></tr>
<tr>
<td>Ziprasidone</td>
<td>112</td>
<td>54.67</td>
<td>0.73</td>
<td>13</td>
<td>60.95</td>
<td>6.31</td>
<td>18</td>
<td>160</td>
<td>68</td>
<td>44</td>
<td>30</td>
<td>4.35</td>
<td>7.85</td>
<td>52.9</td>
<td>0.1678</td>
<td>62.67</td>
<td>&gt;10,000</td>
<td>&gt;10,000
</td></tr>
<tr>
<td>Zotepine</td>
<td>151</td>
<td>470.5</td>
<td>2.7</td>
<td>3.2</td>
<td>6</td>
<td>12</td>
<td>7</td>
<td>208</td>
<td>106</td>
<td>530</td>
<td>71</td>
<td>25</td>
<td>6.4</td>
<td>18</td>
<td>0.108</td>
<td>3.21</td>
<td>18</td>
<td>73
</td></tr>
<tr>
<td colspan="19" style="font-size:88%;">
<p><b>Acronyms used:</b>
</p>
<div>
<table class="multicol" role="presentation" style="border-collapse: collapse; padding: 0; border: 0; background:transparent; width:auto;">

<tbody><tr>
<td style="text-align: left; vertical-align: top;">
<dl><dd>HFC – Human frontal cortex receptor</dd>
<dd>RB – Rat brain receptor</dd>
<dd>RC – Cloned rat receptor</dd>
<dd>ND – No data</dd></dl>
</td>
<td style="text-align: left; vertical-align: top; padding-left: 2em;">
<dl><dd>HB – Human brain receptor</dd>
<dd>HC – Human cortex receptor</dd>
<dd>N-DEBN – N-desethylblonanserin</dd></dl>
<p>&#32;
</p>
</td></tr></tbody></table></div>
</td></tr></tbody></table>
</td></tr></tbody></table>
<table class="wikitable collapsible collapsed" style="font-size:85%; width:100%;">
<tbody><tr>
<th colspan="11" style="font-size:small;">Pharmacokinetics
</th></tr>
<tr>
<td>
<table class="wikitable sortable" style="font-size:small; width:100%;">

<tbody><tr>
<th>Drug<sup id="cite_ref-198" class="reference"><a href="#cite_note-198">&#91;197&#93;</a></sup><sup id="cite_ref-199" class="reference"><a href="#cite_note-199">&#91;198&#93;</a></sup><sup id="cite_ref-DM_200-0" class="reference"><a href="#cite_note-DM-200">&#91;199&#93;</a></sup><sup id="cite_ref-201" class="reference"><a href="#cite_note-201">&#91;200&#93;</a></sup></th>
<th><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></th>
<th><a href="/wiki/Biological_half-life" title="Biological half-life">t<sub>1/2</sub></a> parent drug <br />(active metabolite)</th>
<th>Protein binding</th>
<th><a href="/wiki/Pharmacokinetics#Metrics" title="Pharmacokinetics">t<sub>max</sub></a></th>
<th><a href="/wiki/Pharmacokinetics#Metrics" title="Pharmacokinetics">C<sub>max</sub></a></th>
<th><a href="/wiki/Volume_of_distribution" title="Volume of distribution">V<sub>d</sub></a></th>
<th>Excretion</th>
<th>Routes</th>
<th>Metabolism enzymes<sup id="cite_ref-GG_88-2" class="reference"><a href="#cite_note-GG-88">&#91;88&#93;</a></sup></th>
<th>Active metabolites
</th></tr>
<tr>
<td><a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a></td>
<td>48%</td>
<td>12&#160;h</td>
<td>16%</td>
<td>3–4&#160;h</td>
<td><span class="nowrap">54 ± 4 ng/mL</span></td>
<td>5.8&#160;L/kg</td>
<td>Faeces (20%), urine (50%, when given IV)</td>
<td>Oral</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a></td>
<td>87% (Oral), 100% (IM)</td>
<td>75&#160;h (94&#160;h)</td>
<td>99%</td>
<td>3–5&#160;h</td>
<td>?</td>
<td>4.9&#160;L/kg</td>
<td>Faeces (55%), urine (25%)</td>
<td>Oral, <a href="/wiki/Intramuscular" class="mw-redirect" title="Intramuscular">IM</a> (including depot)</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>, <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>Dehydroaripiprazole
</td></tr>
<tr>
<td><a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></td>
<td>35% (sublingual)</td>
<td>24&#160;h</td>
<td>95%</td>
<td>0.5–1.5&#160;h</td>
<td>4&#160;ng/mL</td>
<td>20–25&#160;L/kg</td>
<td>Urine (50%), faeces (40%)</td>
<td>Sublingual</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a>, <a href="/wiki/UGT1A4" title="UGT1A4">UGT1A4</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a><sup id="cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-2" class="reference"><a href="#cite_note-Deeks,_ED;_Keating,_GM_65–84-164">&#91;164&#93;</a></sup><sup id="cite_ref-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594_165-1" class="reference"><a href="#cite_note-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594-165">&#91;165&#93;</a></sup><sup id="cite_ref-202" class="reference"><a href="#cite_note-202">&#91;201&#93;</a></sup></td>
<td>55%</td>
<td>10.7-16.2&#160;h (single dosing), 67.9&#160;h (repeated dosing)</td>
<td>≥&#160;99.7%</td>
<td>1.5-2&#160;h</td>
<td>0.14-0.76&#160;ng/mL (0.57&#160;ng/mL for repeated dosing)</td>
<td>8560-9500 L</td>
<td>Urine (59%), faeces (30%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>N-desethylblonanserin
</td></tr>
<tr>
<td><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></td>
<td>20%</td>
<td>30&#160;h</td>
<td>92–97%</td>
<td>?</td>
<td>?</td>
<td>20&#160;L/kg</td>
<td>Urine</td>
<td>Oral, <a href="/wiki/Intramuscular" class="mw-redirect" title="Intramuscular">IM</a>, <a href="/wiki/Intravenous" class="mw-redirect" title="Intravenous">IV</a></td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>Several active metabolites
</td></tr>
<tr>
<td><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a></td>
<td>50–60%</td>
<td>12&#160;h</td>
<td>97%</td>
<td>1.5–2.5&#160;h</td>
<td>102-771&#160;ng/mL</td>
<td>4.67&#160;L/kg</td>
<td>Urine (50%), faeces (30%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>, <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td><a href="/wiki/Norclozapine" class="mw-redirect" title="Norclozapine">Norclozapine</a>
</td></tr>
<tr>
<td><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a></td>
<td>?</td>
<td>2&#160;h (8–12&#160;h)</td>
<td>Extensive</td>
<td>60 min (IM)</td>
<td>?</td>
<td>2&#160;L/kg (adults), 0.58&#160;L/kg (children)</td>
<td>Urine (75%), faeces (22%)</td>
<td><a href="/wiki/Intramuscular" class="mw-redirect" title="Intramuscular">IM</a>, <a href="/wiki/Intravenous" class="mw-redirect" title="Intravenous">IV</a></td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol</a></td>
<td>40–55% (Oral)</td>
<td>35&#160;h</td>
<td>?</td>
<td>7 days (depot)</td>
<td>?</td>
<td>12–14&#160;L/kg</td>
<td>Urine</td>
<td>Oral, IM (including depot)</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></td>
<td>2.7% (Oral)</td>
<td>14–16&#160;h, 14 days (depot)</td>
<td>?</td>
<td>2&#160;h (Oral), 8–10&#160;h (depot)</td>
<td>?</td>
<td>?</td>
<td>Urine, faeces</td>
<td>Oral, IM (including depot)</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a></td>
<td>60–70% (Oral)</td>
<td>10–20&#160;h (short-acting IM), 3 weeks (depot)</td>
<td>92%</td>
<td>2–6&#160;h (Oral), 10–20 min (short-acting IM), 6–7 days (depot)</td>
<td>?</td>
<td>8–18&#160;L/kg</td>
<td>Urine (30%), faeces (15%)</td>
<td>Oral, IM, IV</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></td>
<td>96%</td>
<td>?</td>
<td>95%</td>
<td>2–4&#160;h</td>
<td>?</td>
<td>1340–2800 L</td>
<td>Urine (45–58%), faeces (20–22%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None notable.
</td></tr>
<tr>
<td><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine</a></td>
<td>?</td>
<td>30&#160;h</td>
<td>?</td>
<td>2–3&#160;h</td>
<td>?</td>
<td>?</td>
<td>Urine, faeces</td>
<td>IM, IV</td>
<td>?</td>
<td>Methotrimeprazine sulfoxide
</td></tr>
<tr>
<td><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></td>
<td>High</td>
<td>6–8&#160;h (Inhaled), 4–12&#160;h (Oral)</td>
<td>96.6%</td>
<td>2 min (inhaled), 2&#160;h (oral), 5&#160;h (IM)</td>
<td>257&#160;ng/mL (inhaled), 6–13&#160;ng/mL (Oral)</td>
<td>?</td>
<td>Urine (56–70%), faeces [Only oral data available]</td>
<td>Oral, IM, Inhalation</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a>, <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td><a href="/wiki/Amoxapine" title="Amoxapine">Amoxapine</a> (a tricyclic antidepressant), 7-OH loxapine, 8-OH loxapine
</td></tr>
<tr>
<td><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a></td>
<td>9–19%</td>
<td>18&#160;h</td>
<td>99%</td>
<td>1–3&#160;h</td>
<td>?</td>
<td>6173 L</td>
<td>Urine (9%), faeces (80%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>2 active
</td></tr>
<tr>
<td><a href="/wiki/Melperone" title="Melperone">Melperone</a><sup id="cite_ref-203" class="reference"><a href="#cite_note-203">&#91;202&#93;</a></sup></td>
<td>54% (Oral via syrup), 65% (Oral via tablets), 87% (IM)</td>
<td>2.1-6.4&#160;h (Oral), <span class="nowrap">6.6 ± 3.7 h</span> (IM)</td>
<td>50%</td>
<td>1.6-2.4&#160;h (Oral, tablets), 1&#160;h (Oral, syrup)</td>
<td><span class="nowrap">1132 ± 814 ng/mL</span> (25&#160;mg, orally), 2228–3416&#160;ng/mL (50&#160;mg, orally), <span class="nowrap">89539 ± 37001 ng/mL</span> (100&#160;mg, orally)</td>
<td><span class="nowrap">9.9 ± 3.7 L/kg</span> (10&#160;mg), <span class="nowrap">7 ± 1.61 L/kg</span> (20&#160;mg)</td>
<td>Urine (70% as metabolites, 5.5–10.4% as parent drug)</td>
<td>Oral, IM</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a></td>
<td>87% (Oral)</td>
<td>30&#160;h</td>
<td>93%</td>
<td>6&#160;h (Oral), 15–45 min (short-acting IM), 7 days (depot)</td>
<td>4–20.4&#160;mg/mL<sup id="cite_ref-204" class="reference"><a href="#cite_note-204">&#91;203&#93;</a></sup></td>
<td>1000 L</td>
<td>Urine (57%), faeces (30%)</td>
<td>Oral, IM (including depot)</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a></td>
<td>28% (Oral)</td>
<td>23&#160;h (Oral), 25–49 days (IM)</td>
<td>74%</td>
<td>24&#160;h (Oral), 13 days (IM)</td>
<td>8.85-11.7&#160;ng/mL<sup id="cite_ref-205" class="reference"><a href="#cite_note-205">&#91;204&#93;</a></sup></td>
<td>390-487 L</td>
<td>Urine (80%), faeces (11%)</td>
<td>Oral, IM (depot)</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Periciazine" title="Periciazine">Periciazine</a></td>
<td>?</td>
<td>12&#160;h</td>
<td>?</td>
<td>2&#160;h</td>
<td>150&#160;ng/mL</td>
<td>?</td>
<td>Urine</td>
<td>Oral</td>
<td>?</td>
<td>?
</td></tr>
<tr>
<td><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a><sup id="cite_ref-CNS_Drugs_116-1" class="reference"><a href="#cite_note-CNS_Drugs-116">&#91;116&#93;</a></sup></td>
<td>?</td>
<td>1.9–2.5&#160;h</td>
<td>92%</td>
<td>1.5&#160;h</td>
<td>5.7&#160;ng/mL</td>
<td>?</td>
<td>Urine (0.4% as unchanged drug)</td>
<td>Oral</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a></td>
<td>?</td>
<td>9–12&#160;h (10–19&#160;h)</td>
<td>?</td>
<td>1–3&#160;h; 2–4&#160;h (metabolite)</td>
<td>0.984&#160;ng/mL; 0.509&#160;ng/mL</td>
<td>?</td>
<td>Urine, faeces</td>
<td>Oral</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>7-OH perphenazine
</td></tr>
<tr>
<td><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></td>
<td>40–50%</td>
<td>55&#160;h</td>
<td>?</td>
<td>6–8&#160;h</td>
<td>4–19&#160;ng/mL (dose-dependent)</td>
<td>?</td>
<td>Urine</td>
<td>Oral</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a>, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></td>
<td>12.5%</td>
<td>6.8–9&#160;h</td>
<td>High</td>
<td>?</td>
<td>?</td>
<td>12.9–17.7 L/h</td>
<td>Urine, bile</td>
<td>Oral, IM, IV</td>
<td>?</td>
<td>N-desmethylprochlorperazine
</td></tr>
<tr>
<td><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></td>
<td>100%</td>
<td>6&#160;h (IR), 7&#160;h (XR); active metabolite: 12&#160;h</td>
<td>83%</td>
<td>1.5&#160;h (IR), 6&#160;h (XR)</td>
<td>@ 250&#160;mg q8hr 778&#160;ng/mL (male), 879&#160;ng/mL (female)<sup id="cite_ref-206" class="reference"><a href="#cite_note-206">&#91;205&#93;</a></sup></td>
<td>6-14&#160;L/kg</td>
<td>Urine (73%), faeces (20%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>Norquetiapine (a <a href="/wiki/Norepinephrine_reuptake_inhibitor" title="Norepinephrine reuptake inhibitor">norepinephrine reuptake inhibitor</a> and <a href="/wiki/5-HT1A_receptor" title="5-HT1A receptor">5-HT<sub>1A</sub> receptor</a> partial agonist)
</td></tr>
<tr>
<td><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></td>
<td>70%</td>
<td>3–17&#160;h (24&#160;h)</td>
<td>90% (active metabolite: 77%)</td>
<td>3–17&#160;h</td>
<td>?</td>
<td>1–2&#160;L/kg</td>
<td>Urine (70%), faeces (14%)</td>
<td>Oral, IM (including depot)</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a>
</td></tr>
<tr>
<td><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a></td>
<td>?</td>
<td>3 days</td>
<td>99.5%</td>
<td>10&#160;h</td>
<td>?</td>
<td>20&#160;L/kg</td>
<td>Urine (4%), faeces (46–56%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a><sup id="cite_ref-207" class="reference"><a href="#cite_note-207">&#91;206&#93;</a></sup></td>
<td>27 ± 9%</td>
<td>8&#160;h</td>
<td>40%</td>
<td>3-6&#160;h</td>
<td>?</td>
<td><span class="nowrap">2.72 ± 0.66 L/kg</span></td>
<td>Urine, faeces</td>
<td>Oral</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></td>
<td>?</td>
<td>24&#160;h</td>
<td>95%</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Oral</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Tiotixene" title="Tiotixene">Tiotixene</a></td>
<td>?</td>
<td>24&#160;h</td>
<td>90%</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Oral</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></td>
<td>?</td>
<td>24&#160;h</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Oral</td>
<td>?</td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></td>
<td>60% (Oral), 100% (IM)</td>
<td>7&#160;h (Oral), 2–5&#160;h (IM)</td>
<td>99%</td>
<td>6–8&#160;h (Oral), ≤ 60 min (IM)</td>
<td>?</td>
<td>1.5&#160;L/kg</td>
<td>Faeces (66%), urine (20%)</td>
<td>Oral, IM</td>
<td><a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a>, <a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a></td>
<td>None
</td></tr>
<tr>
<td><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a><sup id="cite_ref-208" class="reference"><a href="#cite_note-208">&#91;207&#93;</a></sup><sup id="cite_ref-209" class="reference"><a href="#cite_note-209">&#91;208&#93;</a></sup></td>
<td>7-13%</td>
<td>13.7-15.9&#160;h (12&#160;h)</td>
<td>97%</td>
<td>1-4&#160;h</td>
<td>31-240</td>
<td>10&#160;L/kg</td>
<td>Urine (17%)</td>
<td>Oral</td>
<td><a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a>, <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a></td>
<td>Norzotepine (a norepinephrine reuptake inhibitor)
</td></tr>
<tr>
<td><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></td>
<td>49%</td>
<td>20&#160;h</td>
<td>98%</td>
<td>2–12&#160;h (mean: 4&#160;h)</td>
<td>?</td>
<td>20&#160;L/kg</td>
<td>Faeces, urine (10%)</td>
<td>Oral, IM (including depot)</td>
<td><a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a></td>
<td>None
</td></tr></tbody></table>
</td></tr></tbody></table>
<table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; margin: 1em auto;">
<caption class="nowrap"><style data-mw-deduplicate="TemplateStyles:r1063604349">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Pharmacokinetics_of_long-acting_injectable_antipsychotics" title="Template:Pharmacokinetics of long-acting injectable antipsychotics"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Pharmacokinetics_of_long-acting_injectable_antipsychotics" title="Template talk:Pharmacokinetics of long-acting injectable antipsychotics"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Pharmacokinetics_of_long-acting_injectable_antipsychotics&amp;action=edit"><abbr title="Edit this template">e</abbr></a></li></ul></div> <span style="font-family:sans-serif;font-size:105%;color:black;background-color:transparent;;">Pharmacokinetics of long-acting injectable antipsychotics</span>
</caption>
<tbody><tr>
<th>Medication</th>
<th>Brand name</th>
<th>Class</th>
<th>Vehicle</th>
<th>Dosage</th>
<th>T<sub>max</sub></th>
<th>t<sub>1/2</sub> single</th>
<th>t<sub>1/2</sub> multiple</th>
<th>logP<sup>c</sup></th>
<th>Ref
</th></tr>
<tr>
<td><a href="/wiki/Aripiprazole_lauroxil" title="Aripiprazole lauroxil">Aripiprazole lauroxil</a></td>
<td>Aristada</td>
<td><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></td>
<td><a href="/wiki/Water" title="Water">Water</a><sup>a</sup></td>
<td>441–1064&#160;mg/4–8&#160;weeks</td>
<td>24–35&#160;days</td>
<td>?</td>
<td>54–57&#160;days</td>
<td>7.9–10.0</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Aripiprazole_monohydrate" class="mw-redirect" title="Aripiprazole monohydrate">Aripiprazole monohydrate</a></td>
<td>Abilify Maintena</td>
<td><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></td>
<td><a href="/wiki/Water" title="Water">Water</a><sup>a</sup></td>
<td>300–400&#160;mg/4&#160;weeks</td>
<td>7&#160;days</td>
<td>?</td>
<td>30–47&#160;days</td>
<td>4.9–5.2</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Bromperidol_decanoate" title="Bromperidol decanoate">Bromperidol decanoate</a></td>
<td>Impromen Decanoas</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>40–300&#160;mg/4&#160;weeks</td>
<td>3–9&#160;days</td>
<td>?</td>
<td>21–25&#160;days</td>
<td>7.9</td>
<td><sup id="cite_ref-ParentToussaint1983_210-0" class="reference"><a href="#cite_note-ParentToussaint1983-210">&#91;209&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Clopentixol_decanoate" class="mw-redirect" title="Clopentixol decanoate">Clopentixol decanoate</a></td>
<td>Sordinol Depot</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Viscoleo" title="Viscoleo">Viscoleo</a><sup>b</sup></td>
<td>50–600&#160;mg/1–4&#160;weeks</td>
<td>4–7&#160;days</td>
<td>?</td>
<td>19&#160;days</td>
<td>9.0</td>
<td><sup id="cite_ref-pmid6931472_211-0" class="reference"><a href="#cite_note-pmid6931472-211">&#91;210&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Flupentixol_decanoate" class="mw-redirect" title="Flupentixol decanoate">Flupentixol decanoate</a></td>
<td>Depixol</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Viscoleo" title="Viscoleo">Viscoleo</a><sup>b</sup></td>
<td>10–200&#160;mg/2–4&#160;weeks</td>
<td>4–10&#160;days</td>
<td>8&#160;days</td>
<td>17&#160;days</td>
<td>7.2–9.2</td>
<td><sup id="cite_ref-pmid6931472_211-1" class="reference"><a href="#cite_note-pmid6931472-211">&#91;210&#93;</a></sup><sup id="cite_ref-Reynolds1993_212-0" class="reference"><a href="#cite_note-Reynolds1993-212">&#91;211&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Fluphenazine_decanoate" class="mw-redirect" title="Fluphenazine decanoate">Fluphenazine decanoate</a></td>
<td>Prolixin Decanoate</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>12.5–100&#160;mg/2–5&#160;weeks</td>
<td>1–2&#160;days</td>
<td>1–10&#160;days</td>
<td>14–100&#160;days</td>
<td>7.2–9.0</td>
<td><sup id="cite_ref-pmid6143748_213-0" class="reference"><a href="#cite_note-pmid6143748-213">&#91;212&#93;</a></sup><sup id="cite_ref-pmid444352_214-0" class="reference"><a href="#cite_note-pmid444352-214">&#91;213&#93;</a></sup><sup id="cite_ref-YoungEreshefsky1984_215-0" class="reference"><a href="#cite_note-YoungEreshefsky1984-215">&#91;214&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Fluphenazine_enanthate" class="mw-redirect" title="Fluphenazine enanthate">Fluphenazine enanthate</a></td>
<td>Prolixin Enanthate</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>12.5–100&#160;mg/1–4&#160;weeks</td>
<td>2–3&#160;days</td>
<td>4&#160;days</td>
<td>?</td>
<td>6.4–7.4</td>
<td><sup id="cite_ref-pmid444352_214-1" class="reference"><a href="#cite_note-pmid444352-214">&#91;213&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Fluspirilene" title="Fluspirilene">Fluspirilene</a></td>
<td>Imap, Redeptin</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Water" title="Water">Water</a><sup>a</sup></td>
<td>2–12&#160;mg/1&#160;week</td>
<td>1–8&#160;days</td>
<td>7&#160;days</td>
<td>?</td>
<td>5.2–5.8</td>
<td><sup id="cite_ref-pmid4992598_216-0" class="reference"><a href="#cite_note-pmid4992598-216">&#91;215&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Haloperidol_decanoate" title="Haloperidol decanoate">Haloperidol decanoate</a></td>
<td>Haldol Decanoate</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>20–400&#160;mg/2–4&#160;weeks</td>
<td>3–9&#160;days</td>
<td colspan="2">18–21&#160;days</td>
<td>7.2–7.9</td>
<td><sup id="cite_ref-pmid3545764_217-0" class="reference"><a href="#cite_note-pmid3545764-217">&#91;216&#93;</a></sup><sup id="cite_ref-pmid7185768_218-0" class="reference"><a href="#cite_note-pmid7185768-218">&#91;217&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Olanzapine_pamoate" class="mw-redirect" title="Olanzapine pamoate">Olanzapine pamoate</a></td>
<td>Zyprexa Relprevv</td>
<td><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></td>
<td><a href="/wiki/Water" title="Water">Water</a><sup>a</sup></td>
<td>150–405&#160;mg/2–4&#160;weeks</td>
<td>7&#160;days</td>
<td>?</td>
<td>30&#160;days</td>
<td>–</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Oxyprothepin_decanoate" title="Oxyprothepin decanoate">Oxyprothepin decanoate</a></td>
<td>Meclopin</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>8.5–8.7</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Paliperidone_palmitate" title="Paliperidone palmitate">Paliperidone palmitate</a></td>
<td>Invega Sustenna</td>
<td><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></td>
<td><a href="/wiki/Water" title="Water">Water</a><sup>a</sup></td>
<td>39–819&#160;mg/4–12&#160;weeks</td>
<td>13–33&#160;days</td>
<td>25–139&#160;days</td>
<td>?</td>
<td>8.1–10.1</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Perphenazine_decanoate" class="mw-redirect" title="Perphenazine decanoate">Perphenazine decanoate</a></td>
<td>Trilafon Dekanoat</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>50–200&#160;mg/2–4&#160;weeks</td>
<td>?</td>
<td>?</td>
<td>27&#160;days</td>
<td>8.9</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Perphenazine_enanthate" title="Perphenazine enanthate">Perphenazine enanthate</a></td>
<td>Trilafon Enanthate</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>25–200&#160;mg/2&#160;weeks</td>
<td>2–3&#160;days</td>
<td>?</td>
<td>4–7&#160;days</td>
<td>6.4–7.2</td>
<td><sup id="cite_ref-LarssonAxelsson1984_219-0" class="reference"><a href="#cite_note-LarssonAxelsson1984-219">&#91;218&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pipotiazine_palmitate" class="mw-redirect" title="Pipotiazine palmitate">Pipotiazine palmitate</a></td>
<td>Piportil Longum</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Viscoleo" title="Viscoleo">Viscoleo</a><sup>b</sup></td>
<td>25–400&#160;mg/4&#160;weeks</td>
<td>9–10&#160;days</td>
<td>?</td>
<td>14–21&#160;days</td>
<td>8.5–11.6</td>
<td><sup id="cite_ref-Reynolds1993_212-1" class="reference"><a href="#cite_note-Reynolds1993-212">&#91;211&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pipotiazine_undecylenate" class="mw-redirect" title="Pipotiazine undecylenate">Pipotiazine undecylenate</a></td>
<td>Piportil Medium</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Sesame_oil" title="Sesame oil">Sesame oil</a></td>
<td>100–200&#160;mg/2&#160;weeks</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>8.4</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></td>
<td>Risperdal Consta</td>
<td><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></td>
<td><a href="/wiki/Microsphere" class="mw-redirect" title="Microsphere">Microspheres</a></td>
<td>12.5–75&#160;mg/2&#160;weeks</td>
<td>21&#160;days</td>
<td>?</td>
<td>3–6&#160;days</td>
<td>–</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Zuclopentixol_acetate" class="mw-redirect" title="Zuclopentixol acetate">Zuclopentixol acetate</a></td>
<td>Clopixol Acuphase</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Viscoleo" title="Viscoleo">Viscoleo</a><sup>b</sup></td>
<td>50–200&#160;mg/1–3&#160;days</td>
<td>1–2&#160;days</td>
<td colspan="2">1–2 days</td>
<td>4.7–4.9</td>
<td>
</td></tr>
<tr>
<td><a href="/wiki/Zuclopentixol_decanoate" class="mw-redirect" title="Zuclopentixol decanoate">Zuclopentixol decanoate</a></td>
<td>Clopixol Depot</td>
<td><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></td>
<td><a href="/wiki/Viscoleo" title="Viscoleo">Viscoleo</a><sup>b</sup></td>
<td>50–800&#160;mg/2–4&#160;weeks</td>
<td>4–9&#160;days</td>
<td>?</td>
<td>11–21&#160;days</td>
<td>7.5–9.0</td>
<td>
</td></tr>
<tr class="sortbottom">
<td colspan="10" style="width: 1px; background-color:#eaecf0; background-color:#eaecf0; text-align: center;"><b>Note:</b> All by <a href="/wiki/Intramuscular_injection" title="Intramuscular injection">intramuscular injection</a>. <b>Footnotes:</b> <sup>a</sup> = <a href="/wiki/Microcrystalline" title="Microcrystalline">Microcrystalline</a> or <a href="/wiki/Nanocrystalline" class="mw-redirect" title="Nanocrystalline">nanocrystalline</a> <a href="/wiki/Aqueous_suspension" class="mw-redirect" title="Aqueous suspension">aqueous suspension</a>. <sup>b</sup> = Low-<a href="/wiki/Viscosity" title="Viscosity">viscosity</a> <a href="/wiki/Vegetable_oil" title="Vegetable oil">vegetable oil</a> (specifically <a href="/wiki/Fractionated_coconut_oil" class="mw-redirect" title="Fractionated coconut oil">fractionated coconut oil</a> with <a href="/wiki/Medium-chain_triglyceride" title="Medium-chain triglyceride">medium-chain triglycerides</a>). <sup>c</sup> = Predicted, from <a href="/wiki/PubChem" title="PubChem">PubChem</a> and <a href="/wiki/DrugBank" title="DrugBank">DrugBank</a>. <b>Sources:</b> <i>Main:</i> See template.
</td></tr></tbody></table>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=35" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Thorazine_advert.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/c/c2/Thorazine_advert.jpg/220px-Thorazine_advert.jpg" decoding="async" width="220" height="340" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/c/c2/Thorazine_advert.jpg/330px-Thorazine_advert.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c2/Thorazine_advert.jpg/440px-Thorazine_advert.jpg 2x" data-file-width="927" data-file-height="1433" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Thorazine_advert.jpg" class="internal" title="Enlarge"></a></div>Advertisement for Thorazine (<a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>) from the 1950s, reflecting the perceptions of psychosis, including the now-discredited perception of a tendency towards violence, from the time when antipsychotics were discovered<sup id="cite_ref-220" class="reference"><a href="#cite_note-220">&#91;219&#93;</a></sup></div></div></div>
<p>The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first, <a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, was developed as a surgical <a href="/wiki/Anesthetic" title="Anesthetic">anesthetic</a>. It was first used on psychiatric patients because of its powerful calming effect; at the time it was regarded as a non-permanent "pharmacological <a href="/wiki/Lobotomy" title="Lobotomy">lobotomy</a>".<sup id="cite_ref-pieters_221-0" class="reference"><a href="#cite_note-pieters-221">&#91;220&#93;</a></sup> Lobotomy at the time was used to treat many behavioral disorders, including psychosis, although its effect was to markedly reduce behavior and mental functioning of all types. However, chlorpromazine proved to reduce the effects of psychosis in a more effective and specific manner than lobotomy, even though it was known to be capable of causing severe sedation. The underlying <a href="/wiki/Neurochemistry" title="Neurochemistry">neurochemistry</a> involved has since been studied in detail, and subsequent antipsychotic drugs have been developed by <a href="/wiki/Drug_design" title="Drug design">rational drug design</a>.
</p><p>The discovery of chlorpromazine's psychoactive effects in 1952 led to further research that resulted in the development of <a href="/wiki/Antidepressant" title="Antidepressant">antidepressants</a>, <a href="/wiki/Anxiolytic" title="Anxiolytic">anxiolytics</a>, and the majority of other drugs now used in the management of psychiatric conditions. In 1952, <a href="/wiki/Henri_Laborit" title="Henri Laborit">Henri Laborit</a> described chlorpromazine only as inducing indifference towards what was happening around them in nonpsychotic, nonmanic patients, and <a href="/wiki/Jean_Delay" title="Jean Delay">Jean Delay</a> and <a href="/wiki/Pierre_Deniker" title="Pierre Deniker">Pierre Deniker</a> described it as controlling manic or psychotic agitation. The former claimed to have discovered a treatment for agitation in anyone, and the latter team claimed to have discovered a treatment for psychotic illness.<sup id="cite_ref-222" class="reference"><a href="#cite_note-222">&#91;221&#93;</a></sup>
</p><p>Until the 1970s there was considerable debate within psychiatry on the most appropriate term to use to describe the new drugs.<sup id="cite_ref-king_8-1" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> In the late 1950s the most widely used term was "neuroleptic", followed by "major <a href="/wiki/Tranquilizer" title="Tranquilizer">tranquilizer</a>" and then "ataraxic".<sup id="cite_ref-king_8-2" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> The first recorded use of the term tranquilizer dates from the early nineteenth century.<sup id="cite_ref-223" class="reference"><a href="#cite_note-223">&#91;222&#93;</a></sup> In 1953 Frederik F. Yonkman, a chemist at the Swiss-based <a href="/wiki/Ciba_Specialty_Chemicals" title="Ciba Specialty Chemicals">Cibapharmaceutical</a> company, first used the term tranquilizer to differentiate <a href="/wiki/Reserpine" title="Reserpine">reserpine</a> from the older sedatives.<sup id="cite_ref-224" class="reference"><a href="#cite_note-224">&#91;223&#93;</a></sup> The word <i>neuroleptic</i> was coined in 1955 by Delay and Deniker after their discovery (1952) of the antipsychotic effects of chlorpromazine.<sup id="cite_ref-king_8-3" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> It is derived from the <a href="/wiki/Greek_language" title="Greek language">Greek</a>: <span lang="el">"<a href="https://en.wiktionary.org/wiki/%CE%BD%CE%B5%E1%BF%A6%CF%81%CE%BF%CE%BD" class="extiw" title="wikt:νεῦρον">νεῦρον</a>"</span> (<i>neuron</i>, originally meaning "<a href="/wiki/Sinew" class="mw-redirect" title="Sinew">sinew</a>" but today referring to the <a href="/wiki/Nerve" title="Nerve">nerves</a>) and "<a href="https://en.wiktionary.org/wiki/%CE%BB%CE%B1%CE%BC%CE%B2%CE%AC%CE%BD%CF%89" class="extiw" title="wikt:λαμβάνω">λαμβάνω</a>" (<i>lambanō</i>, meaning "take hold of"). Thus, the word means <i>taking hold of one's nerves</i>. It was often taken to refer also to common side effects such as reduced activity in general, as well as lethargy and impaired motor control. Although these effects are unpleasant and in some cases harmful, they were at one time, along with akathisia, considered a reliable sign that the drug was working.<sup id="cite_ref-pieters_221-1" class="reference"><a href="#cite_note-pieters-221">&#91;220&#93;</a></sup> The term "ataraxy" was coined by the neurologist Howard Fabing and the classicist Alister Cameron to describe the observed effect of psychic indifference and detachment in patients treated with chlorpromazine.<sup id="cite_ref-225" class="reference"><a href="#cite_note-225">&#91;224&#93;</a></sup> This term derived from the Greek adjective "<a href="https://en.wiktionary.org/wiki/%E1%BC%80%CF%84%CE%AC%CF%81%CE%B1%CE%BA%CF%84%CE%BF%CF%82" class="extiw" title="wikt:ἀτάρακτος">ἀτάρακτος</a>" (<i><a href="https://en.wiktionary.org/wiki/ataractic" class="extiw" title="wikt:ataractic">ataraktos</a></i>), which means "not disturbed, not excited, without confusion, steady, calm".<sup id="cite_ref-king_8-4" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat <a href="/wiki/Neurosis" title="Neurosis">neuroses</a>.<sup id="cite_ref-king_8-5" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects.<sup id="cite_ref-king_8-6" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup> Today, "minor tranquilizer" can refer to <a href="/wiki/Anxiolytic" title="Anxiolytic">anxiolytic</a> and/or <a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a> drugs such as the <a href="/wiki/Benzodiazepine" title="Benzodiazepine">benzodiazepines</a> and <a href="/wiki/Nonbenzodiazepines" class="mw-redirect" title="Nonbenzodiazepines">nonbenzodiazepines</a>, which have some antipsychotic properties and are recommended for concurrent use with antipsychotics, and are useful for insomnia or drug-induced psychosis.<sup id="cite_ref-226" class="reference"><a href="#cite_note-226">&#91;225&#93;</a></sup> They are potentially addictive sedatives.
</p><p>Antipsychotics are broadly divided into two groups, the <a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">typical or first-generation antipsychotics</a> and the <a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">atypical or second-generation antipsychotics</a>. The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of <a href="/wiki/5HT2A_receptor" class="mw-redirect" title="5HT2A receptor">5HT2A receptor</a> antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics.<sup id="cite_ref-king_8-7" class="reference"><a href="#cite_note-king-8">&#91;8&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Society_and_culture">Society and culture</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=36" title="Edit section: Society and culture">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Terminology">Terminology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=37" title="Edit section: Terminology">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The term <i>major tranquilizer</i> was used for older antipsychotic drugs. The term <i>neuroleptic</i> is often used as a <a href="/wiki/Synonym" title="Synonym">synonym</a> for <i>antipsychotic</i>, even though – strictly speaking – the two terms are not interchangeable. <i>Antipsychotic</i> drugs are a subgroup of <i>neuroleptic</i> drugs, because the latter have a wider range of effects.<sup id="cite_ref-:1_227-0" class="reference"><a href="#cite_note-:1-227">&#91;226&#93;</a></sup><sup id="cite_ref-228" class="reference"><a href="#cite_note-228">&#91;227&#93;</a></sup>
</p><p>Antipsychotics are a type of <a href="/wiki/Psychoactive" class="mw-redirect" title="Psychoactive">psychoactive</a> or psychotropic medication.<sup id="cite_ref-229" class="reference"><a href="#cite_note-229">&#91;228&#93;</a></sup><sup id="cite_ref-230" class="reference"><a href="#cite_note-230">&#91;229&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Sales">Sales</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=38" title="Edit section: Sales">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Antipsychotics were once among the biggest selling and most profitable of all drugs, generating $22&#160;billion in global sales in 2008.<sup id="cite_ref-healthcarefinancenews.com_231-0" class="reference"><a href="#cite_note-healthcarefinancenews.com-231">&#91;230&#93;</a></sup> By 2003 in the US, an estimated 3.21&#160;million patients received antipsychotics, worth an estimated $2.82&#160;billion. Over 2/3 of prescriptions were for the newer, more expensive atypicals, each costing on average $164 per year, compared to $40 for the older types.<sup id="cite_ref-pmid17158480_232-0" class="reference"><a href="#cite_note-pmid17158480-232">&#91;231&#93;</a></sup> By 2008, sales in the US reached $14.6&#160;billion, the biggest selling drugs in the US by therapeutic class.<sup id="cite_ref-233" class="reference"><a href="#cite_note-233">&#91;232&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Overprescription">Overprescription</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=39" title="Edit section: Overprescription">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Antipsychotics in the nursing home population are often overprescribed, often for the purposes of making it easier to handle dementia patients. Federal efforts to reduce the use of antipsychotics in US nursing homes has led to a nationwide decrease in their usage in 2012.<sup id="cite_ref-234" class="reference"><a href="#cite_note-234">&#91;233&#93;</a></sup><sup id="cite_ref-235" class="reference"><a href="#cite_note-235">&#91;234&#93;</a></sup><sup id="cite_ref-236" class="reference"><a href="#cite_note-236">&#91;235&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Legal">Legal</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=40" title="Edit section: Legal">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Antipsychotics are sometimes administered as part of compulsory psychiatric treatment via <a href="/wiki/Involuntary_commitment" title="Involuntary commitment">inpatient (hospital) commitment</a> or <a href="/wiki/Outpatient_commitment" title="Outpatient commitment">outpatient commitment</a>.
</p>
<h3><span class="mw-headline" id="Formulations">Formulations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=41" title="Edit section: Formulations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>They may be administered orally or, in some cases, through long-acting (depot) injections administered in the <a href="/wiki/Dorsogluteal_muscle" class="mw-redirect" title="Dorsogluteal muscle">dorsgluteal</a>, <a href="/wiki/Ventrogluteal_area" class="mw-redirect" title="Ventrogluteal area">ventrogluteal</a> or <a href="/wiki/Deltoid_muscle" title="Deltoid muscle">deltoid muscle</a>. Short-acting parenteral formulations also exist, which are generally reserved for emergencies or when oral administration is otherwise impossible. The oral formulations include immediate release, extended release, and orally disintegrating products (which are not sublingual, and can help ensure that medications are swallowed instead of "cheeked"). Sublingual products (e.g. <a href="/wiki/Asenapine" title="Asenapine">asenapine</a>) also exist, which must be held under the tongue for absorption. The first transdermal formulation of an antipsychotic (transdermal asenapine, marketed as Secuado), was FDA-approved in 2019.
</p>
<h3><span class="mw-headline" id="Recreational_use">Recreational use</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=42" title="Edit section: Recreational use">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Certain second-generation antipsychotics are <a href="/wiki/Substance_abuse#Drug_misuse" title="Substance abuse">misused</a> or <a href="/wiki/Substance_abuse" title="Substance abuse">abused</a> for their sedative, tranquilizing, and (paradoxically) "hallucinogenic" effects.<sup id="cite_ref-Bogart_2011_237-0" class="reference"><a href="#cite_note-Bogart_2011-237">&#91;236&#93;</a></sup> The most commonly second-generation antipsychotic implicated is <a href="/wiki/Quetiapine" title="Quetiapine">quetiapine</a>.<sup id="cite_ref-Bogart_2011_237-1" class="reference"><a href="#cite_note-Bogart_2011-237">&#91;236&#93;</a></sup> In case reports, quetiapine has been abused in doses taken by mouth (which is how the drug is available from the manufacturer), but also crushed and insufflated or mixed with water for injection into a vein.<sup id="cite_ref-Bogart_2011_237-2" class="reference"><a href="#cite_note-Bogart_2011-237">&#91;236&#93;</a></sup> <a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a>, another sedating second-generation antipsychotic, has also been misused for similar reasons.<sup id="cite_ref-Bogart_2011_237-3" class="reference"><a href="#cite_note-Bogart_2011-237">&#91;236&#93;</a></sup> There is no standard treatment for antipsychotic abuse, though switching to a second-generation antipsychotic with less abuse potential (e.g. <a href="/wiki/Aripiprazole" title="Aripiprazole">aripiprazole</a>) has been used.<sup id="cite_ref-Bogart_2011_237-4" class="reference"><a href="#cite_note-Bogart_2011-237">&#91;236&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Controversy">Controversy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=43" title="Edit section: Controversy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Joanna_Moncrieff" title="Joanna Moncrieff">Joanna Moncrieff</a> has argued that antipsychotic drug treatment is often undertaken as a means of control rather than to treat specific symptoms experienced by the patient.<sup id="cite_ref-guard_1_238-0" class="reference"><a href="#cite_note-guard_1-238">&#91;237&#93;</a></sup>
</p><p>Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff.<sup id="cite_ref-239" class="reference"><a href="#cite_note-239">&#91;238&#93;</a></sup> In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year.<sup id="cite_ref-240" class="reference"><a href="#cite_note-240">&#91;239&#93;</a></sup><sup id="cite_ref-241" class="reference"><a href="#cite_note-241">&#91;240&#93;</a></sup> In the US, the government has initiated legal action against the pharmaceutical company <a href="/wiki/Johnson_%26_Johnson" title="Johnson &amp; Johnson">Johnson &amp; Johnson</a> for allegedly paying <a href="/wiki/Kickback_(bribery)" title="Kickback (bribery)">kickbacks</a> to <a href="/wiki/Omnicare" title="Omnicare">Omnicare</a> to promote its antipsychotic <a href="/wiki/Risperidone" title="Risperidone">risperidone</a> (Risperdal) in nursing homes.<sup id="cite_ref-Hilzenrath_242-0" class="reference"><a href="#cite_note-Hilzenrath-242">&#91;241&#93;</a></sup>
</p><p>There has also been controversy about the <a href="/wiki/Pharmaceutical_marketing" title="Pharmaceutical marketing">role of pharmaceutical companies in marketing</a> and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations.<sup id="cite_ref-bied2010_243-0" class="reference"><a href="#cite_note-bied2010-243">&#91;242&#93;</a></sup> One case involved <a href="/wiki/Eli_Lilly_and_Company" title="Eli Lilly and Company">Eli Lilly and Company</a>'s antipsychotic <a href="/wiki/Zyprexa" class="mw-redirect" title="Zyprexa">Zyprexa</a>, and the other involved <a href="/wiki/Bextra" class="mw-redirect" title="Bextra">Bextra</a>. In the Bextra case, the government also charged <a href="/wiki/Pfizer" title="Pfizer">Pfizer</a> with illegally marketing another antipsychotic, <a href="/wiki/Geodon" class="mw-redirect" title="Geodon">Geodon</a>.<sup id="cite_ref-bied2010_243-1" class="reference"><a href="#cite_note-bied2010-243">&#91;242&#93;</a></sup> In addition, <a href="/wiki/Astrazeneca" class="mw-redirect" title="Astrazeneca">Astrazeneca</a> faces numerous personal-injury lawsuits from former users of <a href="/wiki/Seroquel" class="mw-redirect" title="Seroquel">Seroquel</a> (quetiapine), amidst federal<sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="The text near this tag may need clarification or removal of jargon. (January 2022)">clarification needed</span></a></i>&#93;</sup> investigations of its marketing practices.<sup id="cite_ref-244" class="reference"><a href="#cite_note-244">&#91;243&#93;</a></sup> By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5&#160;billion and $5.4&#160;billion respectively.<sup id="cite_ref-healthcarefinancenews.com_231-1" class="reference"><a href="#cite_note-healthcarefinancenews.com-231">&#91;230&#93;</a></sup>
</p><p>Harvard University medical professor <a href="/wiki/Joseph_Biederman" title="Joseph Biederman">Joseph Biederman</a> conducted research on bipolar disorder in children that led to an increase in such diagnoses. A 2008 Senate<sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Avoid_weasel_words" class="mw-redirect" title="Wikipedia:Avoid weasel words"><span title="The material near this tag possibly uses too vague attribution or weasel words. (January 2022)">which?</span></a></i>&#93;</sup> investigation found that Biederman also received $1.6 million in speaking and consulting fees between 2000 and 2007, some of them undisclosed to Harvard, from companies including makers of antipsychotic drugs prescribed for children with bipolar disorder. <a href="/wiki/Johnson_%26_Johnson" title="Johnson &amp; Johnson">Johnson &amp; Johnson</a> gave more than $700,000 to a research center that was headed by Biederman from 2002 to 2005, where research was conducted, in part, on <a href="/wiki/Risperdal" class="mw-redirect" title="Risperdal">Risperdal</a>, the company's antipsychotic drug. Biederman has responded saying that the money did not influence him and that he did not promote a specific diagnosis or treatment.<sup id="cite_ref-bied2010_243-2" class="reference"><a href="#cite_note-bied2010-243">&#91;242&#93;</a></sup>
</p><p>Pharmaceutical companies have also been accused of attempting to set the mental health agenda through activities such as funding <a href="/wiki/Consumer_advocacy_groups" class="mw-redirect" title="Consumer advocacy groups">consumer advocacy groups</a>.<sup id="cite_ref-pmid15278977_245-0" class="reference"><a href="#cite_note-pmid15278977-245">&#91;244&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Special_populations">Special populations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=44" title="Edit section: Special populations">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>It is recommended that persons with dementia who exhibit behavioral and psychological symptoms should not be given antipsychotics before trying other treatments.<sup id="cite_ref-APAfive_dementia_246-0" class="reference"><a href="#cite_note-APAfive_dementia-246">&#91;245&#93;</a></sup> When taking antipsychotics this population has increased risk of cerebrovascular effects, <a href="/wiki/Parkinsonism" title="Parkinsonism">parkinsonism</a> or <a href="/wiki/Extrapyramidal_symptoms" title="Extrapyramidal symptoms">extrapyramidal symptoms</a>, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality.<sup id="cite_ref-APAfive_dementia_246-1" class="reference"><a href="#cite_note-APAfive_dementia-246">&#91;245&#93;</a></sup> Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced.<sup id="cite_ref-APAfive_dementia_246-2" class="reference"><a href="#cite_note-APAfive_dementia-246">&#91;245&#93;</a></sup> Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy.<sup id="cite_ref-AGSfive_247-0" class="reference"><a href="#cite_note-AGSfive-247">&#91;246&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=45" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a href="/wiki/List_of_investigational_antipsychotics" title="List of investigational antipsychotics">List of investigational antipsychotics</a></li>
<li><a href="/wiki/Antipsychotic_switching" title="Antipsychotic switching">Antipsychotic switching</a></li></ul>
<h2><span class="mw-headline" id="Notes">Notes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=46" title="Edit section: Notes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<style data-mw-deduplicate="TemplateStyles:r1011085734">.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist">
<div class="mw-references-wrap"><ol class="references">
<li id="cite_note-192"><span class="mw-cite-backlink"><b><a href="#cite_ref-192">^</a></b></span> <span class="reference-text">Bolded drug names indicates drugs that are metabolites of clinically-marketed antipsychotics</span>
</li>
</ol></div></div>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=47" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1011085734"/><div class="reflist reflist-columns references-column-width" style="column-width: 30em;">
<ol class="references">
<li id="cite_note-Fin2009-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Fin2009_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Fin2009_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r1067248974">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style><cite id="CITEREFFinkelClarkCubeddu2009" class="citation book cs1">Finkel R, Clark MA, Cubeddu LX (2009). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Q4hG2gRhy7oC&amp;pg=PA151"><i>Pharmacology</i></a>. Lippincott Williams &amp; Wilkins. p.&#160;151. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780781771559" title="Special:BookSources/9780781771559"><bdi>9780781771559</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20170401065559/https://books.google.com/books?id=Q4hG2gRhy7oC&amp;pg=PA151">Archived</a> from the original on 1 April 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmacology&amp;rft.pages=151&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rft.date=2009&amp;rft.isbn=9780781771559&amp;rft.aulast=Finkel&amp;rft.aufirst=R&amp;rft.au=Clark%2C+MA&amp;rft.au=Cubeddu%2C+LX&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DQ4hG2gRhy7oC%26pg%3DPA151&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLallyMacCabe2015" class="citation journal cs1">Lally J, MacCabe JH (June 2015). <a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fbmb%2Fldv017">"Antipsychotic medication in schizophrenia: a review"</a>. <i>British Medical Bulletin</i>. <b>114</b> (1): 169–79. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fbmb%2Fldv017">10.1093/bmb/ldv017</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25957394">25957394</a>. <q>Antipsychotic medications are mainstays in the treatment of schizophrenia and a range of other psychotic disorders.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=British+Medical+Bulletin&amp;rft.atitle=Antipsychotic+medication+in+schizophrenia%3A+a+review&amp;rft.volume=114&amp;rft.issue=1&amp;rft.pages=169-79&amp;rft.date=2015-06&amp;rft_id=info%3Adoi%2F10.1093%2Fbmb%2Fldv017&amp;rft_id=info%3Apmid%2F25957394&amp;rft.aulast=Lally&amp;rft.aufirst=J&amp;rft.au=MacCabe%2C+JH&amp;rft_id=%2F%2Fdoi.org%2F10.1093%252Fbmb%252Fldv017&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Grande-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-Grande_3-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGrandeBerkBirmaherVieta2016" class="citation journal cs1">Grande I, Berk M, Birmaher B, Vieta E (April 2016). "Bipolar disorder". <i>Lancet</i>. <b>387</b> (10027): 1561–1572. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2815%2900241-X">10.1016/S0140-6736(15)00241-X</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/26388529">26388529</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205976059">205976059</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Bipolar+disorder&amp;rft.volume=387&amp;rft.issue=10027&amp;rft.pages=1561-1572&amp;rft.date=2016-04&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205976059%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F26388529&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2815%2900241-X&amp;rft.aulast=Grande&amp;rft.aufirst=I&amp;rft.au=Berk%2C+M&amp;rft.au=Birmaher%2C+B&amp;rft.au=Vieta%2C+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHoAndreasenZiebellPierson2011" class="citation journal cs1">Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (February 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3476840">"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia"</a>. <i>Archives of General Psychiatry</i>. <b>68</b> (2): 128–137. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Farchgenpsychiatry.2010.199">10.1001/archgenpsychiatry.2010.199</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3476840">3476840</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21300943">21300943</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Archives+of+General+Psychiatry&amp;rft.atitle=Long-term+antipsychotic+treatment+and+brain+volumes%3A+a+longitudinal+study+of+first-episode+schizophrenia&amp;rft.volume=68&amp;rft.issue=2&amp;rft.pages=128-137&amp;rft.date=2011-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3476840%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F21300943&amp;rft_id=info%3Adoi%2F10.1001%2Farchgenpsychiatry.2010.199&amp;rft.aulast=Ho&amp;rft.aufirst=BC&amp;rft.au=Andreasen%2C+NC&amp;rft.au=Ziebell%2C+S&amp;rft.au=Pierson%2C+R&amp;rft.au=Magnotta%2C+V&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3476840&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMoncrieffLeo2010" class="citation journal cs1">Moncrieff J, Leo J (September 2010). "A systematic review of the effects of antipsychotic drugs on brain volume". <i>Psychological Medicine</i>. <b>40</b> (9): 1409–1422. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1017%2FS0033291709992297">10.1017/S0033291709992297</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20085668">20085668</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:23522488">23522488</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychological+Medicine&amp;rft.atitle=A+systematic+review+of+the+effects+of+antipsychotic+drugs+on+brain+volume&amp;rft.volume=40&amp;rft.issue=9&amp;rft.pages=1409-1422&amp;rft.date=2010-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A23522488%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20085668&amp;rft_id=info%3Adoi%2F10.1017%2FS0033291709992297&amp;rft.aulast=Moncrieff&amp;rft.aufirst=J&amp;rft.au=Leo%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Shen-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-Shen_6-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFShen1999" class="citation journal cs1">Shen WW (December 1999). "A history of antipsychotic drug development". <i>Comprehensive Psychiatry</i>. <b>40</b> (6): 407–14. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fs0010-440x%2899%2990082-2">10.1016/s0010-440x(99)90082-2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10579370">10579370</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Comprehensive+Psychiatry&amp;rft.atitle=A+history+of+antipsychotic+drug+development&amp;rft.volume=40&amp;rft.issue=6&amp;rft.pages=407-14&amp;rft.date=1999-12&amp;rft_id=info%3Adoi%2F10.1016%2Fs0010-440x%2899%2990082-2&amp;rft_id=info%3Apmid%2F10579370&amp;rft.aulast=Shen&amp;rft.aufirst=WW&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Aringhieri-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-Aringhieri_7-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAringhieriCarliKolachalamVerdesca2018" class="citation journal cs1">Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M,  et&#160;al. (December 2018). "Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences". <i>Pharmacology &amp; Therapeutics</i>. <b>192</b>: 20–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.pharmthera.2018.06.012">10.1016/j.pharmthera.2018.06.012</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29953902">29953902</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:49602956">49602956</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacology+%26+Therapeutics&amp;rft.atitle=Molecular+targets+of+atypical+antipsychotics%3A+From+mechanism+of+action+to+clinical+differences&amp;rft.volume=192&amp;rft.pages=20-41&amp;rft.date=2018-12&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A49602956%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F29953902&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2018.06.012&amp;rft.aulast=Aringhieri&amp;rft.aufirst=S&amp;rft.au=Carli%2C+M&amp;rft.au=Kolachalam%2C+S&amp;rft.au=Verdesca%2C+V&amp;rft.au=Cini%2C+E&amp;rft.au=Rossi%2C+M&amp;rft.au=McCormick%2C+PJ&amp;rft.au=Corsini%2C+GU&amp;rft.au=Maggio%2C+R&amp;rft.au=Scarselli%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-king-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-king_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-king_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-king_8-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-king_8-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-king_8-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-king_8-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-king_8-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-king_8-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKingVoruganti2002" class="citation journal cs1">King C, Voruganti LN (May 2002). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC161646">"What's in a name? The evolution of the nomenclature of antipsychotic drugs"</a>. <i>Journal of Psychiatry &amp; Neuroscience</i>. <b>27</b> (3): 168–75. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC161646">161646</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/12066446">12066446</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychiatry+%26+Neuroscience&amp;rft.atitle=What%27s+in+a+name%3F+The+evolution+of+the+nomenclature+of+antipsychotic+drugs&amp;rft.volume=27&amp;rft.issue=3&amp;rft.pages=168-75&amp;rft.date=2002-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC161646%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F12066446&amp;rft.aulast=King&amp;rft.aufirst=C&amp;rft.au=Voruganti%2C+LN&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC161646&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lancet2009-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Lancet2009_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Lancet2009_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Lancet2009_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Lancet2009_9-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Lancet2009_9-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLeuchtCorvesArbterEngel2009" class="citation journal cs1">Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". <i>Lancet</i>. <b>373</b> (9657): 31–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2808%2961764-X">10.1016/S0140-6736(08)61764-X</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19058842">19058842</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:1071537">1071537</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia%3A+a+meta-analysis&amp;rft.volume=373&amp;rft.issue=9657&amp;rft.pages=31-41&amp;rft.date=2009-01&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A1071537%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19058842&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2808%2961764-X&amp;rft.aulast=Leucht&amp;rft.aufirst=S&amp;rft.au=Corves%2C+C&amp;rft.au=Arbter%2C+D&amp;rft.au=Engel%2C+RR&amp;rft.au=Li%2C+C&amp;rft.au=Davis%2C+JM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Haldep-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-Haldep_10-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGoikoleaColomTorresCapapey2013" class="citation journal cs1">Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E (January 2013). "Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol". <i>Journal of Affective Disorders</i>. <b>144</b> (3): 191–8. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jad.2012.07.038">10.1016/j.jad.2012.07.038</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23089129">23089129</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Affective+Disorders&amp;rft.atitle=Lower+rate+of+depressive+switch+following+antimanic+treatment+with+second-generation+antipsychotics+versus+haloperidol&amp;rft.volume=144&amp;rft.issue=3&amp;rft.pages=191-8&amp;rft.date=2013-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jad.2012.07.038&amp;rft_id=info%3Apmid%2F23089129&amp;rft.aulast=Goikolea&amp;rft.aufirst=JM&amp;rft.au=Colom%2C+F&amp;rft.au=Torres%2C+I&amp;rft.au=Capapey%2C+J&amp;rft.au=Valent%C3%AD%2C+M&amp;rft.au=Undurraga%2C+J&amp;rft.au=Grande%2C+I&amp;rft.au=Sanchez-Moreno%2C+J&amp;rft.au=Vieta%2C+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Maudsley-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Maudsley_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Maudsley_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Maudsley_11-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Maudsley_11-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Maudsley_11-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Maudsley_11-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTaylorPatonKapurTaylor2012" class="citation book cs1">Taylor D, Paton C, Kapur S, Taylor D (2012). <i>The Maudsley prescribing guidelines in psychiatry</i> (11th&#160;ed.). Chichester, West Sussex, UK: Wiley-Blackwell. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-470-97948-8" title="Special:BookSources/978-0-470-97948-8"><bdi>978-0-470-97948-8</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Maudsley+prescribing+guidelines+in+psychiatry&amp;rft.place=Chichester%2C+West+Sussex%2C+UK&amp;rft.edition=11th&amp;rft.pub=Wiley-Blackwell&amp;rft.date=2012&amp;rft.isbn=978-0-470-97948-8&amp;rft.aulast=Taylor&amp;rft.aufirst=D&amp;rft.au=Paton%2C+C&amp;rft.au=Kapur%2C+S&amp;rft.au=Taylor%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Choose2013-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Choose2013_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Choose2013_12-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Choose2013_12-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">"American Psychiatric Association Five Things Physicians and Patients Should Question"</a>. <i>Choosing Wisely</i>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131203174206/http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">Archived</a> from the original on 3 December 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">23 September</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Choosing+Wisely&amp;rft.atitle=American+Psychiatric+Association+Five+Things+Physicians+and+Patients+Should+Question&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Famerican-psychiatric-association%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBudman2014" class="citation journal cs1">Budman CL (July 2014). "The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview". <i>Drugs</i>. <b>74</b> (11): 1177–1193. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40265-014-0254-0">10.1007/s40265-014-0254-0</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25034359">25034359</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:24378317">24378317</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=The+role+of+atypical+antipsychotics+for+treatment+of+Tourette%27s+syndrome%3A+an+overview&amp;rft.volume=74&amp;rft.issue=11&amp;rft.pages=1177-1193&amp;rft.date=2014-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A24378317%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F25034359&amp;rft_id=info%3Adoi%2F10.1007%2Fs40265-014-0254-0&amp;rft.aulast=Budman&amp;rft.aufirst=CL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBassonGilks2018" class="citation journal cs1">Basson R, Gilks T (1 January 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5900810">"Women's sexual dysfunction associated with psychiatric disorders and their treatment"</a>. <i>Women's Health</i>. <b>14</b>: 1745506518762664. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1745506518762664">10.1177/1745506518762664</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5900810">5900810</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29649948">29649948</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Women%27s+Health&amp;rft.atitle=Women%27s+sexual+dysfunction+associated+with+psychiatric+disorders+and+their+treatment&amp;rft.volume=14&amp;rft.pages=1745506518762664&amp;rft.date=2018-01-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5900810%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F29649948&amp;rft_id=info%3Adoi%2F10.1177%2F1745506518762664&amp;rft.aulast=Basson&amp;rft.aufirst=R&amp;rft.au=Gilks%2C+T&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5900810&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKreysPhan2015" class="citation journal cs1">Kreys TJ, Phan SV (February 2015). "A literature review of quetiapine for generalized anxiety disorder". <i>Pharmacotherapy</i>. <b>35</b> (2): 175–188. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2Fphar.1529">10.1002/phar.1529</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25689246">25689246</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:24744675">24744675</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=A+literature+review+of+quetiapine+for+generalized+anxiety+disorder&amp;rft.volume=35&amp;rft.issue=2&amp;rft.pages=175-188&amp;rft.date=2015-02&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A24744675%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F25689246&amp;rft_id=info%3Adoi%2F10.1002%2Fphar.1529&amp;rft.aulast=Kreys&amp;rft.aufirst=TJ&amp;rft.au=Phan%2C+SV&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-NICE-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-NICE_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NICE_16-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NICE_16-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NICE_16-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://guidance.nice.org.uk/CG178">"Psychosis and schizophrenia in adults (CG178)"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20140304005556/http://guidance.nice.org.uk/CG178">Archived</a> from the original on 4 March 2014.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Psychosis+and+schizophrenia+in+adults+%28CG178%29&amp;rft_id=http%3A%2F%2Fguidance.nice.org.uk%2FCG178&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-APA-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-APA_17-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://psychiatryonline.org/guidelines.aspx">"PsychiatryOnline &#124; Guidelines"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=PsychiatryOnline+%26%23124%3B+Guidelines&amp;rft_id=http%3A%2F%2Fpsychiatryonline.org%2Fguidelines.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-BAP-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-BAP_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-BAP_18-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-BAP_18-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-BAP_18-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-BAP_18-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-BAP_18-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-BAP_18-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBarnes2011" class="citation journal cs1">Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". <i>Journal of Psychopharmacology</i>. <b>25</b> (5): 567–620. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F0269881110391123">10.1177/0269881110391123</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21292923">21292923</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:40089561">40089561</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychopharmacology&amp;rft.atitle=Evidence-based+guidelines+for+the+pharmacological+treatment+of+schizophrenia%3A+recommendations+from+the+British+Association+for+Psychopharmacology&amp;rft.volume=25&amp;rft.issue=5&amp;rft.pages=567-620&amp;rft.date=2011-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A40089561%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21292923&amp;rft_id=info%3Adoi%2F10.1177%2F0269881110391123&amp;rft.aulast=Barnes&amp;rft.aufirst=TR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMiyamotoMiyakeJarskogFleischhacker2012" class="citation journal cs1">Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (December 2012). <a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fmp.2012.47">"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents"</a>. <i>Molecular Psychiatry</i>. <b>17</b> (12): 1206–27. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fmp.2012.47">10.1038/mp.2012.47</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22584864">22584864</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Psychiatry&amp;rft.atitle=Pharmacological+treatment+of+schizophrenia%3A+a+critical+review+of+the+pharmacology+and+clinical+effects+of+current+and+future+therapeutic+agents&amp;rft.volume=17&amp;rft.issue=12&amp;rft.pages=1206-27&amp;rft.date=2012-12&amp;rft_id=info%3Adoi%2F10.1038%2Fmp.2012.47&amp;rft_id=info%3Apmid%2F22584864&amp;rft.aulast=Miyamoto&amp;rft.aufirst=S&amp;rft.au=Miyake%2C+N&amp;rft.au=Jarskog%2C+LF&amp;rft.au=Fleischhacker%2C+WW&amp;rft.au=Lieberman%2C+JA&amp;rft_id=%2F%2Fdoi.org%2F10.1038%252Fmp.2012.47&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-ReferenceA-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-ReferenceA_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ReferenceA_20-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHartlingAbou-SettaDursunMousavi2012" class="citation journal cs1">Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (October 2012). <a rel="nofollow" class="external text" href="https://doi.org/10.7326%2F0003-4819-157-7-201210020-00525">"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis"</a>. <i>Annals of Internal Medicine</i>. <b>157</b> (7): 498–511. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.7326%2F0003-4819-157-7-201210020-00525">10.7326/0003-4819-157-7-201210020-00525</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22893011">22893011</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Internal+Medicine&amp;rft.atitle=Antipsychotics+in+adults+with+schizophrenia%3A+comparative+effectiveness+of+first-generation+versus+second-generation+medications%3A+a+systematic+review+and+meta-analysis&amp;rft.volume=157&amp;rft.issue=7&amp;rft.pages=498-511&amp;rft.date=2012-10&amp;rft_id=info%3Adoi%2F10.7326%2F0003-4819-157-7-201210020-00525&amp;rft_id=info%3Apmid%2F22893011&amp;rft.aulast=Hartling&amp;rft.aufirst=L&amp;rft.au=Abou-Setta%2C+AM&amp;rft.au=Dursun%2C+S&amp;rft.au=Mousavi%2C+SS&amp;rft.au=Pasichnyk%2C+D&amp;rft.au=Newton%2C+AS&amp;rft_id=%2F%2Fdoi.org%2F10.7326%252F0003-4819-157-7-201210020-00525&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFurukawaLevineTanakaGoldberg2015" class="citation journal cs1">Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (January 2015). <a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjamapsychiatry.2014.2127">"Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies"</a>. <i>JAMA Psychiatry</i>. <b>72</b> (1): 14–21. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjamapsychiatry.2014.2127">10.1001/jamapsychiatry.2014.2127</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25372935">25372935</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA+Psychiatry&amp;rft.atitle=Initial+severity+of+schizophrenia+and+efficacy+of+antipsychotics%3A+participant-level+meta-analysis+of+6+placebo-controlled+studies&amp;rft.volume=72&amp;rft.issue=1&amp;rft.pages=14-21&amp;rft.date=2015-01&amp;rft_id=info%3Adoi%2F10.1001%2Fjamapsychiatry.2014.2127&amp;rft_id=info%3Apmid%2F25372935&amp;rft.aulast=Furukawa&amp;rft.aufirst=TA&amp;rft.au=Levine%2C+SZ&amp;rft.au=Tanaka%2C+S&amp;rft.au=Goldberg%2C+Y&amp;rft.au=Samara%2C+M&amp;rft.au=Davis%2C+JM&amp;rft.au=Cipriani%2C+A&amp;rft.au=Leucht%2C+S&amp;rft_id=%2F%2Fdoi.org%2F10.1001%252Fjamapsychiatry.2014.2127&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKeefeSilvaPerkinsLieberman1999" class="citation journal cs1">Keefe RS, Silva SG, Perkins DO, Lieberman JA (1 January 1999). <a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Foxfordjournals.schbul.a033374">"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis"</a>. <i>Schizophrenia Bulletin</i>. <b>25</b> (2): 201–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Foxfordjournals.schbul.a033374">10.1093/oxfordjournals.schbul.a033374</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10416727">10416727</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Bulletin&amp;rft.atitle=The+effects+of+atypical+antipsychotic+drugs+on+neurocognitive+impairment+in+schizophrenia%3A+a+review+and+meta-analysis&amp;rft.volume=25&amp;rft.issue=2&amp;rft.pages=201-22&amp;rft.date=1999-01-01&amp;rft_id=info%3Adoi%2F10.1093%2Foxfordjournals.schbul.a033374&amp;rft_id=info%3Apmid%2F10416727&amp;rft.aulast=Keefe&amp;rft.aufirst=RS&amp;rft.au=Silva%2C+SG&amp;rft.au=Perkins%2C+DO&amp;rft.au=Lieberman%2C+JA&amp;rft_id=%2F%2Fdoi.org%2F10.1093%252Foxfordjournals.schbul.a033374&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.nice.org.uk/guidance/cg178/resources/cg178-psychosis-and-schizophrenia-in-adults-full-guideline3">"NICE Treatment Guidance 2014"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20140813081133/http://www.nice.org.uk/guidance/cg178/resources/cg178-psychosis-and-schizophrenia-in-adults-full-guideline3">Archived</a> from the original on 13 August 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">7 August</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NICE+Treatment+Guidance+2014&amp;rft_id=http%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fcg178%2Fresources%2Fcg178-psychosis-and-schizophrenia-in-adults-full-guideline3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-McGorry-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-McGorry_24-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMcGorryHartmannSpoonerNelson2018" class="citation journal cs1">McGorry PD, Hartmann JA, Spooner R, Nelson B (June 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5980504">"Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry"</a>. <i>World Psychiatry</i>. <b>17</b> (2): 133–142. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2Fwps.20514">10.1002/wps.20514</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5980504">5980504</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29856558">29856558</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Psychiatry&amp;rft.atitle=Beyond+the+%22at+risk+mental+state%22+concept%3A+transitioning+to+transdiagnostic+psychiatry&amp;rft.volume=17&amp;rft.issue=2&amp;rft.pages=133-142&amp;rft.date=2018-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5980504%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F29856558&amp;rft_id=info%3Adoi%2F10.1002%2Fwps.20514&amp;rft.aulast=McGorry&amp;rft.aufirst=PD&amp;rft.au=Hartmann%2C+JA&amp;rft.au=Spooner%2C+R&amp;rft.au=Nelson%2C+B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5980504&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-drug-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-drug_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-drug_25-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFStarzerNordentoftHjorthøj2018" class="citation journal cs1">Starzer MS, Nordentoft M, Hjorthøj C (April 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.2017.17020223">"Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis"</a>. <i>The American Journal of Psychiatry</i>. American Psychiatric Association Publishing. <b>175</b> (4): 343–350. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.2017.17020223">10.1176/appi.ajp.2017.17020223</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29179576">29179576</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=Rates+and+Predictors+of+Conversion+to+Schizophrenia+or+Bipolar+Disorder+Following+Substance-Induced+Psychosis&amp;rft.volume=175&amp;rft.issue=4&amp;rft.pages=343-350&amp;rft.date=2018-04&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.2017.17020223&amp;rft_id=info%3Apmid%2F29179576&amp;rft.aulast=Starzer&amp;rft.aufirst=MS&amp;rft.au=Nordentoft%2C+M&amp;rft.au=Hjorth%C3%B8j%2C+C&amp;rft_id=%2F%2Fdoi.org%2F10.1176%252Fappi.ajp.2017.17020223&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRobinsonGallegoJohnPetrides2015" class="citation journal cs1">Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP,  et&#160;al. (November 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4601722">"A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes"</a>. <i>Schizophrenia Bulletin</i>. <b>41</b> (6): 1227–1236. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fschbul%2Fsbv125">10.1093/schbul/sbv125</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4601722">4601722</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/26338693">26338693</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Bulletin&amp;rft.atitle=A+Randomized+Comparison+of+Aripiprazole+and+Risperidone+for+the+Acute+Treatment+of+First-Episode+Schizophrenia+and+Related+Disorders%3A+3-Month+Outcomes&amp;rft.volume=41&amp;rft.issue=6&amp;rft.pages=1227-1236&amp;rft.date=2015-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4601722%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26338693&amp;rft_id=info%3Adoi%2F10.1093%2Fschbul%2Fsbv125&amp;rft.aulast=Robinson&amp;rft.aufirst=DG&amp;rft.au=Gallego%2C+JA&amp;rft.au=John%2C+M&amp;rft.au=Petrides%2C+G&amp;rft.au=Hassoun%2C+Y&amp;rft.au=Zhang%2C+JP&amp;rft.au=Lopez%2C+L&amp;rft.au=Braga%2C+RJ&amp;rft.au=Sevy%2C+SM&amp;rft.au=Addington%2C+J&amp;rft.au=Kellner%2C+CH&amp;rft.au=Tohen%2C+M&amp;rft.au=Naraine%2C+M&amp;rft.au=Bennett%2C+N&amp;rft.au=Greenberg%2C+J&amp;rft.au=Lencz%2C+T&amp;rft.au=Correll%2C+CU&amp;rft.au=Kane%2C+JM&amp;rft.au=Malhotra%2C+AK&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4601722&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGómez-RevueltaPelayo-TeránJuncal-RuizVázquez-Bourgon2020" class="citation journal cs1">Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R,  et&#160;al. (April 2020). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7177160">"Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone"</a>. <i>The International Journal of Neuropsychopharmacology</i>. <b>23</b> (4): 217–229. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fijnp%2Fpyaa004">10.1093/ijnp/pyaa004</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7177160">7177160</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/31974576">31974576</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+International+Journal+of+Neuropsychopharmacology&amp;rft.atitle=Antipsychotic+Treatment+Effectiveness+in+First+Episode+of+Psychosis%3A+PAFIP+3-Year+Follow-Up+Randomized+Clinical+Trials+Comparing+Haloperidol%2C+Olanzapine%2C+Risperidone%2C+Aripiprazole%2C+Quetiapine%2C+and+Ziprasidone&amp;rft.volume=23&amp;rft.issue=4&amp;rft.pages=217-229&amp;rft.date=2020-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7177160%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F31974576&amp;rft_id=info%3Adoi%2F10.1093%2Fijnp%2Fpyaa004&amp;rft.aulast=G%C3%B3mez-Revuelta&amp;rft.aufirst=M&amp;rft.au=Pelayo-Ter%C3%A1n%2C+JM&amp;rft.au=Juncal-Ruiz%2C+M&amp;rft.au=V%C3%A1zquez-Bourgon%2C+J&amp;rft.au=Su%C3%A1rez-Pinilla%2C+P&amp;rft.au=Romero-Jim%C3%A9nez%2C+R&amp;rft.au=Seti%C3%A9n+Suero%2C+E&amp;rft.au=Ayesa-Arriola%2C+R&amp;rft.au=Crespo-Facorro%2C+B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7177160&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLeuchtArbterEngelKissling2009" class="citation journal cs1">Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (April 2009). <a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fsj.mp.4002136">"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials"</a>. <i>Molecular Psychiatry</i>. <b>14</b> (4): 429–47. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fsj.mp.4002136">10.1038/sj.mp.4002136</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18180760">18180760</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Psychiatry&amp;rft.atitle=How+effective+are+second-generation+antipsychotic+drugs%3F+A+meta-analysis+of+placebo-controlled+trials&amp;rft.volume=14&amp;rft.issue=4&amp;rft.pages=429-47&amp;rft.date=2009-04&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.mp.4002136&amp;rft_id=info%3Apmid%2F18180760&amp;rft.aulast=Leucht&amp;rft.aufirst=S&amp;rft.au=Arbter%2C+D&amp;rft.au=Engel%2C+RR&amp;rft.au=Kissling%2C+W&amp;rft.au=Davis%2C+JM&amp;rft_id=%2F%2Fdoi.org%2F10.1038%252Fsj.mp.4002136&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Leucht_2013-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-Leucht_2013_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Leucht_2013_29-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLeuchtCiprianiSpineliMavridis2013" class="citation journal cs1">Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". <i>Lancet</i>. <b>382</b> (9896): 951–62. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2813%2960733-3">10.1016/S0140-6736(13)60733-3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23810019">23810019</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:32085212">32085212</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Comparative+efficacy+and+tolerability+of+15+antipsychotic+drugs+in+schizophrenia%3A+a+multiple-treatments+meta-analysis&amp;rft.volume=382&amp;rft.issue=9896&amp;rft.pages=951-62&amp;rft.date=2013-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A32085212%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23810019&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2813%2960733-3&amp;rft.aulast=Leucht&amp;rft.aufirst=S&amp;rft.au=Cipriani%2C+A&amp;rft.au=Spineli%2C+L&amp;rft.au=Mavridis%2C+D&amp;rft.au=Orey%2C+D&amp;rft.au=Richter%2C+F&amp;rft.au=Samara%2C+M&amp;rft.au=Barbui%2C+C&amp;rft.au=Engel%2C+RR&amp;rft.au=Geddes%2C+JR&amp;rft.au=Kissling%2C+W&amp;rft.au=Stapf%2C+MP&amp;rft.au=L%C3%A4ssig%2C+B&amp;rft.au=Salanti%2C+G&amp;rft.au=Davis%2C+JM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBeitingerLinKisslingLeucht2008" class="citation journal cs1">Beitinger R, Lin J, Kissling W, Leucht S (October 2008). "Comparative remission rates of schizophrenic patients using various remission criteria". <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i>. <b>32</b> (7): 1643–51. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.pnpbp.2008.06.008">10.1016/j.pnpbp.2008.06.008</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18616969">18616969</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:207408308">207408308</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Progress+in+Neuro-Psychopharmacology+%26+Biological+Psychiatry&amp;rft.atitle=Comparative+remission+rates+of+schizophrenic+patients+using+various+remission+criteria&amp;rft.volume=32&amp;rft.issue=7&amp;rft.pages=1643-51&amp;rft.date=2008-10&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A207408308%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18616969&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pnpbp.2008.06.008&amp;rft.aulast=Beitinger&amp;rft.aufirst=R&amp;rft.au=Lin%2C+J&amp;rft.au=Kissling%2C+W&amp;rft.au=Leucht%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Ceraso_2020-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ceraso_2020_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ceraso_2020_31-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCerasoLinSchneider-ThomaSiafis2020" class="citation journal cs1">Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K,  et&#160;al. (August 2020). "Maintenance treatment with antipsychotic drugs for schizophrenia". <i>The Cochrane Database of Systematic Reviews</i>. <b>2020</b> (8): CD008016. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD008016.pub3">10.1002/14651858.CD008016.pub3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/32840872">32840872</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:221306099">221306099</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Maintenance+treatment+with+antipsychotic+drugs+for+schizophrenia&amp;rft.volume=2020&amp;rft.issue=8&amp;rft.pages=CD008016&amp;rft.date=2020-08&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A221306099%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F32840872&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008016.pub3&amp;rft.aulast=Ceraso&amp;rft.aufirst=A&amp;rft.au=Lin%2C+JJ&amp;rft.au=Schneider-Thoma%2C+J&amp;rft.au=Siafis%2C+S&amp;rft.au=Tardy%2C+M&amp;rft.au=Komossa%2C+K&amp;rft.au=Heres%2C+S&amp;rft.au=Kissling%2C+W&amp;rft.au=Davis%2C+JM&amp;rft.au=Leucht%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Tiihonen_Tanskanen_Taipale_2018_pp._765–773-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tiihonen_Tanskanen_Taipale_2018_pp._765–773_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tiihonen_Tanskanen_Taipale_2018_pp._765–773_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTiihonenTanskanenTaipale2018" class="citation journal cs1">Tiihonen J, Tanskanen A, Taipale H (August 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.2018.17091001">"20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia"</a>. <i>The American Journal of Psychiatry</i>. American Psychiatric Association Publishing. <b>175</b> (8): 765–773. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.2018.17091001">10.1176/appi.ajp.2018.17091001</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29621900">29621900</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=20-Year+Nationwide+Follow-Up+Study+on+Discontinuation+of+Antipsychotic+Treatment+in+First-Episode+Schizophrenia&amp;rft.volume=175&amp;rft.issue=8&amp;rft.pages=765-773&amp;rft.date=2018-08&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.2018.17091001&amp;rft_id=info%3Apmid%2F29621900&amp;rft.aulast=Tiihonen&amp;rft.aufirst=J&amp;rft.au=Tanskanen%2C+A&amp;rft.au=Taipale%2C+H&amp;rft_id=%2F%2Fdoi.org%2F10.1176%252Fappi.ajp.2018.17091001&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKinonAscher-SvanumAdamsChen2008" class="citation journal cs1">Kinon BJ, Ascher-Svanum H, Adams DH, Chen L (October 2008). "The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials". <i>Journal of Clinical Psychopharmacology</i>. <b>28</b> (5): 544–9. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FJCP.0b013e318185e74a">10.1097/JCP.0b013e318185e74a</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18794651">18794651</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:203910">203910</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Psychopharmacology&amp;rft.atitle=The+temporal+relationship+between+symptom+change+and+treatment+discontinuation+in+a+pooled+analysis+of+4+schizophrenia+trials&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=544-9&amp;rft.date=2008-10&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A203910%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18794651&amp;rft_id=info%3Adoi%2F10.1097%2FJCP.0b013e318185e74a&amp;rft.aulast=Kinon&amp;rft.aufirst=BJ&amp;rft.au=Ascher-Svanum%2C+H&amp;rft.au=Adams%2C+DH&amp;rft.au=Chen%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-lai-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-lai_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-lai_34-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFParkChoiChoiPark2018" class="citation journal cs1">Park SC, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK,  et&#160;al. (November 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6245299">"Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis"</a>. <i>Clinical Psychopharmacology and Neuroscience</i>. <b>16</b> (4): 361–375. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.9758%2Fcpn.2018.16.4.361">10.9758/cpn.2018.16.4.361</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6245299">6245299</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/30466208">30466208</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Psychopharmacology+and+Neuroscience&amp;rft.atitle=Comparative+Efficacy+and+Safety+of+Long-acting+Injectable+and+Oral+Second-generation+Antipsychotics+for+the+Treatment+of+Schizophrenia%3A+A+Systematic+Review+and+Meta-analysis&amp;rft.volume=16&amp;rft.issue=4&amp;rft.pages=361-375&amp;rft.date=2018-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6245299%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F30466208&amp;rft_id=info%3Adoi%2F10.9758%2Fcpn.2018.16.4.361&amp;rft.aulast=Park&amp;rft.aufirst=SC&amp;rft.au=Choi%2C+MY&amp;rft.au=Choi%2C+J&amp;rft.au=Park%2C+E&amp;rft.au=Tchoe%2C+HJ&amp;rft.au=Suh%2C+JK&amp;rft.au=Kim%2C+YH&amp;rft.au=Won%2C+SH&amp;rft.au=Chung%2C+YC&amp;rft.au=Bae%2C+KY&amp;rft.au=Lee%2C+SK&amp;rft.au=Park%2C+CM&amp;rft.au=Lee%2C+SH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6245299&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-nice-full-guidelines-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-nice-full-guidelines_35-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.nice.org.uk/guidance/cg178/evidence/full-guideline-490503565">"PSYCHOSIS and Schizophreniain adults: THE NICE GUIDELINE ON TREATMENT AND MANAGEMENT"</a>. p.&#160;10.11.1.27.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=PSYCHOSIS+and+Schizophreniain+adults%3A+THE+NICE+GUIDELINE+ON+TREATMENT+AND+MANAGEMENT&amp;rft.pages=10.11.1.27&amp;rft_id=https%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fcg178%2Fevidence%2Ffull-guideline-490503565&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-cto-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-cto_36-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLambertSinghPatel2009" class="citation journal cs1">Lambert TJ, Singh BS, Patel MX (November 2009). <a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.195.52.s57">"Community treatment orders and antipsychotic long-acting injections"</a>. <i>The British Journal of Psychiatry. Supplement</i>. Royal College of Psychiatrists. <b>52</b> (S52): S57-62. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.195.52.s57">10.1192/bjp.195.52.s57</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19880919">19880919</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Journal+of+Psychiatry.+Supplement&amp;rft.atitle=Community+treatment+orders+and+antipsychotic+long-acting+injections&amp;rft.volume=52&amp;rft.issue=S52&amp;rft.pages=S57-62&amp;rft.date=2009-11&amp;rft_id=info%3Adoi%2F10.1192%2Fbjp.195.52.s57&amp;rft_id=info%3Apmid%2F19880919&amp;rft.aulast=Lambert&amp;rft.aufirst=TJ&amp;rft.au=Singh%2C+BS&amp;rft.au=Patel%2C+MX&amp;rft_id=%2F%2Fdoi.org%2F10.1192%252Fbjp.195.52.s57&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Young-37"><span class="mw-cite-backlink">^ <a href="#cite_ref-Young_37-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Young_37-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFYoungKradjanGuglielmoCorelli2009" class="citation book cs1">Young LL, Kradjan WA, Guglielmo BJ, Corelli RL, Williams BR, Koda-Kimble MA (2009). <i>Applied therapeutics: the clinical use of drugs</i> (9th&#160;ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. p.&#160;3040. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-7817-6555-8" title="Special:BookSources/978-0-7817-6555-8"><bdi>978-0-7817-6555-8</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Applied+therapeutics%3A+the+clinical+use+of+drugs&amp;rft.place=Philadelphia&amp;rft.pages=3040&amp;rft.edition=9th&amp;rft.pub=Wolters+Kluwer+Health%2FLippincott+Williams+%26+Wilkins&amp;rft.date=2009&amp;rft.isbn=978-0-7817-6555-8&amp;rft.aulast=Young&amp;rft.aufirst=LL&amp;rft.au=Kradjan%2C+WA&amp;rft.au=Guglielmo%2C+BJ&amp;rft.au=Corelli%2C+RL&amp;rft.au=Williams%2C+BR&amp;rft.au=Koda-Kimble%2C+MA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid20402706-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20402706_38-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCorrellSheridanDelBello2010" class="citation journal cs1">Correll CU, Sheridan EM, DelBello MP (March 2010). "Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials". <i>Bipolar Disorders</i>. <b>12</b> (2): 116–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1399-5618.2010.00798.x">10.1111/j.1399-5618.2010.00798.x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20402706">20402706</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bipolar+Disorders&amp;rft.atitle=Antipsychotic+and+mood+stabilizer+efficacy+and+tolerability+in+pediatric+and+adult+patients+with+bipolar+I+mania%3A+a+comparative+analysis+of+acute%2C+randomized%2C+placebo-controlled+trials&amp;rft.volume=12&amp;rft.issue=2&amp;rft.pages=116-41&amp;rft.date=2010-03&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1399-5618.2010.00798.x&amp;rft_id=info%3Apmid%2F20402706&amp;rft.aulast=Correll&amp;rft.aufirst=CU&amp;rft.au=Sheridan%2C+EM&amp;rft.au=DelBello%2C+MP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lur-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-Lur_39-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLowes" class="citation web cs1">Lowes R. <a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/807204">"Lurasidone Approved for Bipolar Depression"</a>. <i>Medscape</i>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131002013831/http://www.medscape.com/viewarticle/807204">Archived</a> from the original on 2 October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Medscape&amp;rft.atitle=Lurasidone+Approved+for+Bipolar+Depression&amp;rft.aulast=Lowes&amp;rft.aufirst=R&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F807204&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-OLD-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-OLD_40-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTohenKatagiriFujikoshiKanba2013" class="citation journal cs1">Tohen M, Katagiri H, Fujikoshi S, Kanba S (July 2013). "Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies". <i>Journal of Affective Disorders</i>. <b>149</b> (1–3): 196–201. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jad.2013.01.022">10.1016/j.jad.2013.01.022</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23485111">23485111</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Affective+Disorders&amp;rft.atitle=Efficacy+of+olanzapine+monotherapy+in+acute+bipolar+depression%3A+a+pooled+analysis+of+controlled+studies&amp;rft.volume=149&amp;rft.issue=1%E2%80%933&amp;rft.pages=196-201&amp;rft.date=2013-07&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jad.2013.01.022&amp;rft_id=info%3Apmid%2F23485111&amp;rft.aulast=Tohen&amp;rft.aufirst=M&amp;rft.au=Katagiri%2C+H&amp;rft.au=Fujikoshi%2C+S&amp;rft.au=Kanba%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-QuetD-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-QuetD_41-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFThase2008" class="citation journal cs1">Thase ME (February 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2515925">"Quetiapine monotherapy for bipolar depression"</a>. <i>Neuropsychiatric Disease and Treatment</i>. <b>4</b> (1): 11–21. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2147%2Fndt.s1162">10.2147/ndt.s1162</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2515925">2515925</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18728771">18728771</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropsychiatric+Disease+and+Treatment&amp;rft.atitle=Quetiapine+monotherapy+for+bipolar+depression&amp;rft.volume=4&amp;rft.issue=1&amp;rft.pages=11-21&amp;rft.date=2008-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2515925%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F18728771&amp;rft_id=info%3Adoi%2F10.2147%2Fndt.s1162&amp;rft.aulast=Thase&amp;rft.aufirst=ME&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2515925&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-OlanM-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-OlanM_42-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTohenGreilCalabreseSachs2005" class="citation journal cs1">Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL (July 2005). "Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial". <i>The American Journal of Psychiatry</i>. <b>162</b> (7): 1281–90. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.162.7.1281">10.1176/appi.ajp.162.7.1281</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15994710">15994710</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=Olanzapine+versus+lithium+in+the+maintenance+treatment+of+bipolar+disorder%3A+a+12-month%2C+randomized%2C+double-blind%2C+controlled+clinical+trial&amp;rft.volume=162&amp;rft.issue=7&amp;rft.pages=1281-90&amp;rft.date=2005-07&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.162.7.1281&amp;rft_id=info%3Apmid%2F15994710&amp;rft.aulast=Tohen&amp;rft.aufirst=M&amp;rft.au=Greil%2C+W&amp;rft.au=Calabrese%2C+JR&amp;rft.au=Sachs%2C+GS&amp;rft.au=Yatham%2C+LN&amp;rft.au=Oerlinghausen%2C+BM&amp;rft.au=Koukopoulos%2C+A&amp;rft.au=Cassano%2C+GB&amp;rft.au=Grunze%2C+H&amp;rft.au=Licht%2C+RW&amp;rft.au=Dell%27Osso%2C+L&amp;rft.au=Evans%2C+AR&amp;rft.au=Risser%2C+R&amp;rft.au=Baker%2C+RW&amp;rft.au=Crane%2C+H&amp;rft.au=Dossenbach%2C+MR&amp;rft.au=Bowden%2C+CL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-QuetM1-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-QuetM1_43-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDuffyMilinGrof2009" class="citation journal cs1">Duffy A, Milin R, Grof P (February 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2644292">"Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine"</a>. <i>BMC Psychiatry</i>. <b>9</b>: 4. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1186%2F1471-244X-9-4">10.1186/1471-244X-9-4</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2644292">2644292</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19200370">19200370</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMC+Psychiatry&amp;rft.atitle=Maintenance+treatment+of+adolescent+bipolar+disorder%3A+open+study+of+the+effectiveness+and+tolerability+of+quetiapine&amp;rft.volume=9&amp;rft.pages=4&amp;rft.date=2009-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2644292%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F19200370&amp;rft_id=info%3Adoi%2F10.1186%2F1471-244X-9-4&amp;rft.aulast=Duffy&amp;rft.aufirst=A&amp;rft.au=Milin%2C+R&amp;rft.au=Grof%2C+P&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2644292&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-QuetM2-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-QuetM2_44-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWeislerNolenNeijberHellqvist2011" class="citation journal cs1">Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (November 2011). "Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)". <i>The Journal of Clinical Psychiatry</i>. <b>72</b> (11): 1452–64. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.4088%2FJCP.11m06878">10.4088/JCP.11m06878</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22054050">22054050</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Continuation+of+quetiapine+versus+switching+to+placebo+or+lithium+for+maintenance+treatment+of+bipolar+I+disorder+%28Trial+144%3A+a+randomized+controlled+study%29&amp;rft.volume=72&amp;rft.issue=11&amp;rft.pages=1452-64&amp;rft.date=2011-11&amp;rft_id=info%3Adoi%2F10.4088%2FJCP.11m06878&amp;rft_id=info%3Apmid%2F22054050&amp;rft.aulast=Weisler&amp;rft.aufirst=RH&amp;rft.au=Nolen%2C+WA&amp;rft.au=Neijber%2C+A&amp;rft.au=Hellqvist%2C+A&amp;rft.au=Paulsson%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCiprianiRendellGeddes2009" class="citation journal cs1">Cipriani A, Rendell JM, Geddes J (January 2009).  Cipriani A (ed.). "Olanzapine in long-term treatment for bipolar disorder". <i>The Cochrane Database of Systematic Reviews</i> (1): CD004367. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD004367.pub2">10.1002/14651858.CD004367.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19160237">19160237</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205173641">205173641</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Olanzapine+in+long-term+treatment+for+bipolar+disorder&amp;rft.issue=1&amp;rft.pages=CD004367&amp;rft.date=2009-01&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205173641%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19160237&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD004367.pub2&amp;rft.aulast=Cipriani&amp;rft.aufirst=A&amp;rft.au=Rendell%2C+JM&amp;rft.au=Geddes%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid15000267-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15000267_46-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLehmanLiebermanDixonMcGlashan2004" class="citation journal cs1">Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (February 2004). "Practice guideline for the treatment of patients with schizophrenia, second edition". <i>The American Journal of Psychiatry</i>. <b>161</b> (2 Suppl): 1–56. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15000267">15000267</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=Practice+guideline+for+the+treatment+of+patients+with+schizophrenia%2C+second+edition&amp;rft.volume=161&amp;rft.issue=2+Suppl&amp;rft.pages=1-56&amp;rft.date=2004-02&amp;rft_id=info%3Apmid%2F15000267&amp;rft.aulast=Lehman&amp;rft.aufirst=AF&amp;rft.au=Lieberman%2C+JA&amp;rft.au=Dixon%2C+LB&amp;rft.au=McGlashan%2C+TH&amp;rft.au=Miller%2C+AL&amp;rft.au=Perkins%2C+DO&amp;rft.au=Kreyenbuhl%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Centre-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-Centre_47-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFNational_Collaborating_Centre2009" class="citation journal cs1">National Collaborating Centre (2009). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/books/NBK11681/">"Schizophrenia"</a>. <i>NCBI Bookshelf</i>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20704054">20704054</a><span class="reference-accessdate">. Retrieved <span class="nowrap">9 March</span> 2021</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NCBI+Bookshelf&amp;rft.atitle=Schizophrenia&amp;rft.date=2009&amp;rft_id=info%3Apmid%2F20704054&amp;rft.au=National+Collaborating+Centre&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK11681%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid21191528-48"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21191528_48-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21191528_48-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid21191528_48-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid21191528_48-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVentimigliaKalaliVahiaJeste2010" class="citation journal cs1">Ventimiglia J, Kalali AH, Vahia IV, Jeste DV (November 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3010964">"An analysis of the intended use of atypical antipsychotics in dementia"</a>. <i>Psychiatry</i>. <b>7</b> (11): 14–17. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3010964">3010964</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21191528">21191528</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychiatry&amp;rft.atitle=An+analysis+of+the+intended+use+of+atypical+antipsychotics+in+dementia&amp;rft.volume=7&amp;rft.issue=11&amp;rft.pages=14-17&amp;rft.date=2010-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3010964%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F21191528&amp;rft.aulast=Ventimiglia&amp;rft.aufirst=J&amp;rft.au=Kalali%2C+AH&amp;rft.au=Vahia%2C+IV&amp;rft.au=Jeste%2C+DV&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3010964&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAMDA_–_The_Society_for_Post-Acute_and_Long-Term_Care_Medicine2014" class="citation cs2"><a href="/wiki/AMDA_%E2%80%93_The_Society_for_Post-Acute_and_Long-Term_Care_Medicine" title="AMDA – The Society for Post-Acute and Long-Term Care Medicine">AMDA – The Society for Post-Acute and Long-Term Care Medicine</a> (February 2014), <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/amda/">"Ten Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" class="mw-redirect" title="ABIM Foundation">ABIM Foundation</a></i>, AMDA – The Society for Post-Acute and Long-Term Care Medicine, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20140913011101/http://www.choosingwisely.org/doctor-patient-lists/amda/">archived</a> from the original on 13 September 2014<span class="reference-accessdate">, retrieved <span class="nowrap">20 April</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.atitle=Ten+Things+Physicians+and+Patients+Should+Question&amp;rft.date=2014-02&amp;rft.au=AMDA+%E2%80%93+The+Society+for+Post-Acute+and+Long-Term+Care+Medicine&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Famda%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span>.</span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBallardWaite2006" class="citation journal cs1">Ballard C, Waite J (January 2006).  Ballard CG (ed.). "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease". <i>The Cochrane Database of Systematic Reviews</i> (1): CD003476. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD003476.pub2">10.1002/14651858.CD003476.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16437455">16437455</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=The+effectiveness+of+atypical+antipsychotics+for+the+treatment+of+aggression+and+psychosis+in+Alzheimer%27s+disease&amp;rft.issue=1&amp;rft.pages=CD003476&amp;rft.date=2006-01&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003476.pub2&amp;rft_id=info%3Apmid%2F16437455&amp;rft.aulast=Ballard&amp;rft.aufirst=C&amp;rft.au=Waite%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRichterMeyerMöhlerKöpke2012" class="citation journal cs1">Richter T, Meyer G, Möhler R, Köpke S (December 2012).  Köpke S (ed.). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6492452">"Psychosocial interventions for reducing antipsychotic medication in care home residents"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>12</b>: CD008634. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD008634.pub2">10.1002/14651858.CD008634.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6492452">6492452</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23235663">23235663</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Psychosocial+interventions+for+reducing+antipsychotic+medication+in+care+home+residents&amp;rft.volume=12&amp;rft.pages=CD008634&amp;rft.date=2012-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6492452%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23235663&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008634.pub2&amp;rft.aulast=Richter&amp;rft.aufirst=T&amp;rft.au=Meyer%2C+G&amp;rft.au=M%C3%B6hler%2C+R&amp;rft.au=K%C3%B6pke%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6492452&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Cochrane_Dep-52"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_Dep_52-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_Dep_52-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKomossaDeppingGaudchauKissling2010" class="citation journal cs1">Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". <i>The Cochrane Database of Systematic Reviews</i> (12): CD008121. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD008121.pub2">10.1002/14651858.CD008121.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21154393">21154393</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Second-generation+antipsychotics+for+major+depressive+disorder+and+dysthymia&amp;rft.issue=12&amp;rft.pages=CD008121&amp;rft.date=2010-12&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008121.pub2&amp;rft_id=info%3Apmid%2F21154393&amp;rft.aulast=Komossa&amp;rft.aufirst=K&amp;rft.au=Depping%2C+AM&amp;rft.au=Gaudchau%2C+A&amp;rft.au=Kissling%2C+W&amp;rft.au=Leucht%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Plos-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-Plos_53-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSpielmansBermanLinardatosRosenlicht2013" class="citation journal cs1">Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3595214">"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes"</a>. <i>PLOS Medicine</i>. <b>10</b> (3): e1001403. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1371%2Fjournal.pmed.1001403">10.1371/journal.pmed.1001403</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3595214">3595214</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23554581">23554581</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+Medicine&amp;rft.atitle=Adjunctive+atypical+antipsychotic+treatment+for+major+depressive+disorder%3A+a+meta-analysis+of+depression%2C+quality+of+life%2C+and+safety+outcomes&amp;rft.volume=10&amp;rft.issue=3&amp;rft.pages=e1001403&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3595214%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23554581&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pmed.1001403&amp;rft.aulast=Spielmans&amp;rft.aufirst=GI&amp;rft.au=Berman%2C+MI&amp;rft.au=Linardatos%2C+E&amp;rft.au=Rosenlicht%2C+NZ&amp;rft.au=Perry%2C+A&amp;rft.au=Tsai%2C+AC&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3595214&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-DrugPoint-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-DrugPoint_54-0">^</a></b></span> <span class="reference-text">Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Oct 2]. Greenwood Village, CO: Thomsen Healthcare; 2013.</span>
</li>
<li id="cite_note-AACAP_FDA_Psychopharm_QTP_Recap-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-AACAP_FDA_Psychopharm_QTP_Recap_55-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.aacap.org/App_Themes/AACAP/docs/Advocacy/regulatory_issues/2009/FDA_Psychopharm_Hearing_Summary_Final.pdf">"FDA Psychopharmacologic Drugs Advisory Committee Hearing"</a> <span class="cs1-format">(PDF)</span>. <i>American Academy of Child &amp; Adolescent Psychiatry</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 May</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=American+Academy+of+Child+%26+Adolescent+Psychiatry&amp;rft.atitle=FDA+Psychopharmacologic+Drugs+Advisory+Committee+Hearing&amp;rft_id=https%3A%2F%2Fwww.aacap.org%2FApp_Themes%2FAACAP%2Fdocs%2FAdvocacy%2Fregulatory_issues%2F2009%2FFDA_Psychopharm_Hearing_Summary_Final.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Rand2012-56"><span class="mw-cite-backlink">^ <a href="#cite_ref-Rand2012_56-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Rand2012_56-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMaherTheodore2012" class="citation journal cs1">Maher AR, Theodore G (June 2012). <a rel="nofollow" class="external text" href="https://doi.org/10.18553%2Fjmcp.2012.18.s5-b.1">"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics"</a>. <i>Journal of Managed Care Pharmacy</i>. <b>18</b> (5 Suppl B): S1–20. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.18553%2Fjmcp.2012.18.s5-b.1">10.18553/jmcp.2012.18.s5-b.1</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22784311">22784311</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Managed+Care+Pharmacy&amp;rft.atitle=Summary+of+the+comparative+effectiveness+review+on+off-label+use+of+atypical+antipsychotics&amp;rft.volume=18&amp;rft.issue=5+Suppl+B&amp;rft.pages=S1-20&amp;rft.date=2012-06&amp;rft_id=info%3Adoi%2F10.18553%2Fjmcp.2012.18.s5-b.1&amp;rft_id=info%3Apmid%2F22784311&amp;rft.aulast=Maher&amp;rft.aufirst=AR&amp;rft.au=Theodore%2C+G&amp;rft_id=%2F%2Fdoi.org%2F10.18553%252Fjmcp.2012.18.s5-b.1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Off-Label_Use-57"><span class="mw-cite-backlink">^ <a href="#cite_ref-Off-Label_Use_57-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Off-Label_Use_57-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMaglioneMaherHuWang2011" class="citation book cs1">Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ (2011). <i>Off-Label Use of Atypical Antipsychotics: An Update</i>. Comparative Effectiveness Reviews, No. 43. Rockville: Agency for Healthcare Research and Quality. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22973576">22973576</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Off-Label+Use+of+Atypical+Antipsychotics%3A+An+Update&amp;rft.place=Rockville&amp;rft.series=Comparative+Effectiveness+Reviews%2C+No.+43&amp;rft.pub=Agency+for+Healthcare+Research+and+Quality&amp;rft.date=2011&amp;rft_id=info%3Apmid%2F22973576&amp;rft.aulast=Maglione&amp;rft.aufirst=M&amp;rft.au=Maher%2C+AR&amp;rft.au=Hu%2C+J&amp;rft.au=Wang%2C+Z&amp;rft.au=Shanman%2C+R&amp;rft.au=Shekelle%2C+PG&amp;rft.au=Roth%2C+B&amp;rft.au=Hilton%2C+L&amp;rft.au=Suttorp%2C+MJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCoeHong2012" class="citation journal cs1">Coe HV, Hong IS (May 2012). "Safety of low doses of quetiapine when used for insomnia". <i>The Annals of Pharmacotherapy</i>. <b>46</b> (5): 718–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1345%2Faph.1Q697">10.1345/aph.1Q697</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22510671">22510671</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:9888209">9888209</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Annals+of+Pharmacotherapy&amp;rft.atitle=Safety+of+low+doses+of+quetiapine+when+used+for+insomnia&amp;rft.volume=46&amp;rft.issue=5&amp;rft.pages=718-22&amp;rft.date=2012-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A9888209%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F22510671&amp;rft_id=info%3Adoi%2F10.1345%2Faph.1Q697&amp;rft.aulast=Coe&amp;rft.aufirst=HV&amp;rft.au=Hong%2C+IS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWork_Group_on_Borderline_Personality_Disorder2001" class="citation book cs1">Work Group on Borderline Personality Disorder (2001). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=xvQ2QKok3-oC"><i>Practice Guideline for the Treatment of Patients With Borderline Personality Disorder</i></a>. American Psychiatric Association Publications. p.&#160;4. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0890423196" title="Special:BookSources/978-0890423196"><bdi>978-0890423196</bdi></a><span class="reference-accessdate">. Retrieved <span class="nowrap">5 June</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Practice+Guideline+for+the+Treatment+of+Patients+With+Borderline+Personality+Disorder&amp;rft.pages=4&amp;rft.pub=American+Psychiatric+Association+Publications&amp;rft.date=2001&amp;rft.isbn=978-0890423196&amp;rft.au=Work+Group+on+Borderline+Personality+Disorder&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DxvQ2QKok3-oC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFZuddasZanniUsala2011" class="citation journal cs1">Zuddas A, Zanni R, Usala T (August 2011). "Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies". <i>European Neuropsychopharmacology</i>. <b>21</b> (8): 600–20. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.euroneuro.2011.04.001">10.1016/j.euroneuro.2011.04.001</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21550212">21550212</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:1254352">1254352</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Neuropsychopharmacology&amp;rft.atitle=Second+generation+antipsychotics+%28SGAs%29+for+non-psychotic+disorders+in+children+and+adolescents%3A+a+review+of+the+randomized+controlled+studies&amp;rft.volume=21&amp;rft.issue=8&amp;rft.pages=600-20&amp;rft.date=2011-08&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A1254352%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21550212&amp;rft_id=info%3Adoi%2F10.1016%2Fj.euroneuro.2011.04.001&amp;rft.aulast=Zuddas&amp;rft.aufirst=A&amp;rft.au=Zanni%2C+R&amp;rft.au=Usala%2C+T&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPringsheimDojaGormanMcKinlay2012" class="citation journal cs1">Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (March 2012). <a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F070674371205700302">"Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy"</a>. <i>Canadian Journal of Psychiatry</i>. <b>57</b> (3): 133–43. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F070674371205700302">10.1177/070674371205700302</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22397999">22397999</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Canadian+Journal+of+Psychiatry&amp;rft.atitle=Canadian+guidelines+for+the+evidence-based+treatment+of+tic+disorders%3A+pharmacotherapy&amp;rft.volume=57&amp;rft.issue=3&amp;rft.pages=133-43&amp;rft.date=2012-03&amp;rft_id=info%3Adoi%2F10.1177%2F070674371205700302&amp;rft_id=info%3Apmid%2F22397999&amp;rft.aulast=Pringsheim&amp;rft.aufirst=T&amp;rft.au=Doja%2C+A&amp;rft.au=Gorman%2C+D&amp;rft.au=McKinlay%2C+D&amp;rft.au=Day%2C+L&amp;rft.au=Billinghurst%2C+L&amp;rft.au=Carroll%2C+A&amp;rft.au=Dion%2C+Y&amp;rft.au=Luscombe%2C+S&amp;rft.au=Steeves%2C+T&amp;rft.au=Sandor%2C+P&amp;rft_id=%2F%2Fdoi.org%2F10.1177%252F070674371205700302&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMcPheetersWarrenSatheBruzek2011" class="citation journal cs1">McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (May 2011). "A systematic review of medical treatments for children with autism spectrum disorders". <i>Pediatrics</i>. <b>127</b> (5): e1312–21. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1542%2Fpeds.2011-0427">10.1542/peds.2011-0427</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21464191">21464191</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:2903864">2903864</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pediatrics&amp;rft.atitle=A+systematic+review+of+medical+treatments+for+children+with+autism+spectrum+disorders&amp;rft.volume=127&amp;rft.issue=5&amp;rft.pages=e1312-21&amp;rft.date=2011-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A2903864%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21464191&amp;rft_id=info%3Adoi%2F10.1542%2Fpeds.2011-0427&amp;rft.aulast=McPheeters&amp;rft.aufirst=ML&amp;rft.au=Warren%2C+Z&amp;rft.au=Sathe%2C+N&amp;rft.au=Bruzek%2C+JL&amp;rft.au=Krishnaswami%2C+S&amp;rft.au=Jerome%2C+RN&amp;rft.au=Veenstra-Vanderweele%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://archive.ahrq.gov/news/press/pr2007/antipsypr.htm">"Evidence Lacking to Support Many Off-label Uses of Atypical Antipsychotics"</a> (Press release). <a href="/wiki/Agency_for_Healthcare_Research_and_Quality" title="Agency for Healthcare Research and Quality">Agency for Healthcare Research and Quality</a>. 17 January 2007. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20130225052120/http://archive.ahrq.gov/news/press/pr2007/antipsypr.htm">Archived</a> from the original on 25 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">29 July</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Evidence+Lacking+to+Support+Many+Off-label+Uses+of+Atypical+Antipsychotics&amp;rft.pub=Agency+for+Healthcare+Research+and+Quality&amp;rft.date=2007-01-17&amp;rft_id=http%3A%2F%2Farchive.ahrq.gov%2Fnews%2Fpress%2Fpr2007%2Fantipsypr.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJames2010" class="citation journal cs1">James AC (2010). <a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fapt.bp.108.005652">"Prescribing antipsychotics for children and adolescents"</a>. <i>Advances in Psychiatric Treatment</i>. <b>16</b> (1): 63–75. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fapt.bp.108.005652">10.1192/apt.bp.108.005652</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Advances+in+Psychiatric+Treatment&amp;rft.atitle=Prescribing+antipsychotics+for+children+and+adolescents&amp;rft.volume=16&amp;rft.issue=1&amp;rft.pages=63-75&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.1192%2Fapt.bp.108.005652&amp;rft.aulast=James&amp;rft.aufirst=AC&amp;rft_id=%2F%2Fdoi.org%2F10.1192%252Fapt.bp.108.005652&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-DD-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-DD_65-0">^</a></b></span> <span class="reference-text">Truven Health Analytics, Inc. DRUGDEX System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.</span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRomeoKnappTyrerCrawford2009" class="citation journal cs1">Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P (July 2009). "The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis". <i>Journal of Intellectual Disability Research</i>. <b>53</b> (7): 633–43. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1365-2788.2009.01180.x">10.1111/j.1365-2788.2009.01180.x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19460067">19460067</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:34448894">34448894</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Intellectual+Disability+Research&amp;rft.atitle=The+treatment+of+challenging+behaviour+in+intellectual+disabilities%3A+cost-effectiveness+analysis&amp;rft.volume=53&amp;rft.issue=7&amp;rft.pages=633-43&amp;rft.date=2009-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A34448894%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19460067&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2788.2009.01180.x&amp;rft.aulast=Romeo&amp;rft.aufirst=R&amp;rft.au=Knapp%2C+M&amp;rft.au=Tyrer%2C+P&amp;rft.au=Crawford%2C+M&amp;rft.au=Oliver-Africano%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLintonBarrHonerProcyshyn2013" class="citation journal cs1">Linton D, Barr AM, Honer WG, Procyshyn RM (May 2013). "Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability". <i>Current Psychiatry Reports</i>. <b>15</b> (5): 355. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs11920-013-0355-6">10.1007/s11920-013-0355-6</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23539465">23539465</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:45484062">45484062</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Psychiatry+Reports&amp;rft.atitle=Antipsychotic+and+psychostimulant+drug+combination+therapy+in+attention+deficit%2Fhyperactivity+and+disruptive+behavior+disorders%3A+a+systematic+review+of+efficacy+and+tolerability&amp;rft.volume=15&amp;rft.issue=5&amp;rft.pages=355&amp;rft.date=2013-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A45484062%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23539465&amp;rft_id=info%3Adoi%2F10.1007%2Fs11920-013-0355-6&amp;rft.aulast=Linton&amp;rft.aufirst=D&amp;rft.au=Barr%2C+AM&amp;rft.au=Honer%2C+WG&amp;rft.au=Procyshyn%2C+RM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFOhNeedhamNikooieWilson2019" class="citation journal cs1">Oh ES, Needham DM, Nikooie R, Wilson LM, Zhang A, Robinson KA, Neufeld KJ (October 2019). <a rel="nofollow" class="external text" href="https://doi.org/10.7326%2FM19-1859">"Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review"</a>. <i>Annals of Internal Medicine</i>. <b>171</b> (7): 474–484. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.7326%2FM19-1859">10.7326/M19-1859</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/31476766">31476766</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Internal+Medicine&amp;rft.atitle=Antipsychotics+for+Preventing+Delirium+in+Hospitalized+Adults%3A+A+Systematic+Review&amp;rft.volume=171&amp;rft.issue=7&amp;rft.pages=474-484&amp;rft.date=2019-10&amp;rft_id=info%3Adoi%2F10.7326%2FM19-1859&amp;rft_id=info%3Apmid%2F31476766&amp;rft.aulast=Oh&amp;rft.aufirst=ES&amp;rft.au=Needham%2C+DM&amp;rft.au=Nikooie%2C+R&amp;rft.au=Wilson%2C+LM&amp;rft.au=Zhang%2C+A&amp;rft.au=Robinson%2C+KA&amp;rft.au=Neufeld%2C+KJ&amp;rft_id=%2F%2Fdoi.org%2F10.7326%252FM19-1859&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKaneCorrell2010" class="citation journal cs1">Kane JM, Correll CU (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3085113">"Pharmacologic treatment of schizophrenia"</a>. <i>Dialogues in Clinical Neuroscience</i>. <b>12</b> (3): 345–57. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.31887%2FDCNS.2010.12.3%2Fjkane">10.31887/DCNS.2010.12.3/jkane</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3085113">3085113</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20954430">20954430</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Dialogues+in+Clinical+Neuroscience&amp;rft.atitle=Pharmacologic+treatment+of+schizophrenia&amp;rft.volume=12&amp;rft.issue=3&amp;rft.pages=345-57&amp;rft.date=2010&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3085113%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F20954430&amp;rft_id=info%3Adoi%2F10.31887%2FDCNS.2010.12.3%2Fjkane&amp;rft.aulast=Kane&amp;rft.aufirst=JM&amp;rft.au=Correll%2C+CU&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3085113&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-barry_2012-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-barry_2012_70-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBarryGaughanHunter2012" class="citation journal cs1">Barry SJ, Gaughan TM, Hunter R (June 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3385413">"Schizophrenia"</a>. <i>BMJ Clinical Evidence</i>. <b>2012</b>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3385413">3385413</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23870705">23870705</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ+Clinical+Evidence&amp;rft.atitle=Schizophrenia&amp;rft.volume=2012&amp;rft.date=2012-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3385413%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23870705&amp;rft.aulast=Barry&amp;rft.aufirst=SJ&amp;rft.au=Gaughan%2C+TM&amp;rft.au=Hunter%2C+R&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3385413&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AFP07-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-AFP07_71-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSchultzNorthShields2007" class="citation journal cs1">Schultz SH, North SW, Shields CG (June 2007). <a rel="nofollow" class="external text" href="https://www.aafp.org/afp/2007/0615/p1821.html">"Schizophrenia: a review"</a>. <i>American Family Physician</i>. <b>75</b> (12): 1821–9. <a href="/wiki/CiteSeerX_(identifier)" class="mw-redirect" title="CiteSeerX (identifier)">CiteSeerX</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.602.7571">10.1.1.602.7571</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17619525">17619525</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Family+Physician&amp;rft.atitle=Schizophrenia%3A+a+review&amp;rft.volume=75&amp;rft.issue=12&amp;rft.pages=1821-9&amp;rft.date=2007-06&amp;rft_id=%2F%2Fciteseerx.ist.psu.edu%2Fviewdoc%2Fsummary%3Fdoi%3D10.1.1.602.7571%23id-name%3DCiteSeerX&amp;rft_id=info%3Apmid%2F17619525&amp;rft.aulast=Schultz&amp;rft.aufirst=SH&amp;rft.au=North%2C+SW&amp;rft.au=Shields%2C+CG&amp;rft_id=https%3A%2F%2Fwww.aafp.org%2Fafp%2F2007%2F0615%2Fp1821.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTaylorDuncan-McConnell2000" class="citation journal cs1">Taylor DM, Duncan-McConnell D (2000). "Refractory schizophrenia and atypical antipsychotics". <i>Journal of Psychopharmacology</i>. <b>14</b> (4): 409–18. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F026988110001400411">10.1177/026988110001400411</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/11198061">11198061</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:27270415">27270415</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychopharmacology&amp;rft.atitle=Refractory+schizophrenia+and+atypical+antipsychotics&amp;rft.volume=14&amp;rft.issue=4&amp;rft.pages=409-18&amp;rft.date=2000&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A27270415%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F11198061&amp;rft_id=info%3Adoi%2F10.1177%2F026988110001400411&amp;rft.aulast=Taylor&amp;rft.aufirst=DM&amp;rft.au=Duncan-McConnell%2C+D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFEssaliAl-Haj_HaasanLiRathbone2009" class="citation journal cs1">Essali A, Al-Haj Haasan N, Li C, Rathbone J (January 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7065592">"Clozapine versus typical neuroleptic medication for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (1): CD000059. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD000059.pub2">10.1002/14651858.CD000059.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7065592">7065592</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19160174">19160174</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Clozapine+versus+typical+neuroleptic+medication+for+schizophrenia&amp;rft.issue=1&amp;rft.pages=CD000059&amp;rft.date=2009-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7065592%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F19160174&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD000059.pub2&amp;rft.aulast=Essali&amp;rft.aufirst=A&amp;rft.au=Al-Haj+Haasan%2C+N&amp;rft.au=Li%2C+C&amp;rft.au=Rathbone%2C+J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7065592&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHeresDavisMainoJetzinger2006" class="citation journal cs1">Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (February 2006). "Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics". <i>The American Journal of Psychiatry</i>. <b>163</b> (2): 185–94. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.163.2.185">10.1176/appi.ajp.163.2.185</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16449469">16449469</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:3849348">3849348</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=Why+olanzapine+beats+risperidone%2C+risperidone+beats+quetiapine%2C+and+quetiapine+beats+olanzapine%3A+an+exploratory+analysis+of+head-to-head+comparison+studies+of+second-generation+antipsychotics&amp;rft.volume=163&amp;rft.issue=2&amp;rft.pages=185-94&amp;rft.date=2006-02&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A3849348%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16449469&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.163.2.185&amp;rft.aulast=Heres&amp;rft.aufirst=S&amp;rft.au=Davis%2C+J&amp;rft.au=Maino%2C+K&amp;rft.au=Jetzinger%2C+E&amp;rft.au=Kissling%2C+W&amp;rft.au=Leucht%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLiebermanStroupMcEvoySwartz2005" class="citation journal cs1">Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (September 2005). <a rel="nofollow" class="external text" href="https://cdr.lib.unc.edu/downloads/g732dk11n">"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia"</a>. <i>The New England Journal of Medicine</i>. <b>353</b> (12): 1209–23. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa051688">10.1056/NEJMoa051688</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16172203">16172203</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:22499842">22499842</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Effectiveness+of+antipsychotic+drugs+in+patients+with+chronic+schizophrenia&amp;rft.volume=353&amp;rft.issue=12&amp;rft.pages=1209-23&amp;rft.date=2005-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A22499842%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16172203&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa051688&amp;rft.aulast=Lieberman&amp;rft.aufirst=JA&amp;rft.au=Stroup%2C+TS&amp;rft.au=McEvoy%2C+JP&amp;rft.au=Swartz%2C+MS&amp;rft.au=Rosenheck%2C+RA&amp;rft.au=Perkins%2C+DO&amp;rft.au=Keefe%2C+RS&amp;rft.au=Davis%2C+SM&amp;rft.au=Davis%2C+CE&amp;rft.au=Lebowitz%2C+BD&amp;rft.au=Severe%2C+J&amp;rft.au=Hsiao%2C+JK&amp;rft_id=https%3A%2F%2Fcdr.lib.unc.edu%2Fdownloads%2Fg732dk11n&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVorugantiBakerAwad2008" class="citation journal cs1">Voruganti LP, Baker LK, Awad AG (March 2008). "New generation antipsychotic drugs and compliance behaviour". <i>Current Opinion in Psychiatry</i>. <b>21</b> (2): 133–9. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FYCO.0b013e3282f52851">10.1097/YCO.0b013e3282f52851</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18332660">18332660</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:34935">34935</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Psychiatry&amp;rft.atitle=New+generation+antipsychotic+drugs+and+compliance+behaviour&amp;rft.volume=21&amp;rft.issue=2&amp;rft.pages=133-9&amp;rft.date=2008-03&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A34935%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18332660&amp;rft_id=info%3Adoi%2F10.1097%2FYCO.0b013e3282f52851&amp;rft.aulast=Voruganti&amp;rft.aufirst=LP&amp;rft.au=Baker%2C+LK&amp;rft.au=Awad%2C+AG&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPaczynskiAlexanderChinchilliKruszewski2012" class="citation journal cs1">Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (January 2012). "Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications". <i>The International Journal of Risk &amp; Safety in Medicine</i>. <b>24</b> (3): 137–146. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.3233%2FJRS-2012-0567">10.3233/JRS-2012-0567</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22936056">22936056</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+International+Journal+of+Risk+%26+Safety+in+Medicine&amp;rft.atitle=Quality+of+evidence+in+drug+compendia+supporting+off-label+use+of+typical+and+atypical+antipsychotic+medications&amp;rft.volume=24&amp;rft.issue=3&amp;rft.pages=137-146&amp;rft.date=2012-01&amp;rft_id=info%3Adoi%2F10.3233%2FJRS-2012-0567&amp;rft_id=info%3Apmid%2F22936056&amp;rft.aulast=Paczynski&amp;rft.aufirst=RP&amp;rft.au=Alexander%2C+GC&amp;rft.au=Chinchilli%2C+VM&amp;rft.au=Kruszewski%2C+SP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFOwens2008" class="citation journal cs1">Owens DC (2008). <a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fapt.bp.107.003970">"How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia"</a>. <i>Advances in Psychiatric Treatment</i>. <b>14</b> (1): 17–28. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fapt.bp.107.003970">10.1192/apt.bp.107.003970</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Advances+in+Psychiatric+Treatment&amp;rft.atitle=How+CATIE+brought+us+back+to+Kansas%3A+a+critical+re-evaluation+of+the+concept+of+atypical+antipsychotics+and+their+place+in+the+treatment+of+schizophrenia&amp;rft.volume=14&amp;rft.issue=1&amp;rft.pages=17-28&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1192%2Fapt.bp.107.003970&amp;rft.aulast=Owens&amp;rft.aufirst=DC&amp;rft_id=%2F%2Fdoi.org%2F10.1192%252Fapt.bp.107.003970&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFischer-BarnicolLanquillonHaenZofel2008" class="citation journal cs1">Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). "Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)". <i>Neuropsychobiology</i>. <b>57</b> (1–2): 80–87. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1159%2F000135641">10.1159/000135641</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18515977">18515977</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:2669203">2669203</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropsychobiology&amp;rft.atitle=Typical+and+atypical+antipsychotics--the+misleading+dichotomy.+Results+from+the+Working+Group+%27Drugs+in+Psychiatry%27+%28AGATE%29&amp;rft.volume=57&amp;rft.issue=1%E2%80%932&amp;rft.pages=80-87&amp;rft.date=2008&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A2669203%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18515977&amp;rft_id=info%3Adoi%2F10.1159%2F000135641&amp;rft.aulast=Fischer-Barnicol&amp;rft.aufirst=D&amp;rft.au=Lanquillon%2C+S&amp;rft.au=Haen%2C+E&amp;rft.au=Zofel%2C+P&amp;rft.au=Koch%2C+HJ&amp;rft.au=Dose%2C+M&amp;rft.au=Klein%2C+HE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid10190226-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10190226_80-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCasey1999" class="citation journal cs1">Casey DE (March 1999). "Tardive dyskinesia and atypical antipsychotic drugs". <i>Schizophrenia Research</i>. <b>35</b> (Suppl 1): S61–S66. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0920-9964%2898%2900160-1">10.1016/S0920-9964(98)00160-1</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10190226">10190226</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:31807817">31807817</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research&amp;rft.atitle=Tardive+dyskinesia+and+atypical+antipsychotic+drugs&amp;rft.volume=35&amp;rft.issue=Suppl+1&amp;rft.pages=S61-S66&amp;rft.date=1999-03&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A31807817%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F10190226&amp;rft_id=info%3Adoi%2F10.1016%2FS0920-9964%2898%2900160-1&amp;rft.aulast=Casey&amp;rft.aufirst=DE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid20098227-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20098227_81-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMakhinson2010" class="citation journal cs1">Makhinson M (January 2010). "Biases in medication prescribing: the case of second-generation antipsychotics". <i>Journal of Psychiatric Practice</i>. <b>16</b> (1): 15–21. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2F01.pra.0000367774.11260.e4">10.1097/01.pra.0000367774.11260.e4</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20098227">20098227</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:46530288">46530288</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychiatric+Practice&amp;rft.atitle=Biases+in+medication+prescribing%3A+the+case+of+second-generation+antipsychotics&amp;rft.volume=16&amp;rft.issue=1&amp;rft.pages=15-21&amp;rft.date=2010-01&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A46530288%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20098227&amp;rft_id=info%3Adoi%2F10.1097%2F01.pra.0000367774.11260.e4&amp;rft.aulast=Makhinson&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-APAfive_polypharmacy-82"><span class="mw-cite-backlink">^ <a href="#cite_ref-APAfive_polypharmacy_82-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-APAfive_polypharmacy_82-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-APAfive_polypharmacy_82-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Psychiatric_Association2013" class="citation cs2"><a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a> (September 2013), <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">"Five Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" class="mw-redirect" title="ABIM Foundation">ABIM Foundation</a></i>, <a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a>, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131203174206/http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">archived</a> from the original on 3 December 2013<span class="reference-accessdate">, retrieved <span class="nowrap">30 December</span> 2013</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.atitle=Five+Things+Physicians+and+Patients+Should+Question&amp;rft.date=2013-09&amp;rft.au=American+Psychiatric+Association&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Famerican-psychiatric-association%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span>, which cites
<ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation book cs1"><i>Practice Guideline for the Treatment of Patients With Schizophrenia</i>. Vol.&#160;1 (Second&#160;ed.). American Psychiatric Association. 2006. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.books.9780890423363.45859">10.1176/appi.books.9780890423363.45859</a>. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-89042-336-3" title="Special:BookSources/978-0-89042-336-3"><bdi>978-0-89042-336-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Practice+Guideline+for+the+Treatment+of+Patients+With+Schizophrenia&amp;rft.edition=Second&amp;rft.pub=American+Psychiatric+Association&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.books.9780890423363.45859&amp;rft.isbn=978-0-89042-336-3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJoint_Commission2013" class="citation cs2"><a href="/wiki/Joint_Commission" title="Joint Commission">Joint Commission</a> (30 June 2013), <a rel="nofollow" class="external text" href="http://manual.jointcommission.org/releases/TJC2013A/MIF0119.html">"HBIPS-4, Patients discharged on multiple antipsychotic medications"</a>, <a rel="nofollow" class="external text" href="http://www.jointcommission.org/specifications_manual_joint_commission_national_quality_core_measures.aspx"><i>Specifications Manual for Joint Commission National Quality Core Measures</i></a>, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131110024015/http://www.jointcommission.org/specifications_manual_joint_commission_national_quality_core_measures.aspx">archived</a> from the original on 10 November 2013<span class="reference-accessdate">, retrieved <span class="nowrap">27 October</span> 2013</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=HBIPS-4%2C+Patients+discharged+on+multiple+antipsychotic+medications&amp;rft.btitle=Specifications+Manual+for+Joint+Commission+National+Quality+Core+Measures&amp;rft.date=2013-06-30&amp;rft.au=Joint+Commission&amp;rft_id=http%3A%2F%2Fmanual.jointcommission.org%2Freleases%2FTJC2013A%2FMIF0119.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFStahlGrady2004" class="citation journal cs1">Stahl SM, Grady MM (February 2004). "A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation". <i>Current Medicinal Chemistry</i>. <b>11</b> (3): 313–27. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2174%2F0929867043456070">10.2174/0929867043456070</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/14965234">14965234</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Medicinal+Chemistry&amp;rft.atitle=A+critical+review+of+atypical+antipsychotic+utilization%3A+comparing+monotherapy+with+polypharmacy+and+augmentation&amp;rft.volume=11&amp;rft.issue=3&amp;rft.pages=313-27&amp;rft.date=2004-02&amp;rft_id=info%3Adoi%2F10.2174%2F0929867043456070&amp;rft_id=info%3Apmid%2F14965234&amp;rft.aulast=Stahl&amp;rft.aufirst=SM&amp;rft.au=Grady%2C+MM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li></ul>
</span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMoorePuri2012" class="citation book cs1">Moore DP, Puri BK (2012). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Sy7OBgAAQBAJ&amp;pg=PA791"><i>Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience, Third Edition</i></a>. CRC Press. p.&#160;791. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781444164947" title="Special:BookSources/9781444164947"><bdi>9781444164947</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20171125213437/https://books.google.com/books?id=Sy7OBgAAQBAJ&amp;pg=PA791">Archived</a> from the original on 25 November 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Textbook+of+Clinical+Neuropsychiatry+and+Behavioral+Neuroscience%2C+Third+Edition&amp;rft.pages=791&amp;rft.pub=CRC+Press&amp;rft.date=2012&amp;rft.isbn=9781444164947&amp;rft.aulast=Moore&amp;rft.aufirst=DP&amp;rft.au=Puri%2C+BK&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DSy7OBgAAQBAJ%26pg%3DPA791&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMuenchHamer2010" class="citation journal cs1">Muench J, Hamer AM (March 2010). "Adverse effects of antipsychotic medications". <i>American Family Physician</i>. <b>81</b> (5): 617–22. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20187598">20187598</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Family+Physician&amp;rft.atitle=Adverse+effects+of+antipsychotic+medications&amp;rft.volume=81&amp;rft.issue=5&amp;rft.pages=617-22&amp;rft.date=2010-03&amp;rft_id=info%3Apmid%2F20187598&amp;rft.aulast=Muench&amp;rft.aufirst=J&amp;rft.au=Hamer%2C+AM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lieberman,_2004-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-Lieberman,_2004_85-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLieberman2004" class="citation journal cs1">Lieberman JA (2004). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC487008">"Managing anticholinergic side effects"</a>. <i>Primary Care Companion to the Journal of Clinical Psychiatry</i>. <b>6</b> (Suppl 2): 20–3. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC487008">487008</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16001097">16001097</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Primary+Care+Companion+to+the+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Managing+anticholinergic+side+effects&amp;rft.volume=6&amp;rft.issue=Suppl+2&amp;rft.pages=20-3&amp;rft.date=2004&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC487008%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F16001097&amp;rft.aulast=Lieberman&amp;rft.aufirst=JA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC487008&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKollerDoraiswamy2002" class="citation journal cs1">Koller EA, Doraiswamy PM (July 2002). <a rel="nofollow" class="external text" href="https://zenodo.org/record/1236343">"Olanzapine-associated diabetes mellitus"</a>. <i>Pharmacotherapy</i>. <b>22</b> (7): 841–52. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1592%2Fphco.22.11.841.33629">10.1592/phco.22.11.841.33629</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/12126218">12126218</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:27314943">27314943</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=Olanzapine-associated+diabetes+mellitus&amp;rft.volume=22&amp;rft.issue=7&amp;rft.pages=841-52&amp;rft.date=2002-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A27314943%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F12126218&amp;rft_id=info%3Adoi%2F10.1592%2Fphco.22.11.841.33629&amp;rft.aulast=Koller&amp;rft.aufirst=EA&amp;rft.au=Doraiswamy%2C+PM&amp;rft_id=https%3A%2F%2Fzenodo.org%2Frecord%2F1236343&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWeston-GreenHuangDeng2010" class="citation journal cs1">Weston-Green K, Huang XF, Deng C (February 2010). <a rel="nofollow" class="external text" href="https://ro.uow.edu.au/cgi/viewcontent.cgi?article=2408&amp;context=smhpapers">"Sensitivity of the female rat to olanzapine-induced weight gain—far from the clinic?"</a>. <i>Schizophrenia Research</i>. <b>116</b> (2–3): 299–300. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.schres.2009.09.034">10.1016/j.schres.2009.09.034</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19840894">19840894</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:30384727">30384727</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research&amp;rft.atitle=Sensitivity+of+the+female+rat+to+olanzapine-induced+weight+gain%E2%80%94far+from+the+clinic%3F&amp;rft.volume=116&amp;rft.issue=2%E2%80%933&amp;rft.pages=299-300&amp;rft.date=2010-02&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A30384727%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19840894&amp;rft_id=info%3Adoi%2F10.1016%2Fj.schres.2009.09.034&amp;rft.aulast=Weston-Green&amp;rft.aufirst=K&amp;rft.au=Huang%2C+XF&amp;rft.au=Deng%2C+C&amp;rft_id=https%3A%2F%2Fro.uow.edu.au%2Fcgi%2Fviewcontent.cgi%3Farticle%3D2408%26context%3Dsmhpapers&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-GG-88"><span class="mw-cite-backlink">^ <a href="#cite_ref-GG_88-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-GG_88-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-GG_88-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBruntonChabnerKnollmann2011" class="citation book cs1">Brunton LL, Chabner B, Knollmann BC, eds. (2011). <a href="/wiki/Goodman_%26_Gilman%27s_The_Pharmacological_Basis_of_Therapeutics" title="Goodman &amp; Gilman&#39;s The Pharmacological Basis of Therapeutics"><i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i></a> (12th&#160;ed.). New York: McGraw-Hill. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-162442-8" title="Special:BookSources/978-0-07-162442-8"><bdi>978-0-07-162442-8</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Goodman+%26+Gilman%27s+The+Pharmacological+Basis+of+Therapeutics&amp;rft.place=New+York&amp;rft.edition=12th&amp;rft.pub=McGraw-Hill&amp;rft.date=2011&amp;rft.isbn=978-0-07-162442-8&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWeston-GreenHuangDeng2012" class="citation journal cs1">Weston-Green K, Huang XF, Deng C (2012).  Chang AY (ed.). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3306411">"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain"</a>. <i>PLOS ONE</i>. <b>7</b> (3): e33548. <a href="/wiki/Bibcode_(identifier)" class="mw-redirect" title="Bibcode (identifier)">Bibcode</a>:<a rel="nofollow" class="external text" href="https://ui.adsabs.harvard.edu/abs/2012PLoSO...733548W">2012PLoSO...733548W</a>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1371%2Fjournal.pone.0033548">10.1371/journal.pone.0033548</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3306411">3306411</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22438946">22438946</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLOS+ONE&amp;rft.atitle=Alterations+to+melanocortinergic%2C+GABAergic+and+cannabinoid+neurotransmission+associated+with+olanzapine-induced+weight+gain&amp;rft.volume=7&amp;rft.issue=3&amp;rft.pages=e33548&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3306411%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22438946&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0033548&amp;rft_id=info%3Abibcode%2F2012PLoSO...733548W&amp;rft.aulast=Weston-Green&amp;rft.aufirst=K&amp;rft.au=Huang%2C+XF&amp;rft.au=Deng%2C+C&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3306411&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid14524644-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14524644_90-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKollerCrossDoraiswamyMalozowski2003" class="citation journal cs1">Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (September 2003). <a rel="nofollow" class="external text" href="https://zenodo.org/record/1236345">"Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports"</a>. <i>Pharmacotherapy</i>. <b>23</b> (9): 1123–30. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1592%2Fphco.23.10.1123.32759">10.1592/phco.23.10.1123.32759</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/14524644">14524644</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:39945446">39945446</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=Pancreatitis+associated+with+atypical+antipsychotics%3A+from+the+Food+and+Drug+Administration%27s+MedWatch+surveillance+system+and+published+reports&amp;rft.volume=23&amp;rft.issue=9&amp;rft.pages=1123-30&amp;rft.date=2003-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A39945446%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F14524644&amp;rft_id=info%3Adoi%2F10.1592%2Fphco.23.10.1123.32759&amp;rft.aulast=Koller&amp;rft.aufirst=EA&amp;rft.au=Cross%2C+JT&amp;rft.au=Doraiswamy%2C+PM&amp;rft.au=Malozowski%2C+SN&amp;rft_id=https%3A%2F%2Fzenodo.org%2Frecord%2F1236345&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWeinmannReadAderhold2009" class="citation journal cs1">Weinmann S, Read J, Aderhold V (August 2009). "Influence of antipsychotics on mortality in schizophrenia: systematic review". <i>Schizophrenia Research</i>. <b>113</b> (1): 1–11. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.schres.2009.05.018">10.1016/j.schres.2009.05.018</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19524406">19524406</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:8143217">8143217</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research&amp;rft.atitle=Influence+of+antipsychotics+on+mortality+in+schizophrenia%3A+systematic+review&amp;rft.volume=113&amp;rft.issue=1&amp;rft.pages=1-11&amp;rft.date=2009-08&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A8143217%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19524406&amp;rft_id=info%3Adoi%2F10.1016%2Fj.schres.2009.05.018&amp;rft.aulast=Weinmann&amp;rft.aufirst=S&amp;rft.au=Read%2C+J&amp;rft.au=Aderhold%2C+V&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJoukamaaHeliövaaraKnektAromaa2006" class="citation journal cs1">Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (February 2006). <a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.188.2.122">"Schizophrenia, neuroleptic medication and mortality"</a>. <i>The British Journal of Psychiatry</i>. <b>188</b> (2): 122–7. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.188.2.122">10.1192/bjp.188.2.122</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16449697">16449697</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Journal+of+Psychiatry&amp;rft.atitle=Schizophrenia%2C+neuroleptic+medication+and+mortality&amp;rft.volume=188&amp;rft.issue=2&amp;rft.pages=122-7&amp;rft.date=2006-02&amp;rft_id=info%3Adoi%2F10.1192%2Fbjp.188.2.122&amp;rft_id=info%3Apmid%2F16449697&amp;rft.aulast=Joukamaa&amp;rft.aufirst=M&amp;rft.au=Heli%C3%B6vaara%2C+M&amp;rft.au=Knekt%2C+P&amp;rft.au=Aromaa%2C+A&amp;rft.au=Raitasalo%2C+R&amp;rft.au=Lehtinen%2C+V&amp;rft_id=%2F%2Fdoi.org%2F10.1192%252Fbjp.188.2.122&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Geriatrics_Society_2012_Beers_Criteria_Update_Expert_Panel2012" class="citation journal cs1">American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3571677">"American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults"</a>. <i>Journal of the American Geriatrics Society</i>. <b>60</b> (4): 616–31. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1532-5415.2012.03923.x">10.1111/j.1532-5415.2012.03923.x</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3571677">3571677</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22376048">22376048</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+American+Geriatrics+Society&amp;rft.atitle=American+Geriatrics+Society+updated+Beers+Criteria+for+potentially+inappropriate+medication+use+in+older+adults&amp;rft.volume=60&amp;rft.issue=4&amp;rft.pages=616-31&amp;rft.date=2012-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3571677%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22376048&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1532-5415.2012.03923.x&amp;rft.au=American+Geriatrics+Society+2012+Beers+Criteria+Update+Expert+Panel&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3571677&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-utdp-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-utdp_94-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMedfordSierraBakerDavid2005" class="citation journal cs1">Medford N, Sierra M, Baker D, David A (2005). <a rel="nofollow" class="external text" href="http://apt.rcpsych.org/cgi/content/full/11/2/92#SEC5">"Understanding and treating depersonalisation disorder"</a>. <i>Advances in Psychiatric Treatment</i>. <b>11</b> (2): 92–100. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fapt.11.2.92">10.1192/apt.11.2.92</a></span>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20110716095835/http://apt.rcpsych.org/cgi/content/full/11/2/92#SEC5">Archived</a> from the original on 16 July 2011.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Advances+in+Psychiatric+Treatment&amp;rft.atitle=Understanding+and+treating+depersonalisation+disorder&amp;rft.volume=11&amp;rft.issue=2&amp;rft.pages=92-100&amp;rft.date=2005&amp;rft_id=info%3Adoi%2F10.1192%2Fapt.11.2.92&amp;rft.aulast=Medford&amp;rft.aufirst=N&amp;rft.au=Sierra%2C+M&amp;rft.au=Baker%2C+D&amp;rft.au=David%2C+A&amp;rft_id=http%3A%2F%2Fapt.rcpsych.org%2Fcgi%2Fcontent%2Ffull%2F11%2F2%2F92%23SEC5&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPatrickLevinSchleifer2005" class="citation journal cs1">Patrick V, Levin E, Schleifer S (July 2005). "Antipsychotic polypharmacy: is there evidence for its use?". <i>Journal of Psychiatric Practice</i>. <b>11</b> (4): 248–57. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2F00131746-200507000-00005">10.1097/00131746-200507000-00005</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16041235">16041235</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:43114395">43114395</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychiatric+Practice&amp;rft.atitle=Antipsychotic+polypharmacy%3A+is+there+evidence+for+its+use%3F&amp;rft.volume=11&amp;rft.issue=4&amp;rft.pages=248-57&amp;rft.date=2005-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A43114395%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16041235&amp;rft_id=info%3Adoi%2F10.1097%2F00131746-200507000-00005&amp;rft.aulast=Patrick&amp;rft.aufirst=V&amp;rft.au=Levin%2C+E&amp;rft.au=Schleifer%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFItoKoyamaHiguchi2005" class="citation journal cs1">Ito H, Koyama A, Higuchi T (September 2005). <a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.187.3.243">"Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription"</a>. <i>The British Journal of Psychiatry</i>. <b>187</b> (3): 243–7. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1192%2Fbjp.187.3.243">10.1192/bjp.187.3.243</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16135861">16135861</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Journal+of+Psychiatry&amp;rft.atitle=Polypharmacy+and+excessive+dosing%3A+psychiatrists%27+perceptions+of+antipsychotic+drug+prescription&amp;rft.volume=187&amp;rft.issue=3&amp;rft.pages=243-7&amp;rft.date=2005-09&amp;rft_id=info%3Adoi%2F10.1192%2Fbjp.187.3.243&amp;rft_id=info%3Apmid%2F16135861&amp;rft.aulast=Ito&amp;rft.aufirst=H&amp;rft.au=Koyama%2C+A&amp;rft.au=Higuchi%2C+T&amp;rft_id=%2F%2Fdoi.org%2F10.1192%252Fbjp.187.3.243&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVitaDe_PeriDesteSacchetti2012" class="citation journal cs1">Vita A, De Peri L, Deste G, Sacchetti E (November 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3565772">"Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies"</a>. <i>Translational Psychiatry</i>. <b>2</b> (11): e190. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Ftp.2012.116">10.1038/tp.2012.116</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3565772">3565772</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23168990">23168990</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Translational+Psychiatry&amp;rft.atitle=Progressive+loss+of+cortical+gray+matter+in+schizophrenia%3A+a+meta-analysis+and+meta-regression+of+longitudinal+MRI+studies&amp;rft.volume=2&amp;rft.issue=11&amp;rft.pages=e190&amp;rft.date=2012-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3565772%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23168990&amp;rft_id=info%3Adoi%2F10.1038%2Ftp.2012.116&amp;rft.aulast=Vita&amp;rft.aufirst=A&amp;rft.au=De+Peri%2C+L&amp;rft.au=Deste%2C+G&amp;rft.au=Sacchetti%2C+E&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3565772&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRaduaBorgwardtCresciniMataix-Cols2012" class="citation journal cs1">Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (November 2012). <a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.neubiorev.2012.07.012">"Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication"</a>. <i>Neuroscience and Biobehavioral Reviews</i>. <b>36</b> (10): 2325–33. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.neubiorev.2012.07.012">10.1016/j.neubiorev.2012.07.012</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22910680">22910680</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuroscience+and+Biobehavioral+Reviews&amp;rft.atitle=Multimodal+meta-analysis+of+structural+and+functional+brain+changes+in+first+episode+psychosis+and+the+effects+of+antipsychotic+medication&amp;rft.volume=36&amp;rft.issue=10&amp;rft.pages=2325-33&amp;rft.date=2012-11&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2012.07.012&amp;rft_id=info%3Apmid%2F22910680&amp;rft.aulast=Radua&amp;rft.aufirst=J&amp;rft.au=Borgwardt%2C+S&amp;rft.au=Crescini%2C+A&amp;rft.au=Mataix-Cols%2C+D&amp;rft.au=Meyer-Lindenberg%2C+A&amp;rft.au=McGuire%2C+PK&amp;rft.au=Fusar-Poli%2C+P&amp;rft_id=%2F%2Fdoi.org%2F10.1016%252Fj.neubiorev.2012.07.012&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Nature_2005-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nature_2005_99-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDorph-PetersenPierriPerelSun2005" class="citation journal cs1">Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (September 2005). "The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys". <i>Neuropsychopharmacology</i>. <b>30</b> (9): 1649–1661. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fsj.npp.1300710">10.1038/sj.npp.1300710</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15756305">15756305</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205679212">205679212</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropsychopharmacology&amp;rft.atitle=The+influence+of+chronic+exposure+to+antipsychotic+medications+on+brain+size+before+and+after+tissue+fixation%3A+a+comparison+of+haloperidol+and+olanzapine+in+macaque+monkeys&amp;rft.volume=30&amp;rft.issue=9&amp;rft.pages=1649-1661&amp;rft.date=2005-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205679212%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F15756305&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.npp.1300710&amp;rft.aulast=Dorph-Petersen&amp;rft.aufirst=KA&amp;rft.au=Pierri%2C+JN&amp;rft.au=Perel%2C+JM&amp;rft.au=Sun%2C+Z&amp;rft.au=Sampson%2C+AR&amp;rft.au=Lewis%2C+DA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid14609248-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14609248_100-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHirose2003" class="citation journal cs1">Hirose S (2003). "The causes of underdiagnosing akathisia". <i>Schizophrenia Bulletin</i>. <b>29</b> (3): 547–58. <a href="/wiki/CiteSeerX_(identifier)" class="mw-redirect" title="CiteSeerX (identifier)">CiteSeerX</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.618.3326">10.1.1.618.3326</a></span>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Foxfordjournals.schbul.a007027">10.1093/oxfordjournals.schbul.a007027</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/14609248">14609248</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Bulletin&amp;rft.atitle=The+causes+of+underdiagnosing+akathisia&amp;rft.volume=29&amp;rft.issue=3&amp;rft.pages=547-58&amp;rft.date=2003&amp;rft_id=%2F%2Fciteseerx.ist.psu.edu%2Fviewdoc%2Fsummary%3Fdoi%3D10.1.1.618.3326%23id-name%3DCiteSeerX&amp;rft_id=info%3Apmid%2F14609248&amp;rft_id=info%3Adoi%2F10.1093%2Foxfordjournals.schbul.a007027&amp;rft.aulast=Hirose&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRehseBartolovicBaumRichter2016" class="citation journal cs1">Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D (2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4842070">"Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia"</a>. <i>Schizophrenia Research and Treatment</i>. <b>2016</b>: 8213165. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1155%2F2016%2F8213165">10.1155/2016/8213165</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4842070">4842070</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/27144021">27144021</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research+and+Treatment&amp;rft.atitle=Influence+of+Antipsychotic+and+Anticholinergic+Loads+on+Cognitive+Functions+in+Patients+with+Schizophrenia&amp;rft.volume=2016&amp;rft.pages=8213165&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4842070%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27144021&amp;rft_id=info%3Adoi%2F10.1155%2F2016%2F8213165&amp;rft.aulast=Rehse&amp;rft.aufirst=M&amp;rft.au=Bartolovic%2C+M&amp;rft.au=Baum%2C+K&amp;rft.au=Richter%2C+D&amp;rft.au=Weisbrod%2C+M&amp;rft.au=Roesch-Ely%2C+D&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4842070&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-102">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTampiTampiBalachandranSrinivasan2016" class="citation journal cs1">Tampi RR, Tampi DJ, Balachandran S, Srinivasan S (September 2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4994396">"Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses"</a>. <i>Therapeutic Advances in Chronic Disease</i>. <b>7</b> (5): 229–245. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F2040622316658463">10.1177/2040622316658463</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4994396">4994396</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/27583123">27583123</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutic+Advances+in+Chronic+Disease&amp;rft.atitle=Antipsychotic+use+in+dementia%3A+a+systematic+review+of+benefits+and+risks+from+meta-analyses&amp;rft.volume=7&amp;rft.issue=5&amp;rft.pages=229-245&amp;rft.date=2016-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4994396%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27583123&amp;rft_id=info%3Adoi%2F10.1177%2F2040622316658463&amp;rft.aulast=Tampi&amp;rft.aufirst=RR&amp;rft.au=Tampi%2C+DJ&amp;rft.au=Balachandran%2C+S&amp;rft.au=Srinivasan%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4994396&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMacKenzieKowalchukAgarwalCosta-Dookhan2018" class="citation journal cs1">MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P,  et&#160;al. (5 December 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6290646">"Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia"</a>. <i>Frontiers in Psychiatry</i>. <b>9</b>: 622. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.3389%2Ffpsyt.2018.00622">10.3389/fpsyt.2018.00622</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6290646">6290646</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/30568606">30568606</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Psychiatry&amp;rft.atitle=Antipsychotics%2C+Metabolic+Adverse+Effects%2C+and+Cognitive+Function+in+Schizophrenia&amp;rft.volume=9&amp;rft.pages=622&amp;rft.date=2018-12-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6290646%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F30568606&amp;rft_id=info%3Adoi%2F10.3389%2Ffpsyt.2018.00622&amp;rft.aulast=MacKenzie&amp;rft.aufirst=NE&amp;rft.au=Kowalchuk%2C+C&amp;rft.au=Agarwal%2C+SM&amp;rft.au=Costa-Dookhan%2C+KA&amp;rft.au=Caravaggio%2C+F&amp;rft.au=Gerretsen%2C+P&amp;rft.au=Chintoh%2C+A&amp;rft.au=Remington%2C+GJ&amp;rft.au=Taylor%2C+VH&amp;rft.au=M%C3%BCeller%2C+DJ&amp;rft.au=Graff-Guerrero%2C+A&amp;rft.au=Hahn%2C+MK&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6290646&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-104">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMuellerJohnPereraAarsland2021" class="citation journal cs1">Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R (January 2021). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435">"Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes"</a>. <i>European Journal of Epidemiology</i>. <b>36</b> (1): 89–101. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs10654-020-00643-2">10.1007/s10654-020-00643-2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435">7847435</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/32415541">32415541</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Epidemiology&amp;rft.atitle=Antipsychotic+use+in+dementia%3A+the+relationship+between+neuropsychiatric+symptom+profiles+and+adverse+outcomes&amp;rft.volume=36&amp;rft.issue=1&amp;rft.pages=89-101&amp;rft.date=2021-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7847435%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F32415541&amp;rft_id=info%3Adoi%2F10.1007%2Fs10654-020-00643-2&amp;rft.aulast=Mueller&amp;rft.aufirst=C&amp;rft.au=John%2C+C&amp;rft.au=Perera%2C+G&amp;rft.au=Aarsland%2C+D&amp;rft.au=Ballard%2C+C&amp;rft.au=Stewart%2C+R&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7847435&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-105">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSteinbergLyketsos2012" class="citation journal cs1">Steinberg M, Lyketsos CG (September 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3516138">"Atypical antipsychotic use in patients with dementia: managing safety concerns"</a>. <i>The American Journal of Psychiatry</i>. <b>169</b> (9): 900–906. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ajp.2012.12030342">10.1176/appi.ajp.2012.12030342</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3516138">3516138</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22952071">22952071</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Psychiatry&amp;rft.atitle=Atypical+antipsychotic+use+in+patients+with+dementia%3A+managing+safety+concerns&amp;rft.volume=169&amp;rft.issue=9&amp;rft.pages=900-906&amp;rft.date=2012-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3516138%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22952071&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ajp.2012.12030342&amp;rft.aulast=Steinberg&amp;rft.aufirst=M&amp;rft.au=Lyketsos%2C+CG&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3516138&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Group_2009_192-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-Group_2009_192_106-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJoint_Formulary_Committee2009" class="citation book cs1">Joint Formulary Committee, BMJ, ed. (March 2009). "4.2.1". <i>British National Formulary</i> (57&#160;ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p.&#160;192. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-85369-845-6" title="Special:BookSources/978-0-85369-845-6"><bdi>978-0-85369-845-6</bdi></a>. <q>Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=4.2.1&amp;rft.btitle=British+National+Formulary&amp;rft.place=United+Kingdom&amp;rft.pages=192&amp;rft.edition=57&amp;rft.pub=Royal+Pharmaceutical+Society+of+Great+Britain&amp;rft.date=2009-03&amp;rft.isbn=978-0-85369-845-6&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Had2004-107"><span class="mw-cite-backlink">^ <a href="#cite_ref-Had2004_107-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Had2004_107-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Had2004_107-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Had2004_107-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Had2004_107-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHaddadHaddadDursunDeakin2004" class="citation book cs1">Haddad P, Haddad PM, Dursun S, Deakin B (2004). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=CWR7DwAAQBAJ&amp;pg=PA207"><i>Adverse Syndromes and Psychiatric Drugs: A Clinical Guide</i></a>. OUP Oxford. pp.&#160;207–216. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780198527480" title="Special:BookSources/9780198527480"><bdi>9780198527480</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Adverse+Syndromes+and+Psychiatric+Drugs%3A+A+Clinical+Guide&amp;rft.pages=207-216&amp;rft.pub=OUP+Oxford&amp;rft.date=2004&amp;rft.isbn=9780198527480&amp;rft.aulast=Haddad&amp;rft.aufirst=P&amp;rft.au=Haddad%2C+PM&amp;rft.au=Dursun%2C+S&amp;rft.au=Deakin%2C+B&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DCWR7DwAAQBAJ%26pg%3DPA207&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-ReferenceB-108"><span class="mw-cite-backlink">^ <a href="#cite_ref-ReferenceB_108-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ReferenceB_108-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMoncrieff2006" class="citation journal cs1">Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". <i>Acta Psychiatrica Scandinavica</i>. <b>114</b> (1): 3–13. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1600-0447.2006.00787.x">10.1111/j.1600-0447.2006.00787.x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16774655">16774655</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:6267180">6267180</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Psychiatrica+Scandinavica&amp;rft.atitle=Does+antipsychotic+withdrawal+provoke+psychosis%3F+Review+of+the+literature+on+rapid+onset+psychosis+%28supersensitivity+psychosis%29+and+withdrawal-related+relapse&amp;rft.volume=114&amp;rft.issue=1&amp;rft.pages=3-13&amp;rft.date=2006-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A6267180%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16774655&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.2006.00787.x&amp;rft.aulast=Moncrieff&amp;rft.aufirst=J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-109">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSacchettiVitaSiracusanoFleischhacker2013" class="citation book cs1">Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=odE-AgAAQBAJ&amp;pg=PA85"><i>Adherence to Antipsychotics in Schizophrenia</i></a>. Springer Science &amp; Business Media. p.&#160;85. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9788847026797" title="Special:BookSources/9788847026797"><bdi>9788847026797</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Adherence+to+Antipsychotics+in+Schizophrenia&amp;rft.pages=85&amp;rft.pub=Springer+Science+%26+Business+Media&amp;rft.date=2013&amp;rft.isbn=9788847026797&amp;rft.aulast=Sacchetti&amp;rft.aufirst=E&amp;rft.au=Vita%2C+A&amp;rft.au=Siracusano%2C+A&amp;rft.au=Fleischhacker%2C+W&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DodE-AgAAQBAJ%26pg%3DPA85&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Nakata-110"><span class="mw-cite-backlink"><b><a href="#cite_ref-Nakata_110-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFNakataKanaharaIyo2017" class="citation journal cs1">Nakata Y, Kanahara N, Iyo M (December 2017). "Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice". <i>Journal of Psychopharmacology</i>. <b>31</b> (12): 1511–1518. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F0269881117728428">10.1177/0269881117728428</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/28925317">28925317</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:1957881">1957881</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychopharmacology&amp;rft.atitle=Dopamine+supersensitivity+psychosis+in+schizophrenia%3A+Concepts+and+implications+in+clinical+practice&amp;rft.volume=31&amp;rft.issue=12&amp;rft.pages=1511-1518&amp;rft.date=2017-12&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A1957881%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F28925317&amp;rft_id=info%3Adoi%2F10.1177%2F0269881117728428&amp;rft.aulast=Nakata&amp;rft.aufirst=Y&amp;rft.au=Kanahara%2C+N&amp;rft.au=Iyo%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Glazer-2000-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-Glazer-2000_111-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGlazer2000" class="citation journal cs1">Glazer WM (2000). "Expected incidence of tardive dyskinesia associated with atypical antipsychotics". <i>The Journal of Clinical Psychiatry</i>. <b>61</b> (Suppl 4): 21–6. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10739327">10739327</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Expected+incidence+of+tardive+dyskinesia+associated+with+atypical+antipsychotics&amp;rft.volume=61&amp;rft.issue=Suppl+4&amp;rft.pages=21-6&amp;rft.date=2000&amp;rft_id=info%3Apmid%2F10739327&amp;rft.aulast=Glazer&amp;rft.aufirst=WM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lambert-2007-112"><span class="mw-cite-backlink"><b><a href="#cite_ref-Lambert-2007_112-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLambert2007" class="citation journal cs1">Lambert TJ (2007). "Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes". <i>The Journal of Clinical Psychiatry</i>. <b>68</b> (Suppl 6): 10–3. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17650054">17650054</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Switching+antipsychotic+therapy%3A+what+to+expect+and+clinical+strategies+for+improving+therapeutic+outcomes&amp;rft.volume=68&amp;rft.issue=Suppl+6&amp;rft.pages=10-3&amp;rft.date=2007&amp;rft_id=info%3Apmid%2F17650054&amp;rft.aulast=Lambert&amp;rft.aufirst=TJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-113"><span class="mw-cite-backlink"><b><a href="#cite_ref-113">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBMJ_Group2009" class="citation book cs1">BMJ Group (March 2009). "4.2.1". <i>British National Formulary</i> (57&#160;ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p.&#160;192. <q>Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=4.2.1&amp;rft.btitle=British+National+Formulary&amp;rft.place=United+Kingdom&amp;rft.pages=192&amp;rft.edition=57&amp;rft.pub=Royal+Pharmaceutical+Society+of+Great+Britain&amp;rft.date=2009-03&amp;rft.au=BMJ+Group&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-114"><span class="mw-cite-backlink"><b><a href="#cite_ref-114">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.hsj.co.uk/mental-health/exclusive-up-to-100000-on-antipsychotics-with-no-review/7026726.article?">"Up to 100,000 on antipsychotics with no review"</a>. Health Service Journal. 27 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">22 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Up+to+100%2C000+on+antipsychotics+with+no+review&amp;rft.date=2020-01-27&amp;rft_id=https%3A%2F%2Fwww.hsj.co.uk%2Fmental-health%2Fexclusive-up-to-100000-on-antipsychotics-with-no-review%2F7026726.article%3F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-atyp-115"><span class="mw-cite-backlink"><b><a href="#cite_ref-atyp_115-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSeeman2004" class="citation journal cs1">Seeman P (January 2004). <a rel="nofollow" class="external text" href="https://focus.psychiatryonline.org/doi/full/10.1176/foc.2.1.48">"Atypical Antipsychotics: Mechanism of Action"</a>. <i>Focus</i>. <b>2</b> (1): 48–58. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Ffoc.2.1.48">10.1176/foc.2.1.48</a> (inactive 31 October 2021).</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Focus&amp;rft.atitle=Atypical+Antipsychotics%3A+Mechanism+of+Action&amp;rft.volume=2&amp;rft.issue=1&amp;rft.pages=48-58&amp;rft.date=2004-01&amp;rft_id=info%3Adoi%2F10.1176%2Ffoc.2.1.48&amp;rft.aulast=Seeman&amp;rft.aufirst=P&amp;rft_id=https%3A%2F%2Ffocus.psychiatryonline.org%2Fdoi%2Ffull%2F10.1176%2Ffoc.2.1.48&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span><span class="cs1-maint citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_journal" title="Template:Cite journal">cite journal</a>}}</code>:  CS1 maint: DOI inactive as of October 2021 (<a href="/wiki/Category:CS1_maint:_DOI_inactive_as_of_October_2021" title="Category:CS1 maint: DOI inactive as of October 2021">link</a>)</span></span>
</li>
<li id="cite_note-CNS_Drugs-116"><span class="mw-cite-backlink">^ <a href="#cite_ref-CNS_Drugs_116-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-CNS_Drugs_116-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFOnrustMcClellan2001" class="citation journal cs1">Onrust SV, McClellan K (2001). "Perospirone". <i>CNS Drugs</i>. <b>15</b> (4): 329–37, discussion 338. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00023210-200115040-00006">10.2165/00023210-200115040-00006</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/11463136">11463136</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Perospirone&amp;rft.volume=15&amp;rft.issue=4&amp;rft.pages=329-37%2C+discussion+338&amp;rft.date=2001&amp;rft_id=info%3Adoi%2F10.2165%2F00023210-200115040-00006&amp;rft_id=info%3Apmid%2F11463136&amp;rft.aulast=Onrust&amp;rft.aufirst=SV&amp;rft.au=McClellan%2C+K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-117"><span class="mw-cite-backlink"><b><a href="#cite_ref-117">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFNemeroffLiebermanWeidenHarvey2005" class="citation journal cs1">Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG (November 2005). "From clinical research to clinical practice: a 4-year review of ziprasidone". <i>CNS Spectrums</i>. <b>10</b> (11 Suppl 17): 1–20. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1017%2FS1092852900019842">10.1017/S1092852900019842</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16381088">16381088</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:26738197">26738197</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Spectrums&amp;rft.atitle=From+clinical+research+to+clinical+practice%3A+a+4-year+review+of+ziprasidone&amp;rft.volume=10&amp;rft.issue=11+Suppl+17&amp;rft.pages=1-20&amp;rft.date=2005-11&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A26738197%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16381088&amp;rft_id=info%3Adoi%2F10.1017%2FS1092852900019842&amp;rft.aulast=Nemeroff&amp;rft.aufirst=CB&amp;rft.au=Lieberman%2C+JA&amp;rft.au=Weiden%2C+PJ&amp;rft.au=Harvey%2C+PD&amp;rft.au=Newcomer%2C+JW&amp;rft.au=Schatzberg%2C+AF&amp;rft.au=Kilts%2C+CD&amp;rft.au=Daniel%2C+DG&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-118"><span class="mw-cite-backlink"><b><a href="#cite_ref-118">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSwainston_HarrisonPerry2004" class="citation journal cs1">Swainston Harrison T, Perry CM (2004). "Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder". <i>Drugs</i>. <b>64</b> (15): 1715–36. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00003495-200464150-00010">10.2165/00003495-200464150-00010</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15257633">15257633</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Aripiprazole%3A+a+review+of+its+use+in+schizophrenia+and+schizoaffective+disorder&amp;rft.volume=64&amp;rft.issue=15&amp;rft.pages=1715-36&amp;rft.date=2004&amp;rft_id=info%3Adoi%2F10.2165%2F00003495-200464150-00010&amp;rft_id=info%3Apmid%2F15257633&amp;rft.aulast=Swainston+Harrison&amp;rft.aufirst=T&amp;rft.au=Perry%2C+CM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-119">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPickarLitmanKonickiWolkowitz1990" class="citation journal cs1">Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A (1990). "Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia". <i>Modern Problems of Pharmacopsychiatry</i>. Modern Trends in Pharmacopsychiatry. <b>24</b>: 124–151. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1159%2F000418015">10.1159/000418015</a>. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-3-8055-5050-5" title="Special:BookSources/978-3-8055-5050-5"><bdi>978-3-8055-5050-5</bdi></a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/1970851">1970851</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Modern+Problems+of+Pharmacopsychiatry&amp;rft.atitle=Neurochemical+and+Neural+Mechanisms+of+Positive+and+Negative+Symptoms+in+Schizophrenia&amp;rft.volume=24&amp;rft.pages=124-151&amp;rft.date=1990&amp;rft_id=info%3Apmid%2F1970851&amp;rft_id=info%3Adoi%2F10.1159%2F000418015&amp;rft.isbn=978-3-8055-5050-5&amp;rft.aulast=Pickar&amp;rft.aufirst=D&amp;rft.au=Litman%2C+RE&amp;rft.au=Konicki%2C+PE&amp;rft.au=Wolkowitz%2C+OM&amp;rft.au=Breier%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-120"><span class="mw-cite-backlink"><b><a href="#cite_ref-120">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLiemburgKnegteringKleinKortekaas2012" class="citation journal cs1">Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A (June 2012). "Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings". <i>European Neuropsychopharmacology</i>. <b>22</b> (6): 387–400. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.euroneuro.2011.12.008">10.1016/j.euroneuro.2011.12.008</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22300864">22300864</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:24877454">24877454</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Neuropsychopharmacology&amp;rft.atitle=Antipsychotic+medication+and+prefrontal+cortex+activation%3A+a+review+of+neuroimaging+findings&amp;rft.volume=22&amp;rft.issue=6&amp;rft.pages=387-400&amp;rft.date=2012-06&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A24877454%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F22300864&amp;rft_id=info%3Adoi%2F10.1016%2Fj.euroneuro.2011.12.008&amp;rft.aulast=Liemburg&amp;rft.aufirst=EJ&amp;rft.au=Knegtering%2C+H&amp;rft.au=Klein%2C+HC&amp;rft.au=Kortekaas%2C+R&amp;rft.au=Aleman%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-McDonald_41–63-121"><span class="mw-cite-backlink">^ <a href="#cite_ref-McDonald_41–63_121-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-McDonald_41–63_121-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMcDonaldMurphy2003" class="citation journal cs1">McDonald C, Murphy KC (March 2003). "The new genetics of schizophrenia". <i>The Psychiatric Clinics of North America</i>. <b>26</b> (1): 41–63. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0193-953X%2802%2900030-8">10.1016/S0193-953X(02)00030-8</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/12683259">12683259</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Psychiatric+Clinics+of+North+America&amp;rft.atitle=The+new+genetics+of+schizophrenia&amp;rft.volume=26&amp;rft.issue=1&amp;rft.pages=41-63&amp;rft.date=2003-03&amp;rft_id=info%3Adoi%2F10.1016%2FS0193-953X%2802%2900030-8&amp;rft_id=info%3Apmid%2F12683259&amp;rft.aulast=McDonald&amp;rft.aufirst=C&amp;rft.au=Murphy%2C+KC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-122"><span class="mw-cite-backlink"><b><a href="#cite_ref-122">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSchmidtSorensenKehneCarr1995" class="citation journal cs1">Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). "The role of 5-HT2A receptors in antipsychotic activity". <i>Life Sciences</i>. <b>56</b> (25): 2209–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2F0024-3205%2895%2900210-W">10.1016/0024-3205(95)00210-W</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/7791509">7791509</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Life+Sciences&amp;rft.atitle=The+role+of+5-HT2A+receptors+in+antipsychotic+activity&amp;rft.volume=56&amp;rft.issue=25&amp;rft.pages=2209-22&amp;rft.date=1995&amp;rft_id=info%3Adoi%2F10.1016%2F0024-3205%2895%2900210-W&amp;rft_id=info%3Apmid%2F7791509&amp;rft.aulast=Schmidt&amp;rft.aufirst=CJ&amp;rft.au=Sorensen%2C+SM&amp;rft.au=Kehne%2C+JH&amp;rft.au=Carr%2C+AA&amp;rft.au=Palfreyman%2C+MG&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Atypicality-123"><span class="mw-cite-backlink">^ <a href="#cite_ref-Atypicality_123-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Atypicality_123-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFStahl2003" class="citation journal cs1">Stahl SM (2003). <a rel="nofollow" class="external text" href="https://www.psychiatrist.com/wp-content/uploads/2021/02/24453_describing-atypical-antipsychotic-receptor-binding.pdf">"Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology"</a> <span class="cs1-format">(PDF)</span>. <i>Primary Care Companion to the Journal of Clinical Psychiatry</i>. <b>5</b> (Suppl. 3): 9–13.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Primary+Care+Companion+to+the+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Describing+an+Atypical+Antipsychotic%3A+Receptor+Binding+and+Its+Role+in+Pathophysiology&amp;rft.volume=5&amp;rft.issue=Suppl.+3&amp;rft.pages=9-13&amp;rft.date=2003&amp;rft.aulast=Stahl&amp;rft.aufirst=SM&amp;rft_id=https%3A%2F%2Fwww.psychiatrist.com%2Fwp-content%2Fuploads%2F2021%2F02%2F24453_describing-atypical-antipsychotic-receptor-binding.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-124"><span class="mw-cite-backlink"><b><a href="#cite_ref-124">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMeltzer2012" class="citation journal cs1">Meltzer HY (2012). "Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics". Handbook of Experimental Pharmacology. <b>212</b> (212): 87–124. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2F978-3-642-25761-2_4">10.1007/978-3-642-25761-2_4</a>. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-3-642-25760-5" title="Special:BookSources/978-3-642-25760-5"><bdi>978-3-642-25760-5</bdi></a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23129329">23129329</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonergic+Mechanisms+as+Targets+for+Existing+and+Novel+Antipsychotics&amp;rft.volume=212&amp;rft.issue=212&amp;rft.pages=87-124&amp;rft.date=2012&amp;rft_id=info%3Apmid%2F23129329&amp;rft_id=info%3Adoi%2F10.1007%2F978-3-642-25761-2_4&amp;rft.isbn=978-3-642-25760-5&amp;rft.aulast=Meltzer&amp;rft.aufirst=HY&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span> <span class="cs1-hidden-error citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_journal" title="Template:Cite journal">cite journal</a>}}</code>: </span><span class="cs1-hidden-error citation-comment">Cite journal requires <code class="cs1-code">&#124;journal=</code> (<a href="/wiki/Help:CS1_errors#missing_periodical" title="Help:CS1 errors">help</a>)</span></span>
</li>
<li id="cite_note-Sanchez2012-125"><span class="mw-cite-backlink">^ <a href="#cite_ref-Sanchez2012_125-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-33"><sup><i><b>ah</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-34"><sup><i><b>ai</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-35"><sup><i><b>aj</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-36"><sup><i><b>ak</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-37"><sup><i><b>al</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-38"><sup><i><b>am</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-39"><sup><i><b>an</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-40"><sup><i><b>ao</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-41"><sup><i><b>ap</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-42"><sup><i><b>aq</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-43"><sup><i><b>ar</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-44"><sup><i><b>as</b></i></sup></a> <a href="#cite_ref-Sanchez2012_125-45"><sup><i><b>at</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSanchez2012" class="citation book cs1">Sanchez M (May 2012). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=oV1VVH_AE-kC&amp;pg=PA148"><i>Farmacología y endocrinología del comportamiento</i></a>. Editorial UOC. pp.&#160;148–149. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-84-9788-424-2" title="Special:BookSources/978-84-9788-424-2"><bdi>978-84-9788-424-2</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20171125213437/https://books.google.com/books?id=oV1VVH_AE-kC&amp;pg=PA148">Archived</a> from the original on 25 November 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Farmacolog%C3%ADa+y+endocrinolog%C3%ADa+del+comportamiento&amp;rft.pages=148-149&amp;rft.pub=Editorial+UOC&amp;rft.date=2012-05&amp;rft.isbn=978-84-9788-424-2&amp;rft.aulast=Sanchez&amp;rft.aufirst=M&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DoV1VVH_AE-kC%26pg%3DPA148&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-IUPACFischer2006-126"><span class="mw-cite-backlink"><b><a href="#cite_ref-IUPACFischer2006_126-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFischerGanellin2006" class="citation book cs1">Fischer J, Ganellin CR (13 December 2006). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=FjKfqkaKkAAC&amp;pg=PA305"><i>Analogue-based Drug Discovery</i></a>. John Wiley &amp; Sons. pp.&#160;305–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-3-527-60749-5" title="Special:BookSources/978-3-527-60749-5"><bdi>978-3-527-60749-5</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Analogue-based+Drug+Discovery&amp;rft.pages=305-&amp;rft.pub=John+Wiley+%26+Sons&amp;rft.date=2006-12-13&amp;rft.isbn=978-3-527-60749-5&amp;rft.aulast=Fischer&amp;rft.aufirst=J&amp;rft.au=Ganellin%2C+CR&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DFjKfqkaKkAAC%26pg%3DPA305&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lidow2000-127"><span class="mw-cite-backlink">^ <a href="#cite_ref-Lidow2000_127-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Lidow2000_127-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Lidow2000_127-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLidow2000" class="citation book cs1">Lidow MS (22 June 2000). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=HIHLBQAAQBAJ&amp;pg=PA23"><i>Neurotransmitter Receptors in Actions of Antipsychotic Medications</i></a>. CRC Press. pp.&#160;23–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1-4200-4177-4" title="Special:BookSources/978-1-4200-4177-4"><bdi>978-1-4200-4177-4</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Neurotransmitter+Receptors+in+Actions+of+Antipsychotic+Medications&amp;rft.pages=23-&amp;rft.pub=CRC+Press&amp;rft.date=2000-06-22&amp;rft.isbn=978-1-4200-4177-4&amp;rft.aulast=Lidow&amp;rft.aufirst=MS&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DHIHLBQAAQBAJ%26pg%3DPA23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid16082416-128"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16082416_128-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-pmid16082416_128-24"><sup><i><b>y</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSilvestreProus2005" class="citation journal cs1">Silvestre JS, Prous J (June 2005). "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes". <i>Methods and Findings in Experimental and Clinical Pharmacology</i>. <b>27</b> (5): 289–304. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1358%2Fmf.2005.27.5.908643">10.1358/mf.2005.27.5.908643</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16082416">16082416</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Methods+and+Findings+in+Experimental+and+Clinical+Pharmacology&amp;rft.atitle=Research+on+adverse+drug+events.+I.+Muscarinic+M3+receptor+binding+affinity+could+predict+the+risk+of+antipsychotics+to+induce+type+2+diabetes&amp;rft.volume=27&amp;rft.issue=5&amp;rft.pages=289-304&amp;rft.date=2005-06&amp;rft_id=info%3Adoi%2F10.1358%2Fmf.2005.27.5.908643&amp;rft_id=info%3Apmid%2F16082416&amp;rft.aulast=Silvestre&amp;rft.aufirst=JS&amp;rft.au=Prous%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Aripiprazole-Lauroxil-129"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Aripiprazole-Lauroxil_129-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800033484">"Aripiprazole lauroxil – Alkermes – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Aripiprazole+lauroxil+%E2%80%93+Alkermes+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800033484&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Asenapine-130"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Asenapine_130-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800001124">"Asenapine – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Asenapine+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800001124&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Blonanserin-131"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Blonanserin_131-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800001321">"Blonanserin – Sumitomo Dainippon Pharma – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Blonanserin+%E2%80%93+Sumitomo+Dainippon+Pharma+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800001321&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Brexpiprazole-132"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Brexpiprazole_132-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800029282">"Brexpiprazole – Lundbeck/Otsuka – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20161011194233/http://adisinsight.springer.com/drugs/800029282">Archived</a> from the original on 11 October 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">27 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Brexpiprazole+%E2%80%93+Lundbeck%2FOtsuka+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800029282&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Cariprazine-133"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Cariprazine_133-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800021768">"Cariprazine – Gedeon Richter – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20170818092946/http://adisinsight.springer.com/drugs/800021768">Archived</a> from the original on 18 August 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Cariprazine+%E2%80%93+Gedeon+Richter+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800021768&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Csernansky2012-134"><span class="mw-cite-backlink">^ <a href="#cite_ref-Csernansky2012_134-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Csernansky2012_134-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCsernansky2012" class="citation book cs1">Csernansky JG (6 December 2012). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=hiz6CAAAQBAJ&amp;pg=PA360"><i>Antipsychotics</i></a>. Springer Science &amp; Business Media. pp.&#160;360–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-3-642-61007-3" title="Special:BookSources/978-3-642-61007-3"><bdi>978-3-642-61007-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Antipsychotics&amp;rft.pages=360-&amp;rft.pub=Springer+Science+%26+Business+Media&amp;rft.date=2012-12-06&amp;rft.isbn=978-3-642-61007-3&amp;rft.aulast=Csernansky&amp;rft.aufirst=JG&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3Dhiz6CAAAQBAJ%26pg%3DPA360&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2013-135"><span class="mw-cite-backlink"><b><a href="#cite_ref-Publishing2013_135-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=_J2ti4EkYpkC&amp;pg=PA1077"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.&#160;1077–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1856-3" title="Special:BookSources/978-0-8155-1856-3"><bdi>978-0-8155-1856-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=1077-&amp;rft.pub=Elsevier&amp;rft.date=2013-10-22&amp;rft.isbn=978-0-8155-1856-3&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D_J2ti4EkYpkC%26pg%3DPA1077&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2013-Clopenthixol-136"><span class="mw-cite-backlink">^ <a href="#cite_ref-Publishing2013-Clopenthixol_136-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Publishing2013-Clopenthixol_136-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=_J2ti4EkYpkC&amp;pg=PA1102"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.&#160;1102–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1856-3" title="Special:BookSources/978-0-8155-1856-3"><bdi>978-0-8155-1856-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=1102-&amp;rft.pub=Elsevier&amp;rft.date=2013-10-22&amp;rft.isbn=978-0-8155-1856-3&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D_J2ti4EkYpkC%26pg%3DPA1102&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Protiva2010-137"><span class="mw-cite-backlink"><b><a href="#cite_ref-Protiva2010_137-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFProtiva2010" class="citation journal cs1">Protiva M (2010). "ChemInform Abstract: Fifty Years in Chemical Drug Research". <i>ChemInform</i>. <b>23</b> (9): no. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2Fchin.199209338">10.1002/chin.199209338</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0931-7597">0931-7597</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ChemInform&amp;rft.atitle=ChemInform+Abstract%3A+Fifty+Years+in+Chemical+Drug+Research&amp;rft.volume=23&amp;rft.issue=9&amp;rft.pages=no&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.1002%2Fchin.199209338&amp;rft.issn=0931-7597&amp;rft.aulast=Protiva&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid5576292-138"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid5576292_138-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMelich1971" class="citation journal cs1 cs1-prop-foreign-lang-source">Melich H (April 1971). "[Clotepin]". <i>Časopis lékařů českých</i> (in Czech). <b>110</b> (17): 404–5. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/5576292">5576292</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=%C4%8Casopis+l%C3%A9ka%C5%99%C5%AF+%C4%8Desk%C3%BDch&amp;rft.atitle=%5BClotepin%5D&amp;rft.volume=110&amp;rft.issue=17&amp;rft.pages=404-5&amp;rft.date=1971-04&amp;rft_id=info%3Apmid%2F5576292&amp;rft.aulast=Melich&amp;rft.aufirst=H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-GaleResearch1991-139"><span class="mw-cite-backlink">^ <a href="#cite_ref-GaleResearch1991_139-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-GaleResearch1991_139-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation book cs1"><a rel="nofollow" class="external text" href="https://books.google.com/books?id=2x1tAAAAMAAJ"><i>Drugs Available Abroad</i></a>. Gale Research. 1991. p.&#160;52,169. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8103-7177-4" title="Special:BookSources/978-0-8103-7177-4"><bdi>978-0-8103-7177-4</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20170722224557/https://books.google.com/books?id=2x1tAAAAMAAJ">Archived</a> from the original on 22 July 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Drugs+Available+Abroad&amp;rft.pages=52%2C169&amp;rft.pub=Gale+Research&amp;rft.date=1991&amp;rft.isbn=978-0-8103-7177-4&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D2x1tAAAAMAAJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid16126373-140"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16126373_140-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGellerGorzaltsanShleiferBelmaker2005" class="citation journal cs1">Geller V, Gorzaltsan I, Shleifer T, Belmaker RH, Bersudsky Y (December 2005). "Clotiapine compared with chlorpromazine in chronic schizophrenia". <i>Schizophrenia Research</i>. <b>80</b> (2–3): 343–7. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.schres.2005.07.007">10.1016/j.schres.2005.07.007</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/16126373">16126373</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:22340010">22340010</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research&amp;rft.atitle=Clotiapine+compared+with+chlorpromazine+in+chronic+schizophrenia&amp;rft.volume=80&amp;rft.issue=2%E2%80%933&amp;rft.pages=343-7&amp;rft.date=2005-12&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A22340010%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16126373&amp;rft_id=info%3Adoi%2F10.1016%2Fj.schres.2005.07.007&amp;rft.aulast=Geller&amp;rft.aufirst=V&amp;rft.au=Gorzaltsan%2C+I&amp;rft.au=Shleifer%2C+T&amp;rft.au=Belmaker%2C+RH&amp;rft.au=Bersudsky%2C+Y&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid15492772-141"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15492772_141-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBourinDaillyHascöet2004" class="citation journal cs1">Bourin M, Dailly E, Hascöet M (2004). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6741725">"Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome"</a>. <i>CNS Drug Reviews</i>. <b>10</b> (3): 219–29. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1527-3458.2004.tb00023.x">10.1111/j.1527-3458.2004.tb00023.x</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6741725">6741725</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15492772">15492772</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drug+Reviews&amp;rft.atitle=Preclinical+and+clinical+pharmacology+of+cyamemazine%3A+anxiolytic+effects+and+prevention+of+alcohol+and+benzodiazepine+withdrawal+syndrome&amp;rft.volume=10&amp;rft.issue=3&amp;rft.pages=219-29&amp;rft.date=2004&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6741725%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F15492772&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1527-3458.2004.tb00023.x&amp;rft.aulast=Bourin&amp;rft.aufirst=M&amp;rft.au=Dailly%2C+E&amp;rft.au=Hasc%C3%B6et%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6741725&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-LamberthDinges2012-142"><span class="mw-cite-backlink"><b><a href="#cite_ref-LamberthDinges2012_142-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLamberthDinges2012" class="citation book cs1">Lamberth C, Dinges J (16 August 2012). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=35uKnWKD9V8C&amp;pg=PA3"><i>Bioactive Heterocyclic Compound Classes: Pharmaceuticals</i></a>. John Wiley &amp; Sons. pp.&#160;3–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-3-527-66447-4" title="Special:BookSources/978-3-527-66447-4"><bdi>978-3-527-66447-4</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Bioactive+Heterocyclic+Compound+Classes%3A+Pharmaceuticals&amp;rft.pages=3-&amp;rft.pub=John+Wiley+%26+Sons&amp;rft.date=2012-08-16&amp;rft.isbn=978-3-527-66447-4&amp;rft.aulast=Lamberth&amp;rft.aufirst=C&amp;rft.au=Dinges%2C+J&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D35uKnWKD9V8C%26pg%3DPA3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Pedersen1996-143"><span class="mw-cite-backlink">^ <a href="#cite_ref-Pedersen1996_143-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pedersen1996_143-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPedersen1996" class="citation journal cs1">Pedersen V (1996). "Thioxanthene antipsychotics". <i>European Psychiatry</i>. <b>11</b>: 236s. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2F0924-9338%2896%2988706-2">10.1016/0924-9338(96)88706-2</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0924-9338">0924-9338</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Psychiatry&amp;rft.atitle=Thioxanthene+antipsychotics&amp;rft.volume=11&amp;rft.pages=236s&amp;rft.date=1996&amp;rft_id=info%3Adoi%2F10.1016%2F0924-9338%2896%2988706-2&amp;rft.issn=0924-9338&amp;rft.aulast=Pedersen&amp;rft.aufirst=V&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Iloperidone-144"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Iloperidone_144-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800001330">"Iloperidone – Vanda Pharmaceuticals – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20151211102105/http://adisinsight.springer.com/drugs/800001330">Archived</a> from the original on 11 December 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">27 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Iloperidone+%E2%80%93+Vanda+Pharmaceuticals+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800001330&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Shorter2009-145"><span class="mw-cite-backlink">^ <a href="#cite_ref-Shorter2009_145-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Shorter2009_145-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFShorter2009" class="citation book cs1">Shorter E (2009). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=nCtnDAAAQBAJ&amp;pg=PR14"><i>Before Prozac: The Troubled History of Mood Disorders in Psychiatry</i></a>. Oxford University Press, USA. pp.&#160;14–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-19-536874-1" title="Special:BookSources/978-0-19-536874-1"><bdi>978-0-19-536874-1</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Before+Prozac%3A+The+Troubled+History+of+Mood+Disorders+in+Psychiatry&amp;rft.pages=14-&amp;rft.pub=Oxford+University+Press%2C+USA&amp;rft.date=2009&amp;rft.isbn=978-0-19-536874-1&amp;rft.aulast=Shorter&amp;rft.aufirst=E&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DnCtnDAAAQBAJ%26pg%3DPR14&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid10340686-146"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10340686_146-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGlazer1999" class="citation journal cs1">Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". <i>The Journal of Clinical Psychiatry</i>. <b>60</b> (Suppl 10): 42–6. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10340686">10340686</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Does+loxapine+have+%22atypical%22+properties%3F+Clinical+evidence&amp;rft.volume=60&amp;rft.issue=Suppl+10&amp;rft.pages=42-6&amp;rft.date=1999&amp;rft_id=info%3Apmid%2F10340686&amp;rft.aulast=Glazer&amp;rft.aufirst=WM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Lurasidone-147"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Lurasidone_147-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800007206">"Lurasidone - Sumitomo Dainippon Pharma – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20160510014459/http://adisinsight.springer.com/drugs/800007206">Archived</a> from the original on 10 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Lurasidone+-+Sumitomo+Dainippon+Pharma+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800007206&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Nemonapride-148"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Nemonapride_148-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800007270">"Nemonapride – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Nemonapride+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800007270&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Paliperidone-149"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Paliperidone_149-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800020763">"Paliperidone – Johnson &amp; Johnson – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Paliperidone+%E2%80%93+Johnson+%26+Johnson+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800020763&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Paliperidone-Palmitate-150"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Paliperidone-Palmitate_150-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800040526">"Paliperidone palmitate – Johnson &amp; Johnson – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20161030135731/http://adisinsight.springer.com/drugs/800040526">Archived</a> from the original on 30 October 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">27 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Paliperidone+palmitate+%E2%80%93+Johnson+%26+Johnson+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800040526&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Vardanyan2017-151"><span class="mw-cite-backlink">^ <a href="#cite_ref-Vardanyan2017_151-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Vardanyan2017_151-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVardanyan2017" class="citation book cs1">Vardanyan R (12 June 2017). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=szxHDgAAQBAJ&amp;pg=PA195"><i>Piperidine-Based Drug Discovery</i></a>. Elsevier Science. pp.&#160;158, 195–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-12-813428-3" title="Special:BookSources/978-0-12-813428-3"><bdi>978-0-12-813428-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Piperidine-Based+Drug+Discovery&amp;rft.pages=158%2C+195-&amp;rft.pub=Elsevier+Science&amp;rft.date=2017-06-12&amp;rft.isbn=978-0-12-813428-3&amp;rft.aulast=Vardanyan&amp;rft.aufirst=R&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DszxHDgAAQBAJ%26pg%3DPA195&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid4604881-152"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid4604881_152-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRoelofs1974" class="citation journal cs1">Roelofs GA (1974). "Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation". <i>Acta Psychiatrica Scandinavica</i>. <b>50</b> (2): 219–24. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1600-0447.1974.tb08210.x">10.1111/j.1600-0447.1974.tb08210.x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/4604881">4604881</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:40524276">40524276</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Psychiatrica+Scandinavica&amp;rft.atitle=Penfluridol+%28R+16341%29+as+a+maintenance+therapy+in+chronic+psychotic+patients%3A+a+double-blind+clinical+evaluation&amp;rft.volume=50&amp;rft.issue=2&amp;rft.pages=219-24&amp;rft.date=1974&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A40524276%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F4604881&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.1974.tb08210.x&amp;rft.aulast=Roelofs&amp;rft.aufirst=GA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid24425538-153"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid24425538_153-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLeuchtHelferHartung2014" class="citation journal cs1">Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". <i>The Cochrane Database of Systematic Reviews</i> (1): CD002832. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD002832.pub3">10.1002/14651858.CD002832.pub3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24425538">24425538</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Perazine+for+schizophrenia&amp;rft.issue=1&amp;rft.pages=CD002832&amp;rft.date=2014-01&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD002832.pub3&amp;rft_id=info%3Apmid%2F24425538&amp;rft.aulast=Leucht&amp;rft.aufirst=S&amp;rft.au=Helfer%2C+B&amp;rft.au=Hartung%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid24825770-154"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid24825770_154-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMatarAlmerieMakhoulXia2014" class="citation journal cs1">Matar HE, Almerie MQ, Makhoul S, Xia J, Humphreys P (May 2014). "Pericyazine for schizophrenia". <i>The Cochrane Database of Systematic Reviews</i> (5): CD007479. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD007479.pub2">10.1002/14651858.CD007479.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24825770">24825770</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Pericyazine+for+schizophrenia&amp;rft.issue=5&amp;rft.pages=CD007479&amp;rft.date=2014-05&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007479.pub2&amp;rft_id=info%3Apmid%2F24825770&amp;rft.aulast=Matar&amp;rft.aufirst=HE&amp;rft.au=Almerie%2C+MQ&amp;rft.au=Makhoul%2C+S&amp;rft.au=Xia%2C+J&amp;rft.au=Humphreys%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Perospirone-155"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Perospirone_155-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800000573">"Perospirone – AdisInsight"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Perospirone+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800000573&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AdisInsight-Pimavanserin-156"><span class="mw-cite-backlink"><b><a href="#cite_ref-AdisInsight-Pimavanserin_156-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800014997">"Pimavanserin – ACADIA Pharmaceuticals – AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20170925225849/http://adisinsight.springer.com/drugs/800014997">Archived</a> from the original on 25 September 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">27 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pimavanserin+%E2%80%93+ACADIA+Pharmaceuticals+%E2%80%93+AdisInsight&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800014997&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2013-Pipotiazine-157"><span class="mw-cite-backlink"><b><a href="#cite_ref-Publishing2013-Pipotiazine_157-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=_J2ti4EkYpkC&amp;pg=PA2935-IA349"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.&#160;2935–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1856-3" title="Special:BookSources/978-0-8155-1856-3"><bdi>978-0-8155-1856-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=2935-&amp;rft.pub=Elsevier&amp;rft.date=2013-10-22&amp;rft.isbn=978-0-8155-1856-3&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D_J2ti4EkYpkC%26pg%3DPA2935-IA349&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2007-Spiperone-158"><span class="mw-cite-backlink"><b><a href="#cite_ref-Publishing2007-Spiperone_158-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2007" class="citation book cs1">William Andrew Publishing (2007). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=dXpUAAAAMAAJ"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. William Andrew Pub. p.&#160;3059. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1526-5" title="Special:BookSources/978-0-8155-1526-5"><bdi>978-0-8155-1526-5</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=3059&amp;rft.pub=William+Andrew+Pub.&amp;rft.date=2007&amp;rft.isbn=978-0-8155-1526-5&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DdXpUAAAAMAAJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2013-Sultopride-159"><span class="mw-cite-backlink"><b><a href="#cite_ref-Publishing2013-Sultopride_159-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=_J2ti4EkYpkC&amp;pg=PA3129"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.&#160;3129–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1856-3" title="Special:BookSources/978-0-8155-1856-3"><bdi>978-0-8155-1856-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=3129-&amp;rft.pub=Elsevier&amp;rft.date=2013-10-22&amp;rft.isbn=978-0-8155-1856-3&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D_J2ti4EkYpkC%26pg%3DPA3129&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Publishing2013-Tiotixene-160"><span class="mw-cite-backlink"><b><a href="#cite_ref-Publishing2013-Tiotixene_160-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=_J2ti4EkYpkC&amp;pg=PA3214"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.&#160;3214–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8155-1856-3" title="Special:BookSources/978-0-8155-1856-3"><bdi>978-0-8155-1856-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Pharmaceutical+Manufacturing+Encyclopedia&amp;rft.pages=3214-&amp;rft.pub=Elsevier&amp;rft.date=2013-10-22&amp;rft.isbn=978-0-8155-1856-3&amp;rft.au=William+Andrew+Publishing&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D_J2ti4EkYpkC%26pg%3DPA3214&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-AMH-161"><span class="mw-cite-backlink"><b><a href="#cite_ref-AMH_161-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRossi,_S2013" class="citation book cs1">Rossi, S, ed. (2013). <i>Australian Medicines Handbook</i> (2013&#160;ed.). Adelaide: The Australian Medicines Handbook Unit Trust. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-9805790-9-3" title="Special:BookSources/978-0-9805790-9-3"><bdi>978-0-9805790-9-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Australian+Medicines+Handbook&amp;rft.place=Adelaide&amp;rft.edition=2013&amp;rft.pub=The+Australian+Medicines+Handbook+Unit+Trust&amp;rft.date=2013&amp;rft.isbn=978-0-9805790-9-3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-BNF-162"><span class="mw-cite-backlink"><b><a href="#cite_ref-BNF_162-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJoint_Formulary_Committee2013" class="citation book cs1">Joint Formulary Committee (2013). <i>British National Formulary (BNF)</i> (65&#160;ed.). London, UK: Pharmaceutical Press. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-85711-084-8" title="Special:BookSources/978-0-85711-084-8"><bdi>978-0-85711-084-8</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=British+National+Formulary+%28BNF%29&amp;rft.place=London%2C+UK&amp;rft.edition=65&amp;rft.pub=Pharmaceutical+Press&amp;rft.date=2013&amp;rft.isbn=978-0-85711-084-8&amp;rft.au=Joint+Formulary+Committee&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-163"><span class="mw-cite-backlink"><b><a href="#cite_ref-163">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFIsbisterBalitMacleodDuffull2010" class="citation journal cs1">Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". <i>Journal of Clinical Psychopharmacology</i>. <b>30</b> (4): 391–5. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FJCP.0b013e3181e5c14c">10.1097/JCP.0b013e3181e5c14c</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20531221">20531221</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205710487">205710487</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Psychopharmacology&amp;rft.atitle=Amisulpride+overdose+is+frequently+associated+with+QT+prolongation+and+torsades+de+pointes&amp;rft.volume=30&amp;rft.issue=4&amp;rft.pages=391-5&amp;rft.date=2010-08&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205710487%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20531221&amp;rft_id=info%3Adoi%2F10.1097%2FJCP.0b013e3181e5c14c&amp;rft.aulast=Isbister&amp;rft.aufirst=GK&amp;rft.au=Balit%2C+CR&amp;rft.au=Macleod%2C+D&amp;rft.au=Duffull%2C+SB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Deeks,_ED;_Keating,_GM_65–84-164"><span class="mw-cite-backlink">^ <a href="#cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Deeks,_ED;_Keating,_GM_65–84_164-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDeeksKeating2010" class="citation journal cs1">Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". <i>CNS Drugs</i>. <b>24</b> (1): 65–84. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F11202620-000000000-00000">10.2165/11202620-000000000-00000</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20030420">20030420</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Blonanserin%3A+a+review+of+its+use+in+the+management+of+schizophrenia&amp;rft.volume=24&amp;rft.issue=1&amp;rft.pages=65-84&amp;rft.date=2010-01&amp;rft_id=info%3Adoi%2F10.2165%2F11202620-000000000-00000&amp;rft_id=info%3Apmid%2F20030420&amp;rft.aulast=Deeks&amp;rft.aufirst=ED&amp;rft.au=Keating%2C+GM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594-165"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594_165-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tenjin,_T;_Miyamoto,_S;_Ninomiya,_Y;_Kitajima,_R;_Ogino,_S;_Miyake,_N;_Yamaguchi,_N_2013_587–594_165-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTenjinMiyamotoNinomiyaKitajima2013" class="citation journal cs1">Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, Yamaguchi N (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3677929">"Profile of blonanserin for the treatment of schizophrenia"</a>. <i>Neuropsychiatric Disease and Treatment</i>. <b>9</b>: 587–94. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2147%2FNDT.S34433">10.2147/NDT.S34433</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3677929">3677929</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23766647">23766647</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropsychiatric+Disease+and+Treatment&amp;rft.atitle=Profile+of+blonanserin+for+the+treatment+of+schizophrenia&amp;rft.volume=9&amp;rft.pages=587-94&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3677929%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23766647&amp;rft_id=info%3Adoi%2F10.2147%2FNDT.S34433&amp;rft.aulast=Tenjin&amp;rft.aufirst=T&amp;rft.au=Miyamoto%2C+S&amp;rft.au=Ninomiya%2C+Y&amp;rft.au=Kitajima%2C+R&amp;rft.au=Ogino%2C+S&amp;rft.au=Miyake%2C+N&amp;rft.au=Yamaguchi%2C+N&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3677929&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-166"><span class="mw-cite-backlink"><b><a href="#cite_ref-166">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.medicinescomplete.com/mc/martindale/current/12595-x.htm">"Clozapine"</a>. <i>Martindale: The Complete Drug Reference</i>. Royal Pharmaceutical Society of Great Britain. 30 January 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Martindale%3A+The+Complete+Drug+Reference&amp;rft.atitle=Clozapine&amp;rft.date=2013-01-30&amp;rft_id=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2Fcurrent%2F12595-x.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-167"><span class="mw-cite-backlink"><b><a href="#cite_ref-167">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMatarAlmerieSampson2018" class="citation journal cs1">Matar HE, Almerie MQ, Sampson S (June 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3796096">"Fluphenazine (oral) versus placebo for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>7</b> (7): CD006352. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD006352.pub3">10.1002/14651858.CD006352.pub3</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3796096">3796096</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/29893410">29893410</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Fluphenazine+%28oral%29+versus+placebo+for+schizophrenia&amp;rft.volume=7&amp;rft.issue=7&amp;rft.pages=CD006352&amp;rft.date=2018-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3796096%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F29893410&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD006352.pub3&amp;rft.aulast=Matar&amp;rft.aufirst=HE&amp;rft.au=Almerie%2C+MQ&amp;rft.au=Sampson%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3796096&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-168"><span class="mw-cite-backlink"><b><a href="#cite_ref-168">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFChakrabartiBagnallChueFenton2007" class="citation journal cs1">Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007).  Chakrabarti A (ed.). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7017975">"Loxapine for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (4): CD001943. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD001943.pub2">10.1002/14651858.CD001943.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7017975">7017975</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17943763">17943763</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Loxapine+for+schizophrenia&amp;rft.issue=4&amp;rft.pages=CD001943&amp;rft.date=2007-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7017975%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F17943763&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD001943.pub2&amp;rft.aulast=Chakrabarti&amp;rft.aufirst=A&amp;rft.au=Bagnall%2C+A&amp;rft.au=Chue%2C+P&amp;rft.au=Fenton%2C+M&amp;rft.au=Palaniswamy%2C+V&amp;rft.au=Wong%2C+W&amp;rft.au=Xia%2C+J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7017975&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-169"><span class="mw-cite-backlink"><b><a href="#cite_ref-169">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHarveyOgasaCucchiaroLoebel2011" class="citation journal cs1">Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS (April 2011). "Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone". <i>Schizophrenia Research</i>. <b>127</b> (1–3): 188–94. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.schres.2011.01.004">10.1016/j.schres.2011.01.004</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21277745">21277745</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:8805912">8805912</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Schizophrenia+Research&amp;rft.atitle=Performance+and+interview-based+assessments+of+cognitive+change+in+a+randomized%2C+double-blind+comparison+of+lurasidone+vs.+ziprasidone&amp;rft.volume=127&amp;rft.issue=1%E2%80%933&amp;rft.pages=188-94&amp;rft.date=2011-04&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A8805912%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21277745&amp;rft_id=info%3Adoi%2F10.1016%2Fj.schres.2011.01.004&amp;rft.aulast=Harvey&amp;rft.aufirst=PD&amp;rft.au=Ogasa%2C+M&amp;rft.au=Cucchiaro%2C+J&amp;rft.au=Loebel%2C+A&amp;rft.au=Keefe%2C+RS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-170"><span class="mw-cite-backlink"><b><a href="#cite_ref-170">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRöhrichtGadhiaAlamWillis2012" class="citation journal cs1">Röhricht F, Gadhia S, Alam R, Willis M (2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3330679">"Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia"</a>. <i>TheScientificWorldJournal</i>. <b>2012</b>: 1–5. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1100%2F2012%2F512047">10.1100/2012/512047</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3330679">3330679</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22566771">22566771</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=TheScientificWorldJournal&amp;rft.atitle=Auditing+clinical+outcomes+after+introducing+off-licence+prescribing+of+atypical+antipsychotic+melperone+for+patients+with+treatment+refractory+schizophrenia&amp;rft.volume=2012&amp;rft.pages=1-5&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3330679%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22566771&amp;rft_id=info%3Adoi%2F10.1100%2F2012%2F512047&amp;rft.aulast=R%C3%B6hricht&amp;rft.aufirst=F&amp;rft.au=Gadhia%2C+S&amp;rft.au=Alam%2C+R&amp;rft.au=Willis%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3330679&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-MD-171"><span class="mw-cite-backlink">^ <a href="#cite_ref-MD_171-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-MD_171-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation book cs1"><a rel="nofollow" class="external text" href="http://www.medicinescomplete.com/mc/martindale/current/7072-k.htm"><i>Molindone Hydrochloride</i></a>. <i>Martindale: The Complete Drug Reference</i>. The Royal Pharmaceutical Society of Great Britain. 30 January 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Molindone+Hydrochloride&amp;rft.pub=The+Royal+Pharmaceutical+Society+of+Great+Britain&amp;rft.date=2013-01-30&amp;rft_id=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2Fcurrent%2F7072-k.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-172"><span class="mw-cite-backlink"><b><a href="#cite_ref-172">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLeuchtHelferHartung2014" class="citation journal cs1">Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". <i>The Cochrane Database of Systematic Reviews</i> (1): CD002832. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD002832.pub3">10.1002/14651858.CD002832.pub3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24425538">24425538</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Perazine+for+schizophrenia&amp;rft.issue=1&amp;rft.pages=CD002832&amp;rft.date=2014-01&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD002832.pub3&amp;rft_id=info%3Apmid%2F24425538&amp;rft.aulast=Leucht&amp;rft.aufirst=S&amp;rft.au=Helfer%2C+B&amp;rft.au=Hartung%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-173"><span class="mw-cite-backlink"><b><a href="#cite_ref-173">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFOnrustMcClellan2001" class="citation journal cs1">Onrust SV, McClellan K (April 2001). "Perospirone". <i>CNS Drugs</i>. <b>15</b> (4): 329–37, discussion 338. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00023210-200115040-00006">10.2165/00023210-200115040-00006</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/11463136">11463136</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Perospirone&amp;rft.volume=15&amp;rft.issue=4&amp;rft.pages=329-37%2C+discussion+338&amp;rft.date=2001-04&amp;rft_id=info%3Adoi%2F10.2165%2F00023210-200115040-00006&amp;rft_id=info%3Apmid%2F11463136&amp;rft.aulast=Onrust&amp;rft.aufirst=SV&amp;rft.au=McClellan%2C+K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Mart-174"><span class="mw-cite-backlink">^ <a href="#cite_ref-Mart_174-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Mart_174-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBrayfield2011" class="citation book cs1">Brayfield A, ed. (23 September 2011). <a rel="nofollow" class="external text" href="http://www.medicinescomplete.com/mc/martindale/current/15232-k.htm"><i>Perospirone</i></a>. <i>Martindale: The Complete Drug Reference</i>. London, UK: Pharmaceutical Press<span class="reference-accessdate">. Retrieved <span class="nowrap">3 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Perospirone&amp;rft.place=London%2C+UK&amp;rft.pub=Pharmaceutical+Press&amp;rft.date=2011-09-23&amp;rft_id=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2Fcurrent%2F15232-k.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-175"><span class="mw-cite-backlink"><b><a href="#cite_ref-175">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHartungSampsonLeucht2015" class="citation journal cs1">Hartung B, Sampson S, Leucht S (March 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7173727">"Perphenazine for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (3): CD003443. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD003443.pub3">10.1002/14651858.CD003443.pub3</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7173727">7173727</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25749632">25749632</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Perphenazine+for+schizophrenia&amp;rft.issue=3&amp;rft.pages=CD003443&amp;rft.date=2015-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7173727%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F25749632&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003443.pub3&amp;rft.aulast=Hartung&amp;rft.aufirst=B&amp;rft.au=Sampson%2C+S&amp;rft.au=Leucht%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7173727&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-176"><span class="mw-cite-backlink"><b><a href="#cite_ref-176">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMothiSampson2013" class="citation journal cs1">Mothi M, Sampson S (November 2013). "Pimozide for schizophrenia or related psychoses". <i>The Cochrane Database of Systematic Reviews</i> (11): CD001949. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD001949.pub3">10.1002/14651858.CD001949.pub3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24194433">24194433</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Pimozide+for+schizophrenia+or+related+psychoses&amp;rft.issue=11&amp;rft.pages=CD001949&amp;rft.date=2013-11&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD001949.pub3&amp;rft_id=info%3Apmid%2F24194433&amp;rft.aulast=Mothi&amp;rft.aufirst=M&amp;rft.au=Sampson%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-177"><span class="mw-cite-backlink"><b><a href="#cite_ref-177">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWangSampson2014" class="citation journal cs1">Wang J, Sampson S (April 2014). "Sulpiride versus placebo for schizophrenia". <i>The Cochrane Database of Systematic Reviews</i> (4): CD007811. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD007811.pub2">10.1002/14651858.CD007811.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24729184">24729184</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Sulpiride+versus+placebo+for+schizophrenia&amp;rft.issue=4&amp;rft.pages=CD007811&amp;rft.date=2014-04&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007811.pub2&amp;rft_id=info%3Apmid%2F24729184&amp;rft.aulast=Wang&amp;rft.aufirst=J&amp;rft.au=Sampson%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-178"><span class="mw-cite-backlink"><b><a href="#cite_ref-178">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFentonRathboneReillySultana2007" class="citation journal cs1">Fenton M, Rathbone J, Reilly J, Sultana A (July 2007).  Reilly J (ed.). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6718212">"Thioridazine for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (3): CD001944. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD001944.pub2">10.1002/14651858.CD001944.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6718212">6718212</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17636691">17636691</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Thioridazine+for+schizophrenia&amp;rft.issue=3&amp;rft.pages=CD001944&amp;rft.date=2007-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6718212%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F17636691&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD001944.pub2&amp;rft.aulast=Fenton&amp;rft.aufirst=M&amp;rft.au=Rathbone%2C+J&amp;rft.au=Reilly%2C+J&amp;rft.au=Sultana%2C+A&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6718212&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-179"><span class="mw-cite-backlink"><b><a href="#cite_ref-179">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFornaroCalabriaCoralloPicotti2002" class="citation journal cs1">Fornaro P, Calabria G, Corallo G, Picotti GB (July 2002). "Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis". <i>Documenta Ophthalmologica. Advances in Ophthalmology</i>. <b>105</b> (1): 41–9. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1023%2FA%3A1015768114192">10.1023/A:1015768114192</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/12152801">12152801</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:23618581">23618581</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Documenta+Ophthalmologica.+Advances+in+Ophthalmology&amp;rft.atitle=Pathogenesis+of+degenerative+retinopathies+induced+by+thioridazine+and+other+antipsychotics%3A+a+dopamine+hypothesis&amp;rft.volume=105&amp;rft.issue=1&amp;rft.pages=41-9&amp;rft.date=2002-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A23618581%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F12152801&amp;rft_id=info%3Adoi%2F10.1023%2FA%3A1015768114192&amp;rft.aulast=Fornaro&amp;rft.aufirst=P&amp;rft.au=Calabria%2C+G&amp;rft.au=Corallo%2C+G&amp;rft.au=Picotti%2C+GB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-180"><span class="mw-cite-backlink"><b><a href="#cite_ref-180">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMarquesLimaSoares2004" class="citation journal cs1">Marques LO, Lima MS, Soares BG (2004).  de Oliveira Marques L (ed.). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7003674">"Trifluoperazine for schizophrenia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (1): CD003545. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD003545.pub2">10.1002/14651858.CD003545.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC7003674">7003674</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/14974020">14974020</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Trifluoperazine+for+schizophrenia&amp;rft.issue=1&amp;rft.pages=CD003545&amp;rft.date=2004&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7003674%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F14974020&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003545.pub2&amp;rft.aulast=Marques&amp;rft.aufirst=LO&amp;rft.au=Lima%2C+MS&amp;rft.au=Soares%2C+BG&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7003674&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-181"><span class="mw-cite-backlink"><b><a href="#cite_ref-181">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.medicinescomplete.com/mc/martindale/current/2479-d.htm?">"Zotepine"</a>. <i>Martindale: The Complete Drug Reference</i>. Royal Pharmaceutical Society of Great Britain. 16 August 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Martindale%3A+The+Complete+Drug+Reference&amp;rft.atitle=Zotepine&amp;rft.date=2013-08-16&amp;rft_id=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2Fcurrent%2F2479-d.htm%3F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Lancet_11-182"><span class="mw-cite-backlink"><b><a href="#cite_ref-Lancet_11_182-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCiprianiBarbuiSalantiRendell2011" class="citation journal cs1">Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S,  et&#160;al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". <i>Lancet</i>. <b>378</b> (9799): 1306–1315. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2811%2960873-8">10.1016/S0140-6736(11)60873-8</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21851976">21851976</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:25512763">25512763</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Comparative+efficacy+and+acceptability+of+antimanic+drugs+in+acute+mania%3A+a+multiple-treatments+meta-analysis&amp;rft.volume=378&amp;rft.issue=9799&amp;rft.pages=1306-1315&amp;rft.date=2011-10&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A25512763%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21851976&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2811%2960873-8&amp;rft.aulast=Cipriani&amp;rft.aufirst=A&amp;rft.au=Barbui%2C+C&amp;rft.au=Salanti%2C+G&amp;rft.au=Rendell%2C+J&amp;rft.au=Brown%2C+R&amp;rft.au=Stockton%2C+S&amp;rft.au=Purgato%2C+M&amp;rft.au=Spineli%2C+LM&amp;rft.au=Goodwin%2C+GM&amp;rft.au=Geddes%2C+JR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-183"><span class="mw-cite-backlink"><b><a href="#cite_ref-183">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCitrome2013" class="citation journal cs1">Citrome L (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3665578">"Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents"</a>. <i>Therapeutics and Clinical Risk Management</i>. <b>9</b>: 235–245. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2147%2FTCRM.S31484">10.2147/TCRM.S31484</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3665578">3665578</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23723707">23723707</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutics+and+Clinical+Risk+Management&amp;rft.atitle=Addressing+the+need+for+rapid+treatment+of+agitation+in+schizophrenia+and+bipolar+disorder%3A+focus+on+inhaled+loxapine+as+an+alternative+to+injectable+agents&amp;rft.volume=9&amp;rft.pages=235-245&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3665578%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23723707&amp;rft_id=info%3Adoi%2F10.2147%2FTCRM.S31484&amp;rft.aulast=Citrome&amp;rft.aufirst=L&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3665578&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-184"><span class="mw-cite-backlink"><b><a href="#cite_ref-184">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCruzSanchez-MorenoTorresGoikolea2010" class="citation journal cs1">Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (February 2010). <a rel="nofollow" class="external text" href="https://doi.org/10.1017%2FS1461145709990344">"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis"</a>. <i>The International Journal of Neuropsychopharmacology</i>. <b>13</b> (1): 5–14. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1017%2FS1461145709990344">10.1017/S1461145709990344</a></span>. <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<a rel="nofollow" class="external text" href="//hdl.handle.net/2445%2F53243">2445/53243</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/19638254">19638254</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+International+Journal+of+Neuropsychopharmacology&amp;rft.atitle=Efficacy+of+modern+antipsychotics+in+placebo-controlled+trials+in+bipolar+depression%3A+a+meta-analysis&amp;rft.volume=13&amp;rft.issue=1&amp;rft.pages=5-14&amp;rft.date=2010-02&amp;rft_id=info%3Ahdl%2F2445%2F53243&amp;rft_id=info%3Apmid%2F19638254&amp;rft_id=info%3Adoi%2F10.1017%2FS1461145709990344&amp;rft.aulast=Cruz&amp;rft.aufirst=N&amp;rft.au=Sanchez-Moreno%2C+J&amp;rft.au=Torres%2C+F&amp;rft.au=Goikolea%2C+JM&amp;rft.au=Valent%C3%AD%2C+M&amp;rft.au=Vieta%2C+E&amp;rft_id=%2F%2Fdoi.org%2F10.1017%252FS1461145709990344&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-185"><span class="mw-cite-backlink"><b><a href="#cite_ref-185">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPopovicReinaresGoikoleaBonnin2012" class="citation journal cs1">Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E (May 2012). "Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder". <i>European Neuropsychopharmacology</i>. <b>22</b> (5): 339–346. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.euroneuro.2011.09.008">10.1016/j.euroneuro.2011.09.008</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22000157">22000157</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:8067809">8067809</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Neuropsychopharmacology&amp;rft.atitle=Polarity+index+of+pharmacological+agents+used+for+maintenance+treatment+of+bipolar+disorder&amp;rft.volume=22&amp;rft.issue=5&amp;rft.pages=339-346&amp;rft.date=2012-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A8067809%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F22000157&amp;rft_id=info%3Adoi%2F10.1016%2Fj.euroneuro.2011.09.008&amp;rft.aulast=Popovic&amp;rft.aufirst=D&amp;rft.au=Reinares%2C+M&amp;rft.au=Goikolea%2C+JM&amp;rft.au=Bonnin%2C+CM&amp;rft.au=Gonzalez-Pinto%2C+A&amp;rft.au=Vieta%2C+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-186"><span class="mw-cite-backlink"><b><a href="#cite_ref-186">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVietaGüntherLocklearEkman2011" class="citation journal cs1">Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML,  et&#160;al. (September 2011). "Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials". <i>The International Journal of Neuropsychopharmacology</i>. <b>14</b> (8): 1029–1049. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1017%2FS1461145711000885">10.1017/S1461145711000885</a>. <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//hdl.handle.net/2445%2F51726">2445/51726</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21733231">21733231</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+International+Journal+of+Neuropsychopharmacology&amp;rft.atitle=Effectiveness+of+psychotropic+medications+in+the+maintenance+phase+of+bipolar+disorder%3A+a+meta-analysis+of+randomized+controlled+trials&amp;rft.volume=14&amp;rft.issue=8&amp;rft.pages=1029-1049&amp;rft.date=2011-09&amp;rft_id=info%3Ahdl%2F2445%2F51726&amp;rft_id=info%3Apmid%2F21733231&amp;rft_id=info%3Adoi%2F10.1017%2FS1461145711000885&amp;rft.aulast=Vieta&amp;rft.aufirst=E&amp;rft.au=G%C3%BCnther%2C+O&amp;rft.au=Locklear%2C+J&amp;rft.au=Ekman%2C+M&amp;rft.au=Miltenburger%2C+C&amp;rft.au=Chatterton%2C+ML&amp;rft.au=%C3%85str%C3%B6m%2C+M&amp;rft.au=Paulsson%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-MDD-187"><span class="mw-cite-backlink"><b><a href="#cite_ref-MDD_187-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKomossaDeppingGaudchauKissling2010" class="citation journal cs1">Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". <i>The Cochrane Database of Systematic Reviews</i> (12): CD008121. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.CD008121.pub2">10.1002/14651858.CD008121.pub2</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21154393">21154393</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Second-generation+antipsychotics+for+major+depressive+disorder+and+dysthymia&amp;rft.issue=12&amp;rft.pages=CD008121&amp;rft.date=2010-12&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008121.pub2&amp;rft_id=info%3Apmid%2F21154393&amp;rft.aulast=Komossa&amp;rft.aufirst=K&amp;rft.au=Depping%2C+AM&amp;rft.au=Gaudchau%2C+A&amp;rft.au=Kissling%2C+W&amp;rft.au=Leucht%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-188"><span class="mw-cite-backlink"><b><a href="#cite_ref-188">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFArafatRahmanHaqueShah2016" class="citation journal cs1">Arafat SM, Rahman SM, Haque MM, Shah MA, Algin S, Nahar JS (2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4976188">"Clozapine Can Be the Good Option in Resistant Mania"</a>. <i>Case Reports in Psychiatry</i>. <b>2016</b>: 3081704. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1155%2F2016%2F3081704">10.1155/2016/3081704</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4976188">4976188</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/27525148">27525148</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Case+Reports+in+Psychiatry&amp;rft.atitle=Clozapine+Can+Be+the+Good+Option+in+Resistant+Mania&amp;rft.volume=2016&amp;rft.pages=3081704&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4976188%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27525148&amp;rft_id=info%3Adoi%2F10.1155%2F2016%2F3081704&amp;rft.aulast=Arafat&amp;rft.aufirst=SM&amp;rft.au=Rahman%2C+SM&amp;rft.au=Haque%2C+MM&amp;rft.au=Shah%2C+MA&amp;rft.au=Algin%2C+S&amp;rft.au=Nahar%2C+JS&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4976188&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-189"><span class="mw-cite-backlink"><b><a href="#cite_ref-189">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilkowskaCubała2019" class="citation journal cs1">Wilkowska A, Cubała WJ (9 October 2019). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6790347">"Clozapine As Transformative Treatment In Bipolar Patients"</a>. <i>Neuropsychiatric Disease and Treatment</i>. <b>15</b>: 2901–2905. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2147%2FNDT.S227196">10.2147/NDT.S227196</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6790347">6790347</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/31632038">31632038</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neuropsychiatric+Disease+and+Treatment&amp;rft.atitle=Clozapine+As+Transformative+Treatment+In+Bipolar+Patients&amp;rft.volume=15&amp;rft.pages=2901-2905&amp;rft.date=2019-10-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6790347%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F31632038&amp;rft_id=info%3Adoi%2F10.2147%2FNDT.S227196&amp;rft.aulast=Wilkowska&amp;rft.aufirst=A&amp;rft.au=Cuba%C5%82a%2C+WJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6790347&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-190"><span class="mw-cite-backlink"><b><a href="#cite_ref-190">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://www.has-sante.fr/upload/docs/application/pdf/2012-04/anti_psychotiques_rapport.pdf">https://www.has-sante.fr/upload/docs/application/pdf/2012-04/anti_psychotiques_rapport.pdf</a><sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citing_sources#What_information_to_include" title="Wikipedia:Citing sources"><span title="A complete citation is needed. (June 2021)">full citation needed</span></a></i>&#93;</sup></span>
</li>
<li id="cite_note-191"><span class="mw-cite-backlink"><b><a href="#cite_ref-191">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKishiIwata2013" class="citation journal cs1">Kishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials". <i>CNS Drugs</i>. <b>27</b> (9): 731–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40263-013-0085-7">10.1007/s40263-013-0085-7</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23812802">23812802</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:11543666">11543666</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Efficacy+and+tolerability+of+perospirone+in+schizophrenia%3A+a+systematic+review+and+meta-analysis+of+randomized+controlled+trials&amp;rft.volume=27&amp;rft.issue=9&amp;rft.pages=731-41&amp;rft.date=2013-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A11543666%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23812802&amp;rft_id=info%3Adoi%2F10.1007%2Fs40263-013-0085-7&amp;rft.aulast=Kishi&amp;rft.aufirst=T&amp;rft.au=Iwata%2C+N&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-193"><span class="mw-cite-backlink"><b><a href="#cite_ref-193">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRothDriscol2011" class="citation web cs1"><a href="/wiki/Bryan_Roth" title="Bryan Roth">Roth BL</a>, Driscol J (12 January 2011). <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php">"PDSP K<sub>i</sub> Database"</a>. <i>Psychoactive Drug Screening Program (PDSP)</i>. University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from <a rel="nofollow" class="external text" href="http://pdsp.med.unc.edu/pdsp.php">the original</a> on 8 November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">11 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Psychoactive+Drug+Screening+Program+%28PDSP%29&amp;rft.atitle=PDSP+K%3Csub%3Ei%3C%2Fsub%3E+Database&amp;rft.date=2011-01-12&amp;rft.aulast=Roth&amp;rft.aufirst=BL&amp;rft.au=Driscol%2C+J&amp;rft_id=http%3A%2F%2Fpdsp.med.unc.edu%2Fpdsp.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid18308814-194"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18308814_194-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFShahidWalkerZornWong2009" class="citation journal cs1">Shahid M, Walker GB, Zorn SH, Wong EH (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". <i>Journal of Psychopharmacology</i>. <b>23</b> (1): 65–73. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F0269881107082944">10.1177/0269881107082944</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18308814">18308814</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:206489515">206489515</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Psychopharmacology&amp;rft.atitle=Asenapine%3A+a+novel+psychopharmacologic+agent+with+a+unique+human+receptor+signature&amp;rft.volume=23&amp;rft.issue=1&amp;rft.pages=65-73&amp;rft.date=2009-01&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A206489515%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18308814&amp;rft_id=info%3Adoi%2F10.1177%2F0269881107082944&amp;rft.aulast=Shahid&amp;rft.aufirst=M&amp;rft.au=Walker%2C+GB&amp;rft.au=Zorn%2C+SH&amp;rft.au=Wong%2C+EH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Ishiyama_2007-195"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ishiyama_2007_195-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ishiyama_2007_195-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFIshiyamaTokudaIshibashiIto2007" class="citation journal cs1">Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (October 2007). "Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test". <i>European Journal of Pharmacology</i>. <b>572</b> (2–3): 160–70. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.ejphar.2007.06.058">10.1016/j.ejphar.2007.06.058</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17662268">17662268</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Pharmacology&amp;rft.atitle=Lurasidone+%28SM-13496%29%2C+a+novel+atypical+antipsychotic+drug%2C+reverses+MK-801-induced+impairment+of+learning+and+memory+in+the+rat+passive-avoidance+test&amp;rft.volume=572&amp;rft.issue=2%E2%80%933&amp;rft.pages=160-70&amp;rft.date=2007-10&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejphar.2007.06.058&amp;rft_id=info%3Apmid%2F17662268&amp;rft.aulast=Ishiyama&amp;rft.aufirst=T&amp;rft.au=Tokuda%2C+K&amp;rft.au=Ishibashi%2C+T&amp;rft.au=Ito%2C+A&amp;rft.au=Toma%2C+S&amp;rft.au=Ohno%2C+Y&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid20404009-196"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20404009_196-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFIshibashiHorisawaTokudaIshiyama2010" class="citation journal cs1">Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". <i>The Journal of Pharmacology and Experimental Therapeutics</i>. <b>334</b> (1): 171–81. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1124%2Fjpet.110.167346">10.1124/jpet.110.167346</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20404009">20404009</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:12893717">12893717</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Pharmacology+and+Experimental+Therapeutics&amp;rft.atitle=Pharmacological+profile+of+lurasidone%2C+a+novel+antipsychotic+agent+with+potent+5-hydroxytryptamine+7+%285-HT7%29+and+5-HT1A+receptor+activity&amp;rft.volume=334&amp;rft.issue=1&amp;rft.pages=171-81&amp;rft.date=2010-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A12893717%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20404009&amp;rft_id=info%3Adoi%2F10.1124%2Fjpet.110.167346&amp;rft.aulast=Ishibashi&amp;rft.aufirst=T&amp;rft.au=Horisawa%2C+T&amp;rft.au=Tokuda%2C+K&amp;rft.au=Ishiyama%2C+T&amp;rft.au=Ogasa%2C+M&amp;rft.au=Tagashira%2C+R&amp;rft.au=Matsumoto%2C+K&amp;rft.au=Nishikawa%2C+H&amp;rft.au=Ueda%2C+Y&amp;rft.au=Toma%2C+S&amp;rft.au=Oki%2C+H&amp;rft.au=Tanno%2C+N&amp;rft.au=Saji%2C+I&amp;rft.au=Ito%2C+A&amp;rft.au=Ohno%2C+Y&amp;rft.au=Nakamura%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid24062697-197"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid24062697_197-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLópez-MuñozAlamo2013" class="citation journal cs1">López-Muñoz F, Alamo C (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3770982">"Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders"</a>. <i>Frontiers in Psychiatry</i>. <b>4</b>: 102. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.3389%2Ffpsyt.2013.00102">10.3389/fpsyt.2013.00102</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3770982">3770982</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24062697">24062697</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Psychiatry&amp;rft.atitle=Active+metabolites+as+antidepressant+drugs%3A+the+role+of+norquetiapine+in+the+mechanism+of+action+of+quetiapine+in+the+treatment+of+mood+disorders&amp;rft.volume=4&amp;rft.pages=102&amp;rft.date=2013-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3770982%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F24062697&amp;rft_id=info%3Adoi%2F10.3389%2Ffpsyt.2013.00102&amp;rft.aulast=L%C3%B3pez-Mu%C3%B1oz&amp;rft.aufirst=F&amp;rft.au=Alamo%2C+C&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3770982&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-198"><span class="mw-cite-backlink"><b><a href="#cite_ref-198">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://reference.medscape.com/medscapetoday">"Medscape home page"</a>. <i><a href="/wiki/Medscape" title="Medscape">Medscape</a></i>. <a href="/wiki/WebMD" title="WebMD">WebMD</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131113205740/http://reference.medscape.com/medscapetoday">Archived</a> from the original on 13 November 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Medscape&amp;rft.atitle=Medscape+home+page&amp;rft_id=http%3A%2F%2Freference.medscape.com%2Fmedscapetoday&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-199"><span class="mw-cite-backlink"><b><a href="#cite_ref-199">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.ebs.tga.gov.au/">"Therapeutic Goods Administration home page"</a>. <i><a href="/wiki/Therapeutic_Goods_Administration" title="Therapeutic Goods Administration">Therapeutic Goods Administration</a></i>. <a href="/wiki/Department_of_Health_(Australia)" title="Department of Health (Australia)">Department of Health (Australia)</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20130421054308/https://www.ebs.tga.gov.au/">Archived</a> from the original on 21 April 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Therapeutic+Goods+Administration&amp;rft.atitle=Therapeutic+Goods+Administration+home+page&amp;rft_id=https%3A%2F%2Fwww.ebs.tga.gov.au%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-DM-200"><span class="mw-cite-backlink"><b><a href="#cite_ref-DM_200-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://dailymed.nlm.nih.gov/dailymed/index.cfm">"Daily Med home page"</a>. <i><a href="/wiki/Daily_Med" class="mw-redirect" title="Daily Med">Daily Med</a></i>. United States National Library of Medicine. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20130618062135/http://www.dailymed.nlm.nih.gov/dailymed/index.cfm">Archived</a> from the original on 18 June 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Daily+Med&amp;rft.atitle=Daily+Med+home+page&amp;rft_id=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Findex.cfm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-201"><span class="mw-cite-backlink"><b><a href="#cite_ref-201">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.medicines.org.uk/emc/">"electronic Medicines Compendium (eMC) home page"</a>. <i>electronic Medicines Compendium</i>. Datapharm. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131127215911/http://www.medicines.org.uk/emc/">Archived</a> from the original on 27 November 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=electronic+Medicines+Compendium&amp;rft.atitle=electronic+Medicines+Compendium+%28eMC%29+home+page&amp;rft_id=http%3A%2F%2Fwww.medicines.org.uk%2Femc%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-202"><span class="mw-cite-backlink"><b><a href="#cite_ref-202">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWenShangXieWang2013" class="citation journal cs1">Wen YG, Shang DW, Xie HZ, Wang XP, Ni XJ, Zhang M, Lu W, Qiu C, Liu X, Li FF, Li X, Luo FT (March 2013). "Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake". <i>Human Psychopharmacology</i>. <b>28</b> (2): 134–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2Fhup.2290">10.1002/hup.2290</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23417765">23417765</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:12623938">12623938</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Human+Psychopharmacology&amp;rft.atitle=Population+pharmacokinetics+of+blonanserin+in+Chinese+healthy+volunteers+and+the+effect+of+the+food+intake&amp;rft.volume=28&amp;rft.issue=2&amp;rft.pages=134-41&amp;rft.date=2013-03&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A12623938%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23417765&amp;rft_id=info%3Adoi%2F10.1002%2Fhup.2290&amp;rft.aulast=Wen&amp;rft.aufirst=YG&amp;rft.au=Shang%2C+DW&amp;rft.au=Xie%2C+HZ&amp;rft.au=Wang%2C+XP&amp;rft.au=Ni%2C+XJ&amp;rft.au=Zhang%2C+M&amp;rft.au=Lu%2C+W&amp;rft.au=Qiu%2C+C&amp;rft.au=Liu%2C+X&amp;rft.au=Li%2C+FF&amp;rft.au=Li%2C+X&amp;rft.au=Luo%2C+FT&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-203"><span class="mw-cite-backlink"><b><a href="#cite_ref-203">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBorgströmLarssonMolander1982" class="citation journal cs1">Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". <i>European Journal of Clinical Pharmacology</i>. <b>23</b> (2): 173–6. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2FBF00545974">10.1007/BF00545974</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/7140807">7140807</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:36697288">36697288</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Clinical+Pharmacology&amp;rft.atitle=Pharmacokinetics+of+parenteral+and+oral+melperone+in+man&amp;rft.volume=23&amp;rft.issue=2&amp;rft.pages=173-6&amp;rft.date=1982&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A36697288%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F7140807&amp;rft_id=info%3Adoi%2F10.1007%2FBF00545974&amp;rft.aulast=Borgstr%C3%B6m&amp;rft.aufirst=L&amp;rft.au=Larsson%2C+H&amp;rft.au=Molander%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-204"><span class="mw-cite-backlink"><b><a href="#cite_ref-204">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCallaghanBergstromPtakBeasley1999" class="citation journal cs1">Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (September 1999). "Olanzapine. Pharmacokinetic and pharmacodynamic profile". <i>Clinical Pharmacokinetics</i>. <b>37</b> (3): 177–93. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00003088-199937030-00001">10.2165/00003088-199937030-00001</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/10511917">10511917</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Pharmacokinetics&amp;rft.atitle=Olanzapine.+Pharmacokinetic+and+pharmacodynamic+profile&amp;rft.volume=37&amp;rft.issue=3&amp;rft.pages=177-93&amp;rft.date=1999-09&amp;rft_id=info%3Adoi%2F10.2165%2F00003088-199937030-00001&amp;rft_id=info%3Apmid%2F10511917&amp;rft.aulast=Callaghan&amp;rft.aufirst=JT&amp;rft.au=Bergstrom%2C+RF&amp;rft.au=Ptak%2C+LR&amp;rft.au=Beasley%2C+CM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-205"><span class="mw-cite-backlink"><b><a href="#cite_ref-205">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFVermeirNaessensRemmerieMannens2008" class="citation journal cs1">Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A (April 2008). "Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans". <i>Drug Metabolism and Disposition</i>. <b>36</b> (4): 769–79. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1124%2Fdmd.107.018275">10.1124/dmd.107.018275</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18227146">18227146</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:41656">41656</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Metabolism+and+Disposition&amp;rft.atitle=Absorption%2C+metabolism%2C+and+excretion+of+paliperidone%2C+a+new+monoaminergic+antagonist%2C+in+humans&amp;rft.volume=36&amp;rft.issue=4&amp;rft.pages=769-79&amp;rft.date=2008-04&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A41656%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18227146&amp;rft_id=info%3Adoi%2F10.1124%2Fdmd.107.018275&amp;rft.aulast=Vermeir&amp;rft.aufirst=M&amp;rft.au=Naessens%2C+I&amp;rft.au=Remmerie%2C+B&amp;rft.au=Mannens%2C+G&amp;rft.au=Hendrickx%2C+J&amp;rft.au=Sterkens%2C+P&amp;rft.au=Talluri%2C+K&amp;rft.au=Boom%2C+S&amp;rft.au=Eerdekens%2C+M&amp;rft.au=van+Osselaer%2C+N&amp;rft.au=Cleton%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-206"><span class="mw-cite-backlink"><b><a href="#cite_ref-206">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDeVaneNemeroff2001" class="citation journal cs1">DeVane CL, Nemeroff CB (2001). "Clinical pharmacokinetics of quetiapine: an atypical antipsychotic". <i>Clinical Pharmacokinetics</i>. <b>40</b> (7): 509–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00003088-200140070-00003">10.2165/00003088-200140070-00003</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/11510628">11510628</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:33802262">33802262</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Pharmacokinetics&amp;rft.atitle=Clinical+pharmacokinetics+of+quetiapine%3A+an+atypical+antipsychotic&amp;rft.volume=40&amp;rft.issue=7&amp;rft.pages=509-22&amp;rft.date=2001&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A33802262%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F11510628&amp;rft_id=info%3Adoi%2F10.2165%2F00003088-200140070-00003&amp;rft.aulast=DeVane&amp;rft.aufirst=CL&amp;rft.au=Nemeroff%2C+CB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-207"><span class="mw-cite-backlink"><b><a href="#cite_ref-207">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWieselAlfredssonEhrneboSedvall1980" class="citation journal cs1">Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (May 1980). "The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects". <i>European Journal of Clinical Pharmacology</i>. <b>17</b> (5): 385–91. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2FBF00558453">10.1007/BF00558453</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/7418717">7418717</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:28141135">28141135</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Clinical+Pharmacology&amp;rft.atitle=The+pharmacokinetics+of+intravenous+and+oral+sulpiride+in+healthy+human+subjects&amp;rft.volume=17&amp;rft.issue=5&amp;rft.pages=385-91&amp;rft.date=1980-05&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A28141135%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F7418717&amp;rft_id=info%3Adoi%2F10.1007%2FBF00558453&amp;rft.aulast=Wiesel&amp;rft.aufirst=FA&amp;rft.au=Alfredsson%2C+G&amp;rft.au=Ehrnebo%2C+M&amp;rft.au=Sedvall%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-208"><span class="mw-cite-backlink"><b><a href="#cite_ref-208">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPrakashLamb1998" class="citation journal cs1">Prakash A, Lamb HM (January 1998). "Zotepine: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Schizophrenia". <i>CNS Drugs</i>. <b>9</b> (2): 153–175. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00023210-199809020-00006">10.2165/00023210-199809020-00006</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNS+Drugs&amp;rft.atitle=Zotepine%3A+A+Review+of+its+Pharmacodynamic+and+Pharmacokinetic+Properties+and+Therapeutic+Efficacy+in+the+Management+of+Schizophrenia&amp;rft.volume=9&amp;rft.issue=2&amp;rft.pages=153-175&amp;rft.date=1998-01&amp;rft_id=info%3Adoi%2F10.2165%2F00023210-199809020-00006&amp;rft.aulast=Prakash&amp;rft.aufirst=A&amp;rft.au=Lamb%2C+HM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-209"><span class="mw-cite-backlink"><b><a href="#cite_ref-209">^</a></b></span> <span class="reference-text">Product Information: Nipolept(R), zotepine. Klinge Pharma GmbH, Munich, 1996.</span>
</li>
<li id="cite_note-ParentToussaint1983-210"><span class="mw-cite-backlink"><b><a href="#cite_ref-ParentToussaint1983_210-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFParentToussaintGilson1983" class="citation journal cs1">Parent M, Toussaint C, Gilson H (1983). "Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation". <i>Current Therapeutic Research</i>. <b>34</b> (1): 1–6.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Therapeutic+Research&amp;rft.atitle=Long-term+treatment+of+chronic+psychotics+with+bromperidol+decanoate%3A+clinical+and+pharmacokinetic+evaluation.&amp;rft.volume=34&amp;rft.issue=1&amp;rft.pages=1-6&amp;rft.date=1983&amp;rft.aulast=Parent&amp;rft.aufirst=M&amp;rft.au=Toussaint%2C+C&amp;rft.au=Gilson%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid6931472-211"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid6931472_211-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid6931472_211-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJørgensenOverø1980" class="citation journal cs1">Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". <i>Acta Psychiatrica Scandinavica. Supplementum</i>. <b>279</b>: 41–54. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1600-0447.1980.tb07082.x">10.1111/j.1600-0447.1980.tb07082.x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/6931472">6931472</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Psychiatrica+Scandinavica.+Supplementum&amp;rft.atitle=Clopenthixol+and+flupenthixol+depot+preparations+in+outpatient+schizophrenics.+III.+Serum+levels&amp;rft.volume=279&amp;rft.pages=41-54&amp;rft.date=1980&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0447.1980.tb07082.x&amp;rft_id=info%3Apmid%2F6931472&amp;rft.aulast=J%C3%B8rgensen&amp;rft.aufirst=A&amp;rft.au=Over%C3%B8%2C+KF&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Reynolds1993-212"><span class="mw-cite-backlink">^ <a href="#cite_ref-Reynolds1993_212-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Reynolds1993_212-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFReynolds1993" class="citation book cs1">Reynolds JE (1993). "Anxiolytic sedatives, hypnotics and neuroleptics.". <i>Martindale: The Extra Pharmacopoeia</i> (30th&#160;ed.). London: Pharmaceutical Press. pp.&#160;364–623.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Anxiolytic+sedatives%2C+hypnotics+and+neuroleptics.&amp;rft.btitle=Martindale%3A+The+Extra+Pharmacopoeia&amp;rft.place=London&amp;rft.pages=364-623&amp;rft.edition=30th&amp;rft.pub=Pharmaceutical+Press&amp;rft.date=1993&amp;rft.aulast=Reynolds&amp;rft.aufirst=JE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid6143748-213"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid6143748_213-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFEreshefskySakladJannDavis1984" class="citation journal cs1">Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". <i>The Journal of Clinical Psychiatry</i>. <b>45</b> (5 Pt 2): 50–9. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/6143748">6143748</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Psychiatry&amp;rft.atitle=Future+of+depot+neuroleptic+therapy%3A+pharmacokinetic+and+pharmacodynamic+approaches&amp;rft.volume=45&amp;rft.issue=5+Pt+2&amp;rft.pages=50-9&amp;rft.date=1984-05&amp;rft_id=info%3Apmid%2F6143748&amp;rft.aulast=Ereshefsky&amp;rft.aufirst=L&amp;rft.au=Saklad%2C+SR&amp;rft.au=Jann%2C+MW&amp;rft.au=Davis%2C+CM&amp;rft.au=Richards%2C+A&amp;rft.au=Seidel%2C+DR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid444352-214"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid444352_214-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid444352_214-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFCurryWhelptonde_SchepperVranckx1979" class="citation journal cs1">Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1429660">"Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man"</a>. <i>British Journal of Clinical Pharmacology</i>. <b>7</b> (4): 325–31. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1365-2125.1979.tb00941.x">10.1111/j.1365-2125.1979.tb00941.x</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1429660">1429660</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/444352">444352</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=British+Journal+of+Clinical+Pharmacology&amp;rft.atitle=Kinetics+of+fluphenazine+after+fluphenazine+dihydrochloride%2C+enanthate+and+decanoate+administration+to+man&amp;rft.volume=7&amp;rft.issue=4&amp;rft.pages=325-31&amp;rft.date=1979-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1429660%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F444352&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2125.1979.tb00941.x&amp;rft.aulast=Curry&amp;rft.aufirst=SH&amp;rft.au=Whelpton%2C+R&amp;rft.au=de+Schepper%2C+PJ&amp;rft.au=Vranckx%2C+S&amp;rft.au=Schiff%2C+AA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1429660&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-YoungEreshefsky1984-215"><span class="mw-cite-backlink"><b><a href="#cite_ref-YoungEreshefsky1984_215-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFYoungEreshefskySakladJann1984" class="citation conference cs1">Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N (1984). <i>Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.)</i>. 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=conference&amp;rft.btitle=Explaining+the+pharmacokinetics+of+fluphenazine+through+computer+simulations.+%28Abstract.%29&amp;rft.place=Dallas%2C+Texas&amp;rft.date=1984&amp;rft.aulast=Young&amp;rft.aufirst=D&amp;rft.au=Ereshefsky%2C+L&amp;rft.au=Saklad%2C+SR&amp;rft.au=Jann%2C+MW&amp;rft.au=Garcia%2C+N&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid4992598-216"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid4992598_216-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJanssenNiemegeersSchellekensLenaerts1970" class="citation journal cs1">Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM,  et&#160;al. (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". <i>Arzneimittel-Forschung</i>. <b>20</b> (11): 1689–98. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/4992598">4992598</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Arzneimittel-Forschung&amp;rft.atitle=The+pharmacology+of+fluspirilene+%28R+6218%29%2C+a+potent%2C+long-acting+and+injectable+neuroleptic+drug&amp;rft.volume=20&amp;rft.issue=11&amp;rft.pages=1689-98&amp;rft.date=1970-11&amp;rft_id=info%3Apmid%2F4992598&amp;rft.aulast=Janssen&amp;rft.aufirst=PA&amp;rft.au=Niemegeers%2C+CJ&amp;rft.au=Schellekens%2C+KH&amp;rft.au=Lenaerts%2C+FM&amp;rft.au=Verbruggen%2C+FJ&amp;rft.au=van+Nueten%2C+JM&amp;rft.au=Marsboom%2C+RH&amp;rft.au=H%C3%A9rin%2C+VV&amp;rft.au=Schaper%2C+WK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid3545764-217"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid3545764_217-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBeresfordWard1987" class="citation journal cs1">Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". <i>Drugs</i>. <b>33</b> (1): 31–49. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2165%2F00003495-198733010-00002">10.2165/00003495-198733010-00002</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/3545764">3545764</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Haloperidol+decanoate.+A+preliminary+review+of+its+pharmacodynamic+and+pharmacokinetic+properties+and+therapeutic+use+in+psychosis&amp;rft.volume=33&amp;rft.issue=1&amp;rft.pages=31-49&amp;rft.date=1987-01&amp;rft_id=info%3Adoi%2F10.2165%2F00003495-198733010-00002&amp;rft_id=info%3Apmid%2F3545764&amp;rft.aulast=Beresford&amp;rft.aufirst=R&amp;rft.au=Ward%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid7185768-218"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid7185768_218-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFReyntigensHeykantsWoestenborghsGelders1982" class="citation journal cs1">Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". <i>International Pharmacopsychiatry</i>. <b>17</b> (4): 238–46. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1159%2F000468580">10.1159/000468580</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/7185768">7185768</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Pharmacopsychiatry&amp;rft.atitle=Pharmacokinetics+of+haloperidol+decanoate.+A+2-year+follow-up&amp;rft.volume=17&amp;rft.issue=4&amp;rft.pages=238-46&amp;rft.date=1982&amp;rft_id=info%3Adoi%2F10.1159%2F000468580&amp;rft_id=info%3Apmid%2F7185768&amp;rft.aulast=Reyntigens&amp;rft.aufirst=AJ&amp;rft.au=Heykants%2C+JJ&amp;rft.au=Woestenborghs%2C+RJ&amp;rft.au=Gelders%2C+YG&amp;rft.au=Aerts%2C+TJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-LarssonAxelsson1984-219"><span class="mw-cite-backlink"><b><a href="#cite_ref-LarssonAxelsson1984_219-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLarssonAxelssonForsman1984" class="citation journal cs1">Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate". <i>Current Therapeutic Research</i>. <b>36</b> (6): 1071–88.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Therapeutic+Research&amp;rft.atitle=On+the+pharmacokinetics+of+perphenazine%3A+a+clinical+study+of+perphenazine+enanthate+and+decanoate.&amp;rft.volume=36&amp;rft.issue=6&amp;rft.pages=1071-88&amp;rft.date=1984&amp;rft.aulast=Larsson&amp;rft.aufirst=M&amp;rft.au=Axelsson%2C+R&amp;rft.au=Forsman%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-220"><span class="mw-cite-backlink"><b><a href="#cite_ref-220">^</a></b></span> <span class="reference-text">The text reads: "When the patient lashes out against 'them' – THORAZINE (brand of chlorpromazine) quickly puts an end to his violent outburst. 'Thorazine' is especially effective when the psychotic episode is triggered by delusions or hallucinations. At the outset of treatment, Thorazine's combination of antipsychotic and sedative effects provides both emotional and physical calming. Assaultive or destructive behavior is rapidly controlled. As therapy continues, the initial sedative effect gradually disappears. But the antipsychotic effect continues, helping to dispel or modify delusions, hallucinations and confusion, while keeping the patient calm and approachable. SMITH KLINE AND FRENCH LABORATORIES leaders in psychopharmaceutical research."</span>
</li>
<li id="cite_note-pieters-221"><span class="mw-cite-backlink">^ <a href="#cite_ref-pieters_221-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pieters_221-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPietersMajerus2011" class="citation journal cs1">Pieters T, Majerus B (December 2011). <a rel="nofollow" class="external text" href="http://orbilu.uni.lu/handle/10993/2251">"The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features"</a>. <i>Studies in History and Philosophy of Biological and Biomedical Sciences</i>. <b>42</b> (4): 443–452. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.shpsc.2011.05.003">10.1016/j.shpsc.2011.05.003</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22035718">22035718</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Studies+in+History+and+Philosophy+of+Biological+and+Biomedical+Sciences&amp;rft.atitle=The+introduction+of+chlorpromazine+in+Belgium+and+the+Netherlands+%281951-1968%29%3B+tango+between+old+and+new+treatment+features&amp;rft.volume=42&amp;rft.issue=4&amp;rft.pages=443-452&amp;rft.date=2011-12&amp;rft_id=info%3Adoi%2F10.1016%2Fj.shpsc.2011.05.003&amp;rft_id=info%3Apmid%2F22035718&amp;rft.aulast=Pieters&amp;rft.aufirst=T&amp;rft.au=Majerus%2C+B&amp;rft_id=http%3A%2F%2Forbilu.uni.lu%2Fhandle%2F10993%2F2251&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-222"><span class="mw-cite-backlink"><b><a href="#cite_ref-222">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHealy2005" class="citation book cs1">Healy D (2005). <i>Psychiatric Drugs Explained</i> (4th&#160;ed.). Britain: Elsevier Limited. pp.&#160;8, 17.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Psychiatric+Drugs+Explained.&amp;rft.place=Britain&amp;rft.pages=8%2C+17&amp;rft.edition=4th&amp;rft.pub=Elsevier+Limited&amp;rft.date=2005&amp;rft.aulast=Healy&amp;rft.aufirst=D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-223"><span class="mw-cite-backlink"><b><a href="#cite_ref-223">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.oed.com/view/Entry/204569">"tranquillizer, n"</a>. <i>Oxford English Dictionary</i>. 1989<span class="reference-accessdate">. Retrieved <span class="nowrap">9 August</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Oxford+English+Dictionary&amp;rft.atitle=tranquillizer%2C+n&amp;rft.date=1989&amp;rft_id=http%3A%2F%2Fwww.oed.com%2Fview%2FEntry%2F204569&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-224"><span class="mw-cite-backlink"><b><a href="#cite_ref-224">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHealy2008" class="citation book cs1">Healy D (2008). "The intersection of psychopharmacology and psychiatry in the second half of the twentieth century".  In Wallace ER, Gach J (eds.). <i>History of Psychiatry and Medical Psychology</i>. Boston, MA: Springer US. p.&#160;421. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2F978-0-387-34708-0_13">10.1007/978-0-387-34708-0_13</a>. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-387-34707-3" title="Special:BookSources/978-0-387-34707-3"><bdi>978-0-387-34707-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=The+intersection+of+psychopharmacology+and+psychiatry+in+the+second+half+of+the+twentieth+century&amp;rft.btitle=History+of+Psychiatry+and+Medical+Psychology&amp;rft.place=Boston%2C+MA&amp;rft.pages=421&amp;rft.pub=Springer+US&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1007%2F978-0-387-34708-0_13&amp;rft.isbn=978-0-387-34707-3&amp;rft.aulast=Healy&amp;rft.aufirst=D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-225"><span class="mw-cite-backlink"><b><a href="#cite_ref-225">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFOwens1999" class="citation book cs1">Owens DG (13 April 1999). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=RwRSahg71GkC&amp;pg=PA12"><i>A guide to the extrapyramidal side-effects of antipsychotic drugs</i></a>. Cambridge University Press. p.&#160;12. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-521-63353-6" title="Special:BookSources/978-0-521-63353-6"><bdi>978-0-521-63353-6</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20160318004651/https://books.google.com/books?id=RwRSahg71GkC&amp;pg=PA12">Archived</a> from the original on 18 March 2016.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=A+guide+to+the+extrapyramidal+side-effects+of+antipsychotic+drugs&amp;rft.pages=12&amp;rft.pub=Cambridge+University+Press&amp;rft.date=1999-04-13&amp;rft.isbn=978-0-521-63353-6&amp;rft.aulast=Owens&amp;rft.aufirst=DG&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DRwRSahg71GkC%26pg%3DPA12&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-226"><span class="mw-cite-backlink"><b><a href="#cite_ref-226">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTasman1997" class="citation book cs1">Tasman A (1997). <i>Psychiatry Volume 2</i>. Saunders. p.&#160;956. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-7216-5257-3" title="Special:BookSources/978-0-7216-5257-3"><bdi>978-0-7216-5257-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Psychiatry+Volume+2&amp;rft.pages=956&amp;rft.pub=Saunders&amp;rft.date=1997&amp;rft.isbn=978-0-7216-5257-3&amp;rft.aulast=Tasman&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-:1-227"><span class="mw-cite-backlink"><b><a href="#cite_ref-:1_227-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAyd2000" class="citation book cs1">Ayd FJ (2000). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=ea_QVG2BFy8C&amp;pg=PA675">"neuroleptic"</a>. <i>Lexicon of Psychiatry, Neurology, and the Neurosciences</i>. Lippincott Williams &amp; Wilkins. p.&#160;675. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780781724685" title="Special:BookSources/9780781724685"><bdi>9780781724685</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=neuroleptic&amp;rft.btitle=Lexicon+of+Psychiatry%2C+Neurology%2C+and+the+Neurosciences&amp;rft.pages=675&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rft.date=2000&amp;rft.isbn=9780781724685&amp;rft.aulast=Ayd&amp;rft.aufirst=FJ&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3Dea_QVG2BFy8C%26pg%3DPA675&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-228"><span class="mw-cite-backlink"><b><a href="#cite_ref-228">^</a></b></span> <span class="reference-text">R. Elliott Ingersoll, Carl F. Rak (2015): <i>Psychopharmacology for Mental Health Professionals: An Integrative Approach</i>, Cengage Learning, Boston, pp. 150-186 and 342-349, <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781305537231" title="Special:BookSources/9781305537231">9781305537231</a>.</span>
</li>
<li id="cite_note-229"><span class="mw-cite-backlink"><b><a href="#cite_ref-229">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPatelJakopac2011" class="citation book cs1">Patel SC, Jakopac KA (2011). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=fN9932sGu1kC"><i>Manual of Psychiatric Nursing Skills</i></a>. Jones &amp; Bartlett Publishers. p.&#160;317. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781449613563" title="Special:BookSources/9781449613563"><bdi>9781449613563</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Manual+of+Psychiatric+Nursing+Skills&amp;rft.pages=317&amp;rft.pub=Jones+%26+Bartlett+Publishers&amp;rft.date=2011&amp;rft.isbn=9781449613563&amp;rft.aulast=Patel&amp;rft.aufirst=SC&amp;rft.au=Jakopac%2C+KA&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DfN9932sGu1kC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-230"><span class="mw-cite-backlink"><b><a href="#cite_ref-230">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation book cs1"><a rel="nofollow" class="external text" href="https://books.google.com/books?id=Byur1yIJBaUC&amp;pg=PA329"><i>Drug Policy and the Public Good</i></a>. OUP Oxford. 2010. p.&#160;329. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780199557127" title="Special:BookSources/9780199557127"><bdi>9780199557127</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Drug+Policy+and+the+Public+Good&amp;rft.pages=329&amp;rft.pub=OUP+Oxford&amp;rft.date=2010&amp;rft.isbn=9780199557127&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DByur1yIJBaUC%26pg%3DPA329&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-healthcarefinancenews.com-231"><span class="mw-cite-backlink">^ <a href="#cite_ref-healthcarefinancenews.com_231-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-healthcarefinancenews.com_231-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20120218005726/http://www.healthcarefinancenews.com/press-release/pipeline-antipsychotic-drugs-drive-next-market-evolution">Pipelineantipsychotic drugs to drive next market evolution (2009)</a>. Healthcarefinancenews.com (7 August 2009).</span>
</li>
<li id="cite_note-pmid17158480-232"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17158480_232-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAparasuBhatara2006" class="citation journal cs1">Aparasu RR, Bhatara V (December 2006). "Antipsychotic use and expenditure in the United States". <i>Psychiatric Services</i>. <b>57</b> (12): 1693. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ps.57.12.1693">10.1176/appi.ps.57.12.1693</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17158480">17158480</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychiatric+Services&amp;rft.atitle=Antipsychotic+use+and+expenditure+in+the+United+States&amp;rft.volume=57&amp;rft.issue=12&amp;rft.pages=1693&amp;rft.date=2006-12&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ps.57.12.1693&amp;rft_id=info%3Apmid%2F17158480&amp;rft.aulast=Aparasu&amp;rft.aufirst=RR&amp;rft.au=Bhatara%2C+V&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-233"><span class="mw-cite-backlink"><b><a href="#cite_ref-233">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=85f4a56216a10210VgnVCM100000ed152ca2RCRD&amp;cpsextcurrchannel=1">2008 U.S. Sales and Prescription Information: Top Therapeutic Classes by U.S. Sales (PDF)</a> <a rel="nofollow" class="external text" href="https://web.archive.org/web/20100416162222/http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=85f4a56216a10210VgnVCM100000ed152ca2RCRD&amp;cpsextcurrchannel=1">Archived</a> 16 April 2010 at the <a href="/wiki/Wayback_Machine" title="Wayback Machine">Wayback Machine</a>. Imshealth.com.</span>
</li>
<li id="cite_note-234"><span class="mw-cite-backlink"><b><a href="#cite_ref-234">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGustafssonKarlssonLövheim2013" class="citation journal cs1">Gustafsson M, Karlsson S, Lövheim H (February 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575309">"Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units"</a>. <i>BMC Pharmacology &amp; Toxicology</i>. <b>14</b> (1): 10. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1186%2F2050-6511-14-10">10.1186/2050-6511-14-10</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575309">3575309</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23391323">23391323</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMC+Pharmacology+%26+Toxicology&amp;rft.atitle=Inappropriate+long-term+use+of+antipsychotic+drugs+is+common+among+people+with+dementia+living+in+specialized+care+units&amp;rft.volume=14&amp;rft.issue=1&amp;rft.pages=10&amp;rft.date=2013-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3575309%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23391323&amp;rft_id=info%3Adoi%2F10.1186%2F2050-6511-14-10&amp;rft.aulast=Gustafsson&amp;rft.aufirst=M&amp;rft.au=Karlsson%2C+S&amp;rft.au=L%C3%B6vheim%2C+H&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3575309&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-235"><span class="mw-cite-backlink"><b><a href="#cite_ref-235">^</a></b></span> <span class="reference-text">Risky Antipsychotic Drugs Still Overprescribed In Nursing Homes, <a rel="nofollow" class="external free" href="https://www.npr.org/sections/health-shots/2018/02/05/583435517/risky-antipsychotic-drugs-still-overprescribed-in-nursing-homes">https://www.npr.org/sections/health-shots/2018/02/05/583435517/risky-antipsychotic-drugs-still-overprescribed-in-nursing-homes</a></span>
</li>
<li id="cite_note-236"><span class="mw-cite-backlink"><b><a href="#cite_ref-236">^</a></b></span> <span class="reference-text">Atypical antipsychotics: overrated and overprescribed, Glen Spielsman, <a rel="nofollow" class="external free" href="https://pharmaceutical-journal.com/article/opinion/atypical-antipsychotics-overrated-and-overprescribed">https://pharmaceutical-journal.com/article/opinion/atypical-antipsychotics-overrated-and-overprescribed</a></span>
</li>
<li id="cite_note-Bogart_2011-237"><span class="mw-cite-backlink">^ <a href="#cite_ref-Bogart_2011_237-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Bogart_2011_237-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Bogart_2011_237-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Bogart_2011_237-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Bogart_2011_237-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBogart2011" class="citation journal cs1">Bogart G (2011). <a rel="nofollow" class="external text" href="https://www.mdedge.com/psychiatry/article/64323/addiction-medicine/abuse-second-generation-antipsychotics-what-prescribers">"Abuse of second-generation antipsychotics: What prescribers need to know"</a>. <i>Current Psychiatry</i>. <b>10</b> (5): 77–79.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Psychiatry&amp;rft.atitle=Abuse+of+second-generation+antipsychotics%3A+What+prescribers+need+to+know&amp;rft.volume=10&amp;rft.issue=5&amp;rft.pages=77-79&amp;rft.date=2011&amp;rft.aulast=Bogart&amp;rft.aufirst=G&amp;rft_id=https%3A%2F%2Fwww.mdedge.com%2Fpsychiatry%2Farticle%2F64323%2Faddiction-medicine%2Fabuse-second-generation-antipsychotics-what-prescribers&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-guard_1-238"><span class="mw-cite-backlink"><b><a href="#cite_ref-guard_1_238-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFJames2008" class="citation news cs1">James A (2 March 2008). <a rel="nofollow" class="external text" href="https://www.theguardian.com/commentisfree/2008/mar/02/mythoftheantipsychotic">"Myth of the antipsychotic"</a>. <i>The Guardian</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Guardian&amp;rft.atitle=Myth+of+the+antipsychotic&amp;rft.date=2008-03-02&amp;rft.aulast=James&amp;rft.aufirst=A&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fcommentisfree%2F2008%2Fmar%2F02%2Fmythoftheantipsychotic&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-239"><span class="mw-cite-backlink"><b><a href="#cite_ref-239">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.chemistanddruggist.co.uk/cpd-article/gps-under-pressure-issue-neuroleptics-claims-professor">"GPs under 'pressure' to issue neuroleptics, claims professor"</a>. <i>Chemist+Druggist</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Chemist%2BDruggist&amp;rft.atitle=GPs+under+%27pressure%27+to+issue+neuroleptics%2C+claims+professor&amp;rft_id=https%3A%2F%2Fwww.chemistanddruggist.co.uk%2Fcpd-article%2Fgps-under-pressure-issue-neuroleptics-claims-professor&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span><sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Reliable_sources" title="Wikipedia:Reliable sources"><span title="The material near this tag may rely on an unreliable source. (May 2020)">unreliable source?</span></a></i>&#93;</sup></span>
</li>
<li id="cite_note-240"><span class="mw-cite-backlink"><b><a href="#cite_ref-240">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFTriggle2009" class="citation news cs1">Triggle N (12 November 2009). <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/2/hi/health/8356423.stm">"Dementia drug use 'killing many'<span class="cs1-kern-right"></span>"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dementia+drug+use+%27killing+many%27&amp;rft.date=2009-11-12&amp;rft.aulast=Triggle&amp;rft.aufirst=N&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F2%2Fhi%2Fhealth%2F8356423.stm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-241"><span class="mw-cite-backlink"><b><a href="#cite_ref-241">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.reuters.com/article/dementia-drugs/uk-study-warns-against-anti-psychotics-for-dementia-idUSLC44347420091112">"UK study warns against anti-psychotics for dementia"</a>. <i>Reuters</i>. 12 November 2009.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=UK+study+warns+against+anti-psychotics+for+dementia&amp;rft.date=2009-11-12&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fdementia-drugs%2Fuk-study-warns-against-anti-psychotics-for-dementia-idUSLC44347420091112&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-Hilzenrath-242"><span class="mw-cite-backlink"><b><a href="#cite_ref-Hilzenrath_242-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFHilzenrath2010" class="citation news cs1">Hilzenrath DS (16 January 2010). <a rel="nofollow" class="external text" href="https://www.washingtonpost.com/wp-dyn/content/article/2010/01/15/AR2010011503903.html">"Justice suit accuses Johnson &amp; Johnson of paying kickbacks"</a>. <i><a href="/wiki/The_Washington_Post" title="The Washington Post">The Washington Post</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Washington+Post&amp;rft.atitle=Justice+suit+accuses+Johnson+%26+Johnson+of+paying+kickbacks&amp;rft.date=2010-01-16&amp;rft.aulast=Hilzenrath&amp;rft.aufirst=DS&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Fwp-dyn%2Fcontent%2Farticle%2F2010%2F01%2F15%2FAR2010011503903.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-bied2010-243"><span class="mw-cite-backlink">^ <a href="#cite_ref-bied2010_243-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-bied2010_243-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-bied2010_243-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilson2010" class="citation news cs1">Wilson D (2 October 2010). <a rel="nofollow" class="external text" href="https://web.archive.org/web/20101005023740/http://www.nytimes.com/2010/10/03/business/03psych.html">"Side Effects May Include Lawsuits"</a>. <i>The New York Times</i>. Archived from <span class="cs1-lock-limited" title="Free access subject to limited trial, subscription normally required"><a rel="nofollow" class="external text" href="https://www.nytimes.com/2010/10/03/business/03psych.html">the original</a></span> on 5 October 2010.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Side+Effects+May+Include+Lawsuits&amp;rft.date=2010-10-02&amp;rft.aulast=Wilson&amp;rft.aufirst=D&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2010%2F10%2F03%2Fbusiness%2F03psych.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-244"><span class="mw-cite-backlink"><b><a href="#cite_ref-244">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFWilson2009" class="citation news cs1">Wilson D (27 February 2009). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2009/02/28/business/28drug.html">"Drug Maker's E-Mail Released in Seroquel Lawsuit"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Drug+Maker%27s+E-Mail+Released+in+Seroquel+Lawsuit&amp;rft.date=2009-02-27&amp;rft.aulast=Wilson&amp;rft.aufirst=D&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2009%2F02%2F28%2Fbusiness%2F28drug.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></span>
</li>
<li id="cite_note-pmid15278977-245"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15278977_245-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGosdenBeder2001" class="citation journal cs1">Gosden R, Beder S (1 January 2001). "Pharmaceutical industry agenda setting in mental health policies". <i>Ethical Human Sciences and Services</i>. <b>3</b> (3): 147–159. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1891%2F1523-150X.3.3.147">10.1891/1523-150X.3.3.147</a> (inactive 31 October 2021). <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/15278977">15278977</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ethical+Human+Sciences+and+Services&amp;rft.atitle=Pharmaceutical+industry+agenda+setting+in+mental+health+policies&amp;rft.volume=3&amp;rft.issue=3&amp;rft.pages=147-159&amp;rft.date=2001-01-01&amp;rft_id=info%3Adoi%2F10.1891%2F1523-150X.3.3.147&amp;rft_id=info%3Apmid%2F15278977&amp;rft.aulast=Gosden&amp;rft.aufirst=R&amp;rft.au=Beder%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span><span class="cs1-maint citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_journal" title="Template:Cite journal">cite journal</a>}}</code>:  CS1 maint: DOI inactive as of October 2021 (<a href="/wiki/Category:CS1_maint:_DOI_inactive_as_of_October_2021" title="Category:CS1 maint: DOI inactive as of October 2021">link</a>)</span></span>
</li>
<li id="cite_note-APAfive_dementia-246"><span class="mw-cite-backlink">^ <a href="#cite_ref-APAfive_dementia_246-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-APAfive_dementia_246-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-APAfive_dementia_246-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Psychiatric_Association2013" class="citation cs2"><a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a> (September 2013), <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">"Five Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" class="mw-redirect" title="ABIM Foundation">ABIM Foundation</a></i>, <a href="/wiki/American_Psychiatric_Association" title="American Psychiatric Association">American Psychiatric Association</a>, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20131203174206/http://www.choosingwisely.org/doctor-patient-lists/american-psychiatric-association/">archived</a> from the original on 3 December 2013<span class="reference-accessdate">, retrieved <span class="nowrap">30 December</span> 2013</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.atitle=Five+Things+Physicians+and+Patients+Should+Question&amp;rft.date=2013-09&amp;rft.au=American+Psychiatric+Association&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Famerican-psychiatric-association%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span>, which cites
<ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Psychiatric_Association2006" class="citation book cs1">American Psychiatric Association (2006). "Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias". <i>APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches</i>. Vol.&#160;1 (Second&#160;ed.). <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.books.9780890423967.152139">10.1176/appi.books.9780890423967.152139</a>. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-89042-336-3" title="Special:BookSources/978-0-89042-336-3"><bdi>978-0-89042-336-3</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Practice+Guideline+for+the+Treatment+of+Patients+with+Alzheimer%27s+Disease+and+Other+Dementias&amp;rft.btitle=APA+Practice+Guidelines+for+the+Treatment+of+Psychiatric+Disorders%3A+Comprehensive+Guidelines+and+Guideline+Watches&amp;rft.edition=Second&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.books.9780890423967.152139&amp;rft.isbn=978-0-89042-336-3&amp;rft.au=American+Psychiatric+Association&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAparasuBhatara2006" class="citation journal cs1">Aparasu RR, Bhatara V (December 2006). "Antipsychotic use and expenditure in the United States". <i>Psychiatric Services</i>. <b>57</b> (12): 1693. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1176%2Fappi.ps.57.12.1693">10.1176/appi.ps.57.12.1693</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17158480">17158480</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psychiatric+Services&amp;rft.atitle=Antipsychotic+use+and+expenditure+in+the+United+States&amp;rft.volume=57&amp;rft.issue=12&amp;rft.pages=1693&amp;rft.date=2006-12&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.ps.57.12.1693&amp;rft_id=info%3Apmid%2F17158480&amp;rft.aulast=Aparasu&amp;rft.aufirst=RR&amp;rft.au=Bhatara%2C+V&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFGitlinKalesLyketsos2012" class="citation journal cs1">Gitlin LN, Kales HC, Lyketsos CG (November 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3711645">"Nonpharmacologic management of behavioral symptoms in dementia"</a>. <i>JAMA</i>. <b>308</b> (19): 2020–9. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2012.36918">10.1001/jama.2012.36918</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3711645">3711645</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23168825">23168825</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Nonpharmacologic+management+of+behavioral+symptoms+in+dementia&amp;rft.volume=308&amp;rft.issue=19&amp;rft.pages=2020-9&amp;rft.date=2012-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3711645%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23168825&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2012.36918&amp;rft.aulast=Gitlin&amp;rft.aufirst=LN&amp;rft.au=Kales%2C+HC&amp;rft.au=Lyketsos%2C+CG&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3711645&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMaglioneMaherHuWang2011" class="citation journal cs1">Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T (September 2011). "Off-Label Use of Atypical Antipsychotics: An Update". <i>AHRQ Comparative Effectiveness Reviews</i>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22132426">22132426</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AHRQ+Comparative+Effectiveness+Reviews&amp;rft.atitle=Off-Label+Use+of+Atypical+Antipsychotics%3A+An+Update&amp;rft.date=2011-09&amp;rft_id=info%3Apmid%2F22132426&amp;rft.aulast=Maglione&amp;rft.aufirst=M&amp;rft.au=Maher%2C+AR&amp;rft.au=Hu%2C+J&amp;rft.au=Wang%2C+Z&amp;rft.au=Shanman%2C+R&amp;rft.au=Shekelle%2C+PG&amp;rft.au=Roth%2C+B&amp;rft.au=Hilton%2C+L&amp;rft.au=Suttorp%2C+MJ&amp;rft.au=Ewing%2C+BA&amp;rft.au=Motala%2C+A&amp;rft.au=Perry%2C+T&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFRichterMeyerMöhlerKöpke2012" class="citation journal cs1">Richter T, Meyer G, Möhler R, Köpke S (December 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6492452">"Psychosocial interventions for reducing antipsychotic medication in care home residents"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>12</b>: CD008634. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2F14651858.cd008634.pub2">10.1002/14651858.cd008634.pub2</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC6492452">6492452</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23235663">23235663</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:42099598">42099598</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Psychosocial+interventions+for+reducing+antipsychotic+medication+in+care+home+residents&amp;rft.volume=12&amp;rft.pages=CD008634&amp;rft.date=2012-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6492452%23id-name%3DPMC&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A42099598%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23235663&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.cd008634.pub2&amp;rft.aulast=Richter&amp;rft.aufirst=T&amp;rft.au=Meyer%2C+G&amp;rft.au=M%C3%B6hler%2C+R&amp;rft.au=K%C3%B6pke%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6492452&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li></ul>
</span></li>
<li id="cite_note-AGSfive-247"><span class="mw-cite-backlink"><b><a href="#cite_ref-AGSfive_247-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Geriatrics_Society" class="citation cs2"><a href="/wiki/American_Geriatrics_Society" title="American Geriatrics Society">American Geriatrics Society</a>, <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/american-geriatrics-society/">"Ten Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" class="mw-redirect" title="ABIM Foundation">ABIM Foundation</a></i>, American Geriatrics Society, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20130901100140/http://www.choosingwisely.org/doctor-patient-lists/american-geriatrics-society/">archived</a> from the original on 1 September 2013<span class="reference-accessdate">, retrieved <span class="nowrap">1 August</span> 2013</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.atitle=Ten+Things+Physicians+and+Patients+Should+Question&amp;rft.au=American+Geriatrics+Society&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Famerican-geriatrics-society%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span>, which cites
<ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAmerican_Geriatrics_Society_2012_Beers_Criteria_Update_Expert_Panel2012" class="citation journal cs1">American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3571677">"American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults"</a>. <i>Journal of the American Geriatrics Society</i>. <b>60</b> (4): 616–31. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fj.1532-5415.2012.03923.x">10.1111/j.1532-5415.2012.03923.x</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3571677">3571677</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/22376048">22376048</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+American+Geriatrics+Society&amp;rft.atitle=American+Geriatrics+Society+updated+Beers+Criteria+for+potentially+inappropriate+medication+use+in+older+adults&amp;rft.volume=60&amp;rft.issue=4&amp;rft.pages=616-31&amp;rft.date=2012-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3571677%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22376048&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1532-5415.2012.03923.x&amp;rft.au=American+Geriatrics+Society+2012+Beers+Criteria+Update+Expert+Panel&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3571677&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFNICE2013" class="citation cs2"><a href="/wiki/National_Institute_for_Health_and_Care_Excellence" title="National Institute for Health and Care Excellence">NICE</a> (8 May 2013), <a rel="nofollow" class="external text" href="http://www.nice.org.uk/CG042"><i>Dementia: Supporting people with dementia and their carers in health and social care Clinical guidelines, CG42</i></a>, NICE, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20130627220803/http://www.nice.org.uk/CG042">archived</a> from the original on 27 June 2013<span class="reference-accessdate">, retrieved <span class="nowrap">23 October</span> 2013</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Dementia%3A+Supporting+people+with+dementia+and+their+carers+in+health+and+social+care+Clinical+guidelines%2C+CG42&amp;rft.pub=NICE&amp;rft.date=2013-05-08&amp;rft.au=NICE&amp;rft_id=http%3A%2F%2Fwww.nice.org.uk%2FCG042&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMaherMaglioneBagleySuttorp2011" class="citation journal cs1">Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (September 2011). <a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2011.1360">"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis"</a>. <i>JAMA</i>. <b>306</b> (12): 1359–69. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2011.1360">10.1001/jama.2011.1360</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/21954480">21954480</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Efficacy+and+comparative+effectiveness+of+atypical+antipsychotic+medications+for+off-label+uses+in+adults%3A+a+systematic+review+and+meta-analysis&amp;rft.volume=306&amp;rft.issue=12&amp;rft.pages=1359-69&amp;rft.date=2011-09&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2011.1360&amp;rft_id=info%3Apmid%2F21954480&amp;rft.aulast=Maher&amp;rft.aufirst=AR&amp;rft.au=Maglione%2C+M&amp;rft.au=Bagley%2C+S&amp;rft.au=Suttorp%2C+M&amp;rft.au=Hu%2C+JH&amp;rft.au=Ewing%2C+B&amp;rft.au=Wang%2C+Z&amp;rft.au=Timmer%2C+M&amp;rft.au=Sultzer%2C+D&amp;rft.au=Shekelle%2C+PG&amp;rft_id=%2F%2Fdoi.org%2F10.1001%252Fjama.2011.1360&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li>
<li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSchneiderTariotDagermanDavis2006" class="citation journal cs1">Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA (October 2006). <a rel="nofollow" class="external text" href="https://cdr.lib.unc.edu/downloads/h989rc48f">"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease"</a>. <i>The New England Journal of Medicine</i>. <b>355</b> (15): 1525–38. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1056%2Fnejmoa061240">10.1056/nejmoa061240</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/17035647">17035647</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:5861676">5861676</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Effectiveness+of+atypical+antipsychotic+drugs+in+patients+with+Alzheimer%27s+disease&amp;rft.volume=355&amp;rft.issue=15&amp;rft.pages=1525-38&amp;rft.date=2006-10&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A5861676%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F17035647&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmoa061240&amp;rft.aulast=Schneider&amp;rft.aufirst=LS&amp;rft.au=Tariot%2C+PN&amp;rft.au=Dagerman%2C+KS&amp;rft.au=Davis%2C+SM&amp;rft.au=Hsiao%2C+JK&amp;rft.au=Ismail%2C+MS&amp;rft.au=Lebowitz%2C+BD&amp;rft.au=Lyketsos%2C+CG&amp;rft.au=Ryan%2C+JM&amp;rft.au=Stroup%2C+TS&amp;rft.au=Sultzer%2C+DL&amp;rft.au=Weintraub%2C+D&amp;rft.au=Lieberman%2C+JA&amp;rft_id=https%3A%2F%2Fcdr.lib.unc.edu%2Fdownloads%2Fh989rc48f&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li></ul>
</span></li>
</ol></div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=48" title="Edit section: Further reading">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<style data-mw-deduplicate="TemplateStyles:r1054258005">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li{margin-left:0;padding-left:3.2em;text-indent:-3.2em}.mw-parser-output .refbegin-hanging-indents ul,.mw-parser-output .refbegin-hanging-indents ul li{list-style:none}@media(max-width:720px){.mw-parser-output .refbegin-hanging-indents>ul>li{padding-left:1.6em;text-indent:-1.6em}}.mw-parser-output .refbegin-columns{margin-top:0.3em}.mw-parser-output .refbegin-columns ul{margin-top:0}.mw-parser-output .refbegin-columns li{page-break-inside:avoid;break-inside:avoid-column}</style><div class="refbegin" style="">
<ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFFallonDursunDeakin2012" class="citation journal cs1">Fallon P, Dursun S, Deakin B (February 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3736929">"Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients"</a>. <i>Therapeutic Advances in Psychopharmacology</i>. <b>2</b> (1): 13–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F2045125311431105">10.1177/2045125311431105</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3736929">3736929</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/23983951">23983951</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutic+Advances+in+Psychopharmacology&amp;rft.atitle=Drug-induced+supersensitivity+psychosis+revisited%3A+characteristics+of+relapse+in+treatment-compliant+patients&amp;rft.volume=2&amp;rft.issue=1&amp;rft.pages=13-22&amp;rft.date=2012-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3736929%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23983951&amp;rft_id=info%3Adoi%2F10.1177%2F2045125311431105&amp;rft.aulast=Fallon&amp;rft.aufirst=P&amp;rft.au=Dursun%2C+S&amp;rft.au=Deakin%2C+B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3736929&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAntipsychotic" class="Z3988"></span></li></ul>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Antipsychotic&amp;action=edit&amp;section=49" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table role="presentation" class="mbox-small plainlinks sistersitebox" style="background-color:#f9f9f9;border:1px solid #aaa;color:#000">
<tbody><tr>
<td class="mbox-image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png" decoding="async" width="30" height="40" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x" data-file-width="1024" data-file-height="1376" /></td>
<td class="mbox-text plainlist">Wikimedia Commons has media related to <span style="font-weight: bold; font-style: italic;"><a href="https://commons.wikimedia.org/wiki/Category:Antipsychotic_drugs" class="extiw" title="commons:Category:Antipsychotic drugs">Antipsychotic drugs</a></span>.</td></tr>
</tbody></table>
<ul><li><a rel="nofollow" class="external text" href="https://web.archive.org/web/20140613015650/http://www.who.int/mental_health/mhgap/evidence/psychosis/q1/en/">Recommendations for the use of antipsychotics for treating psychosis</a>, <a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> 2012</li>
<li><a rel="nofollow" class="external text" href="https://web.archive.org/web/20091216100740/http://www.australianprescriber.com/magazine/27/6/146/9">Are atypical antipsychotics advantageous? – the case for</a>, Australian Prescriber 2005 (note: pharmaceutical company conflict of interest statement at the end)</li>
<li><a rel="nofollow" class="external text" href="https://web.archive.org/web/20100527054436/http://www.australianprescriber.com/magazine/27/6/149/51/">Are atypical antipsychotics advantageous? – the case against</a>, Australian Prescriber 2005</li>
<li><a rel="nofollow" class="external text" href="http://psychopharmacologyinstitute.com/antipsychotics/first-generation-antipsychotics/">First Generation Antipsychotics: An Introduction</a>, Psychopharmacology Institute, 2012</li>
<li><a rel="nofollow" class="external text" href="https://web.archive.org/web/20060218075500/http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html">FDA Public Health Advisory</a> – Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients, fda.gov</li>
<li><a rel="nofollow" class="external text" href="http://www.rcpsych.ac.uk/mentalhealthinfo/treatments/antipsychoticmedication.aspx">Antipsychotic Medication</a> – information from mental health charity The Royal College of Psychiatrists</li>
<li><span class="languageicon">(in Portuguese)</span> <a rel="nofollow" class="external text" href="https://web.archive.org/web/20061012215858/http://www.medicina.ufrj.br/cursos/FROTA%20LIVRO%20I%20%26%20II.pdf">FROTA LH. <i>Fifty Years of Antipsychotic Drugs in Psychiatry. "Cinqüenta Anos de Medicamentos Antipsicóticos em Psiquiatria."</i></a> 1st ed; Ebook: CD-Rom/On-Line Portuguese, <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1067248974"/><a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/85-903827-1-0" title="Special:BookSources/85-903827-1-0">85-903827-1-0</a>, File .pdf (Adobe Acrobat) 6Mb, Informática, Rio de Janeiro, August 2003, 486pp., medicina.ufrj.br</li></ul>
<div class="navbox-styles nomobile"><style data-mw-deduplicate="TemplateStyles:r1061467846">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}</style></div><div role="navigation" class="navbox" aria-labelledby="Antipsychotics_(N05A)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1063604349"/><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Antipsychotics" title="Template:Antipsychotics"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Antipsychotics" title="Template talk:Antipsychotics"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Antipsychotics&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Antipsychotics_(N05A)" style="font-size:114%;margin:0 4em"><a class="mw-selflink selflink">Antipsychotics</a> (<a href="/wiki/ATC_code_N05#N05A" title="ATC code N05">N05A</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Typical_antipsychotic" title="Typical antipsychotic">Typical</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><b><a href="/wiki/Butyrophenone" title="Butyrophenone">Butyrophenones</a>:</b> <a href="/wiki/Benperidol" title="Benperidol">Benperidol</a></li>
<li><a href="/wiki/Bromperidol" title="Bromperidol">Bromperidol</a>
<ul><li><a href="/wiki/Bromperidol_decanoate" title="Bromperidol decanoate">Bromperidol decanoate</a></li></ul></li>
<li><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a></li>
<li><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a><sup>#</sup>
<ul><li><a href="/wiki/Haloperidol_decanoate" title="Haloperidol decanoate">Haloperidol decanoate</a></li></ul></li>
<li><a href="/wiki/Moperone" title="Moperone">Moperone</a></li>
<li><a href="/wiki/Pipamperone" title="Pipamperone">Pipamperone</a></li>
<li><a href="/wiki/Spiperone" title="Spiperone">Spiperone</a></li>
<li><a href="/wiki/Timiperone" title="Timiperone">Timiperone</a></li>
<li><a href="/wiki/Trifluperidol" title="Trifluperidol">Trifluperidol</a></li></ul>
<ul><li><b><a href="/wiki/Diphenylbutylpiperidine" title="Diphenylbutylpiperidine">Diphenylbutylpiperidines</a>:</b> <a href="/wiki/Fluspirilene" title="Fluspirilene">Fluspirilene</a></li>
<li><a href="/wiki/Penfluridol" title="Penfluridol">Penfluridol</a></li>
<li><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></li></ul>
<ul><li><b><a href="/wiki/Phenothiazine" title="Phenothiazine">Phenothiazines</a>:</b> <a href="/wiki/Acepromazine" title="Acepromazine">Acepromazine</a></li>
<li><a href="/wiki/Acetophenazine" title="Acetophenazine">Acetophenazine</a></li>
<li><a href="/wiki/Butaperazine" title="Butaperazine">Butaperazine</a></li>
<li><a href="/wiki/Carfenazine" title="Carfenazine">Carphenazine (carfenazine)</a><sup>‡</sup></li>
<li><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="/wiki/Cyamemazine" title="Cyamemazine">Cyamemazine</a></li>
<li><a href="/wiki/Dixyrazine" title="Dixyrazine">Dixyrazine</a></li>
<li><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a>
<ul><li><a href="/wiki/Fluphenazine_decanoate" class="mw-redirect" title="Fluphenazine decanoate">Fluphenazine decanoate</a></li>
<li><a href="/wiki/Fluphenazine_enanthate" class="mw-redirect" title="Fluphenazine enanthate">Fluphenazine enanthate</a></li></ul></li>
<li><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine (methotrimeprazine)</a></li>
<li><a href="/wiki/Mesoridazine" title="Mesoridazine">Mesoridazine</a></li>
<li><a href="/wiki/Perazine" title="Perazine">Perazine</a></li>
<li><a href="/wiki/Periciazine" title="Periciazine">Periciazine</a></li>
<li><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a>
<ul><li><a href="/wiki/BL-1020" title="BL-1020">BL-1020</a></li>
<li><a href="/wiki/Perphenazine_decanoate" class="mw-redirect" title="Perphenazine decanoate">Perphenazine decanoate</a></li>
<li><a href="/wiki/Perphenazine_enanthate" title="Perphenazine enanthate">Perphenazine enanthate</a></li></ul></li>
<li><a href="/wiki/Piperacetazine" title="Piperacetazine">Piperacetazine</a></li>
<li><a href="/wiki/Pipotiazine" title="Pipotiazine">Pipotiazine</a>
<ul><li><a href="/wiki/Pipotiazine_palmitate" class="mw-redirect" title="Pipotiazine palmitate">Pipotiazine palmitate</a></li>
<li><a href="/wiki/Pipotiazine_undecylenate" class="mw-redirect" title="Pipotiazine undecylenate">Pipotiazine undecylenate</a></li></ul></li>
<li><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></li>
<li><a href="/wiki/Promazine" title="Promazine">Promazine</a></li>
<li><a href="/wiki/Sulforidazine" title="Sulforidazine">Sulforidazine</a></li>
<li><a href="/wiki/Thiopropazate" title="Thiopropazate">Thiopropazate</a></li>
<li><a href="/wiki/Thioproperazine" title="Thioproperazine">Thioproperazine</a></li>
<li><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></li>
<li><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></li>
<li><a href="/wiki/Triflupromazine" title="Triflupromazine">Triflupromazine</a></li></ul>
<ul><li><b><a href="/wiki/Thioxanthene" title="Thioxanthene">Thioxanthenes</a>:</b> <a href="/wiki/Chlorprothixene" title="Chlorprothixene">Chlorprothixene</a></li>
<li><a href="/wiki/Clopenthixol" title="Clopenthixol">Clopenthixol</a>
<ul><li><a href="/wiki/Clopenthixol_decanoate" class="mw-redirect" title="Clopenthixol decanoate">Clopenthixol decanoate</a></li></ul></li>
<li><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol</a>
<ul><li><a href="/wiki/Flupentixol_decanoate" class="mw-redirect" title="Flupentixol decanoate">Flupentixol decanoate</a></li></ul></li>
<li><a href="/wiki/Tiotixene" title="Tiotixene">Tiotixene (thiothixene)</a></li>
<li><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a>
<ul><li><a href="/wiki/Zuclopenthixol_acetate" class="mw-redirect" title="Zuclopenthixol acetate">Zuclopenthixol acetate</a></li>
<li><a href="/wiki/Zuclopenthixol_decanoate" class="mw-redirect" title="Zuclopenthixol decanoate">Zuclopenthixol decanoate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Disputed</th><td class="navbox-list-with-group navbox-list navbox-even hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><b><a href="/wiki/Benzamide" title="Benzamide">Benzamides</a>:</b> <a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a></li>
<li><a href="/wiki/Levosulpiride" title="Levosulpiride">Levosulpiride</a></li>
<li><a href="/wiki/Nemonapride" title="Nemonapride">Nemonapride</a></li>
<li><a href="/wiki/Remoxipride" title="Remoxipride">Remoxipride</a><sup>‡</sup></li>
<li><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a></li>
<li><a href="/wiki/Sultopride" title="Sultopride">Sultopride</a></li>
<li><a href="/wiki/Tiapride" title="Tiapride">Tiapride</a></li>
<li><a href="/wiki/Veralipride" title="Veralipride">Veralipride</a><sup>‡</sup></li></ul>
<ul><li><b><a href="/wiki/Butyrophenone" title="Butyrophenone">Butyrophenones</a>:</b> <a href="/wiki/Melperone" title="Melperone">Melperone</a></li></ul>
<ul><li><b><a href="/wiki/Tricyclic" title="Tricyclic">Tricyclics</a>:</b> <a href="/wiki/Carpipramine" title="Carpipramine">Carpipramine</a></li>
<li><a href="/wiki/Clocapramine" title="Clocapramine">Clocapramine</a></li>
<li><a href="/wiki/Clorotepine" title="Clorotepine">Clorotepine</a></li>
<li><a href="/wiki/Clotiapine" title="Clotiapine">Clotiapine</a></li>
<li><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></li>
<li><a href="/wiki/Mosapramine" title="Mosapramine">Mosapramine</a></li>
<li><a href="/wiki/Oxyprothepin_decanoate" title="Oxyprothepin decanoate">Oxyprothepin decanoate</a></li></ul>
<ul><li><b>Others:</b> <a href="/wiki/Molindone" title="Molindone">Molindone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><b><a href="/wiki/Benzisoxazole" title="Benzisoxazole">Benzisoxazole</a>/<a href="/wiki/Benzisothiazole" class="mw-redirect" title="Benzisothiazole">benzisothiazoles</a>:</b> <a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></li>
<li><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a></li>
<li><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a>
<ul><li><a href="/wiki/Paliperidone_palmitate" title="Paliperidone palmitate">Paliperidone palmitate</a></li></ul></li>
<li><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a></li>
<li><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a><sup>#</sup></li>
<li><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></li></ul>
<ul><li><b><a href="/wiki/Butyrophenone" title="Butyrophenone">Butyrophenones</a>:</b> <a href="/wiki/Lumateperone" title="Lumateperone">Lumateperone</a></li></ul>
<ul><li><b><a href="/wiki/Phenylpiperazine" title="Phenylpiperazine">Phenylpiperazines</a>/<a href="/wiki/Quinolinone" class="mw-redirect" title="Quinolinone">quinolinones</a>:</b> <a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a>
<ul><li><a href="/wiki/Aripiprazole_lauroxil" title="Aripiprazole lauroxil">Aripiprazole lauroxil</a></li></ul></li>
<li><a href="/wiki/Brilaroxazine" title="Brilaroxazine">Brilaroxazine</a><sup>†</sup></li>
<li><a href="/wiki/Brexpiprazole" title="Brexpiprazole">Brexpiprazole</a></li>
<li><a href="/wiki/Cariprazine" title="Cariprazine">Cariprazine</a></li></ul>
<ul><li><b><a href="/wiki/Tricyclic" title="Tricyclic">Tricyclics</a>:</b> <a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></li>
<li><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a><sup>#</sup></li>
<li><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a></li>
<li><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></li>
<li><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a></li></ul>
<ul><li><b>Others:</b> <a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a></li>
<li><a href="/wiki/Pimavanserin" title="Pimavanserin">Pimavanserin</a></li>
<li><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list-with-group navbox-list navbox-even hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><b><a href="/wiki/Monoamine-depleting_agent" title="Monoamine-depleting agent">Monoamine-depleting agents</a>:</b> <a href="/wiki/Oxypertine" title="Oxypertine">Oxypertine</a></li>
<li><a href="/wiki/Reserpine" title="Reserpine">Reserpine</a></li>
<li><a href="/wiki/Tetrabenazine" title="Tetrabenazine">Tetrabenazine</a></li></ul>
<ul><li><i>Others/unknown:</i> <a href="/wiki/Azacyclonol" title="Azacyclonol">Azacyclonol</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li>
<li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li>
<li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>:
<ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div class="navbox-styles nomobile"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1061467846"/></div><div role="navigation" class="navbox" aria-labelledby="Major_chemical_drug_groups_–_based_upon_the_Anatomical_Therapeutic_Chemical_Classification_System" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1063604349"/><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Major_drug_groups" title="Template:Major drug groups"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Major_drug_groups" title="Template talk:Major drug groups"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Major_drug_groups&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Major_chemical_drug_groups_–_based_upon_the_Anatomical_Therapeutic_Chemical_Classification_System" style="font-size:114%;margin:0 4em">Major chemical drug groups – based upon the <a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">Anatomical Therapeutic Chemical Classification System</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Human_gastrointestinal_tract" class="mw-redirect" title="Human gastrointestinal tract">gastrointestinal tract</a><br />/ <a href="/wiki/Metabolism" title="Metabolism">metabolism</a> (<a href="/wiki/ATC_code_A" title="ATC code A">A</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>stomach acid</i>
<ul><li><a href="/wiki/Antacid" title="Antacid">Antacids</a></li>
<li><a href="/wiki/H2_antagonist" class="mw-redirect" title="H2 antagonist">H<sub>2</sub> antagonists</a></li>
<li><a href="/wiki/Proton-pump_inhibitor" title="Proton-pump inhibitor">Proton-pump inhibitors</a></li></ul></li>
<li><a href="/wiki/Antiemetic" title="Antiemetic">Antiemetics</a></li>
<li><a href="/wiki/Laxative" title="Laxative">Laxatives</a></li>
<li><a href="/wiki/Antidiarrhoeal" title="Antidiarrhoeal">Antidiarrhoeals</a> / <a href="/wiki/Antipropulsive" title="Antipropulsive">Antipropulsives</a></li>
<li><a href="/wiki/Anti-obesity_medication" title="Anti-obesity medication">Anti-obesity drugs</a></li>
<li><a href="/wiki/Diabetes_medication" title="Diabetes medication">Diabetes medication</a></li>
<li><a href="/wiki/Vitamin" title="Vitamin">Vitamins</a></li>
<li><a href="/wiki/Dietary_mineral" class="mw-redirect" title="Dietary mineral">Dietary minerals</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Blood" title="Blood">blood</a> and blood<br />forming organs (<a href="/wiki/ATC_code_B" title="ATC code B">B</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Antithrombotic" title="Antithrombotic">Antithrombotics</a>
<ul><li><a href="/wiki/Antiplatelet_drug" title="Antiplatelet drug">Antiplatelets</a></li>
<li><a href="/wiki/Anticoagulant" title="Anticoagulant">Anticoagulants</a></li>
<li><a href="/wiki/Thrombolytic_drug" class="mw-redirect" title="Thrombolytic drug">Thrombolytics / fibrinolytics</a></li></ul></li>
<li><a href="/wiki/Antihemorrhagic" title="Antihemorrhagic">Antihemorrhagics</a>
<ul><li><a href="/wiki/Platelet" title="Platelet">Platelets</a></li>
<li><a href="/wiki/Coagulation" title="Coagulation">Coagulants</a></li>
<li><a href="/wiki/Antifibrinolytic" title="Antifibrinolytic">Antifibrinolytics</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Circulatory_system" title="Circulatory system">cardiovascular<br />system</a> (<a href="/wiki/ATC_code_C" title="ATC code C">C</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>cardiac therapy / <a href="/wiki/Antianginal" title="Antianginal">antianginals</a></i>
<ul><li><a href="/wiki/Cardiac_glycoside" title="Cardiac glycoside">Cardiac glycosides</a></li>
<li><a href="/wiki/Antiarrhythmic_agent" title="Antiarrhythmic agent">Antiarrhythmics</a></li>
<li><a href="/wiki/Cardiac_stimulant" title="Cardiac stimulant">Cardiac stimulants</a></li></ul></li>
<li><a href="/wiki/Antihypertensive_drug" title="Antihypertensive drug">Antihypertensives</a></li>
<li><a href="/wiki/Diuretic" title="Diuretic">Diuretics</a></li>
<li><a href="/wiki/Vasodilation" title="Vasodilation">Vasodilators</a></li>
<li><a href="/wiki/Beta_blocker" title="Beta blocker">Beta blockers</a></li>
<li><a href="/wiki/Calcium_channel_blocker" title="Calcium channel blocker">Calcium channel blockers</a></li>
<li><i><a href="/wiki/Renin%E2%80%93angiotensin_system" title="Renin–angiotensin system">renin–angiotensin system</a></i>
<ul><li><a href="/wiki/ACE_inhibitor" title="ACE inhibitor">ACE inhibitors</a></li>
<li><a href="/wiki/Angiotensin_II_receptor_antagonist" class="mw-redirect" title="Angiotensin II receptor antagonist">Angiotensin II receptor antagonists</a></li>
<li><a href="/wiki/Renin_inhibitor" title="Renin inhibitor">Renin inhibitors</a></li></ul></li>
<li><a href="/wiki/Hypolipidemic_agent" class="mw-redirect" title="Hypolipidemic agent">Antihyperlipidemics</a>
<ul><li><a href="/wiki/Statin" title="Statin">Statins</a></li>
<li><a href="/wiki/Fibrate" title="Fibrate">Fibrates</a></li>
<li><a href="/wiki/Bile_acid_sequestrant" title="Bile acid sequestrant">Bile acid sequestrants</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Human_skin" title="Human skin">skin</a> (<a href="/wiki/ATC_code_D" title="ATC code D">D</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Emollient" class="mw-redirect" title="Emollient">Emollients</a></li>
<li><a href="/wiki/Cicatrizant" class="mw-redirect" title="Cicatrizant">Cicatrizants</a></li>
<li><a href="/wiki/Antipruritic" title="Antipruritic">Antipruritics</a></li>
<li><a href="/wiki/Antipsoriatic" class="mw-redirect" title="Antipsoriatic">Antipsoriatics</a></li>
<li><a href="/wiki/ATC_code_D09" title="ATC code D09">Medicated dressings</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Genitourinary_system" title="Genitourinary system">genitourinary<br />system</a> (<a href="/wiki/ATC_code_G" title="ATC code G">G</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Hormonal_contraception" title="Hormonal contraception">Hormonal contraception</a></li>
<li><a href="/wiki/Fertility_medication" title="Fertility medication">Fertility agents</a></li>
<li><a href="/wiki/Selective_estrogen_receptor_modulator" title="Selective estrogen receptor modulator">Selective estrogen receptor modulators</a></li>
<li><a href="/wiki/Sex_steroid" class="mw-redirect" title="Sex steroid">Sex hormones</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Endocrine_system" title="Endocrine system">endocrine<br />system</a> (<a href="/wiki/ATC_code_H" title="ATC code H">H</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Hypothalamic%E2%80%93pituitary_hormone" title="Hypothalamic–pituitary hormone">Hypothalamic–pituitary hormones</a></li>
<li><a href="/wiki/Corticosteroid" title="Corticosteroid">Corticosteroids</a>
<ul><li><a href="/wiki/Glucocorticoid" title="Glucocorticoid">Glucocorticoids</a></li>
<li><a href="/wiki/Mineralocorticoid" title="Mineralocorticoid">Mineralocorticoids</a></li></ul></li>
<li><a href="/wiki/Sex_steroid" class="mw-redirect" title="Sex steroid">Sex hormones</a></li>
<li><a href="/wiki/Thyroid_hormone" class="mw-redirect" title="Thyroid hormone">Thyroid hormones</a> / <a href="/wiki/Antithyroid_agent" title="Antithyroid agent">Antithyroid agents</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Infection" title="Infection">infections</a> and<br /><a href="https://en.wiktionary.org/wiki/infestation" class="extiw" title="wikt:infestation">infestations</a> (<a href="/wiki/ATC_code_J" title="ATC code J">J</a>, <a href="/wiki/ATC_code_P" title="ATC code P">P</a>, <a href="/wiki/ATCvet_code_QI" title="ATCvet code QI">QI</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Antimicrobial" title="Antimicrobial">Antimicrobials</a>: <a href="/wiki/Antibacterial" class="mw-redirect" title="Antibacterial">Antibacterials</a> (<a href="/wiki/Antimycobacterial" title="Antimycobacterial">Antimycobacterials</a>)</li>
<li><a href="/wiki/Antifungal_drug" class="mw-redirect" title="Antifungal drug">Antifungals</a></li>
<li><a href="/wiki/Antiviral_drug" title="Antiviral drug">Antivirals</a></li>
<li><a href="/wiki/Antiparasitic" title="Antiparasitic">Antiparasitics</a>
<ul><li><a href="/wiki/Antiprotozoal_agent" class="mw-redirect" title="Antiprotozoal agent">Antiprotozoals</a></li>
<li><a href="/wiki/Anthelmintic" title="Anthelmintic">Anthelmintics</a></li>
<li><a href="/wiki/Ectoparasiticide" title="Ectoparasiticide">Ectoparasiticides</a></li></ul></li>
<li><a href="/wiki/Intravenous_immunoglobulin" class="mw-redirect" title="Intravenous immunoglobulin">Intravenous immunoglobulin</a></li>
<li><a href="/wiki/Vaccine" title="Vaccine">Vaccines</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Malignant" class="mw-redirect" title="Malignant">malignant</a> disease<br />(<a href="/wiki/ATC_code_L" title="ATC code L">L01–L02</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Chemotherapy" title="Chemotherapy">Anticancer agents</a>
<ul><li><a href="/wiki/Antimetabolite" title="Antimetabolite">Antimetabolites</a></li>
<li><a href="/wiki/Alkylating_antineoplastic_agent" title="Alkylating antineoplastic agent">Alkylating</a></li>
<li><a href="/wiki/Spindle_poison" title="Spindle poison">Spindle poisons</a></li>
<li><a href="/wiki/Antineoplastic" class="mw-redirect" title="Antineoplastic">Antineoplastic</a></li>
<li><a href="/wiki/Topoisomerase_inhibitor" title="Topoisomerase inhibitor">Topoisomerase inhibitors</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Immune_system" title="Immune system">immune</a> disease<br />(<a href="/wiki/ATC_code_L" title="ATC code L">L03–L04</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Immunomodulator" class="mw-redirect" title="Immunomodulator">Immunomodulators</a>
<ul><li><a href="/wiki/Immunostimulant" title="Immunostimulant">Immunostimulants</a></li>
<li><a href="/wiki/Immunosuppressive_drug" title="Immunosuppressive drug">Immunosuppressants</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Muscle" class="mw-redirect" title="Muscle">muscles</a>, <a href="/wiki/Bone" title="Bone">bones</a>,<br />and <a href="/wiki/Joint" title="Joint">joints</a> (<a href="/wiki/ATC_code_M" title="ATC code M">M</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Anabolic_steroid" title="Anabolic steroid">Anabolic steroids</a></li>
<li><a href="/wiki/Anti-inflammatory" title="Anti-inflammatory">Anti-inflammatories</a>
<ul><li><a href="/wiki/Non-steroidal_anti-inflammatory_drug" class="mw-redirect" title="Non-steroidal anti-inflammatory drug">Non-steroidal anti-inflammatory drugs</a></li></ul></li>
<li><a href="/wiki/Disease-modifying_antirheumatic_drug" title="Disease-modifying antirheumatic drug">Antirheumatics</a></li>
<li><a href="/wiki/Corticosteroid" title="Corticosteroid">Corticosteroids</a></li>
<li><a href="/wiki/Muscle_relaxant" title="Muscle relaxant">Muscle relaxants</a></li>
<li><a href="/wiki/Bisphosphonate" title="Bisphosphonate">Bisphosphonates</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Human_brain" title="Human brain">brain</a> and<br /><a href="/wiki/Nervous_system" title="Nervous system">nervous system</a> (<a href="/wiki/ATC_code_N" title="ATC code N">N</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Analgesic" title="Analgesic">Analgesics</a></li>
<li><a href="/wiki/Anesthetic" title="Anesthetic">Anesthetics</a>
<ul><li><a href="/wiki/General_anaesthetic" title="General anaesthetic">General</a></li>
<li><a href="/wiki/Local_anesthetic" title="Local anesthetic">Local</a></li></ul></li>
<li><a href="/wiki/Anorectic" title="Anorectic">Anorectics</a></li>
<li><a href="/wiki/Antihyperkinetic" class="mw-redirect" title="Antihyperkinetic">Anti-ADHD agents</a></li>
<li><a href="/wiki/Addiction_medicine" title="Addiction medicine">Antiaddictives</a></li>
<li><a href="/wiki/Anticonvulsant" title="Anticonvulsant">Anticonvulsants</a></li>
<li><a href="/wiki/Antidementia_drug" class="mw-redirect" title="Antidementia drug">Antidementia agents</a></li>
<li><a href="/wiki/Antidepressant" title="Antidepressant">Antidepressants</a></li>
<li><a href="/wiki/Antimigraine_drug" title="Antimigraine drug">Antimigraine agents</a></li>
<li><a href="/wiki/Management_of_Parkinson%27s_disease#Medication" title="Management of Parkinson&#39;s disease">Antiparkinson agents</a></li>
<li><a class="mw-selflink selflink">Antipsychotics</a></li>
<li><a href="/wiki/Anxiolytic" title="Anxiolytic">Anxiolytics</a></li>
<li><a href="/wiki/Aphrodisiac" title="Aphrodisiac">Aphrodisiacs</a></li>
<li><a href="/wiki/Depressant" title="Depressant">Depressants</a></li>
<li><a href="/wiki/Entactogen" class="mw-redirect" title="Entactogen">Entactogens</a></li>
<li><a href="/wiki/Entheogen" title="Entheogen">Entheogens</a></li>
<li><a href="/wiki/Euphoria" title="Euphoria">Euphoriants</a></li>
<li><a href="/wiki/Psychedelics,_dissociatives_and_deliriants" class="mw-redirect" title="Psychedelics, dissociatives and deliriants">Hallucinogens</a>
<ul><li><a href="/wiki/Psychedelic_drug" title="Psychedelic drug">Psychedelics</a></li>
<li><a href="/wiki/Dissociative" title="Dissociative">Dissociatives</a></li>
<li><a href="/wiki/Deliriant" title="Deliriant">Deliriants</a></li></ul></li>
<li><a href="/wiki/Hypnotic" title="Hypnotic">Hypnotics</a> / <a href="/wiki/Sedative" title="Sedative">Sedatives</a></li>
<li><a href="/wiki/Mood_stabilizer" title="Mood stabilizer">Mood stabilizers</a></li>
<li><a href="/wiki/Neuroprotective" class="mw-redirect" title="Neuroprotective">Neuroprotectives</a></li>
<li><a href="/wiki/Nootropic" title="Nootropic">Nootropics</a></li>
<li><a href="/wiki/Neurotoxin" title="Neurotoxin">Neurotoxins</a></li>
<li><a href="/wiki/Orexigenic" class="mw-redirect" title="Orexigenic">Orexigenics</a></li>
<li><a href="/wiki/Serenic" title="Serenic">Serenics</a></li>
<li><a href="/wiki/Stimulant" title="Stimulant">Stimulants</a></li>
<li><a href="/wiki/Wakefulness-promoting_agent" class="mw-redirect" title="Wakefulness-promoting agent">Wakefulness-promoting agents</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Respiratory_system" title="Respiratory system">respiratory<br />system</a> (<a href="/wiki/ATC_code_R" title="ATC code R">R</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Decongestant" title="Decongestant">Decongestants</a></li>
<li><a href="/wiki/Bronchodilator" title="Bronchodilator">Bronchodilators</a></li>
<li><a href="/wiki/Cough_medicine" class="mw-redirect" title="Cough medicine">Cough medicines</a></li>
<li><a href="/wiki/H1_antagonist" title="H1 antagonist">H<sub>1</sub> antagonists</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Sense" title="Sense">sensory organs</a> (<a href="/wiki/ATC_code_S" title="ATC code S">S</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Ophthalmology" title="Ophthalmology">Ophthalmologicals</a></li>
<li><a href="/wiki/Otology" title="Otology">Otologicals</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">other <a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC</a> (<a href="/wiki/ATC_code_V" title="ATC code V">V</a>)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Antidote" title="Antidote">Antidotes</a></li>
<li><a href="/wiki/Contrast_medium" class="mw-redirect" title="Contrast medium">Contrast media</a></li>
<li><a href="/wiki/Radiopharmacology" title="Radiopharmacology">Radiopharmaceuticals</a></li>
<li><a href="/wiki/Dressing_(medical)" title="Dressing (medical)">Dressings</a></li>
<li><a href="/wiki/Senotherapeutics" class="mw-redirect" title="Senotherapeutics">Senotherapeutics</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<ul><li><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/9/96/Symbol_category_class.svg/16px-Symbol_category_class.svg.png" decoding="async" title="Category" width="16" height="16" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/96/Symbol_category_class.svg/23px-Symbol_category_class.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/96/Symbol_category_class.svg/31px-Symbol_category_class.svg.png 2x" data-file-width="180" data-file-height="185" />&#160;<a href="/wiki/Category:Drugs" title="Category:Drugs">Drugs</a></li>
<li><a href="/wiki/Category:Pharmacological_classification_systems" title="Category:Pharmacological classification systems">Pharmacological classification systems</a></li>
<li><a href="/wiki/Category:ATC_codes" title="Category:ATC codes">ATC codes</a></li>
<li><a href="/wiki/File:Symbol_portal_class.svg" class="image" title="Portal"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/e/e2/Symbol_portal_class.svg/16px-Symbol_portal_class.svg.png" decoding="async" width="16" height="16" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/en/thumb/e/e2/Symbol_portal_class.svg/23px-Symbol_portal_class.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/e/e2/Symbol_portal_class.svg/31px-Symbol_portal_class.svg.png 2x" data-file-width="180" data-file-height="185" /></a>&#160;<a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine portal</a></li></ul>
</div></td></tr></tbody></table></div>
<div class="navbox-styles nomobile"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1061467846"/></div><div role="navigation" class="navbox" aria-labelledby="Dopamine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1063604349"/><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Dopamine_receptor_modulators" title="Template:Dopamine receptor modulators"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Dopamine_receptor_modulators" title="Template talk:Dopamine receptor modulators"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Dopamine_receptor_modulators&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Dopamine_receptor_modulators" style="font-size:114%;margin:0 4em"><a href="/wiki/Dopamine_receptor" title="Dopamine receptor">Dopamine receptor</a> <a href="/wiki/Receptor_modulator" title="Receptor modulator">modulators</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/D1-like_receptor" title="D1-like receptor">D<sub>1</sub>-like</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Agonists</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Benzazepines</i>: <a href="/wiki/6-Br-APB" title="6-Br-APB">6-Br-APB</a></li>
<li><a href="/wiki/Fenoldopam" title="Fenoldopam">Fenoldopam</a></li>
<li><a href="/wiki/SKF-38,393" title="SKF-38,393">SKF-38,393</a></li>
<li><a href="/wiki/SKF-77,434" title="SKF-77,434">SKF-77,434</a></li>
<li><a href="/wiki/SKF-81,297" title="SKF-81,297">SKF-81,297</a></li>
<li><a href="/wiki/SKF-82,958" title="SKF-82,958">SKF-82,958</a></li>
<li><a href="/wiki/SKF-83,959" title="SKF-83,959">SKF-83,959</a></li>
<li><a href="/wiki/Trepipam" title="Trepipam">Trepipam</a></li>
<li><a href="/w/index.php?title=Zelandopam&amp;action=edit&amp;redlink=1" class="new" title="Zelandopam (page does not exist)">Zelandopam</a></li></ul>
<ul><li><i>Ergolines</i>: <a href="/wiki/Cabergoline" title="Cabergoline">Cabergoline</a></li>
<li><a href="/wiki/CY-208,243" title="CY-208,243">CY-208,243</a></li>
<li><a href="/wiki/Dihydroergocryptine" title="Dihydroergocryptine">Dihydroergocryptine</a></li>
<li><a href="/w/index.php?title=LEK-8829&amp;action=edit&amp;redlink=1" class="new" title="LEK-8829 (page does not exist)">LEK-8829</a></li>
<li><a href="/wiki/Lisuride" title="Lisuride">Lisuride</a></li>
<li><a href="/wiki/Pergolide" title="Pergolide">Pergolide</a></li>
<li><a href="/wiki/Terguride" title="Terguride">Terguride</a></li></ul>
<ul><li><i>Dihydrexidine derivatives</i>: <a href="/wiki/A-77636" title="A-77636">A-77636</a></li>
<li><a href="/wiki/A-86929" title="A-86929">A-86929</a></li>
<li><a href="/wiki/Adrogolide" class="mw-redirect" title="Adrogolide">Adrogolide (ABT-431, DAS-431)</a></li>
<li><a href="/wiki/Dihydrexidine" title="Dihydrexidine">Dihydrexidine</a></li>
<li><a href="/wiki/Dinapsoline" title="Dinapsoline">Dinapsoline</a></li>
<li><a href="/wiki/Dinoxyline" title="Dinoxyline">Dinoxyline</a></li>
<li><a href="/wiki/Doxanthrine" title="Doxanthrine">Doxanthrine</a></li></ul>
<ul><li><i>Phenethylamines</i>: <a href="/w/index.php?title=BCO-001&amp;action=edit&amp;redlink=1" class="new" title="BCO-001 (page does not exist)">BCO-001</a></li>
<li><a href="/wiki/Deoxyepinephrine" title="Deoxyepinephrine">Deoxyepinephrine (N-methyldopamine, epinine)</a></li>
<li><a href="/wiki/Dopexamine" title="Dopexamine">Dopexamine</a></li>
<li><a href="/wiki/Etilevodopa" title="Etilevodopa">Etilevodopa</a></li>
<li><a href="/wiki/Ibopamine" title="Ibopamine">Ibopamine</a></li>
<li><a href="/wiki/L-DOPA" title="L-DOPA"><small>L</small>-DOPA (levodopa)</a></li>
<li><a href="/wiki/Melevodopa" title="Melevodopa">Melevodopa</a></li>
<li><a href="/wiki/Phenylalanine" title="Phenylalanine"><small>L</small>-Phenylalanine</a></li>
<li><a href="/wiki/Tyrosine" title="Tyrosine"><small>L</small>-Tyrosine</a></li>
<li><a href="/w/index.php?title=XP21279&amp;action=edit&amp;redlink=1" class="new" title="XP21279 (page does not exist)">XP21279</a></li></ul>
<ul><li><i>Others</i>: <a href="/wiki/A-68930" title="A-68930">A-68930</a></li>
<li><a href="/wiki/Apomorphine" title="Apomorphine">Apomorphine</a></li>
<li><a href="/w/index.php?title=Isocorypalmine&amp;action=edit&amp;redlink=1" class="new" title="Isocorypalmine (page does not exist)">Isocorypalmine</a></li>
<li><a href="/wiki/Nuciferine" title="Nuciferine">Nuciferine</a></li>
<li><a href="/wiki/PF-6649751" class="mw-redirect" title="PF-6649751">PF-6649751</a></li>
<li><a href="/w/index.php?title=PF_6669571&amp;action=edit&amp;redlink=1" class="new" title="PF 6669571 (page does not exist)">PF 6669571</a></li>
<li><a href="/wiki/Propylnorapomorphine" title="Propylnorapomorphine">Propylnorapomorphine</a></li>
<li><a href="/wiki/Rotigotine" title="Rotigotine">Rotigotine</a></li>
<li><a href="/wiki/SKF-89,145" title="SKF-89,145">SKF-89,145</a></li>
<li><a href="/w/index.php?title=SKF-89,626&amp;action=edit&amp;redlink=1" class="new" title="SKF-89,626 (page does not exist)">SKF-89,626</a></li>
<li><a href="/wiki/Stepholidine" title="Stepholidine">Stepholidine</a></li>
<li><a href="/wiki/Tavapadon" title="Tavapadon">Tavapadon</a></li>
<li><a href="/wiki/Tetrahydropalmatine" title="Tetrahydropalmatine">Tetrahydropalmatine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PAMs</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/w/index.php?title=DETQ&amp;action=edit&amp;redlink=1" class="new" title="DETQ (page does not exist)">DETQ</a></li>
<li><a href="/w/index.php?title=DPTQ&amp;action=edit&amp;redlink=1" class="new" title="DPTQ (page does not exist)">DPTQ</a></li>
<li><a href="/w/index.php?title=Mevidalen&amp;action=edit&amp;redlink=1" class="new" title="Mevidalen (page does not exist)">Mevidalen (LY3154207)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antagonists</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Typical antipsychotics</i>: <a href="/wiki/Butaclamol" title="Butaclamol">Butaclamol</a></li>
<li><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="/wiki/Chlorprothixene" title="Chlorprothixene">Chlorprothixene</a></li>
<li><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol (flupenthixol)</a> (<a href="/wiki/Flupentixol/melitracen" title="Flupentixol/melitracen">+melitracen</a>)</li>
<li><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></li>
<li><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></li>
<li><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a> (<a href="/wiki/Amitriptyline/perphenazine" title="Amitriptyline/perphenazine">+amitriptyline</a>)</li>
<li><a href="/w/index.php?title=Pifluthixol&amp;action=edit&amp;redlink=1" class="new" title="Pifluthixol (page does not exist)">Pifluthixol</a></li>
<li><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></li>
<li><a href="/wiki/Thiothixene" class="mw-redirect" title="Thiothixene">Thiothixene</a></li>
<li><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a> (<a href="/wiki/Tranylcypromine/trifluoperazine" title="Tranylcypromine/trifluoperazine">+tranylcypromine</a>)</li>
<li><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></li></ul>
<ul><li><i>Atypical antipsychotics</i>: <a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></li>
<li><a href="/wiki/Clorotepine" title="Clorotepine">Clorotepine</a></li>
<li><a href="/wiki/Clotiapine" title="Clotiapine">Clotiapine</a></li>
<li><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a></li>
<li><a href="/wiki/DHA-clozapine" title="DHA-clozapine">DHA-clozapine</a></li>
<li><a href="/wiki/Fluperlapine" title="Fluperlapine">Fluperlapine</a></li>
<li><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></li>
<li><a href="/wiki/Norclozapine" class="mw-redirect" title="Norclozapine">Norclozapine</a></li>
<li><a href="/w/index.php?title=Norquetiapine&amp;action=edit&amp;redlink=1" class="new" title="Norquetiapine (page does not exist)">Norquetiapine</a></li>
<li><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a> (<a href="/wiki/Olanzapine/fluoxetine" title="Olanzapine/fluoxetine">+fluoxetine</a>)</li>
<li><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a></li>
<li><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></li>
<li><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></li>
<li><a href="/w/index.php?title=Tefludazine&amp;action=edit&amp;redlink=1" class="new" title="Tefludazine (page does not exist)">Tefludazine</a></li>
<li><a href="/wiki/Zicronapine" title="Zicronapine">Zicronapine</a></li>
<li><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></li>
<li><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a></li></ul>
<ul><li><i>Others</i>: <a href="/w/index.php?title=Berupipam&amp;action=edit&amp;redlink=1" class="new" title="Berupipam (page does not exist)">Berupipam</a></li>
<li><a href="/wiki/Ecopipam" title="Ecopipam">Ecopipam</a></li>
<li><a href="/wiki/N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline" title="N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline">EEDQ</a></li>
<li><a href="/wiki/Metitepine" title="Metitepine">Metitepine (methiothepin)</a></li>
<li><a href="/w/index.php?title=Odapipam&amp;action=edit&amp;redlink=1" class="new" title="Odapipam (page does not exist)">Odapipam</a></li>
<li><a href="/wiki/Perlapine" title="Perlapine">Perlapine</a></li>
<li><a href="/wiki/SCH-23390" title="SCH-23390">SCH-23390</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/D2-like_receptor" title="D2-like receptor">D<sub>2</sub>-like</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Agonists</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Adamantanes</i>: <a href="/wiki/Amantadine" title="Amantadine">Amantadine</a></li>
<li><a href="/wiki/Memantine" title="Memantine">Memantine</a></li>
<li><a href="/wiki/Rimantadine" title="Rimantadine">Rimantadine</a></li></ul>
<ul><li><i>Aminotetralins</i>: <a href="/wiki/5-OH-DPAT" title="5-OH-DPAT">5-OH-DPAT</a></li>
<li><a href="/wiki/7-OH-DPAT" title="7-OH-DPAT">7-OH-DPAT</a></li>
<li><a href="/wiki/8-OH-PBZI" title="8-OH-PBZI">8-OH-PBZI</a></li>
<li><a href="/wiki/Rotigotine" title="Rotigotine">Rotigotine</a></li>
<li><a href="/wiki/UH-232" title="UH-232">UH-232</a></li></ul>
<ul><li><i>Ergolines</i>: <a href="/wiki/Bromocriptine" title="Bromocriptine">Bromocriptine</a></li>
<li><a href="/wiki/Cabergoline" title="Cabergoline">Cabergoline</a></li>
<li><a href="/wiki/Chanoclavine" title="Chanoclavine">Chanoclavine</a></li>
<li><a href="/wiki/Dihydroergocryptine" title="Dihydroergocryptine">Dihydroergocryptine</a></li>
<li><a href="/wiki/Epicriptine" title="Epicriptine">Epicriptine</a></li>
<li><a href="/wiki/Ergocornine" title="Ergocornine">Ergocornine</a></li>
<li><a href="/wiki/Lergotrile" title="Lergotrile">Lergotrile</a></li>
<li><a href="/wiki/Lisuride" title="Lisuride">Lisuride</a></li>
<li><a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">LSD</a></li>
<li><a href="/wiki/Pergolide" title="Pergolide">Pergolide</a></li>
<li><a href="/wiki/Terguride" title="Terguride">Terguride</a></li></ul>
<ul><li><i>Dihydrexidine derivatives</i>: <a href="/wiki/2-OH-NPA" title="2-OH-NPA">2-OH-NPA</a></li>
<li><a href="/wiki/Ciladopa" title="Ciladopa">Ciladopa</a></li>
<li><a href="/wiki/Dihydrexidine" title="Dihydrexidine">Dihydrexidine</a></li>
<li><a href="/wiki/Dinoxyline" title="Dinoxyline">Dinoxyline</a></li>
<li><a href="/w/index.php?title=N,N-Propyldihydrexidine&amp;action=edit&amp;redlink=1" class="new" title="N,N-Propyldihydrexidine (page does not exist)">N,N-Propyldihydrexidine</a></li></ul>
<ul><li><i>Phenethylamines</i>: <a href="/wiki/Deoxyepinephrine" title="Deoxyepinephrine">Deoxyepinephrine (N-methyldopamine, epinine)</a></li>
<li><a href="/wiki/Dopexamine" title="Dopexamine">Dopexamine</a></li>
<li><a href="/wiki/Etilevodopa" title="Etilevodopa">Etilevodopa</a></li>
<li><a href="/wiki/Ibopamine" title="Ibopamine">Ibopamine</a></li>
<li><a href="/wiki/L-DOPA" title="L-DOPA"><small>L</small>-DOPA (levodopa)</a></li>
<li><a href="/wiki/Phenylalanine" title="Phenylalanine"><small>L</small>-Phenylalanine</a></li>
<li><a href="/wiki/Tyrosine" title="Tyrosine"><small>L</small>-Tyrosine</a></li>
<li><a href="/wiki/Melevodopa" title="Melevodopa">Melevodopa</a></li>
<li><a href="/w/index.php?title=XP21279&amp;action=edit&amp;redlink=1" class="new" title="XP21279 (page does not exist)">XP21279</a></li></ul>
<ul><li><i>Atypical antipsychotics</i>: <a href="/wiki/Alentemol" title="Alentemol">Alentemol (U-66444B)</a></li>
<li><a href="/wiki/Aripiprazole" title="Aripiprazole">Aripiprazole</a> (<a href="/wiki/Aripiprazole/sertraline" title="Aripiprazole/sertraline">+sertraline</a>)</li>
<li><a href="/wiki/Aripiprazole_lauroxil" title="Aripiprazole lauroxil">Aripiprazole lauroxil</a></li>
<li><a href="/wiki/Bifeprunox" title="Bifeprunox">Bifeprunox</a></li>
<li><a href="/wiki/Brexpiprazole" title="Brexpiprazole">Brexpiprazole</a></li>
<li><a href="/wiki/Brilaroxazine" title="Brilaroxazine">Brilaroxazine</a></li>
<li><a href="/wiki/Cariprazine" title="Cariprazine">Cariprazine</a></li>
<li><a href="/wiki/F-15063" title="F-15063">F-15063</a></li>
<li><a href="/wiki/Lumateperone" title="Lumateperone">Lumateperone</a></li>
<li><a href="/wiki/Norclozapine" class="mw-redirect" title="Norclozapine">Norclozapine</a></li></ul>
<ul><li><i>Others</i>: <a href="/wiki/3-PPP" title="3-PPP">3-PPP</a></li>
<li><a href="/wiki/A-412997" title="A-412997">A-412997</a></li>
<li><a href="/wiki/ABT-670" title="ABT-670">ABT-670</a></li>
<li><a href="/wiki/ABT-724" title="ABT-724">ABT-724</a></li>
<li><a href="/wiki/Adrafinil" title="Adrafinil">Adrafinil</a></li>
<li><a href="/wiki/Aplindore" title="Aplindore">Aplindore</a></li>
<li><a href="/wiki/Apomorphine" title="Apomorphine">Apomorphine</a></li>
<li><a href="/wiki/Arketamine" title="Arketamine">Arketamine</a></li>
<li><a href="/wiki/Armodafinil" title="Armodafinil">Armodafinil</a></li>
<li><a href="/wiki/BP-897" title="BP-897">BP-897</a></li>
<li><a href="/wiki/Captodiame" title="Captodiame">Captodiame</a></li>
<li><a href="/wiki/CP-226,269" title="CP-226,269">CP-226,269</a></li>
<li><a href="/wiki/Dizocilpine" title="Dizocilpine">Dizocilpine</a></li>
<li><a href="/wiki/Esketamine" title="Esketamine">Esketamine</a></li>
<li><a href="/wiki/Flibanserin" title="Flibanserin">Flibanserin</a></li>
<li><a href="/wiki/Ketamine" title="Ketamine">Ketamine</a></li>
<li><a href="/wiki/Mesulergine" title="Mesulergine">Mesulergine</a></li>
<li><a href="/wiki/Modafinil" title="Modafinil">Modafinil</a></li>
<li><a href="/wiki/OSU-6162" title="OSU-6162">OSU-6162</a></li>
<li><a href="/wiki/Pardoprunox" title="Pardoprunox">Pardoprunox</a></li>
<li><a href="/wiki/PD-128,907" title="PD-128,907">PD-128,907</a></li>
<li><a href="/wiki/PD-168,077" title="PD-168,077">PD-168,077</a></li>
<li><a href="/wiki/PF-219,061" title="PF-219,061">PF-219,061</a></li>
<li><a href="/wiki/PF-592,379" title="PF-592,379">PF-592,379</a></li>
<li><a href="/wiki/Phencyclidine" title="Phencyclidine">Phencyclidine</a></li>
<li><a href="/wiki/Piribedil" title="Piribedil">Piribedil</a></li>
<li><a href="/wiki/Pramipexole" title="Pramipexole">Pramipexole</a></li>
<li><a href="/wiki/Preclamol" class="mw-redirect" title="Preclamol">Preclamol</a></li>
<li><a href="/wiki/Propylnorapomorphine" title="Propylnorapomorphine">Propylnorapomorphine</a></li>
<li><a href="/wiki/Pukateine" title="Pukateine">Pukateine</a></li>
<li><a href="/wiki/Quinagolide" title="Quinagolide">Quinagolide</a></li>
<li><a href="/wiki/Quinelorane" title="Quinelorane">Quinelorane</a></li>
<li><a href="/wiki/Quinpirole" title="Quinpirole">Quinpirole</a></li>
<li><a href="/wiki/RDS-127" title="RDS-127">RDS-127</a></li>
<li><a href="/wiki/Ro10-5824" title="Ro10-5824">Ro10-5824</a></li>
<li><a href="/wiki/Ropinirole" title="Ropinirole">Ropinirole</a></li>
<li><a href="/wiki/Roxindole" title="Roxindole">Roxindole</a></li>
<li><a href="/wiki/Salvinorin_A" title="Salvinorin A">Salvinorin A</a></li>
<li><a href="/wiki/SKF-83,959" title="SKF-83,959">SKF-83,959</a></li>
<li><a href="/wiki/Sumanirole" title="Sumanirole">Sumanirole</a></li>
<li><a href="/wiki/Talipexole" title="Talipexole">Talipexole</a></li>
<li><a href="/wiki/Umespirone" title="Umespirone">Umespirone</a></li>
<li><a href="/wiki/WAY-100,635" class="mw-redirect" title="WAY-100,635">WAY-100,635</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antagonists</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Typical antipsychotics</i>: <a href="/wiki/Acepromazine" title="Acepromazine">Acepromazine</a></li>
<li><a href="/wiki/Acetophenazine" title="Acetophenazine">Acetophenazine</a></li>
<li><a href="/wiki/Azaperone" title="Azaperone">Azaperone</a></li>
<li><a href="/wiki/Benperidol" title="Benperidol">Benperidol</a></li>
<li><a href="/wiki/Bromperidol" title="Bromperidol">Bromperidol</a></li>
<li><a href="/wiki/Butaclamol" title="Butaclamol">Butaclamol</a></li>
<li><a href="/wiki/Butaperazine" title="Butaperazine">Butaperazine</a></li>
<li><a href="/wiki/Chloracizine" class="mw-redirect" title="Chloracizine">Chloracizine</a></li>
<li><a href="/wiki/Chlorproethazine" title="Chlorproethazine">Chlorproethazine</a></li>
<li><a href="/wiki/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="/wiki/Chlorprothixene" title="Chlorprothixene">Chlorprothixene</a></li>
<li><a href="/wiki/Ciclindole" title="Ciclindole">Ciclindole</a></li>
<li><a href="/wiki/Clopenthixol" title="Clopenthixol">Clopenthixol</a></li>
<li><a href="/w/index.php?title=Clothixamide&amp;action=edit&amp;redlink=1" class="new" title="Clothixamide (page does not exist)">Clothixamide</a></li>
<li><a href="/wiki/Clopimozide" title="Clopimozide">Clopimozide</a></li>
<li><a href="/wiki/Droperidol" title="Droperidol">Droperidol</a></li>
<li><a href="/wiki/Fluacizine" title="Fluacizine">Fluacizine</a></li>
<li><a href="/wiki/Fluanisone" title="Fluanisone">Fluanisone</a></li>
<li><a href="/wiki/Flucindole" title="Flucindole">Flucindole</a></li>
<li><a href="/wiki/Fluotracen" title="Fluotracen">Fluotracen</a></li>
<li><a href="/wiki/Flupentixol" title="Flupentixol">Flupentixol (flupenthixol)</a> (<a href="/wiki/Flupentixol/melitracen" title="Flupentixol/melitracen">+melitracen</a>)</li>
<li><a href="/wiki/Fluphenazine" title="Fluphenazine">Fluphenazine</a></li>
<li><a href="/w/index.php?title=Fluprothixene&amp;action=edit&amp;redlink=1" class="new" title="Fluprothixene (page does not exist)">Fluprothixene</a></li>
<li><a href="/wiki/Fluspirilene" title="Fluspirilene">Fluspirilene</a></li>
<li><a href="/wiki/Haloperidol" title="Haloperidol">Haloperidol</a></li>
<li><a href="/wiki/Homopipramol" title="Homopipramol">Homopipramol</a></li>
<li><a href="/wiki/Lenperone" title="Lenperone">Lenperone</a></li>
<li><a href="/wiki/Levomepromazine" title="Levomepromazine">Levomepromazine (methotrimeprazine)</a></li>
<li><a href="/wiki/Levosulpiride" title="Levosulpiride">Levosulpiride</a></li>
<li><a href="/wiki/Loxapine" title="Loxapine">Loxapine</a></li>
<li><a href="/wiki/Mesoridazine" title="Mesoridazine">Mesoridazine</a></li>
<li><a href="/wiki/Moperone" title="Moperone">Moperone</a></li>
<li><a href="/wiki/Naranol" title="Naranol">Naranol</a></li>
<li><a href="/wiki/Nemonapride" title="Nemonapride">Nemonapride</a></li>
<li><a href="/wiki/Penfluridol" title="Penfluridol">Penfluridol</a></li>
<li><a href="/wiki/Perathiepin" title="Perathiepin">Perathiepin</a></li>
<li><a href="/wiki/Perazine" title="Perazine">Perazine</a></li>
<li><a href="/wiki/Periciazine" title="Periciazine">Pericyazine (periciazine)</a></li>
<li><a href="/wiki/Perphenazine" title="Perphenazine">Perphenazine</a> (<a href="/wiki/Amitriptyline/perphenazine" title="Amitriptyline/perphenazine">+amitriptyline</a>)</li>
<li><a href="/w/index.php?title=Piflutixol&amp;action=edit&amp;redlink=1" class="new" title="Piflutixol (page does not exist)">Piflutixol (pifluthixol)</a></li>
<li><a href="/wiki/Pimozide" title="Pimozide">Pimozide</a></li>
<li><a href="/wiki/Pipamperone" title="Pipamperone">Pipamperone</a></li>
<li><a href="/wiki/Preclamol" class="mw-redirect" title="Preclamol">Preclamol</a></li>
<li><a href="/wiki/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></li>
<li><a href="/wiki/Promazine" title="Promazine">Promazine</a></li>
<li><a href="/wiki/Prothipendyl" title="Prothipendyl">Prothipendyl</a></li>
<li><a href="/wiki/Spiperone" title="Spiperone">Spiperone (spiroperidol)</a></li>
<li><a href="/wiki/Sulforidazine" title="Sulforidazine">Sulforidazine</a></li>
<li><a href="/wiki/Sulpiride" title="Sulpiride">Sulpiride</a></li>
<li><a href="/wiki/Sultopride" title="Sultopride">Sultopride</a></li>
<li><a href="/w/index.php?title=Teflutixol&amp;action=edit&amp;redlink=1" class="new" title="Teflutixol (page does not exist)">Teflutixol</a></li>
<li><a href="/wiki/Thiopropazate" title="Thiopropazate">Thiopropazate</a></li>
<li><a href="/wiki/Thioproperazine" title="Thioproperazine">Thioproperazine</a></li>
<li><a href="/wiki/Thioridazine" title="Thioridazine">Thioridazine</a></li>
<li><a href="/wiki/Thiothixene" class="mw-redirect" title="Thiothixene">Thiothixene</a></li>
<li><a href="/wiki/Timiperone" title="Timiperone">Timiperone</a></li>
<li><a href="/wiki/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a> (<a href="/wiki/Tranylcypromine/trifluoperazine" title="Tranylcypromine/trifluoperazine">+tranylcypromine</a>)</li>
<li><a href="/wiki/Triflupromazine" title="Triflupromazine">Triflupromazine</a></li>
<li><a href="/wiki/Trifluperidol" title="Trifluperidol">Trifluperidol</a></li>
<li><a href="/w/index.php?title=Zetidoline&amp;action=edit&amp;redlink=1" class="new" title="Zetidoline (page does not exist)">Zetidoline</a></li>
<li><a href="/wiki/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></li></ul>
<ul><li><i>Atypical antipsychotics</i>: <a href="/wiki/Amisulpride" title="Amisulpride">Amisulpride</a></li>
<li><a href="/wiki/Asenapine" title="Asenapine">Asenapine</a></li>
<li><a href="/wiki/BL-1020" title="BL-1020">BL-1020</a></li>
<li><a href="/wiki/Blonanserin" title="Blonanserin">Blonanserin</a></li>
<li><a href="/wiki/Carpipramine" title="Carpipramine">Carpipramine</a></li>
<li><a href="/w/index.php?title=Cinuperone&amp;action=edit&amp;redlink=1" class="new" title="Cinuperone (page does not exist)">Cinuperone</a></li>
<li><a href="/wiki/Clocapramine" title="Clocapramine">Clocapramine</a></li>
<li><a href="/wiki/Clorotepine" title="Clorotepine">Clorotepine</a></li>
<li><a href="/wiki/Clotiapine" title="Clotiapine">Clotiapine (clothiapine)</a></li>
<li><a href="/wiki/Clozapine" title="Clozapine">Clozapine</a></li>
<li><a href="/wiki/Cyamemazine" title="Cyamemazine">Cyamemazine</a></li>
<li><a href="/wiki/DHA-clozapine" title="DHA-clozapine">DHA-clozapine</a></li>
<li><a href="/wiki/Dixyrazine" title="Dixyrazine">Dixyrazine</a></li>
<li><a href="/wiki/Elopiprazole" title="Elopiprazole">Elopiprazole</a></li>
<li><a href="/wiki/Flumezapine" title="Flumezapine">Flumezapine</a></li>
<li><a href="/wiki/Fluperlapine" title="Fluperlapine">Fluperlapine</a></li>
<li><a href="/wiki/Gevotroline" title="Gevotroline">Gevotroline</a></li>
<li><a href="/wiki/Iloperidone" title="Iloperidone">Iloperidone</a></li>
<li><a href="/wiki/Lurasidone" title="Lurasidone">Lurasidone</a></li>
<li><a href="/wiki/Mazapertine" title="Mazapertine">Mazapertine</a></li>
<li><a href="/wiki/Melperone" title="Melperone">Melperone</a></li>
<li><a href="/wiki/Molindone" title="Molindone">Molindone</a></li>
<li><a href="/wiki/Mosapramine" title="Mosapramine">Mosapramine</a></li>
<li><a href="/wiki/Ocaperidone" title="Ocaperidone">Ocaperidone</a></li>
<li><a href="/wiki/Olanzapine" title="Olanzapine">Olanzapine</a> (<a href="/wiki/Olanzapine/fluoxetine" title="Olanzapine/fluoxetine">+fluoxetine</a>)</li>
<li><a href="/wiki/Paliperidone" title="Paliperidone">Paliperidone</a></li>
<li><a href="/wiki/Perospirone" title="Perospirone">Perospirone</a></li>
<li><a href="/wiki/Piperacetazine" title="Piperacetazine">Piperacetazine</a></li>
<li><a href="/wiki/Pipotiazine" title="Pipotiazine">Pipotiazine</a></li>
<li><a href="/wiki/Piquindone" title="Piquindone">Piquindone</a></li>
<li><a href="/wiki/Quetiapine" title="Quetiapine">Quetiapine</a></li>
<li><a href="/wiki/Remoxipride" title="Remoxipride">Remoxipride</a></li>
<li><a href="/wiki/Risperidone" title="Risperidone">Risperidone</a></li>
<li><a href="/wiki/Sertindole" title="Sertindole">Sertindole</a></li>
<li><a href="/w/index.php?title=Tefludazine&amp;action=edit&amp;redlink=1" class="new" title="Tefludazine (page does not exist)">Tefludazine</a></li>
<li><a href="/wiki/Tenilapine" title="Tenilapine">Tenilapine</a></li>
<li><a href="/wiki/Tiospirone" title="Tiospirone">Tiospirone</a></li>
<li><a href="/wiki/Veralipride" title="Veralipride">Veralipride</a></li>
<li><a href="/wiki/Zicronapine" title="Zicronapine">Zicronapine</a></li>
<li><a href="/wiki/Ziprasidone" title="Ziprasidone">Ziprasidone</a></li>
<li><a href="/wiki/Zotepine" title="Zotepine">Zotepine</a></li></ul>
<ul><li><i>Antiemetics/gastroprokinetics/sedatives</i>: <a href="/wiki/Aceprometazine" title="Aceprometazine">Aceprometazine</a></li>
<li><a href="/wiki/AS-8112" title="AS-8112">AS-8112</a></li>
<li><a href="/wiki/Alimemazine" title="Alimemazine">Alimemazine</a></li>
<li><a href="/wiki/Alizapride" title="Alizapride">Alizapride</a></li>
<li><a href="/wiki/Benzquinamide" title="Benzquinamide">Benzquinamide</a></li>
<li><a href="/wiki/Bromopride" title="Bromopride">Bromopride</a></li>
<li><a href="/wiki/Clebopride" title="Clebopride">Clebopride</a></li>
<li><a href="/wiki/Deudomperidone" title="Deudomperidone">Deudomperidone</a></li>
<li><a href="/wiki/Domperidone" title="Domperidone">Domperidone</a></li>
<li><a href="/wiki/Eticlopride" title="Eticlopride">Eticlopride</a></li>
<li><a href="/wiki/Hydroxyzine" title="Hydroxyzine">Hydroxyzine</a></li>
<li><a href="/wiki/Itopride" title="Itopride">Itopride</a></li>
<li><a href="/wiki/Metoclopramide" title="Metoclopramide">Metoclopramide</a></li>
<li><a href="/wiki/Metopimazine" title="Metopimazine">Metopimazine</a></li>
<li><a href="/wiki/Promethazine" title="Promethazine">Promethazine</a></li>
<li><a href="/wiki/Thiethylperazine" title="Thiethylperazine">Thiethylperazine</a></li>
<li><a href="/wiki/Trimethobenzamide" title="Trimethobenzamide">Trimethobenzamide</a></li></ul>
<ul><li><i>Antidepressants</i>: <a href="/wiki/Amoxapine" title="Amoxapine">Amoxapine</a></li>
<li><a href="/wiki/Nefazodone" title="Nefazodone">Nefazodone</a></li>
<li><a href="/wiki/Opipramol" title="Opipramol">Opipramol</a></li>
<li><a href="/wiki/Propiomazine" title="Propiomazine">Propiomazine</a></li>
<li><a href="/wiki/Trimipramine" title="Trimipramine">Trimipramine</a></li></ul>
<ul><li><i>Others</i>: <a href="/wiki/3-PPP" title="3-PPP">3-PPP</a></li>
<li><a href="/w/index.php?title=Alpiropride&amp;action=edit&amp;redlink=1" class="new" title="Alpiropride (page does not exist)">Alpiropride</a></li>
<li><a href="/wiki/Azapride" title="Azapride">Azapride</a></li>
<li><a href="/wiki/Bromerguride" title="Bromerguride">Bromerguride</a></li>
<li><a href="/wiki/Bromocriptine" title="Bromocriptine">Bromocriptine</a></li>
<li><a href="/wiki/Buspirone" title="Buspirone">Buspirone</a></li>
<li><a href="/wiki/Desmethoxyfallypride" title="Desmethoxyfallypride">Desmethoxyfallypride</a></li>
<li><a href="/wiki/N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline" title="N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline">EEDQ</a></li>
<li><a href="/wiki/F-15063" title="F-15063">F-15063</a></li>
<li><a href="/wiki/Fallypride" title="Fallypride">Fallypride</a></li>
<li><a href="/wiki/Fananserin" title="Fananserin">Fananserin</a></li>
<li><a href="/wiki/Fenfluramine" title="Fenfluramine">Fenfluramine</a></li>
<li><a href="/wiki/Iodobenzamide" title="Iodobenzamide">Iodobenzamide</a></li>
<li><a href="/w/index.php?title=Isocorypalmine&amp;action=edit&amp;redlink=1" class="new" title="Isocorypalmine (page does not exist)">Isocorypalmine</a></li>
<li><a href="/wiki/L-741,626" title="L-741,626">L-741,626</a></li>
<li><a href="/wiki/L-745,870" title="L-745,870">L-745,870</a></li>
<li><a href="/wiki/Levofenfluramine" title="Levofenfluramine">Levofenfluramine</a></li>
<li><a href="/w/index.php?title=LEK-8829&amp;action=edit&amp;redlink=1" class="new" title="LEK-8829 (page does not exist)">LEK-8829</a></li>
<li><a href="/wiki/Metergoline" title="Metergoline">Metergoline</a></li>
<li><a href="/wiki/Metitepine" title="Metitepine">Metitepine (methiothepin)</a></li>
<li><a href="/wiki/N-Methylspiperone" title="N-Methylspiperone">N-Methylspiperone</a></li>
<li><a href="/wiki/Nafadotride" title="Nafadotride">Nafadotride</a></li>
<li><a href="/wiki/Nuciferine" title="Nuciferine">Nuciferine</a></li>
<li><a href="/wiki/PNU-99,194" title="PNU-99,194">PNU-99,194</a></li>
<li><a href="/wiki/Pridopidine" title="Pridopidine">Pridopidine</a></li>
<li><a href="/wiki/Raclopride" title="Raclopride">Raclopride</a></li>
<li><a href="/wiki/Sarizotan" title="Sarizotan">Sarizotan</a></li>
<li><a href="/wiki/SB-277,011-A" title="SB-277,011-A">SB-277,011-A</a></li>
<li><a href="/w/index.php?title=Seridopidine&amp;action=edit&amp;redlink=1" class="new" title="Seridopidine (page does not exist)">Seridopidine</a></li>
<li><a href="/wiki/Sonepiprazole" title="Sonepiprazole">Sonepiprazole</a></li>
<li><a href="/wiki/Spiroxatrine" title="Spiroxatrine">Spiroxatrine</a></li>
<li><a href="/wiki/Stepholidine" title="Stepholidine">Stepholidine</a></li>
<li><a href="/w/index.php?title=SV-293&amp;action=edit&amp;redlink=1" class="new" title="SV-293 (page does not exist)">SV-293</a></li>
<li><a href="/wiki/Terguride" title="Terguride">Terguride</a></li>
<li><a href="/wiki/Tetrahydropalmatine" title="Tetrahydropalmatine">Tetrahydropalmatine</a></li>
<li><a href="/wiki/Tiapride" title="Tiapride">Tiapride</a></li>
<li><a href="/wiki/UH-232" title="UH-232">UH-232</a></li>
<li><a href="/wiki/Yohimbine" title="Yohimbine">Yohimbine</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<ul><li><small><i><b>See also:</b> <a href="/wiki/Template:Receptor_modulators" title="Template:Receptor modulators">Receptor/signaling modulators</a></i></small></li>
<li><small><i><a href="/wiki/Template:Adrenergic_receptor_modulators" title="Template:Adrenergic receptor modulators">Adrenergics</a></i></small></li>
<li><small><i><a href="/wiki/Template:Serotonin_receptor_modulators" title="Template:Serotonin receptor modulators">Serotonergics</a></i></small></li>
<li><small><i><a href="/wiki/Template:Monoamine_reuptake_inhibitors" title="Template:Monoamine reuptake inhibitors">Monoamine reuptake inhibitors</a></i></small></li>
<li><small><i><a href="/wiki/Template:Monoamine_releasing_agents" title="Template:Monoamine releasing agents">Monoamine releasing agents</a></i></small></li>
<li><small><i><a href="/wiki/Template:Monoamine_metabolism_modulators" title="Template:Monoamine metabolism modulators">Monoamine metabolism modulators</a></i></small></li>
<li><small><i><a href="/wiki/Template:Monoamine_neurotoxins" title="Template:Monoamine neurotoxins">Monoamine neurotoxins</a></i></small></li></ul>
</div></td></tr></tbody></table></div>
<div class="navbox-styles nomobile"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1061467846"/></div><div role="navigation" class="navbox" aria-labelledby="Mood_disorder" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1063604349"/><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Mood_disorders" title="Template:Mood disorders"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Mood_disorders" title="Template talk:Mood disorders"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Mood_disorders&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Mood_disorder" style="font-size:114%;margin:0 4em"><a href="/wiki/Mood_disorder" title="Mood disorder">Mood disorder</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Affective_spectrum" title="Affective spectrum">Spectrum</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Bipolar_disorder" title="Bipolar disorder">Bipolar disorder</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Bipolar_I_disorder" title="Bipolar I disorder">Bipolar I</a></li>
<li><a href="/wiki/Bipolar_II_disorder" title="Bipolar II disorder">Bipolar II</a></li>
<li><a href="/wiki/Cyclothymia" title="Cyclothymia">Cyclothymia</a></li>
<li><a href="/wiki/Bipolar_disorder_not_otherwise_specified" title="Bipolar disorder not otherwise specified">Bipolar NOS</a></li>
<li><a href="/wiki/Bipolar_disorder_in_children" title="Bipolar disorder in children">Childhood</a></li>
<li><a href="/wiki/Hypomania" title="Hypomania">Hypomania</a></li>
<li><a href="/wiki/Mania" title="Mania">Mania</a></li>
<li><a href="/wiki/Mixed_affective_state" title="Mixed affective state">Mixed affective state</a></li>
<li><a href="/wiki/Rapid_cycling" class="mw-redirect" title="Rapid cycling">Rapid cycling</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Depression_(mood)" title="Depression (mood)">Depression</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">Major depressive disorder</a></li>
<li><a href="/wiki/Dysthymia" title="Dysthymia">Dysthymia</a></li>
<li><a href="/wiki/Seasonal_affective_disorder" title="Seasonal affective disorder">Seasonal affective disorder</a></li>
<li><a href="/wiki/Atypical_depression" title="Atypical depression">Atypical depression</a></li>
<li><a href="/wiki/Melancholic_depression" title="Melancholic depression">Melancholic depression</a></li>
<li><a href="/wiki/Major_depressive_episode" title="Major depressive episode">Major depressive episode</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Comorbidities</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Schizoaffective_disorder" title="Schizoaffective disorder">Schizoaffective disorder</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Symptom" class="mw-redirect" title="Symptom">Symptoms</a></th><td class="navbox-list-with-group navbox-list navbox-even hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Delusion" title="Delusion">Delusion</a></li>
<li><a href="/wiki/Depression_(differential_diagnoses)" class="mw-redirect" title="Depression (differential diagnoses)">Depression (differential diagnoses)</a></li>
<li><a href="/wiki/Emotional_dysregulation" title="Emotional dysregulation">Emotional dysregulation</a>
<ul><li><a href="/wiki/Anhedonia" title="Anhedonia">Anhedonia</a></li>
<li><a href="/wiki/Dysphoria" title="Dysphoria">Dysphoria</a></li>
<li><a href="/wiki/Suicidal_ideation" title="Suicidal ideation">Suicidal ideation</a></li></ul></li>
<li><a href="/wiki/Hallucination" title="Hallucination">Hallucination</a></li>
<li><a href="/wiki/Mood_swing" title="Mood swing">Mood swing</a></li>
<li><i><a href="/wiki/Sleep_disorder" title="Sleep disorder">Sleep disorder</a></i>
<ul><li><a href="/wiki/Hypersomnia" title="Hypersomnia">Hypersomnia</a></li>
<li><a href="/wiki/Insomnia" title="Insomnia">Insomnia</a></li></ul></li>
<li><a href="/wiki/Psychosis" title="Psychosis">Psychosis</a></li>
<li><a href="/wiki/Psychotic_depression" title="Psychotic depression">Psychotic depression</a></li>
<li><a href="/wiki/Racing_thoughts" title="Racing thoughts">Racing thoughts</a></li>
<li><a href="/wiki/Reduced_affect_display" title="Reduced affect display">Reduced affect display</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/List_of_diagnostic_classification_and_rating_scales_used_in_psychiatry" title="List of diagnostic classification and rating scales used in psychiatry">Diagnosis</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Bipolar_Spectrum_Diagnostic_Scale" title="Bipolar Spectrum Diagnostic Scale">Bipolar Spectrum Diagnostic Scale</a></li>
<li><a href="/wiki/Child_Mania_Rating_Scale" title="Child Mania Rating Scale">Child Mania Rating Scale</a></li>
<li><a href="/wiki/General_Behavior_Inventory" title="General Behavior Inventory">General Behavior Inventory</a></li>
<li><a href="/wiki/Hypomania_Checklist" title="Hypomania Checklist">Hypomania Checklist</a></li>
<li><a href="/wiki/Mood_Disorder_Questionnaire" title="Mood Disorder Questionnaire">Mood Disorder Questionnaire</a></li>
<li><a href="/wiki/Rating_scales_for_depression" title="Rating scales for depression">Rating scales for depression</a></li>
<li><a href="/wiki/Young_Mania_Rating_Scale" title="Young Mania Rating Scale">Young Mania Rating Scale</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Treatment_of_bipolar_disorder" title="Treatment of bipolar disorder">Treatment</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Anticonvulsant" title="Anticonvulsant">Anticonvulsants</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Carbamazepine" title="Carbamazepine">Carbamazepine</a></li>
<li><a href="/wiki/Lamotrigine" title="Lamotrigine">Lamotrigine</a></li>
<li><a href="/wiki/Oxcarbazepine" title="Oxcarbazepine">Oxcarbazepine</a></li>
<li><a href="/wiki/Valproate" title="Valproate">Valproate</a>
<ul><li><a href="/wiki/Sodium_valproate" class="mw-redirect" title="Sodium valproate">Sodium valproate</a></li>
<li><a href="/wiki/Valproate_semisodium" class="mw-redirect" title="Valproate semisodium">Valproate semisodium</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Sympathomimetic_drug" title="Sympathomimetic drug">Sympathomimetics</a>,<br /><a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">SSRIs</a> and similar</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></li>
<li><a href="/wiki/Escitalopram" title="Escitalopram">Escitalopram</a></li>
<li><a href="/wiki/Fluoxetine" title="Fluoxetine">Fluoxetine</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
<li><a href="/wiki/Sertraline" title="Sertraline">Sertraline</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other <a href="/wiki/Mood_stabilizer" title="Mood stabilizer">mood stabilizers</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a class="mw-selflink selflink">Antipsychotics</a></li>
<li><a href="/wiki/Atypical_antipsychotic" title="Atypical antipsychotic">Atypical antipsychotics</a></li>
<li><a href="/wiki/Lithium_(medication)" title="Lithium (medication)">Lithium</a>
<ul><li><a href="/wiki/Lithium_carbonate" title="Lithium carbonate">Lithium carbonate</a></li>
<li><a href="/wiki/Lithium_citrate" title="Lithium citrate">Lithium citrate</a></li>
<li><a href="/wiki/Lithium_sulfate" title="Lithium sulfate">Lithium sulfate</a></li>
<li><a href="/wiki/Lithium_toxicity" title="Lithium toxicity">Lithium toxicity</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-pharmaceutical</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Clinical_psychology" title="Clinical psychology">Clinical psychology</a></li>
<li><a href="/wiki/Cognitive_behavioral_therapy" title="Cognitive behavioral therapy">Cognitive behavioral therapy</a></li>
<li><a href="/wiki/Dialectical_behavior_therapy" title="Dialectical behavior therapy">Dialectical behavior therapy</a></li>
<li><a href="/wiki/Electroconvulsive_therapy" title="Electroconvulsive therapy">Electroconvulsive therapy</a></li>
<li><a href="/wiki/Involuntary_commitment" title="Involuntary commitment">Involuntary commitment</a></li>
<li><a href="/wiki/Light_therapy" title="Light therapy">Light therapy</a></li>
<li><a href="/wiki/Psychotherapy" title="Psychotherapy">Psychotherapy</a></li>
<li><a href="/wiki/Transcranial_magnetic_stimulation" title="Transcranial magnetic stimulation">Transcranial magnetic stimulation</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/History_of_bipolar_disorder" title="History of bipolar disorder">History</a></th><td class="navbox-list-with-group navbox-list navbox-even hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="/wiki/Emil_Kraepelin" title="Emil Kraepelin">Emil Kraepelin</a></li>
<li><a href="/wiki/Frederick_K._Goodwin" title="Frederick K. Goodwin">Frederick K. Goodwin</a></li>
<li><a href="/wiki/John_Cade" title="John Cade">John Cade</a></li>
<li><a href="/wiki/Karl_Leonhard" title="Karl Leonhard">Karl Leonhard</a></li>
<li><a href="/wiki/Kay_Redfield_Jamison" title="Kay Redfield Jamison">Kay Redfield Jamison</a></li>
<li><a href="/wiki/Mogens_Schou" title="Mogens Schou">Mogens Schou</a></li></ul>
</div></td></tr></tbody></table></div>
<div class="navbox-styles nomobile"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1061467846"/></div><div role="navigation" class="navbox authority-control" aria-labelledby="Authority_control:_National_libraries_frameless_&amp;#124;text-top_&amp;#124;10px_&amp;#124;alt=Edit_this_at_Wikidata_&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q208144#identifiers&amp;#124;Edit_this_at_Wikidata" style="padding:3px"><table class="nowraplinks hlist navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th id="Authority_control:_National_libraries_frameless_&amp;#124;text-top_&amp;#124;10px_&amp;#124;alt=Edit_this_at_Wikidata_&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q208144#identifiers&amp;#124;Edit_this_at_Wikidata" scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Help:Authority_control" title="Help:Authority control">Authority control: National libraries</a>  <a href="https://www.wikidata.org/wiki/Q208144#identifiers" title="Edit this at Wikidata"><img alt="Edit this at Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" style="vertical-align: text-top" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20" /></a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><span class="uid"><a rel="nofollow" class="external text" href="https://catalogue.bnf.fr/ark:/12148/cb119422132">France</a> <a rel="nofollow" class="external text" href="https://data.bnf.fr/ark:/12148/cb119422132">(data)</a></span></li>
<li><span class="uid"><a rel="nofollow" class="external text" href="https://d-nb.info/gnd/4041885-6">Germany</a></span></li>
<li><span class="uid"><a rel="nofollow" class="external text" href="https://id.loc.gov/authorities/subjects/sh89002390">United States</a></span></li>
<li><span class="uid"><a rel="nofollow" class="external text" href="https://id.ndl.go.jp/auth/ndlna/01037224">Japan</a></span></li></ul>
</div></td></tr></tbody></table></div></div>